


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update March 29 - April 4, 2021,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 13 2021 1460 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashbord](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford Universtiy Press](#)

[Cambridge Univeristy Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[German \(ICU\) bed capacity](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[COVID reference \(Steinhauser Verlag\)](#)

[Retracted papers](#)

[COVID-19 risk tools - Apps](#)

[Web app for SARS-CoV2 mutations](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

COVID-19 prevention network

Covid-Plex trial - (plasma exchange & convalescent plasma trial)

**Re: Plasma exchange and convalescent plasma in COVID-19 patients with
multi-organ failure –**

**The COVID-19 PLEX + Convalescent Plasma trial –
Enrollment initiated**

The Covid-Plex trial is an investigator initiated, multicenter, parallel-group, open-label randomized clinical trial aiming to randomize patients with severe COVID-19 to standard care or standard care plus plasmapheresis and convalescent plasma.

If you are interested to participate Please contact Wladimir Szpirt, Nicholas Carlson Anders, or Perner Bo Feldt-Rasmussen. Depts. Of Intensive Care Therapy and Nephrology, Copenhagen University Hospital Rigshospitalet, Denmark

Covid-Plex trial

Mainstream Media

New York Times - Corona update

Slovakia Claims a Bait-and-Switch With the Russian Vaccines it Ordered

Has the Era of Overzealous Cleaning Finally Come to an End?

Vaccinated Mothers Are Trying to Give Babies Antibodies via Breast Milk

Online Scammers Have a New Offer for You: Vaccine Cards

Likely Legal, 'Vaccine Passports' Emerge as the Next Coronavirus Divide

Many Children With Serious Inflammatory Syndrome Had No Covid Symptoms

How Will China Vaccinate 560 Million People? Start With Free Ice Cream

Researchers Are Hatching a Low-Cost Coronavirus Vaccine

My Life in Israel's Brave New Post-Pandemic Future

Washington Post - Corona update

The virus is somersaulting toward younger people

Rise of coronavirus variants will define the next phase of the pandemic in the U.S.

Supporters tout anti-parasite drug as covid-19 treatment, but skeptics call it the 'new hydroxychloroquine'

Stress on the front lines of covid-19

Should health-care workers be required to get coronavirus shots?

Are we entering a 'fourth wave' of the pandemic? Experts disagree.

Fully vaccinated people are at low-risk from travel, CDC says

Your questions about coronavirus vaccines, answered

Coronavirus vaccines are coming for kids — but studies have to be finished first

Pfizer, Moderna vaccines are 90% effective after two doses in study of real-life conditions, CDC confirms

Guardian - Corona update

Extent of mental health crisis in England at 'terrifying' level

Publish figures on long Covid to show 'untold suffering', MPs urge

Covid plan for England: trips abroad could be permitted from May.

Brazilian Covid variant: what do we know about P1?

Covid-19: how does it cause heart damage

Key Articles

1. Literature Review of COVID-19, Pulmonary and Extrapulmonary Disease.

Am. J. Med. Sci. 2021; Yazdanpanah F, Asmarz HY, Shadman S.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785204>

In this concise review, those who want to familiarise themselves with COVID-19 disease, and the SARS-COV-2 virus characteristics, are presented with a broad range of relevant topics. This review is based on 59 articles that met inclusion criteria, e.g., Case reports, case series, cohort studies, reviews, meta-analysis. The referenced articles provide more in-depth details for those that have a particular interest in specific topics.

2. COVID-19 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol 2021; Gray KJ, Bordt EA, Atyeo C *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775692>

The large COVID-19 vaccination trials excluded pregnant and lactating women. With the rapid expansion of national vaccination programs, the lack of data on vaccine efficacy and safety is hampering vaccine decision-making for those women. This study included 131 women (84 pregnant, 31 lactating, and 16 non-pregnant women). The findings look reassuring, showing robust humoral immunity and similar immunogenicity and reactogenicity response compared to non-pregnant and lactating women. Immune transfer to neonates occurred via placenta and breastmilk

3. Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification. Int J Environ Res Public Health 2021; 18Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807869>

COVID-19 patients are rarely affected with severe and sometimes fatal complications. A more prolonged and relapsing expression of post-COVID-19 symptoms is observed in hospitalized and non-hospitalized patients quite frequently. To better understand the underlying mechanisms and study post-COVID-19 symptoms, this article's authors propose a clearly defined definition and classification of Post-COVID-19 symptoms.

4. Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. BMC Neurol.

2021; 21:138Yassin A, Nawaiseh M, Shaban A *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784985>

5. **The Primary Prevention of Venous Thromboembolism in Patients with COVID-19 in Japan: Current Status and Future Perspective.** Ann Vasc Dis 2021; 14:1-4 Yamashita Y, Yamada N, Mo M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786092>
6. **The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?** Cells 2021; 10 Saravi B, Li Z, Lang CN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804069>
7. **The variant gambit: COVID-19's next move.** Cell Host Microbe 2021; Plante JA, Mitchell BM, Plante KS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789086>
8. **Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies.** J. Steroid Biochem. Mol. Biol. 2021:105883 Petrelli F, Luciani A, Perego G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775818>
9. **How fast should social restrictions be eased in England as COVID-19 vaccinations are rolled out?** Int J Clin Pract 2021:e14191 Miles DK, Heald AH, Stedman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788370>
10. **Long COVID - An Early Perspective.** J. Insur. Med. 2021; Meagher T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784738>
11. **Genome-wide Analysis of 10664 SARS-CoV-2 Genomes to Identify Virus Strains in 73 Countries based on Single Nucleotide Polymorphism.** Virus Res. 2021:198401 Ghosh N, Saha I, Sharma N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781798>
12. **Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil.** Emerg Infect Dis 2021; 27 Fintelman-Rodrigues N, da Silva APD, Dos Santos MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797393>
13. **Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem.** Adv Ther 2021:1-8 Cugno M, Gualtierotti R, Casazza G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792889>
14. **Renin-angiotensin system blockade in the COVID-19 pandemic.** Clin Kidney J 2021; 14:i48-i59 Cohen JB, South AM, Shaltout HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796285>

15. Fever: Could A Cardinal Sign of COVID-19 Infection Reduce Mortality?

Am. J. Med. Sci. 2021; 361:420-426Cann SAH.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781387>

Basic Science (104 articles)

1. **State-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2.** ACS Appl Mater Interfaces 2021; Derakhshan MA, Amani A, Faridi-Majidi R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779135>
2. **Computational Fluidic Modeling of a Low-Cost Fluidic Oscillator for Conversion of a CPAP Machine into an Emergency Use Mechanical Ventilator.** Adv Nanobiomed Res 2021:2000112Dillon T, Ozturk C, Mendez K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786536>
3. **Differentially expressed immune response genes in COVID-19 patients based on disease severity.** Aging (Albany NY) 2021; 13Li S, Duan X, Li Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33780352>
4. **Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment.** Am. J. Cancer Res. 2021; 11:827-836Chen Y, Huang WC, Yang CS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33791156>
5. **A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples.** Am. J. Respir. Cell Mol. Biol. 2021; Madan T, Biswas B, Varghese PM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784482>
6. **Mechanisms Modified by (-)-Epicatechin and Taxifolin Relevant for the Treatment of Hypertension and Viral Infection: Knowledge from Preclinical Studies.** Antioxidants (Basel) 2021; 10Bernatova I, Liskova S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809620>
7. **Implications of a highly transmissible variant of SARS-CoV-2 for children.** Arch. Dis. Child. 2021; Ratmann O, Bhatt S, Flaxman S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785527>
8. **SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration.** Biochem. Biophys. Res. Commun. 2021; 554:94-98Idrees D, Kumar V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789211>
9. **ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.** Biochem. Biophys. Res. Commun. 2021; 555:134-139Vandyck K, Abdelnabi R, Gupta K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813272>
10. **The Relevance of Bioinformatics Applications in the Discovery of Vaccine Candidates and Potential Drugs for COVID-19 Treatment.** Bioinform. Biol. Insights 2021; 15:11779322211002168Chukwudozie OS, Duru VC, Ndiribe CC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33795932>

11. **Metagenomics Approaches to Investigate the Gut Microbiome of COVID-19 Patients.** Bioinform. Biol. Insights 2021; 15:1177932221999428Sehli S, Allali I, Chahboune R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786001>
12. **Exaptation of Retroviral Syncytin for Development of Syncytialized Placenta, Its Limited Homology to the SARS-CoV-2 Spike Protein and Arguments against Disturbing Narrative in the Context of COVID-19 Vaccination.** Biology (Basel) 2021; 10Kloc M, Uosef A, Kubiak JZ, Ghobrial RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808658>
13. **Low type I interferon response in COVID-19 patients: Interferon response may be a potential treatment for COVID-19.** Biomed Rep 2021; 14:43Salman AA, Waheed MH, Ali-Abdulsahib AA, Atwan ZW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786172>
14. **Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome.** Biomedicines 2021; 9Morales A, Rojo Rello S, Cristóbal H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810394>
15. **Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19).** Biomolecules 2021; 11El-Demerdash A, Metwaly AM, Hassan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808721>
16. **Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis.** Biomolecules 2021; 11Hardy E, Fernandez-Patron C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800947>
17. **Blood Levels of Galectin-9, an Immuno-Regulating Molecule, Reflect the Severity for the Acute and Chronic Infectious Diseases.** Biomolecules 2021; 11Iwasaki-Hozumi H, Chagan-Yasutan H, Ashino Y, Hattori T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804076>
18. **Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients.** Cancers (Basel) 2021; 13Han G, Sinjab A, Hara K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809063>
19. **SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.** Cell 2021; Hoffmann M, Arora P, Groß R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794143>
20. **Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.** Cell Host Microbe 2021; Cerutti G, Guo Y, Zhou T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789084>
21. **The variant gambit: COVID-19's next move.** Cell Host Microbe 2021; Plante JA, Mitchell BM, Plante KS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789086>
22. **Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication.** Cell Rep. 2021:108940Garcia G, Jr., Sharma A, Ramaiah A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784499>
23. **Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class.** Cell Rep. 2021:108950Rapp M, Guo Y, Reddem ER *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794145>
24. **Extracellular Vesicles Analysis in the COVID-19 Era: Insights on Serum Inactivation Protocols towards Downstream Isolation and Analysis.** Cells 2021;

- 10Frigerio R, Musicò A, Brucale M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806297>
25. **Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients.** Cells 2021; 10Raghav A, Khan ZA, Upadhayay VK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799966>
26. **The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?** Cells 2021; 10Saravi B, Li Z, Lang CN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804069>
27. **Thymic Aging May Be Associated with COVID-19 Pathophysiology in the Elderly.** Cells 2021; 10Wang W, Thomas R, Oh J, Su DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808998>
28. **The circadian clock gene Bmal1: Role in COVID-19 and periodontitis.** Chronobiol. Int. 2021;1-6Sehirli A, Chukwunyere U, Aksoy U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792447>
29. **An automated COVID-19 detection based on fused dynamic exemplar pyramid feature extraction and hybrid feature selection using deep learning.** Comput. Biol. Med. 2021; 132:104356Ozyurt F, Tuncer T, Subasi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799219>
30. **Protein-ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.** Curr Med Chem 2021; de Azevedo Junior WF, Bitencourt-Ferreira G, Godoy JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781188>
31. **Comparative Assessment of Sera from Individuals after S-Genome RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays.** Diagnostics (Basel) 2021; 11Dörschug A, Frickmann H, Schwanbeck J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802453>
32. **Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge.** EBioMedicine 2021; 66:103291Winkler MS, Skirecki T, Brunkhorst FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813139>
33. **Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil.** Emerg Infect Dis 2021; 27Fintelman-Rodrigues N, da Silva APD, Dos Santos MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797393>
34. **Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, in British Columbia, Canada.** Emerg Infect Dis 2021; 27Matic N, Lowe CF, Ritchie G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784237>
35. **SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics.** Expert Rev Proteomics 2021;1-14Hartog N, Faber W, Frisch A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779460>
36. **Coronavirus-Induced Host Cubic Membranes and Lipid-Related Antiviral Therapies: A Focus on Bioactive Plasmalogens.** Front Cell Dev Biol 2021; 9:630242Deng Y, Angelova A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791293>
37. **SARS-CoV-2-Indigenous Microbiota Nexus: Does Gut Microbiota Contribute to Inflammation and Disease Severity in COVID-19?** Front Cell Infect Microbiol 2021; 11:590874Chattopadhyay I, Shankar EM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791231>

38. **Dooming Phagocyte Responses: Inflammatory Effects of Endogenous Oxidized Phospholipids.** Front. Endocrinol. (Lausanne) 2021; 12:626842 Di Gioia M, Zanon I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790857>
39. **Network Analysis and Transcriptome Profiling Identify Autophagic and Mitochondrial Dysfunctions in SARS-CoV-2 Infection.** Front Genet 2021; 12:599261 Singh K, Chen YC, Hassanzadeh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796130>
40. **Emergence of Bat-Related Betacoronaviruses: Hazard and Risks.** Front. Microbiol. 2021; 12:591535 Frutos R, Serra-Cobo J, Pinault L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790874>
41. **Comparative analysis of mutational hotspots in the spike protein of SARS-CoV-2 isolates from different geographic origins.** Gene Rep 2021; 23:101100 Lee S, Lee MK, Na H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778182>
42. **A Resource for the Network Representation of Cell Perturbations Caused by SARS-CoV-2 Infection.** Genes (Basel) 2021; 12: Peretto L, Micarelli E, Iannuccelli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809949>
43. **Molecular epidemiology analysis of early variants of SARS-CoV-2 reveals the potential impact of mutations P504L and Y541C (NSP13) in the clinical COVID-19 outcomes.** Infect Genet Evol 2021; 104831 Cao C, He L, Tian Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798758>
44. **Emergence and outcome of the SARS-CoV-2 "Marseille-4" variant.** Int J Infect Dis 2021; Fournier PE, Colson P, Levasseur A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785459>
45. **Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study.** Int J Mol Sci 2021; 22: Abdelaal Ahmed Mahmoud MAA, Georgakis M, Montero Valenzuela LR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804129>
46. **CNBP Binds and Unfolds In Vitro G-Quadruplexes Formed in the SARS-CoV-2 Positive and Negative Genome Strands.** Int J Mol Sci 2021; 22: Bezzi G, Piga EJ, Binolfi A, Armas P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807682>
47. **A Novel Computational Approach for the Discovery of Drug Delivery System Candidates for COVID-19.** Int J Mol Sci 2021; 22: Cho T, Han HS, Jeong J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802169>
48. **SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity.** Int J Mol Sci 2021; 22: Huang SW, Wang SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802729>
49. **Population-Predicted MHC Class II Epitope Presentation of SARS-CoV-2 Structural Proteins Correlates to the Case Fatality Rates of COVID-19 in Different Countries.** Int J Mol Sci 2021; 22: Liang C, Bencurova E, Psota E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807854>
50. **Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro.** Int J Mol Sci 2021; 22: Ohashi H, Wang F, Stappenbeck F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808940>
51. **The History and Mystery of Alveolar Epithelial Type II Cells: Focus on Their Physiologic and Pathologic Role in Lung.** Int J Mol Sci 2021; 22: Ruaro B, Salton

- F, Braga L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806395>
52. **Exosomes from COVID-19 Patients Carry Tenascin-C and Fibrinogen- β in Triggering Inflammatory Signals in Cells of Distant Organ.** Int J Mol Sci 2021; 22:Sur S, Khatun M, Steele R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804769>
 53. **Protein Footprinting, Conformational Dynamics, and Core Interface-Adjacent Neutralization "Hotspots" in the SARS-CoV-2 Spike Protein Receptor Binding Domain/Human ACE2 Interaction.** J. Am. Soc. Mass Spectrom. 2021; Narang D, James DA, Balmer MT, Wilson DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794092>
 54. **Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2.** J Appl Phycol 2021;1-24Petit L, Vernès L, Cadoret JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776210>
 55. **Polymer-based Nano-therapies to Combat COVID-19 related Respiratory Injury: Progress, Prospects, and Challenges.** J. Biomater. Sci. Polym. Ed. 2021:1-33Rana MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787467>
 56. **COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays.** J Biomol Struct Dyn 2021:1-14Kalra RS, Kumar V, Dhanjal JK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797339>
 57. **Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors.** J Biomol Struct Dyn 2021:1-9Khorsandi Z, Afshinpour M, Molaei F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784944>
 58. **In silico characterization of mutations circulating in SARS-CoV-2 structural proteins.** J Biomol Struct Dyn 2021:1-16Periwal N, Rathod SB, Pal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797336>
 59. **Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics.** J. Genet. Eng. Biotechnol. 2021; 19:52Hossain MU, Bhattacharjee A, Emon MTH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797663>
 60. **Comprehensive Comparative Genomic and Microsatellite Analysis of SARS, MERS, BAT-SARS and COVID-19 Coronaviruses.** J Med Virol 2021; Rehman HA, Ramzan F, Basharat Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782990>
 61. **Engineered ultra-high affinity synthetic antibodies for SARS-CoV-2 neutralization and detection.** J. Mol. Biol. 2021:166956Slezak T, Kossiakoff AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775667>
 62. **Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.** J. Mol. Graph. Model. 2021; 105:107904Ibrahim MAA, Mohamed EAR, Abdelrahman AHM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798836>
 63. **Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies.** J Transl Med 2021; 19:139Sciacchitano S, De Vitis C, D'Ascanio M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794925>

64. **A Novel Method for Conserved Sequence Extraction with Prospective Mutation Prediction for SARS-CoV-2 PCR Primer Design.** J. Virol. Methods 2021;114:146Portakal SH, Kanat B, Sayan M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812944>
65. **Molecular profile of oral fluid in new coronavirus infection.** Klin. Lab. Diagn. 2021; 66:133-138Gilmiyarova FN, Gussyakova OA, Konstantinov DY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33793111>
66. **Heparin prevents in vitro glycoalkal shedding induced by plasma from COVID-19 patients.** Life Sci 2021; 276:119376Potje SR, Costa TJ, Fraga-Silva TFC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781826>
67. **An update: the emerging evidence of complement involvement in COVID-19.** Med. Microbiol. Immunol. 2021; Li Q, Chen Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811541>
68. **Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG.** Microorganisms 2021; 9Eberhardt KA, Dewald F, Heger E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807490>
69. **Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.** Microorganisms 2021; 9Taroncher-Oldenburg G, Müller C, Obermann W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807988>
70. **Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines.** Microorganisms 2021; 9Villena J, Li C, Vizoso-Pinto MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810287>
71. **EFFECT OF RAMIPRIL ON KIDNEY, LUNG AND HEART ACE2 IN A DIABETIC MICE MODEL.** Mol. Cell. Endocrinol. 2021;111:263Vergara A, Jacobs-Cachá C, Molina-Van den Bosch M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811970>
72. **An Integrative in Silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease.** Mol Inform 2021; Djokovic N, Ruzic D, Djikic T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787066>
73. **Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential.** Mol. Pharm. 2021; Turek M, Różycka-Sokołowska E, Koprowski M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792313>
74. **Identification of Potential SARS-CoV-2 Main Protease and Spike Protein Inhibitors from the Genus Aloe: An In Silico Study for Drug Development.** Molecules 2021; 26Abouelela ME, Assaf HK, Abdelhamid RA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33801151>
75. **Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme.** Molecules 2021; 26Ahmad S, Waheed Y, Ismail S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800013>
76. **Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study.** Molecules 2021; 26Atkinson EL, Iegre J, Brear PD *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807474>

77. **Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform.** Molecules 2021; 26Chakravarty K, Antontsev VG, Khotimchenko M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805419>
78. **Receptor-Based Pharmacophore Modeling in the Search for Natural Products for COVID-19 M(pro).** Molecules 2021; 26Saeed M, Saeed A, Alam MJ, Alreshidi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799871>
79. **SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.** Molecules 2021; 26Sardanelli AM, Isgrò C, Palese LL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807773>
80. **Molecular Basis of the Therapeutical Potential of Clove (*Syzygium aromaticum* L.) and Clues to Its Anti-COVID-19 Utility.** Molecules 2021; 26Viciodini C, Roviello V, Roviello GN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810416>
81. **SiO₂-Ag Composite as a Highly Virucidal Material: A Roadmap that Rapidly Eliminates SARS-CoV-2.** Nanomaterials (Basel) 2021; 11Assis M, Simoes LGP, Tremiliosi GC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806671>
82. **In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.** Netw Model Anal Health Inform Bioinform 2021; 10:22Udofia IA, Gbayo KO, Oloba-Whenu OA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786291>
83. **miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery.** Noncoding RNA 2021; 7Alam T, Lipovich L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801496>
84. **Zoonotic and reverse zoonotic transmission of severe acute respiratory syndrome coronavirus 2: a review and implications for Africa.** Pan Afr. Med. J. 2021; 38:39Anjorin AA, Ashaka OS, Tijani SO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777307>
85. **Mutations in Animal SARS-CoV-2 Induce Mismatches with the Diagnostic PCR Assays.** Pathogens 2021; 10Elaswad A, Fawzy M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808783>
86. **Why Does SARS-CoV-2 Infection Induce Autoantibody Production?** Pathogens 2021; 10Macela A, Kubelkova K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809954>
87. **Molecular Analysis of SARS-CoV-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level.** Pathogens 2021; 10Sallam M, Mahafzah A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807556>
88. **Understanding the Heart-Brain Axis Response in COVID-19 patients: a Suggestive Perspective for Therapeutic Development.** Pharmacol. Res. 2021;105581Lionetti V, Bollini S, Coppini R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781873>
89. **CD38 in the Age of Covid-19: a Medical Perspective.** Physiol Rev 2021; Horenstein A, Faini AC, Malavasi F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787351>
90. **In silico approach of secondary metabolites from Brazilian herbal medicines to search for potential drugs against SARS-CoV-2.** Phytother. Res. 2021;

Amparo TR, Seibert JB, Almeida TC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797123>

91. **Electrospun Nanofibrous Scaffolds: Review of Current Progress in the Properties and Manufacturing Process, and Possible Applications for COVID-19.** Polymers (Basel) 2021; 13Kchaou M, Alquraish M, Abuhasel K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809662>
92. **CeO(2) Nanoparticle-Containing Polymers for Biomedical Applications: A Review.** Polymers (Basel) 2021; 13Shcherbakov AB, Reukov VV, Yakimansky AV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802821>
93. **Multiple Sites on SARS-CoV-2 Spike Protein are Susceptible to Proteolysis by Cathepsins B, K, L, S, and V.** Protein Sci. 2021; Bollavaram K, Leeman TH, Lee MW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786919>
94. **Characterization of the SARS-CoV-2 E Protein: Sequence, Structure, Viroporin and Inhibitors.** Protein Sci. 2021; Cao Y, Yang R, Lee I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813796>
95. **The Mutation Profile of SARS-CoV-2 Is Primarily Shaped by the Host Antiviral Defense.** Viruses 2021; 13Azgari C, Kilinc Z, Turhan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801257>
96. **Site-Specific O-Glycosylation Analysis of SARS-CoV-2 Spike Protein Produced in Insect and Human Cells.** Viruses 2021; 13Bagdonaite I, Thompson AJ, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806155>
97. **Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions.** Viruses 2021; 13Brown AN, Strobel G, Hanrahan KC, Sears J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807769>
98. **SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations.** Viruses 2021; 13Grabowski F, Preibisch G, Giziński S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804556>
99. **In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2.** Viruses 2021; 13Kiani P, Scholey A, Dahl TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810356>
100. **Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope.** Viruses 2021; 13Makdasi E, Levy Y, Alcalay R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810465>
101. **mRNA-lncRNA Co-Expression Network Analysis Reveals the Role of lncRNAs in Immune Dysfunction during Severe SARS-CoV-2 Infection.** Viruses 2021; 13Mukherjee S, Banerjee B, Karasik D, Frenkel-Morgenstern M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802569>
102. **SARS-CoV-2 Infections in Animals: Reservoirs for Reverse Zoonosis and Models for Study.** Viruses 2021; 13Prince T, Smith SL, Radford AD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802857>
103. **Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.**

[Viruses](#) 2021; 13Singh J, Samal J, Kumar V *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33803400>

104. **Light Sheet Microscopy-Assisted 3D Analysis of SARS-CoV-2 Infection in the Respiratory Tract of the Ferret Model.** [Viruses](#) 2021; 13Zaeck LM, Scheibner D, Sehl J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807059>

Biomarkers - Genetics (147 articles)

1. **On-Chip Optical Detection of Viruses: A Review.** [Adv Photonics Res](#) 2021;2000150Shi Y, Li Z, Liu PY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786535>
2. **Severe vitamin D deficiency is not related to SARS-CoV-2 infection but may increase mortality risk in hospitalized adults: a retrospective case-control study in an Arab Gulf country.** [Aging Clin. Exp. Res.](#) 2021;1-8Alguwaihes AM, Sabico S, Hasanato R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788172>
3. **Blood viscosity of COVID-19 patient: a preliminary report.** [Am. J. Blood Res.](#) 2021; 11:93-95Joob B, Wiwanitkit V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796395>
4. **The association of ABO blood type with the risk and severity of COVID-19 infection.** [Am. J. Blood Res.](#) 2021; 11:53-58Mullins J, Al-Tarbsheh AH, Chieng H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796389>
5. **COVID-19 screening, testing and vaccination: Perceptions from emergency medicine residents and medical students.** [Am J Emerg Med](#) 2021; Cronin AO, Coyne CJ, Castillo EM, Dameff C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810920>
6. **Trends in cholesterol testing during the COVID-19 pandemic: COVID-19 and cholesterol testing.** [Am J Prev Cardiol](#) 2021; 6:100152Gumuser ED, Haidermota S, Finneran P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778798>
7. **Clotting in COVID-19: Is It All in the Genes?** [Am. J. Respir. Cell Mol. Biol.](#) 2021; Hernandez Cordero AI, Sin DD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784208>
8. **Coronavirus Testing Disparities Associated with Community Level Deprivation, Racial Inequalities, and Food Insecurity in West Virginia.** [Ann. Epidemiol.](#) 2021; Hendricks B, Paul R, Smith C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812965>
9. **Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection.** [Antiviral Res](#) 2021;105064Ciccosanti F, Di Rienzo M, Romagnoli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781803>
10. **Sequencing of SARS-CoV-2 genome using different nanopore chemistries.** [Appl. Microbiol. Biotechnol.](#) 2021;1-10González-Recio O, Gutiérrez-Rivas M, Peiró-Pastor R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792750>
11. **Implications of a highly transmissible variant of SARS-CoV-2 for children.** [Arch. Dis. Child.](#) 2021; Ratmann O, Bhatt S, Flaxman S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785527>
12. **Low type I interferon response in COVID-19 patients: Interferon response may be a potential treatment for COVID-19.** [Biomed Rep](#) 2021; 14:43Salman AA,

Waheed MH, Ali-Abdulsahib AA, Atwan ZW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786172>

13. **Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome.** Biomedicines 2021; 9Morales A, Rojo Rello S, Cristóbal H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810394>
14. **Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis.** Biomolecules 2021; 11Hardy E, Fernandez-Patron C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800947>
15. **Blood Levels of Galectin-9, an Immuno-Regulating Molecule, Reflect the Severity for the Acute and Chronic Infectious Diseases.** Biomolecules 2021; 11Iwasaki-Hozumi H, Chagan-Yasutan H, Ashino Y, Hattori T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804076>
16. **Rapid SARS-CoV-2 antigen detection potentiates early diagnosis of COVID-19 disease.** Biosci Trends 2021; Lv Y, Ma Y, Si Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776018>
17. **Sensitive electrochemical biosensor combined with isothermal amplification for point-of-care COVID-19 tests.** Biosens. Bioelectron. 2021; 182:113168Kim HE, Schuck A, Lee SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780853>
18. **Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak.** BMC Infect. Dis. 2021; 21:308Sabaka P, Koščálová A, Straka I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781216>
19. **Is Covid-19 community level testing effective in reaching at-risk populations? Evidence from spatial analysis of New Orleans patient data at walk-up sites.** BMC Public Health 2021; 21:632Hernandez JH, Karletsos D, Avegno J, Reed CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789647>
20. **Assessing critical gaps in COVID-19 testing capacity: the case of delayed results in Ecuador.** BMC Public Health 2021; 21:637Torres I, Sippy R, Sacoto F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794837>
21. **The use of denaturing solution as collection and transport media to improve SARS-CoV-2 RNA detection and reduce infection of laboratory personnel.** Braz. J. Microbiol. 2021:1-9Carvalho AF, Rocha RP, Gonçalves AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788178>
22. **High Levels of Interferon-Alpha Expressing Macrophages in Human Breast Milk During SARS-CoV-2 Infection: A Case Report.** Breastfeed. Med. 2021; Yu JC, Khodadadi H, Salles É L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781080>
23. **Interim guidance on the use of the Abbott ID NOW™ instrument and COVID-19 assay.** Can. Commun. Dis. Rep. 2020; 46:422-426. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776588>
24. **SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region.** Cancers (Basel) 2021; 13Ciniselli CM, Micali A, De Cecco L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801186>
25. **SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.** Cell 2021; Hoffmann M, Arora P, Groß R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794143>

26. **SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.** Cell Host Microbe 2021; Kuzmina A, Khalaila Y, Voloshin O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789085>
27. **Extracellular Vesicles Analysis in the COVID-19 Era: Insights on Serum Inactivation Protocols towards Downstream Isolation and Analysis.** Cells 2021; 10Frigerio R, Musicò A, Brucale M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806297>
28. **The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?** Cells 2021; 10Saravi B, Li Z, Lang CN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804069>
29. **Thymic Aging May Be Associated with COVID-19 Pathophysiology in the Elderly.** Cells 2021; 10Wang W, Thomas R, Oh J, Su DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808998>
30. **Role of Tissue Factor in the Pathogenesis of COVID-19 and the Possible Ways to Inhibit It.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211003983Cañas CA, Cañas F, Bautista-Vargas M, Bonilla-Abadía F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784877>
31. **The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysis.** Clin Epidemiol Glob Health 2021:100727Mahat RK, Panda S, Rathore V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778183>
32. **Immune Response Failure in Paucisymptomatic Long-Standing SARS-CoV-2 Spreaders.** Clin Pract 2021; 11:151-161Corrao S, Gervasi F, Di Bernardo F, Argano C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804326>
33. **Explaining machine learning based diagnosis of COVID-19 from routine blood tests with decision trees and criteria graphs.** Comput. Biol. Med. 2021; 132:104335Alves MA, Castro GZ, Oliveira BAS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812263>
34. **An automated COVID-19 detection based on fused dynamic exemplar pyramid feature extraction and hybrid feature selection using deep learning.** Comput. Biol. Med. 2021; 132:104356Ozyurt F, Tuncer T, Subasi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799219>
35. **Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel).** Curr. Oncol. 2021; 28:1249-1255Franco F, Guirado M, Martínez-Banaclocha N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809772>
36. **Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.** Curr. Probl. Cancer 2021:100739Fujii H, Tsuji T, Sugitani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810911>
37. **Serum IP-10 and IL-7 levels are associated with disease severity of coronavirus disease 2019.** Cytokine 2021:155500Wang GL, Gao HX, Wang YL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810947>

38. **Detecting severe courses early: Urine test helps in prediction of severe COVID-19 diseases.** Deutsche Apotheker Zeitung 2021; 161 Daubitz T.
39. **ASSOCIATION OF HYPERGLYCAEMIA WITH HOSPITAL MORTALITY IN NONDIABETIC COVID-19 PATIENTS: A COHORT STUDY.** Diabetes Metab. 2021;101254 Mamtani M, Athavale AM, Abraham M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781926>
40. **Spatial and Temporal Virus Load Dynamics of SARS-CoV-2: A Single-Center Cohort Study.** Diagnostics (Basel) 2021; 11 Alidjinou EK, Poissy J, Ouafi M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802451>
41. **Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays.** Diagnostics (Basel) 2021; 11 Dörschug A, Frickmann H, Schwanbeck J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802453>
42. **Clinical Evaluation of an Immunochromatographic-Based IgM/IgG Antibody Assay (GenBody™ COVI040) for Detection of Antibody Seroconversion in Patients with SARS-CoV-2 Infection.** Diagnostics (Basel) 2021; 11 Kim D, Lee J, Bal J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802842>
43. **Risk Score for Predicting In-Hospital Mortality in COVID-19 (RIM Score).** Diagnostics (Basel) 2021; 11 López-Escobar A, Madurga R, Castellano JM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33810534>
44. **Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy.** Diagnostics (Basel) 2021; 11 Polvere I, Parrella A, Casamassa G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803299>
45. **Modeling the Contribution of Male Testosterone Levels to the Duration of Positive COVID Testing among Hospitalized Male COVID-19 Patients.** Diagnostics (Basel) 2021; 11 Salciccia S, Eisenberg ML, Maggi M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804969>
46. **Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children - a cross-sectional observational study from southern India.** EBioMedicine 2021; 66:103317 Venkataraman A, Kumar NP, Hanna LE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813138>
47. **Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage.** Elife 2021; 10 Deinhardt-Emmer S, Wittschieber D, Sanft J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781385>
48. **Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, in British Columbia, Canada.** Emerg Infect Dis 2021; 27 Matic N, Lowe CF, Ritchie G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784237>
49. **Microfluidic-based virus detection methods for respiratory diseases.** Emergent Mater 2021;1-26 Tarim EA, Karakuzu B, Oksuz C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786415>
50. **Continuous Glucose Monitoring in the Hospital.** Endocrinol Metab (Seoul) 2021; Perez-Guzman MC, Shang T, Zhang JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789033>
51. **Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.** Eur J Clin Microbiol Infect Dis 2021;1-7 Vauloup-

Fellous C, Maylin S, Périllaud-Dubois C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782783>

52. **Clinical Predictors Of SARS-CoV-2 Neutralizing Antibody Titers In COVID-19 Convalescents: Implications For Convalescent Plasma Donor Recruitment.** Eur. J. Haematol. 2021; Focosi D, Franchini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780551>
53. **Increased B Cell activity with consumption of activated monocytes in severe COVID-19 patients.** Eur. J. Immunol. 2021; Kos I, Balensiefer B, Lesan V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788264>
54. **Upregulation of CCR4 in activated CD8+ T cells indicates enhanced lung-homing in patients with severe acute SARS-CoV-2 infection.** Eur. J. Immunol. 2021; Spoerl S, Kremer AN, Aigner M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784417>
55. **The association between vitamin D levels and the clinical severity and inflammation markers in pediatric COVID-19 patients: single-center experience from a pandemic hospital.** Eur. J. Pediatr. 2021;1-7 Bayramoğlu E, Akkoç G, Ağbaş A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788001>
56. **Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021.** Euro Surveill 2021; 26. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797392>
57. **A comparative review of immunoassays for COVID-19 detection.** Expert Rev. Clin. Immunol. 2021; Mohit E, Rostami Z, Vahidi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787412>
58. **A Saliva-Based RNA Extraction-Free Workflow Integrated With Cas13a for SARS-CoV-2 Detection.** Front Cell Infect Microbiol 2021; 11:632646 Azmi I, Faizan MI, Kumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796478>
59. **Dooming Phagocyte Responses: Inflammatory Effects of Endogenous Oxidized Phospholipids.** Front. Endocrinol. (Lausanne) 2021; 12:626842 Di Gioia M, Zaroni I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790857>
60. **The Double Edge Sword of Testosterone's Role in the COVID-19 Pandemic.** Front. Endocrinol. (Lausanne) 2021; 12:607179 Younis JS, Skorecki K, Abassi Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796068>
61. **The Unique Impact of COVID-19 on Human Gut Microbiome Research.** Front Med (Lausanne) 2021; 8:652464 Burchill E, Lymberopoulos E, Menozzi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796545>
62. **SARS-CoV-2 Testing of 11,884 Healthcare Workers at an Acute NHS Hospital Trust in England: A Retrospective Analysis.** Front Med (Lausanne) 2021; 8:636160 Hanrath AT, Schim van der Loeff I, Lendrem DW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777979>
63. **Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers.** Front Med (Lausanne) 2021; 8:595773 Xiao T, Wang Y, Yuan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791320>
64. **Detection of Microbial Agents in Oropharyngeal and Nasopharyngeal Samples of SARS-CoV-2 Patients.** Front. Microbiol. 2021; 12:637202 Seckar T, Lin X, Bose D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790878>

65. **Epidemiology, Clinical Features and Prognostic Factors of Pediatric SARS-CoV-2 Infection: Results From an Italian Multicenter Study.** Front Pediatr 2021; 9:649358 Garazzino S, Lo Vecchio A, Pierantoni L *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796491>
66. **Antibody titers and rapid antigen testing in elderly patients with SARS-CoV-2 pneumonia vs. staff of ICU and "Covid-19" wards.** GMS Hyg Infect Control 2021; 16:Doc11 Epstude J, Skiba M, Harsch IA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796439>
67. **Findings from the first public COVID-19 temporary test centre in Hong Kong.** Hong Kong Med. J. 2021; Leung WLH, Yu ELM, Wong SC *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33790053>
68. **Haemophilus influenzae and SARS-CoV-2: Is there a role for investigation?** Indian J. Med. Microbiol. 2021; Borkakoty B, Bali NK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781659>
69. **Evaluating the efficiency of specimen (sample) pooling for real-time PCR based diagnosis of COVID-19.** Indian J. Med. Microbiol. 2021; Shukla S, Upadhyay V, Maurya VK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781658>
70. **Prevalence of COVID-19 in healthcare professionals working in hospital emergencies during first wave peak in 2020, Porto Alegre - Brazil.** Infect Control Hosp Epidemiol 2021;1-8 Dubiela ALF, Dalla Lana DF, Aerts APK *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775261>
71. **The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive.** Infect Dis Poverty 2021; 10:45 Zhao H, Zhang C, Chen XX *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789752>
72. **Molecular epidemiology analysis of early variants of SARS-CoV-2 reveals the potential impact of mutations P504L and Y541C (NSP13) in the clinical COVID-19 outcomes.** Infect Genet Evol 2021:104831 Cao C, He L, Tian Y *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798758>
73. **Detectable respiratory SARS-CoV-2 RNA is associated with low vitamin D levels and high social deprivation.** Int J Clin Pract 2021:e14166 Livingston M, Plant A, Dunmore S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797849>
74. **Infectious Diseases Seeker (IDS): An Innovative Tool for Prompt Identification of Infectious Diseases during Outbreaks.** Int J Environ Res Public Health 2021; 18Baldassi F, Carestia M, Moramarco S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804605>
75. **Vitamin D Levels Are Reduced at the Time of Hospital Admission in Sicilian SARS-CoV-2-Positive Patients.** Int J Environ Res Public Health 2021; 18Gaudio A, Murabito AR, Agodi A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801759>
76. **An Overview of Thermal Infrared Imaging-Based Screenings during Pandemic Emergencies.** Int J Environ Res Public Health 2021; 18Perpetuini D, Filippini C, Cardone D, Merla A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810086>
77. **Experimental Investigation of Aerosol and CO(2) Dispersion for Evaluation of COVID-19 Infection Risk in a Concert Hall.** Int J Environ Res Public Health 2021; 18Schade W, Reimer V, Seipenbusch M, Willer U.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809493>

78. **COVID-19 Seroprevalence among Healthcare Workers of a Large COVID-19 Hospital in Rome Reveals Strengths and Limits of Two Different Serological Tests.** Int J Environ Res Public Health 2021; 18Vetrugno G, La Milia DI, D'Ambrosio F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800721>
79. **Circulating activated neutrophils in COVID-19: an independent predictor for mechanical ventilation and death.** Int J Infect Dis 2021; Dennison D, Khabori MA, Mamari SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781906>
80. **Emergence and outcome of the SARS-CoV-2 "Marseille-4" variant.** Int J Infect Dis 2021; Fournier PE, Colson P, Levasseur A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785459>
81. **The Role of Immunogenetics in COVID-19.** Int J Mol Sci 2021; 22Pojero F, Candore G, Caruso C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807915>
82. **Exosomes from COVID-19 Patients Carry Tenascin-C and Fibrinogen- β in Triggering Inflammatory Signals in Cells of Distant Organ.** Int J Mol Sci 2021; 22Sur S, Khatun M, Steele R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804769>
83. **In silico characterization of mutations circulating in SARS-CoV-2 structural proteins.** J Biomol Struct Dyn 2021:1-16Periwal N, Rathod SB, Pal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797336>
84. **Arginase 1 (Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy.** J Clin Med 2021; 10Derakhshani A, Hemmat N, Asadzadeh Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806290>
85. **Characteristics and Detection Rate of SARS-CoV-2 in Alternative Sites and Specimens Pertaining to Dental Practice: An Evidence Summary.** J Clin Med 2021; 10Shirazi S, Stanford CM, Cooper LF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802043>
86. **Cytokeratin 18 cell death assays as biomarkers for quantification of apoptosis and necrosis in COVID-19: a prospective, observational study.** J. Clin. Pathol. 2021; Henry BM, Cheruiyot I, Benoit SW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789919>
87. **SARS-CoV-2 Positivity in Asymptomatic-Screened Dental Patients.** J Dent Res 2021:220345211004849Conway DI, Culshaw S, Edwards M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779355>
88. **Evaluation for the Feasibility and Accuracy of Freestyle Libre Flash Glucose Monitoring System Used By COVID-19 Patients in Intensive Care Unit.** J. Diabetes 2021; Zhang Y, Liu X, Zhang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787006>
89. **Prognostic Implication of Baseline Sarcopenia for Length of Hospital Stay and Survival in Patients with Coronavirus Disease 2019.** J Gerontol A Biol Sci Med Sci 2021; Kim JW, Yoon JS, Kim EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780535>
90. **SARS-CoV-2 diagnostics: Towards a more comprehensive approach to routine patient testing.** J. Immunol. Methods 2021:113044Carter C, Hughes P, McHugh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785349>

91. **Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients.** J. Immunol. Methods 2021;113046Cook AM, Faustini SE, Williams LJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775672>
92. **Association between self-reported signs and symptoms and SARS-CoV-2 antibody detection in UK key workers.** J Infect 2021; Mulchandani R, Taylor-Philips S, Jones HE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775704>
93. **Evaluation of four commercial severe acute respiratory coronavirus 2 antibody tests.** J Infect Chemother 2021; Ashizawa N, Takazono T, Ohyama K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781691>
94. **False positive results in severe acute respiratory coronavirus 2 (SARS-CoV-2) rapid antigen tests for inpatients.** J Infect Chemother 2021; Itoh K, Kawamitsu T, Osaka Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810971>
95. **Prolonged viral clearance of severe acute respiratory syndrome coronavirus 2 in the older aged population.** J Infect Chemother 2021; Ueno A, Kawasuji H, Miyajima Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781692>
96. **Role of biochemical markers in the monitoring of COVID-19 patients.** J Med Biochem 2021; 40:115-128Letelier P, Encina N, Morales P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776561>
97. **Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.** J Med Virol 2021; Callegaro A, Borleri D, Farina C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788281>
98. **A reduction of the number of assays and turnaround time by optimizing Polymerase Chain Reaction (PCR) pooled testing for SARS-CoV-2.** J Med Virol 2021; Christos P, Vasiliki V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783005>
99. **Downregulation of type III interferons in patients with severe COVID-19.** J Med Virol 2021; Fukuda Y, Homma T, Inoue H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811680>
100. **Field evaluation of COVID-19 antigen tests versus RNA based detection: Potential lower sensitivity compensated by immediate results, technical simplicity and low cost.** J Med Virol 2021; Matsuda EM, de Campos IB, de Oliveira IP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788270>
101. **Elevated Monocyte to Lymphocyte Ratio and Increased Mortality among Patients with Chronic Kidney Disease Hospitalized for COVID-19.** J Pers Med 2021; 11Dávila-Collado R, Jarquín-Durán O, Solís-Vallejo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809858>
102. **Predictive Biomarkers of COVID-19 Severity in SARS-CoV-2 Infected Patients with Obesity and Metabolic Syndrome.** J Pers Med 2021; 11Perpiñan C, Bertran L, Terra X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809913>
103. **White Blood Cells and Severe COVID-19: A Mendelian Randomization Study.** J Pers Med 2021; 11Sun Y, Zhou J, Ye K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809027>
104. **The incubation period of coronavirus disease (COVID-19): A tremendous public health threat-Forecasting from publicly available case data in India.** J Public Aff 2021:e2619Dwivedi R, Athe R, Mahesh K, Modem PK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786017>

105. **Emphasizing truthfulness in COVID-19 test declarations.** J Public Health (Oxf). 2021; Gozum IEA, Carreon ADV, Manansala MM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782683>
106. **Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies.** J. Steroid Biochem. Mol. Biol. 2021;105883Petrelli F, Luciani A, Perego G *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775818>
107. **Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies.** J Transl Med 2021; 19:139Sciacchitano S, De Vitis C, D'Ascanio M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794925>
108. **Proteinase K treatment in absence of RNA isolation classical procedures is a quick and cheaper alternative for SARS-CoV-2 molecular detection.** J. Virol. Methods 2021;114131Mallmann L, Hermann BS, Schallenberger K *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798606>
109. **A Novel Method for Conserved Sequence Extraction with Prospective Mutation Prediction for SARS-CoV-2 PCR Primer Design.** J. Virol. Methods 2021;114146Portakal SH, Kanat B, Sayan M *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812944>
110. **Platelets and the Endothelium: Active Participants in Severe COVID-19 Infection.** JACC Basic Transl Sci 2021; 6:219-221Parker WAE, Storey RF.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778209>
111. **Assessment of Galectin-1, Galectin-3, and PGE2 Levels in Patients with COVID-19.** Jpn. J. Infect. Dis. 2021; Kazancioglu S, Yilmaz FM, Bastug A *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33790073>
112. **A family case of COVID-19 pneumonia with different chest CT features and duration of SARS-CoV-2 shedding: a case report from Japan.** Jpn. J. Infect. Dis. 2021; Ochiai S, Kama Y, Hirai K *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790072>
113. **Molecular profile of oral fluid in new coronavirus infection.** Klin. Lab. Diagn. 2021; 66:133-138Gilmiyarova FN, Gussyakova OA, Konstantinov DY *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33793111>
114. **In Vitro Evaluation of the Activity of Terpenes and Cannabidiol against Human Coronavirus E229.** Life (Basel) 2021; 11Chatow L, Nudel A, Neshet I *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33805385>
115. **Testing children with COVID-19 symptoms: what are parents' intentions?** Med. J. Aust. 2021; Measey MA, Hoq M, Rhodes AL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811342>
116. **An update: the emerging evidence of complement involvement in COVID-19.** Med. Microbiol. Immunol. 2021; Li Q, Chen Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811541>
117. **SARS-CoV-2 Detection in Fecal Sample from a Patient with Typical Findings of COVID-19 Pneumonia on CT but Negative to Multiple SARS-CoV-2 RT-PCR Tests on Oropharyngeal and Nasopharyngeal Swab Samples.** Medicina (Kaunas) 2021; 57Brojna B, Brojna C, Petrillo M *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804646>

118. **Quantitative Spectrochip-Coupled Lateral Flow Immunoassay Demonstrates Clinical Potential for Overcoming Coronavirus Disease 2019 Pandemic Screening Challenges.** Micromachines (Basel) 2021; 12Hung KF, Hung CH, Hong C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803850>
119. **Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG.** Microorganisms 2021; 9Eberhardt KA, Dewald F, Heger E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807490>
120. **Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection.** Microorganisms 2021; 9Favresse J, Euchet C, Elsen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800489>
121. **SARS-CoV-2 N501Y Introductions and Transmissions in Switzerland from Beginning of October 2020 to February 2021-Implementation of Swiss-Wide Diagnostic Screening and Whole Genome Sequencing.** Microorganisms 2021; 9Goncalves Cabecinhas AR, Roloff T, Stange M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806013>
122. **A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion.** Nanomaterials (Basel) 2021; 11Azad T, Rezaei R, Singaravelu R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809836>
123. **Folate Levels in Patients Hospitalized with Coronavirus Disease 2019.** Nutrients 2021; 13Meisel E, Efros O, Bleier J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801194>
124. **[Possibilities and pitfalls of virus antigen and antibody detection of SARS-CoV-2].** Orv. Hetil. 2021; 162:563-570Medgyaszai M, Péterfi Z, Valkó A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798101>
125. **Mutations in Animal SARS-CoV-2 Induce Mismatches with the Diagnostic PCR Assays.** Pathogens 2021; 10Elaswad A, Fawzy M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808783>
126. **The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection.** Pathogens 2021; 10Kaseb AO, Mohamed YI, Malek AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809851>
127. **Evaluation of "Caterina assay": An Alternative Tool to the Commercialized Kits Used for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Identification.** Pathogens 2021; 10Orrù G, Scano A, Fais S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802049>
128. **Molecular Analysis of SARS-CoV-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level.** Pathogens 2021; 10Sallam M, Mahafzah A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807556>
129. **Differential clinic in children infected by SARS-CoV-2, traceability of contacts and cost-effectiveness of diagnostic tests: Cross-sectional observational study.** An Pediatr (Engl Ed) 2021; Fiel-Ozores A, González-Durán ML, Novoa-Carballal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778108>
130. **Characterization of the SARS-CoV-2 E Protein: Sequence, Structure, Viroporin and Inhibitors.** Protein Sci. 2021; Cao Y, Yang R, Lee I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813796>

131. **C1q Complement/Tumor Necrosis Factor-Associated Proteins in Cardiovascular Disease and COVID-19.** Proteomes 2021; 9Xie Y, Meng Z, Gao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804408>
132. **The use of neutrophil-to-lymphocyte ratio (NLR) as a marker for COVID-19 infection in Saudi Arabia: A case-control retrospective multicenter study.** Saudi Med. J. 2021; 42:370-376Sayed AA, Allam AA, Sayed AI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795491>
133. **Spatial technologies to strengthen traditional testing for SARS-CoV-2.** Trends Microbiol. 2021; Yang S, Pan X, Zeng P, Jia P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775546>
134. **Scores based on neutrophil percentage and lactate dehydrogenase with or without oxygen saturation predict hospital mortality risk in severe COVID-19 patients.** Virol J 2021; 18:67Fan X, Zhu B, Nouri-Vaskeh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789703>
135. **Genome-wide Analysis of 10664 SARS-CoV-2 Genomes to Identify Virus Strains in 73 Countries based on Single Nucleotide Polymorphism.** Virus Res. 2021:198401Ghosh N, Saha I, Sharma N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781798>
136. **The Mutation Profile of SARS-CoV-2 Is Primarily Shaped by the Host Antiviral Defense.** Viruses 2021; 13Azgari C, Kilinc Z, Turhan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801257>
137. **Adjusting the Cut-Off and Maximum Pool Size in RT-qPCR Pool Testing for SARS-CoV-2.** Viruses 2021; 13Costa MS, Sato HI, Rocha RP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810324>
138. **Evaluation of a Lyophilized CRISPR-Cas12 Assay for a Sensitive, Specific, and Rapid Detection of SARS-CoV-2.** Viruses 2021; 13Curti LA, Primost I, Valla S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807908>
139. **Multiple Early Introductions of SARS-CoV-2 to Cape Town, South Africa.** Viruses 2021; 13Engelbrecht S, Delaney K, Kleinhans B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810168>
140. **Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.** Viruses 2021; 13Fricke-Galindo I, Falfán-Valencia R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807592>
141. **SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations.** Viruses 2021; 13Grabowski F, Preibisch G, Giziński S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804556>
142. **Detection and Genome Sequencing of SARS-CoV-2 in a Domestic Cat with Respiratory Signs in Switzerland.** Viruses 2021; 13Klaus J, Meli ML, Willi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802899>
143. **mRNA-lncRNA Co-Expression Network Analysis Reveals the Role of lncRNAs in Immune Dysfunction during Severe SARS-CoV-2 Infection.** Viruses 2021; 13Mukherjee S, Banerjee B, Karasik D, Frenkel-Morgenstern M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802569>
144. **Profiles of Peripheral Immune Cells of Uncomplicated COVID-19 Cases with Distinct Viral RNA Shedding Periods.** Viruses 2021; 13Putri DU, Wang CH, Tseng PC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808906>

145. **Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19.** *Viruses* 2021; 13Qeadan F, Tingey B, Gu LY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807920>
146. **Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.** *Viruses* 2021; 13Singh J, Samal J, Kumar V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33803400>
147. **Repeated SARS-CoV-2 Positivity: Analysis of 123 Cases.** *Viruses* 2021; 13Váncsa S, Dembrovsky F, Farkas N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808867>

Children (46 articles)

1. **The Impact of the COVID-19 Pandemic on Children's Health in Portugal: The Parental Perspective.** *Acta Med Port* 2021; Poppe M, Aguiar B, Sousa R, Oom P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775275>
2. **SARS-CoV-2 positive child—What to do if inhalation induction of anesthesia is unavoidable?** *Anaesthesist* 2021; Leister N, Yücestepe S, Ulrichs C *et al.*
3. **Implications of a highly transmissible variant of SARS-CoV-2 for children.** *Arch. Dis. Child.* 2021; Ratmann O, Bhatt S, Flaxman S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785527>
4. **Finding ways for children's doctors to care for big 'Kids' and save adults in a pandemic.** *Arch. Dis. Child.* 2021; Robison J, Remy KE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785528>
5. **Psychosocial health of school-aged children during the initial COVID-19 safer-at-home school mandates in Florida: a cross-sectional study.** *BMC Public Health* 2021; 21:603McKune SL, Acosta D, Diaz N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781220>
6. **Acute haemorrhagic oedema of infancy as a manifestation of COVID-19.** *BMJ Case Rep.* 2021; 14Saraiva BM, Lobato MB, Santos E, Garcia AM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782070>
7. **COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE).** *Bull Cancer* 2021; Rouger-Gaudichon J, Bertrand Y, Boissel N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781551>
8. **A Longitudinal Study of Subjective Daytime Sleepiness Changes in Elementary School Children Following a Temporary School Closure Due to COVID-19.** *Children (Basel)* 2021; 8Komada Y, Ishibashi Y, Hagiwara S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804339>
9. **Telemedicine in Pediatric Infectious Diseases.** *Children (Basel)* 2021; 8Pappalardo M, Fanelli U, Chiné V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800549>
10. **Effects of the COVID-19 Lockdown on Portuguese Children's Motor Competence.** *Children (Basel)* 2021; 8Pombo A, Luz C, de Sá C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33800046>

11. **The Relationship between COVID-19 and Innate Immunity in Children: A Review.** Children (Basel) 2021; 8:Valentini P, Sodero G, Buonsenso D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808490>
12. **Influence of COVID-19 pandemic on paediatric dental attendance.** Clin Oral Investig 2021;1-7Üstün N, Akgöl BB, Bayram M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786650>
13. **Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children - a cross-sectional observational study from southern India.** EBioMedicine 2021; 66:103317Venkataraman A, Kumar NP, Hanna LE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813138>
14. **The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPCA.** Ecancermedicalscience 2021; 15:1187Pritchard-Jones K, de CVAS, Esiashvili N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777180>
15. **Early impact of school closure and social distancing for COVID-19 on the number of inpatients with childhood non-COVID-19 acute infections in Japan.** Eur. J. Pediatr. 2021;1-8Kishimoto K, Bun S, Shin JH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33791861>
16. **Clinical characteristics of COVID-19 in neonates and young infants.** Eur. J. Pediatr. 2021;1-5Spoulou V, Noni M, Koukou D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786658>
17. **Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020.** Euro Surveill 2021; 26Sermet-Gaudelus I, Temmam S, Huon C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33797390>
18. **Case Report: SARS-CoV-2 Infection in a Child With Suprasellar Tumor and Hypothalamic-Pituitary Failure.** Front. Endocrinol. (Lausanne) 2021; 12:596654Gaudino R, Orlandi V, Cavarzere P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796066>
19. **COVID-19 in Children With Liver Disease.** Front Pediatr 2021; 9:616381Di Giorgio A, Hartleif S, Warner S, Kelly D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777864>
20. **Epidemiology, Clinical Features and Prognostic Factors of Pediatric SARS-CoV-2 Infection: Results From an Italian Multicenter Study.** Front Pediatr 2021; 9:649358Garazzino S, Lo Vecchio A, Pierantoni L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796491>
21. **Surveillance of Acute SARS-CoV-2 Infections in School Children and Point-Prevalence During a Time of High Community Transmission in Switzerland.** Front Pediatr 2021; 9:645577Kriemler S, Ulyte A, Ammann P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796490>
22. **Effect of COVID-19-Related Home Confinement on Sleep Quality, Screen Time and Physical Activity in Tunisian Boys and Girls: A Survey.** Int J Environ Res Public Health 2021; 18Abid R, Ammar A, Maaloul R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809697>

23. **Daily Life Changes and Life Satisfaction among Korean School-Aged Children in the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Choi J, Park Y, Kim HE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807042>
24. **Mental Health of Children and Adolescents Amidst COVID-19 and Past Pandemics: A Rapid Systematic Review.** Int J Environ Res Public Health 2021; 18Meherali S, Punjani N, Louie-Poon S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810225>
25. **Impact of COVID-19 Restrictions on Western Australian Children's Physical Activity and Screen Time.** Int J Environ Res Public Health 2021; 18Nathan A, George P, Ng M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807520>
26. **The Impact of COVID-19 on High School Student-Athlete Experiences with Physical Activity, Mental Health, and Social Connection.** Int J Environ Res Public Health 2021; 18Shepherd HA, Evans T, Gupta S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805249>
27. **Association between Viral Infections and Risk of Autistic Disorder: An Overview.** Int J Environ Res Public Health 2021; 18Shuid AN, Jayusman PA, Shuid N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802042>
28. **The effects of the COVID-19 pandemic on children's lifestyles and anxiety levels.** J. Child Adolesc. Psychiatr. Nurs. 2021; Zengin M, Yayan EH, Vicnelioğlu E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793012>
29. **Implementation of telehealth during COVID-19: Implications for providing behavioral health services to pediatric patients.** J Child Health Care 2021;13674935211007329Frye WS, Gardner L, Campbell JM, Katzenstein JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779352>
30. **The impact of lockdown on sleep patterns of children and adolescents with ADHD.** J. Clin. Sleep Med. 2021; Bruni O, Giallonardo M, Sacco R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792536>
31. **Global Experiences of Pediatric Palliative Care Teams During the First 6 Months of the SARS-CoV-2 Pandemic.** J Pain Symptom Manage 2021; McNeil MJ, Kaye EC, Vedaraju Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794302>
32. **Multisystem Inflammatory Syndrome in a Child with Scrub Typhus and Macrophage Activation Syndrome.** J. Trop. Pediatr. 2021; 67Gupta A, Gill A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787904>
33. **Testing children with COVID-19 symptoms: what are parents' intentions?** Med. J. Aust. 2021; Measey MA, Hoq M, Rhodes AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811342>
34. **[Impact of the COVID-19 pandemic on appendicitis in COVID-19 negative children].** Monatsschr Kinderheilkd 2021;1-6Meyer T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782626>
35. **Lifestyle Changes and Determinants of Children's and Adolescents' Body Weight Increase during the First COVID-19 Lockdown in Greece: The COV-EAT Study.** Nutrients 2021; 13Androutsos O, Perperidi M, Georgiou C, Chouliaras G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805678>
36. **[Epidemiological and clinical profile of children with Coronavirus disease (COVID-19) at the Center for the Treatment of Epidemics and Infection**

- Prevention (CTEIP) of the University Hospital of Donka in Conakry].** *Pan Afr. Med. J.* 2020; 37:363Camara E, Barry IK, Diallo FB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796176>
37. **Differential clinic in children infected by SARS-CoV-2, traceability of contacts and cost-effectiveness of diagnostic tests: Cross-sectional observational study.** *An Pediatr (Engl Ed)* 2021; Fiel-Ozores A, González-Durán ML, Novoa-Carballal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778108>
 38. **Mental health in Japanese children during school closures due to the COVID-19.** *Pediatr. Int.* 2021; Saito M, Kikuchi Y, Lefor AK, Hoshina M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792099>
 39. **Effectiveness of Preventive Measures in Keeping Low Prevalence of SARS-CoV-2 Infection in Health Care Workers in a Referral Children's Hospital in Southern Italy.** *Pediatr. Rep.* 2021; 13:118-124Caselli D, Loconsole D, Dario R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806472>
 40. **COVID-19 infection in a pediatric kidney transplant population: A single-center experience.** *Pediatr. Transplant.* 2021:e14018Singer PS, Sethna C, Molmenti E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813782>
 41. **COVID-19 in children and adolescents in Europe.** *Pneumologie* 2021; 75Lorenz J.
 42. **Clinical and radiological findings for the new multisystem inflammatory syndrome in children associated with COVID-19.** *Radiologia (Roma)* 2021; Sánchez-Oro R, Fatahi Bandpey ML, García Martínez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785227>
 43. **[COVID 19 infection in young patient with pectus excavatum].** *Rev. Fac. Cien. Med. Univ. Nac. Cordoba* 2021; 78:52-56Puglla Sánchez LR, Sinche Cueva CA, Quilismal Guanochoanga NC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787023>
 44. **Clinical characteristics and outcomes of children with COVID-19 in Saudi Arabia.** *Saudi Med. J.* 2021; 42:391-398Alnajjar AA, Dohain AM, Abdelmohsen GA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795494>
 45. **Mental Health and Physical Activity among Children and Adolescents during the COVID-19 Pandemic.** *Tohoku J. Exp. Med.* 2021; 253:203-215Okuyama J, Seto S, Fukuda Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775993>
 46. **The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Generation 2 questionnaire data capture May-July 2020.** *Wellcome Open Res* 2020; 5:278Smith D, Northstone K, Bowring C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791441>

Clinical Features (42 articles)

1. **The interest of fluticasone nasal spray in COVID-19 related anosmia is still not demonstrated.** *Am. J. Otolaryngol.* 2021:103008Lechien JR, Hoch CC, Vaira LA, Saussez S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810883>
2. **Recovery rate and factors associated with smell and taste disruption in patients with coronavirus disease 2019.** *Am. J. Otolaryngol.* 2020; 42:102648Parente-Arias P, Barreira-Fernandez P, Quintana-Sanjuas A, Patiño-Castiñeira B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799139>

3. **Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines.** Ann. Allergy. Asthma. Immunol. 2021; Kelso JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781933>
4. **Dermatology and COVID-19: Much knowledge to date but still a lot to discover.** Ann. Dermatol. Venereol. 2021; Le Cleach L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781568>
5. **Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection.** Biomedicines 2021; 9Donegani MI, Miceli A, Pardini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808956>
6. **Oral Symptoms Associated with COVID-19 and Their Pathogenic Mechanisms: A Literature Review.** Dent J (Basel) 2021; 9Tsuchiya H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799583>
7. **Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review.** Dermatol Ther (Heidelb) 2021; Gisondi P, Di Leo S, Bellinato F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811315>
8. **No smell in the nose: New findings on the pathogenesis of the smell disorder in COVID-19.** Deutsche Apotheker Zeitung 2021; 161Feldmeier H.
9. **Acute Labyrinthitis Revealing COVID-19.** Diagnostics (Basel) 2021; 11Perret M, Bernard A, Rahmani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803267>
10. **Recurrent keratoconjunctivitis as the sole manifestation of COVID-19 infection: A case report.** Eur. J. Ophthalmol. 2021:11206721211006583Hutama SA, Alkaff FF, Intan RE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781126>
11. **The association between vitamin D levels and the clinical severity and inflammation markers in pediatric COVID-19 patients: single-center experience from a pandemic hospital.** Eur. J. Pediatr. 2021:1-7Bayramoğlu E, Akkoç G, Ağbaş A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788001>
12. **Clinical characteristics of COVID-19 in neonates and young infants.** Eur. J. Pediatr. 2021:1-5Spoulou V, Noni M, Koukou D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786658>
13. **Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.** Front. Immunol. 2021; 12:645013Tang KT, Hsu BC, Chen DY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777042>
14. **Identifying Clinical Phenotypes in Moderate to Severe Acute Respiratory Distress Syndrome Related to COVID-19: The COVADIS Study.** Front Med (Lausanne) 2021; 8:632933Lascarrou JB, Gaultier A, Soumagne T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777977>
15. **Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers.** Front Med (Lausanne) 2021; 8:595773Xiao T, Wang Y, Yuan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791320>
16. **Atypical Presentations among Older Adults with COVID-19 Disease: A Need for Broadening the Differential Diagnosis.** Gerontol Geriatr Med 2021; 7:2333721421999313Oluabunwa U, Turner J, Johnson T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786339>
17. **Clinical Features of the 60 Years and Older Patients Infected with 2019 Novel Coronavirus: Can We Predict Mortality Earlier?** Gerontology 2021:1-8Genc

Yavuz B, Colak S, Guven R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784699>

18. **Ocular Involvement of SARS-CoV-2 in a Polish Cohort of COVID-19-Positive Patients.** Int J Environ Res Public Health 2021; 18Dolar-Szczasny J, Toro MD, Dworżańska A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809199>
19. **COVID-19, a tale of two peaks: patients' characteristics, treatments, and clinical outcomes.** Intern Emerg Med 2021; Banai A, Taieb P, Furie N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797029>
20. **Analysis of the Clinical and Epidemiological Meaning of Screening Test for SARS-CoV-2: Considerations in the Chronic Kidney Disease Patients during the COVID-19 Pandemic.** J Clin Med 2021; 10Martino F, Amici G, Grandesso S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803083>
21. **Smell and Taste Loss Recovery Time in COVID-19 Patients and Disease Severity.** J Clin Med 2021; 10Printza A, Katotomichelakis M, Valsamidis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801170>
22. **Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection.** J Clin Med 2021; 10Riou M, Oulehri W, Momas C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806800>
23. **Impact of COVID-19 at the Ocular Level: A Citation Network Study.** J Clin Med 2021; 10Sánchez-Tena M, Martínez-Pérez C, Villa-Collar C, Álvarez-Peregrina C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804977>
24. **Incidence of delayed asymptomatic COVID-19 recurrences in a 6-month longitudinal study.** J Infect 2021; Masiá M, Padilla S, Galiana A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794262>
25. **Association between self-reported signs and symptoms and SARS-CoV-2 antibody detection in UK key workers.** J Infect 2021; Mulchandani R, Taylor-Philips S, Jones HE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775704>
26. **Comparison of the Simultaneous Conjunctiva and Oropharynx-Nasopharynx Swab Results in Patients Applying to the SARS-CoV-2 Outpatient Clinic for the First Time.** J Med Virol 2021; Gunduz A, Firat M, Turkoglu G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783859>
27. **A family case of COVID-19 pneumonia with different chest CT features and duration of SARS-CoV-2 shedding: a case report from Japan.** Jpn. J. Infect. Dis. 2021; Ochiai S, Kama Y, Hirai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790072>
28. **CPMPARISON between COVID-19 and MERS demographic data in Saudi Arabia: a retrospective study.** Libyan J. Med. 2021; 16:1910195Mohamed R, Abdullah Thagfan F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797350>
29. **Frequency and predictive validity of olfactory and taste dysfunction in patients with SARS-CoV-2 infection.** Med Clin (Barc) 2021; Pérula de Torres L, González-Lama J, Jiménez García C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775400>
30. **Risk Factors for Olfactory and Gustatory Dysfunctions in Patients with SARS-CoV-2 Infection.** Neuroepidemiology 2021;1-8Galluzzi F, Rossi V, Bosetti C, Garavello W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794531>

31. **Severe Intraocular Inflammation following Hydrophilic Acrylic Phakic Intraocular Lens Implantation in A Case with Concealed History of COVID-19: A Case Report and Literature Review.** Ocul Immunol Inflamm 2021;1-4Toprak I, Cetin EN, Gunes CE, Martin-Seker C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793389>
32. **Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time.** Open Forum Infect Dis 2021; 8:ofab090Rodebaugh TL, Frumkin MR, Reiersen AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796601>
33. **Sustained Chemosensory Dysfunction during the COVID-19 Pandemic.** ORL J. Otorhinolaryngol. Relat. Spec. 2021;1-10Schwab J, Jensen CD, Fjaeldstad AW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789309>
34. **Clinical and epidemiological characteristics of 646 hospitalised SARS-Cov-2 positive patients in Rivers State Nigeria: a prospective observational study.** Pan Afr. Med. J. 2021; 38:25Alasia D, Owhonda G, Maduka O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777293>
35. **[Epidemiological and clinical profile of children with Coronavirus disease (COVID-19) at the Center for the Treatment of Epidemics and Infection Prevention (CTEIP) of the University Hospital of Donka in Conakry].** Pan Afr. Med. J. 2020; 37:363Camara E, Barry IK, Diallo FB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796176>
36. **Not all anosmia and fever was COVID-19 infection: a case report.** Pan Afr. Med. J. 2020; 37:371Koffi NP, Abad CEA, Miloud G, Brahim EM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796184>
37. **COVID-19 und Kopfschmerzen COVID-19 and Headaches.** Praxis 2021; 110:201-206Pohl H, Gantenbein AR.
38. **Skin and gastrointestinal symptoms in COVID-19.** Prz Gastroenterol 2020; 15:301-308Ciechanowicz P, Lewandowski K, Szymańska E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777269>
39. **Clinical and radiological findings for the new multisystem inflammatory syndrome in children associated with COVID-19.** Radiologia (Roma) 2021; Sánchez-Oro R, Fatahi Bandpey ML, García Martínez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785227>
40. **Central Retinal Artery Occlusion in Patients with COVID-19: Imaging for Underlying Causes.** Radiology 2021;210479Au SCL, Ko CKL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787341>
41. **Clinical characteristics and outcomes of children with COVID-19 in Saudi Arabia.** Saudi Med. J. 2021; 42:391-398Alnajjar AA, Dohain AM, Abdelmohsen GA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795494>
42. **Orbital apex syndrome in COVID-19 patient, a case report.** Vis J Emerg Med 2021; 23:101006Bagheri M, Jafari A, Jafari S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778167>

CNS (23 articles)

1. **Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay.** Acta Neurol. Belg. 2021; Galassi G, Marchioni A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811309>
2. **Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.** Acta Neurol. Belg. 2021; Županić S, Perić Šitum M, Majdak M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797054>
3. **Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection.** Biomedicines 2021; 9Donegani MI, Miceli A, Pardini M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808956>
4. **Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.** BMC Neurol. 2021; 21:138Yassin A, Nawaiseh M, Shaban A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784985>
5. **Posterior Reversible Encephalopathy Syndrome in a Patient With SARS-CoV-2 Infection Treated With Tocilizumab.** Cureus 2021; 13:e13475Talluri K, Lall N, Moreno MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777563>
6. **Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint.** Curr. Neuroparmacol. 2021; Alborghetti M, Bellucci G, Gentile A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784961>
7. **No smell in the nose: New findings on the pathogenesis of the smell disorder in COVID-19.** Deutsche Apotheker Zeitung 2021; 161Feldmeier H.
8. **Acute Labyrinthitis Revealing COVID-19.** Diagnostics (Basel) 2021; 11Perret M, Bernard A, Rahmani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803267>
9. **Multiple sclerosis patients and COVID-19.** Egypt J Neurol Psychiatr Neurosurg 2021; 57:43Mado H, Adamczyk-Sowa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776407>
10. **Interactions of SARS-CoV-2 with the Blood-Brain Barrier.** Int J Mol Sci 2021; 22Erickson MA, Rhea EM, Knopp RC, Banks WA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33800954>
11. **Changes in EEG Recordings in COVID-19 Patients as a Basis for More Accurate QEEG Diagnostics and EEG Neurofeedback Therapy: A Systematic Review.** J Clin Med 2021; 10Kopańska M, Banaś-Ząbczyk A, Łagowska A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809957>
12. **Neurological manifestations of COVID-19 in confirmed and probable cases: A descriptive study from a large tertiary care center.** J. Clin. Neurosci. 2021; 86:97-102Yuksel H, Gursoy GT, Dirik EB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775354>
13. **COVID-19 encephalopathy: clinical and neurobiological features.** J Med Virol 2021; Uginet M, Breville G, Assal F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782993>
14. **Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients.** J Nucl Med 2021; Blazhenets G, Schröter N, Bormann T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789937>
15. **Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Parkinson's Disease and Their Caregivers: A Single-Center Survey in Tochigi**

- Prefecture.** J. Parkinsons Dis. 2021; Suzuki K, Numao A, Komagamine T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33780375>
16. **COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?** Mult Scler Relat Disord 2021; 51:102915 Etemadifar M, Sedaghat N, Aghababaei A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799284>
 17. **Neuromuscular complications of SARS-CoV-2 infections—Part 1: peripheral nerves.** Nervenarzt 2021; Lehmann HC, Schoser B, Wunderlich G *et al.*
 18. **Neurovascular manifestations of COVID-19.** Nervenarzt 2021; Veltkamp R, Purucker JC, Weber R.
 19. **Acute and Post-Acute Neurological Complications of COVID-19.** Neurol. Int. 2021; 13:102-119 Al-Ramadan A, Rabab'h O, Shah J, Gharaibeh A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33803475>
 20. **SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis.** Neurologia 2021; Piñar Morales R, Ramírez Rivas MA, Barrero Hernández FJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812762>
 21. **Understanding the Heart-Brain Axis Response in COVID-19 patients: a Suggestive Perspective for Therapeutic Development.** Pharmacol. Res. 2021; 105:581 Lionetti V, Bollini S, Coppini R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781873>
 22. **The neurological symptoms of COVID-19: a systematic overview of systematic reviews, comparison with other neurological conditions and implications for healthcare services.** Ther. Adv. Chronic Dis. 2021; 12:2040622320976979 Wildwing T, Holt N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796241>
 23. **COVID-19 and Neurological Impairment: Hypothalamic Circuits and Beyond.** Viruses 2021; 13: Mussa BM, Srivastava A, Verberne AJM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802995>

Coagulation (17 articles)

1. **Blood viscosity of COVID-19 patient: a preliminary report.** Am. J. Blood Res. 2021; 11:93-95 Joob B, Wiwanitkit V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796395>
2. **Clotting in COVID-19: Is It All in the Genes?** Am. J. Respir. Cell Mol. Biol. 2021; Hernandez Cordero AI, Sin DD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784208>
3. **Anticoagulation in COVID-19: not strong for too long?** Anaesth Crit Care Pain Med 2021; 100:857 Tacquard C, Mansour A, Godon A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798761>
4. **The Primary Prevention of Venous Thromboembolism in Patients with COVID-19 in Japan: Current Status and Future Perspective.** Ann Vasc Dis 2021; 14:1-4 Yamashita Y, Yamada N, Mo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786092>
5. **Acute haemorrhagic oedema of infancy as a manifestation of COVID-19.** BMJ Case Rep. 2021; 14: Saraiva BM, Lobato MB, Santos E, Garcia AM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782070>

6. **Role of Tissue Factor in the Pathogenesis of COVID-19 and the Possible Ways to Inhibit It.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211003983Cañas CA, Cañas F, Bautista-Vargas M, Bonilla-Abadía F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784877>
7. **Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine.** Cureus 2021; 13:e14099Malayala SV, Mohan G, Vasireddy D, Atluri P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786251>
8. **Aortic thrombosis in a patient with COVID-19-associated hyperinflammatory syndrome.** Int J Infect Dis 2021; Michotte N, Allard S, Payen MC, Dauby N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813063>
9. **The Year in Coagulation: Selected Highlights from 2020.** J Cardiothorac Vasc Anesth 2021; Patel PA, Henderson RA, Jr., Bolliger D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781668>
10. **SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm.** J Clin Med 2021; 10Akhter MS, Hamali HA, Mobarki AA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806540>
11. **Functional status of mechanically ventilated COVID-19 survivors at ICU and hospital discharge.** J Intensive Care 2021; 9:31Musheyev B, Borg L, Janowicz R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789772>
12. **Impact of a clinical pharmacist on ultrasound-guided venous thromboembolism screening in hospitalized COVID-19 patients: a pilot prospective study.** J Pharm Health Care Sci 2021; 7:19Gillespie L, Khan RZ, Stillson JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795030>
13. **Impact of COVID-19 Pandemic on Patients with Immune Thrombocytopaenia.** Medicina (Kaunas) 2021; 57Román M, Jiménez Yuste V, García Barcenilla S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804346>
14. **COVID-19 Disease and Hypercoagulability Leading to Acute Ischemic Stroke.** Neurohospitalist 2021; 11:131-136Mullaguri N, Hepburn M, Gebel JM, Jr. *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33791056>
15. **Modulation of Hemostasis in COVID-19; Blood Platelets May Be Important Pieces in the COVID-19 Puzzle.** Pathogens 2021; 10Ulanowska M, Olas B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808640>
16. **Successful vascular interventional management of superior mesenteric vein thrombosis in a patient with COVID-19: A case report and review of literature.** Radiol Case Rep 2021; Ebrahiminik H, Nikpour S, Yazdi HR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777280>
17. **[Knowledge of thromboprophylaxis-COVID-19 in healthcare professionals in Spain].** Semergen 2021; García Vallejo O, Frías Vargas M, Gil Gil I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33810943>

Complications (67 articles)

1. **Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay.** Acta Neurol. Belg. 2021; Galassi G, Marchioni A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811309>

2. **Clotting in COVID-19: Is It All in the Genes?** Am. J. Respir. Cell Mol. Biol. 2021; Hernandez Cordero AI, Sin DD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784208>
3. **Correspondence on: 'What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern'.** Ann. Rheum. Dis. 2021; Hočevár A, Ambrožič A, Tomšič M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789871>
4. **Acute haemorrhagic oedema of infancy as a manifestation of COVID-19.** BMJ Case Rep. 2021; 14:Saraiva BM, Lobato MB, Santos E, Garcia AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782070>
5. **Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study.** BMJ Open 2021; 11:e048391Dennis A, Wamil M, Alberts J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785495>
6. **Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study.** Cancers (Basel) 2021; 13:Di Cosimo S, Tagliaferri B, Generali D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809465>
7. **Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients.** Cells 2021; 10:Croci GA, Vaira V, Trabattoni D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801959>
8. **Invasive Pneumococcal Disease in a Patient With COVID-19: A Case Report.** Cureus 2021; 13:e13559Ayad S, Alyacoub R, Gergis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791177>
9. **A Retrospective Review of Outcomes in Intensive Care Unit Patients Infected With SARS-Cov2 in Correlation to Admission Acute Physiologic Assessment and Chronic Health Evaluation II Scores.** Cureus 2021; 13:e14051Singh P, Warren K, Adler H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777587>
10. **COVID-19 Pneumonia on Post-Operative Day 2 after Esophagectomy: Performing Esophago-Gastric Junction Cancer Surgery during the SARS-Cov-2 Second Wave.** Curr. Oncol. 2021; 28:1348-1353Nurczyk K, Chan CE, Nowak N, Skoczylas T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801652>
11. **Antithyroid arthritis syndrome in a case of post-COVID-19 subacute thyroiditis.** Diabetes Metab Syndr 2021; 15:683-686Ghosh R, Dubey S, Sarkar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813242>
12. **SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics.** Expert Rev Proteomics 2021; 1:14Hartog N, Faber W, Frisch A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779460>
13. **T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19.** Front. Immunol. 2021; 12:655934Zenarruzabeitia O, Astarloa-Pando G, Terrén I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777054>
14. **Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.** Front Med (Lausanne) 2021; 8:626425Hegyi PJ, Váncsa S, Ocskay K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777974>

15. **Identifying Clinical Phenotypes in Moderate to Severe Acute Respiratory Distress Syndrome Related to COVID-19: The COVADIS Study.** Front Med (Lausanne) 2021; 8:632933Lascarrou JB, Gaultier A, Soumagne T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777977>
16. **Optimizing Management to Reduce the Mortality of COVID-19: Experience From a Designated Hospital for Severely and Critically Ill Patients in China.** Front Med (Lausanne) 2021; 8:582764Zhu W, Zhang H, Li Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777967>
17. **Skeletal Muscle Wasting and Function Impairment in Intensive Care Patients With Severe COVID-19.** Front. Physiol. 2021; 12:640973de Andrade-Junior MC, de Salles ICD, de Brito CMM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776796>
18. **COVID/HIV Co-Infection: A Syndemic Perspective on What to Ask and How to Answer.** Front Public Health 2021; 9:623468Gesese HA, Mwanri L, Stephens JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791266>
19. **Splenic infarction as a complication of covid-19 in a patient without respiratory symptoms: A case report and literature review.** IDCases 2021:e01062Castro GRA, Collaço IA, Dal Bosco CLB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777695>
20. **A Proposal for Dedicated "Prone Team" and "Prone Bundle of Care" in COVID-19 ICU.** Indian J. Crit. Care Med. 2021; 25:349-350Anand RK, Baidya DK, Maitra S, Ray BR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790522>
21. **Prognostic Value of "Cycle Threshold" in Confirmed COVID-19 Patients.** Indian J. Crit. Care Med. 2021; 25:322-326Rajyalakshmi B, Samavedam S, Reddy PR, Aluru N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790515>
22. **Changes in Mode of Oxygen Delivery and Physiological Parameters with Physiotherapy in COVID-19 Patients: A Retrospective Study.** Indian J. Crit. Care Med. 2021; 25:317-321Verma CV, Arora RD, Mistry HM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33790514>
23. **Aortic thrombosis in a patient with COVID-19-associated hyperinflammatory syndrome.** Int J Infect Dis 2021; Michotte N, Allard S, Payen MC, Dauby N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813063>
24. **COVID-19 and Syndemic challenges in 'Battling the Big Three': HIV, TB and malaria.** Int J Infect Dis 2021; Velavan TP, Meyer CG, Esen M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781904>
25. **The use of non-invasive ventilation in COVID-19: a systematic review.** Int J Infect Dis 2021; Wang Z, Wang Y, Yang Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798720>
26. **Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis.** Int J Mol Sci 2021; 22Chu R, van Eeden C, Suresh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803997>
27. **Interactions of SARS-CoV-2 with the Blood-Brain Barrier.** Int J Mol Sci 2021; 22Erickson MA, Rhea EM, Knopp RC, Banks WA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33800954>
28. **The ROX index can be a useful tool for the triage evaluation of COVID-19 patients with dyspnoea.** J. Adv. Nurs. 2021; Zaboli A, Ausserhofer D, Pfeifer N *et*

al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792953>

29. **Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark.** J Autoimmun 2021; 120:102632 Kjeldsen J, Nielsen J, Ellingsen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812171>
30. **SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm.** J Clin Med 2021; 10 Akhter MS, Hamali HA, Mobarki AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806540>
31. **Spontaneous Pneumomediastinum, Pneumothorax, Pneumopericardium and Subcutaneous Emphysema-Not So Uncommon Complications in Patients with COVID-19 Pulmonary Infection-A Series of Cases.** J Clin Med 2021; 10 Cut TG, Tudoran C, Lazureanu VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805118>
32. **Severe Acute Kidney Injury in Critically Ill Patients with COVID-19 Admitted to ICU: Incidence, Risk Factors, and Outcomes.** J Clin Med 2021; 10 Ghosn M, Attallah N, Badr M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804100>
33. **Prone Position in Mechanically Ventilated COVID-19 Patients: A Multicenter Study.** J Clin Med 2021; 10 Vollenberg R, Matern P, Nowacki T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802479>
34. **Emergence of Candida auris in Brazil in a COVID-19 Intensive Care Unit.** J Fungi (Basel) 2021; 7 de Almeida JN, Jr., Francisco EC, Hagen F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803060>
35. **Proven Fatal Invasive Aspergillosis in a Patient with COVID-19 and Staphylococcus aureus Pneumonia.** J Fungi (Basel) 2021; 7 van Someren Gréve F, du Long R, Talwar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808931>
36. **Right Ventricular Strain Is Common in Intubated COVID-19 Patients and Does Not Reflect Severity of Respiratory Illness.** J. Intensive Care Med. 2021; 8850666211006335 Gibson LE, Fenza RD, Lang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783269>
37. **Downregulation of type III interferons in patients with severe COVID-19.** J Med Virol 2021; Fukuda Y, Homma T, Inoue H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811680>
38. **Impact of a clinical pharmacist on ultrasound-guided venous thromboembolism screening in hospitalized COVID-19 patients: a pilot prospective study.** J Pharm Health Care Sci 2021; 7:19 Gillespie L, Khan RZ, Stillson JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795030>
39. **Extracorporeal Membrane Oxygenation with Right Ventricular Assist Device for COVID-19 ARDS.** J. Surg. Res. 2021; 264:81-89 Cain MT, Smith NJ, Barash M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789179>
40. **Case study of a critically ill person with COVID-19 on ECMO successfully treated with Ieronlimab.** J Transl Autoimmun 2021; 100097 Elneil S, Lalezari JP, Pourhassan NZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778462>
41. **Multisystem Inflammatory Syndrome in a Child with Scrub Typhus and Macrophage Activation Syndrome.** J. Trop. Pediatr. 2021; 67 Gupta A, Gill A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787904>

42. **Platelets and the Endothelium: Active Participants in Severe COVID-19 Infection.** JACC Basic Transl Sci 2021; 6:219-221 Parker WAE, Storey RF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778209>
43. **Implications of COVID-19 Pandemic on the Emergence of Antimicrobial Resistance: Adjusting the Response to Future Outbreaks.** Life (Basel) 2021; 11Rusic D, Vilovic M, Bukic J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801799>
44. **COVID-19 and Pneumocystis jirovecii Pulmonary Coinfection-The First Case Confirmed through Autopsy.** Medicina (Kaunas) 2021; 57Jeican, II, Inişca P, Gheban D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804963>
45. **Impact of COVID-19 Pandemic on Patients with Immune Thrombocytopaenia.** Medicina (Kaunas) 2021; 57Román M, Jiménez Yuste V, García Barcenilla S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804346>
46. **SARS-CoV-2 infection in patients with primary mitochondrial diseases: features and outcomes in Italy.** Mitochondrion 2021; Mancuso M, La Morgia C, Lucia Valentino M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798770>
47. **COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update.** Mult Scler Relat Disord 2021; 51:102929Jack D, Damian D, Nolting A, Galazka A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813097>
48. **Neuromuscular complications of SARS-CoV-2 infections—Part 1: peripheral nerves.** Nervenarzt 2021; Lehmann HC, Schoser B, Wunderlich G *et al.*
49. **Neurovascular manifestations of COVID-19.** Nervenarzt 2021; Veltkamp R, Purucker JC, Weber R.
50. **A 33-year-old man with COVID-19 presented with subacute thyroiditis: A rare case report.** New Microbes New Infect 2021:100871Davoodi L, Oladi Z, Jafarpour H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777402>
51. **New Onset of Unilateral Orbital Myositis following Mild COVID-19 Infection.** Ocul Immunol Inflamm 2021:1-2Mangan MS, Yildiz E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797304>
52. **Severe Intraocular Inflammation following Hydrophilic Acrylic Phakic Intraocular Lens Implantation in A Case with Concealed History of COVID-19: A Case Report and Literature Review.** Ocul Immunol Inflamm 2021:1-4Toprak I, Cetin EN, Gunes CE, Martin-Seker C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793389>
53. **Dysregulated Host Response in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Critical Illness.** Open Forum Infect Dis 2021; 8:ofab019Tiwari-Heckler S, Rauber C, Longhi MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778090>
54. **Heterotopic ossifications after longterm weaning due to COVID-19.** Osteologie 2021; Dahmen A, Roukens R, Lindenberg S, Peters KM.
55. **Spontaneous pneumomediastinum and subcutaneous emphysema in a non-intubated COVID-19 patient: a case report.** Pan Afr. Med. J. 2021; 38:37Jatoi TA, Khan AA, Mohiuddin O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777305>
56. **Why Does SARS-CoV-2 Infection Induce Autoantibody Production?** Pathogens 2021; 10Macela A, Kubelkova K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809954>

57. **Modulation of Hemostasis in COVID-19; Blood Platelets May Be Important Pieces in the COVID-19 Puzzle.** Pathogens 2021; 10Ulanowska M, Olas B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808640>
58. **COVID-19 infection in a pediatric kidney transplant population: A single-center experience.** Pediatr. Transplant. 2021:e14018Singer PS, Sethna C, Molmenti E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813782>
59. **Mitral valve replacement through mini sternotomy after long ECMO course: Case report.** Perfusion 2021:2676591211003237Abdalghafoor T, Sarhan H, Kindawi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779404>
60. **Successful vascular interventional management of superior mesenteric vein thrombosis in a patient with COVID-19: A case report and review of literature.** Radiol Case Rep 2021; Ebrahimini H, Nikpour S, Yazdi HR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777280>
61. **Pericardial and pleural effusion in an elderly woman with Covid-19 pneumonia: CT findings.** Radiol Case Rep 2021; Messina F, Turano L, Tebala C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777279>
62. **Anesthesia Machine Ventilators for Use in Critical Care During the COVID-19 Pandemic.** Respir. Care 2021; Austin PN, Branson RD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785549>
63. **COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions.** RMD Open 2021; 7Landewé RBM, Ramiro S, Mostard RLM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33790049>
64. **Ultraefficiently Calming Cytokine Storm Using Ti(3)C(2)T (x) MXene.** Small Methods 2021:2001108Wang T, Sun X, Guo X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786372>
65. **Care of the critically ill patient.** Surgery (Oxf) 2021; 39:29-36Jackson M, Cairns T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776181>
66. **Likelihood of amyloid formation in COVID-19-induced ARDS.** Trends Microbiol. 2021; Sinha N, Thakur AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795156>
67. **The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score.** Viruses 2021; 13Ghidini M, Indini A, Rijavec E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808623>

Cured – Recovered (20 articles)

1. **Research priorities for Long Covid: refined through an international multi-stakeholder forum.** BMC Med 2021; 19:84Carson G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785027>
2. **Recovery after critical illness in COVID-19 ICU survivors.** Br J Anaesth 2021; Parker AJ, Humbir A, Tiwary P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812669>
3. **A mediating role for mental health in associations between COVID-19-related self-stigma, PTSD, quality of life, and insomnia among patients recovered from COVID-19.** Brain Behav 2021:e02138Mahmoudi H, Saffari M, Movahedi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811451>

4. **Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19.** Diagnostics (Basel) 2021; 11Dorelli G, Braggio M, Gabbiani D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809260>
5. **Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil.** Emerg Infect Dis 2021; 27Fintelman-Rodrigues N, da Silva APD, Dos Santos MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797393>
6. **Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients.** Eur J Radiol 2021; 138:109676Balbi M, Conti C, Imeri G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798931>
7. **The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive.** Infect Dis Poverty 2021; 10:45Zhao H, Zhang C, Chen XX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789752>
8. **Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification.** Int J Environ Res Public Health 2021; 18Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807869>
9. **Prevalence of Symptoms in Patients Discharged from COVID Care Facility of NIMS Hospital: Is RT PCR Negativity Truly Reflecting Recovery? A Single-Centre Observational Study.** Int. J. Gen. Med. 2021; 14:1069-1078Tomar BS, Singh M, Nathiya D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790636>
10. **Residual Lung Function Impairment Is Associated with Hyperventilation in Patients Recovered from Hospitalised COVID-19: A Cross-Sectional Study.** J Clin Med 2021; 10Crisafulli E, Gabbiani D, Magnani G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802359>
11. **Spontaneous Breathing and Evolving Phenotypes of Lung Damage in Patients with COVID-19: Review of Current Evidence and Forecast of a New Scenario.** J Clin Med 2021; 10Tonelli R, Marchioni A, Tabbi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801368>
12. **Post-traumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge.** J Gen Intern Med 2021;1-6Tarsitani L, Vassalini P, Koukopoulos A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782888>
13. **Long COVID - An Early Perspective.** J. Insur. Med. 2021; Meagher T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784738>
14. **Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.** J Med Virol 2021; Callegaro A, Borleri D, Farina C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788281>
15. **Exercise Training and Cardiac Rehabilitation in COVID-19 Patients with Cardiovascular Complications: State of Art.** Life (Basel) 2021; 11Calabrese M, Garofano M, Palumbo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801080>
16. **Post COVID-19 Organizing Pneumonia: The Right Time to Interfere.** Medicina (Kaunas) 2021; 57Bieksiene K, Zaveckiene J, Malakauskas K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803690>
17. **Macular vessel density in patients recovered from COVID-19 disease.** Photodiagnosis Photodyn. Ther. 2021:102267Hazar L, Karahan M, Vural E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785439>

18. **[Long covid: cross sectional study].** Rev. Fac. Cien. Med. Univ. Nac. Cordoba 2021; 78:33-36Prieto MA, Prieto O, Castro HM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33787016>
19. **A Case Series Describing the Recurrence of COVID-19 in Patients Who Recovered from Initial Illness in Bangladesh.** Trop Med Infect Dis 2021; 6Das P, Satter SM, Ross AG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807247>
20. **Repeated SARS-CoV-2 Positivity: Analysis of 123 Cases.** Viruses 2021; 13Váncsa S, Dembrovsky F, Farkas N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808867>

Cardiovascular disease (73 articles)

1. **Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem.** Adv Ther 2021;1-8Cugno M, Gualtierotti R, Casazza G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792889>
2. **Optical coherence tomography angiography features in post COVID-19 pneumonia patients: a pilot study.** Am. J. Ophthalmol. 2021; Cennamo G, Reibaldi M, Montorio D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781767>
3. **Trends in cholesterol testing during the COVID-19 pandemic: COVID-19 and cholesterol testing.** Am J Prev Cardiol 2021; 6:100152Gumuser ED, Haidermota S, Finneran P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778798>
4. **Coronavirus disease 2019 (COVID-19) and QTc prolongation.** BMC Cardiovasc. Disord. 2021; 21:158Changal K, Paternite D, Mack S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784966>
5. **Coronavirus disease 2019 is threatening stroke care systems: a real-world study.** BMC Health Serv. Res. 2021; 21:288Xin J, Huang X, Liu C, Huang Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789627>
6. **Impact on percutaneous coronary intervention for acute coronary syndromes during the COVID-19 outbreak in a non-overwhelmed European healthcare system: COVID-19 ACS-PCI experience in Ireland.** BMJ Open 2021; 11:e045590Connolly NP, Simpkin A, Mylotte D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811055>
7. **Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19.** Br J Cardiol 2020; 27:109-111Esser N, Zraika S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795925>
8. **Supplementary Therapeutic Possibilities to Alleviate Myocardial Damage Due to Microvascular Dysfunction in Coronavirus Disease 2019 (COVID-19).** Cardiol Ther 2021; Medveggy M, Simonyi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811310>
9. **The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?** Cells 2021; 10Saravi B, Li Z, Lang CN *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804069>
10. **Clinical Outcome of Acute Ischemic Strokes in Patients with COVID-19.** Cerebrovasc. Dis. 2021;1-8Calmettes J, Peres R, Goncalves B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784669>

11. **Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.** Circ Res 2021; 128:1062-1079Savoia C, Volpe M, Kreutz R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33793331>
12. **Considerations for Patients With Peripheral Artery Disease During the COVID-19 Pandemic.** Clin. Appl. Thromb. Hemost. 2021; 27:1076029620986877Farhan S, Kamran H, Vogel B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783244>
13. **Renin-angiotensin system blockade in the COVID-19 pandemic.** Clin Kidney J 2021; 14:i48-i59Cohen JB, South AM, Shaltout HA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796285>
14. **Challenges in Managing Pericardial Disease Related to Post Viral Syndrome After COVID-19 Infection.** Cureus 2021; 13:e13461Sollie ZW, Vallepu SR, Tharumia Jagadeesan C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777550>
15. **Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19.** Diagnostics (Basel) 2021; 11Dorelli G, Braggio M, Gabbiani D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809260>
16. **Vascular Abnormalities Detected with Chest CT in COVID-19: Spectrum, Association with Parenchymal Lesions, Cardiac Changes, and Correlation with Clinical Severity (COVID-CAVA Study).** Diagnostics (Basel) 2021; 11Qanadli SD, Sauter AW, Alkadhi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805443>
17. **Predicting the outcome in confirmed COVID-19 patients with coronary artery disease: a key role for the first chest computed tomography.** Egypt Heart J 2021; 73:35Omidi N, Lotfi-Tokaldany M, Shirani S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33788067>
18. **Cardiac operations and interventions during the COVID-19 pandemic: a nationwide perspective.** Europace 2021; Leyva F, Zegard A, Okafor O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778881>
19. **Echocardiographic Characteristics and Outcome in Patients With COVID-19 Infection and Underlying Cardiovascular Disease.** Front Cardiovasc Med 2021; 8:642973Li Y, Fang L, Zhu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796573>
20. **Cardiovascular Disease and COVID-19: Insight From Cases With Heart Failure.** Front Cardiovasc Med 2021; 8:629958Yi Y, Xu Y, Jiang H, Wang J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33791346>
21. **Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of renin-angiotensin-aldosterone system (RAAS) inhibitors: a systematic review.** Futur J Pharm Sci 2021; 7:73Iheanacho CO, Odili VU, Eze UIH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778087>
22. **Heart Failure Care Delivery in the COVID-19 Era: The Patients' Perspective.** Healthcare (Basel) 2021; 9Fraser M, Mutschler M, Newman C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804305>
23. **Atrial Fibrillation as a Predictor of Mortality in High Risk COVID-19 Patients: A Multicentre Study of 171 Patients.** Heart Lung Circ. 2021; Ip RJ, Ali A, Baloch ZQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781697>

24. **Impact of COVID-19 lockdown in patients with implantable cardioverter and cardiac resynchronization therapy defibrillators: insights from daily remote monitoring transmissions.** Heart Vessels 2021;1-7 Mascioli G, Lucca E, Napoli P, Giacomelli D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779824>
25. **Impact of COVID-19 pandemic and infection on in hospital survival for patients presenting with acute coronary syndromes: A multicenter registry.** Int J Cardiol 2021; D'Ascenzo F, De Filippo O, Borin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794235>
26. **Impact of COVID-19 pandemic and infection on in hospital survival for patients presenting with acute coronary syndromes: A multicenter registry.** Int J Cardiol 2021; D'Ascenzo F, De Filippo O, Borin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794235>
27. **Subclinical Left Ventricular Dysfunction in COVID-19.** Int J Cardiol Heart Vasc 2021;100770 Bhatia HS, Bui QM, King K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778152>
28. **Rescue PCI in the management of STEMI: Contemporary results from the Melbourne Interventional Group registry.** Int J Cardiol Heart Vasc 2021; 33:100745 Fernando H, Dinh D, Duffy SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786363>
29. **Cardiac abnormalities due to multisystem inflammatory syndrome temporally associated with Covid-19 among children: A systematic review and meta-analysis.** Int J Cardiol Heart Vasc 2021;100764 Haghighi Aski B, Manafi Anari A, Abolhasan Choobdar F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778151>
30. **Manifestation of Cardiac Injury in Hospitalised Patients with COVID-19.** Int J Clin Pract 2021;e14197 Zhu H, Zhang Y, Pei Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792126>
31. **Pandemics and Burden of Stroke and Epilepsy in Sub-Saharan Africa: Experience from a Longstanding Health Programme.** Int J Environ Res Public Health 2021; 18 Leone M, Ciccacci F, Orlando S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803352>
32. **ACHD-Specific Risk Factors for Severe COVID-19.** J Am Coll Cardiol 2021; 77:1656-1659 Bradley EA, Cavus O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795040>
33. **COVID-19 in Adults With Congenital Heart Disease.** J Am Coll Cardiol 2021; 77:1644-1655 Broberg CS, Kovacs AH, Sadeghi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795039>
34. **Determining which hospitalized COVID-19 patients require an urgent echocardiogram.** J. Am. Soc. Echocardiogr. 2021; Yuan N, Wu S, Rader F, Siegel RJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812952>
35. **SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm.** J Clin Med 2021; 10 Akhter MS, Hamali HA, Mobarki AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806540>
36. **Impact of Coronavirus Disease 2019 on Out-of-Hospital Cardiac Arrest Survival Rate: A Systematic Review with Meta-Analysis.** J Clin Med 2021; 10 Borkowska MJ, Jaguszewski MJ, Koda M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803944>

37. **The Effect of the 2019 Novel Coronavirus Pandemic on Stroke and TIA Patient Admissions: Perspectives and Risk Factors.** J Clin Med 2021; 10Carson L, Kui C, Smith G, Dixit AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806122>
38. **Hypertension and Related Comorbidities as Potential Risk Factors for COVID-19 Hospitalization and Severity: A Prospective Population-Based Cohort Study.** J Clin Med 2021; 10Fresán U, Guevara M, Trobajo-Sanmartín C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809217>
39. **Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns.** J Clin Med 2021; 10Martínez-Botía P, Bernardo Á, Acebes-Huerta A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806709>
40. **SARS-CoV-2 Is a Culprit for Some, but Not All Acute Ischemic Strokes: A Report from the Multinational COVID-19 Stroke Study Group.** J Clin Med 2021; 10Shahjouei S, Anyaehie M, Koza E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804307>
41. **Inappropriate Heart Rate Response to Hypotension in Critically Ill COVID-19-Associated Acute Kidney Injury.** J Clin Med 2021; 10Verney C, Legouis D, Voiriot G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806780>
42. **Missed cerebrovascular events during prolonged sedation for COVID-19 pneumonia.** J. Clin. Neurosci. 2021; 86:180-183Bruce SS, Kahan J, Huq T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775324>
43. **Initial Experience in Monitoring QT Intervals Using a Six-lead Contactless Mobile Electrocardiogram in an Inpatient Setting.** J Innov Card Rhythm Manag 2021; 12:4433-4440Frisch DR, Frankel ES, Farzad DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777482>
44. **Right Ventricular Strain Is Common in Intubated COVID-19 Patients and Does Not Reflect Severity of Respiratory Illness.** J. Intensive Care Med. 2021; 8850666211006335Gibson LE, Fenza RD, Lang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783269>
45. **Management considerations for stroke-like episodes in MELAS with concurrent COVID-19 infection.** J. Neurol. 2021; Sen K, Harrar D, Hahn A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796896>
46. **Alterations of Left Ventricular Function Persisting during Post-Acute COVID-19 in Subjects without Previously Diagnosed Cardiovascular Pathology.** J Pers Med 2021; 11Tudoran M, Tudoran C, Lazureanu VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809873>
47. **Impact of a clinical pharmacist on ultrasound-guided venous thromboembolism screening in hospitalized COVID-19 patients: a pilot prospective study.** J Pharm Health Care Sci 2021; 7:19Gillespie L, Khan RZ, Stillson JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795030>
48. **Acute limb ischemia in a patient with Covid-19 pneumonia: a case report.** J. Thromb. Thrombolysis 2021; Kartikasari U, Djajalaksana S, Martini H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797021>
49. **Development of symptomatic inflammatory aneurysm treated with endovascular repair in COVID-19 infected patient.** J Vasc Surg Cases Innov Tech 2021; Riley CJ, Teixeira P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778230>

50. **Regression of Coronary Aneurysms With Intravenous Immunoglobulins and Steroids for COVID-19 Adult Multisystem Inflammatory Syndrome.** JACC Case Rep 2021; Diakite S, Bousdira N, Tachon G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782672>
51. **An indirect effect of covid-19 on the heart: A case report.** JRSM Cardiovasc Dis 2021; 10:2048004020974238 Tok Ö, Papadopoulos K, Çakıllı Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796279>
52. **Arterial hypertension—What was important in 2020?** Kardiologe 2021; 15:127-132 Mahfoud F, Böhm M, Dörr O *et al.*
53. **Strengthening CoViD-19 therapy via combinations of RAS modulators.** Med. Hypotheses 2021; 150:110571 Uzunova VV, Todev A, Zarkos J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33799164>
54. **EFFECT OF RAMIPRIL ON KIDNEY, LUNG AND HEART ACE2 IN A DIABETIC MICE MODEL.** Mol. Cell. Endocrinol. 2021:111263 Vergara A, Jacobs-Cachá C, Molina-Van den Bosch M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811970>
55. **Decreased Observance of Stroke in the Population Associated With COVID-19 Related Distancing Measures.** Neurohospitalist 2021; 11:137-140 Knox DB, Lanspa MJ, Brown SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791057>
56. **COVID-19 Disease and Hypercoagulability Leading to Acute Ischemic Stroke.** Neurohospitalist 2021; 11:131-136 Mullaguri N, Hepburn M, Gebel JM, Jr. *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33791056>
57. **Effect of COVID-19 pandemic on stroke admissions and quality of stroke interventional treatment in Masovian Voivodeship.** Neurol. Neurochir. Pol. 2021; Dębiec A, Bilik M, Piasecki P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783813>
58. **Consequences of COVID-19 pandemic lockdown on emergency and stroke care in a German tertiary stroke center.** Neurol Res Pract 2021; 3:21 Jansen R, Lee JI, Turowski B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789760>
59. **Undiagnosed SARS-CoV-2 infection and outcome in patients with acute MI and no COVID-19 symptoms.** Open Heart 2021; 8 Akhtar Z, Chowdhury F, Aleem MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811137>
60. **Prolonged QT predicts prognosis in COVID-19.** Pacing Clin. Electrophysiol. 2021; Akhtar Z, Gallagher MM, Yap YG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792080>
61. **Mitral valve replacement through mini sternotomy after long ECMO course: Case report.** Perfusion 2021:2676591211003237 Abdalghafoor T, Sarhan H, Kindawi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779404>
62. **Understanding the Heart-Brain Axis Response in COVID-19 patients: a Suggestive Perspective for Therapeutic Development.** Pharmacol. Res. 2021:105581 Lionetti V, Bollini S, Coppini R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781873>
63. **C1q Complement/Tumor Necrosis Factor-Associated Proteins in Cardiovascular Disease and COVID-19.** Proteomes 2021; 9 Xie Y, Meng Z, Gao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804408>

64. **Successful vascular interventional management of superior mesenteric vein thrombosis in a patient with COVID-19: A case report and review of literature.** Radiol Case Rep 2021; Ebrahiminik H, Nikpour S, Yazdi HR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777280>
65. **Pericardial and pleural effusion in an elderly woman with Covid-19 pneumonia: CT findings.** Radiol Case Rep 2021; Messina F, Turano L, Tebala C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777279>
66. **Case report of amiodarone-associated allergic pneumonitis amidst the COVID-19 pandemic.** Rev Cardiovasc Med 2021; 22:181-184 Azraai M, McMahon M, Dick R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792260>
67. **The impact of COVID-19 on short-term prognosis of ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention in Wuhan China.** Rev Cardiovasc Med 2021; 22:247-256 Lu Q, Wang JL, Chen ZN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792269>
68. **Exploring the impact of the COVID-19 pandemic on provision of cardiology services: a scoping review.** Rev Cardiovasc Med 2021; 22:83-95 Yasmin F, Shujaiddin SM, Naeem A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792250>
69. **Cardiovascular complications of SARS-CoV-2 infection (COVID-19): a systematic review and meta-analysis.** Rev Cardiovasc Med 2021; 22:159-165 Zhao YH, Zhao L, Yang XC, Wang P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792257>
70. **Cardiac arrhythmias in patients presenting with COVID-19 treated in Portuguese hospitals: A national registry from the Portuguese Association of Arrhythmology, Pacing and Electrophysiology.** Rev. Port. Cardiol. 2021; Mesquita D, Carmo P, Cabanelas N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781608>
71. **Maintenance of Acute Stroke Care Service During the COVID-19 Pandemic Lockdown.** Stroke 2021:Strokeaha120032176 Altersberger VL, Stolze LJ, Heldner MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793320>
72. **Managing Vascular Surgery Emergencies and Referrals During the COVID-19 Pandemic at a Tertiary Centre in Oman.** Sultan Qaboos Univ. Med. J. 2021; 21:e116-e119 Stephen E, Al-Adawi SSH, Abdelhady I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777432>
73. **When the patients stayed home: the impact of the COVID-19 pandemic on acute cardiac admissions and cardiac mortality in Malta.** Z Gesundh Wiss 2021:1-7 Grech N, Xuereb R, England K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777653>

Diagnosis (13 articles)

1. **State-of-the-Art of Nanodiagnosics and Nanotherapeutics against SARS-CoV-2.** ACS Appl Mater Interfaces 2021; Derakhshan MA, Amani A, Faridi-Majidi R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779135>
2. **Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines.** Ann. Allergy. Asthma. Immunol. 2021; Kelso JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779135>

term=33781933

3. **Community-acquired Pneumonia Severity Assessment Tools in Patients Hospitalized with COVID-19: a Validation and Clinical Applicability Study.** Clin Microbiol Infect 2021; Neto FL, Marino LO, Torres A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813111>
4. **Explaining machine learning based diagnosis of COVID-19 from routine blood tests with decision trees and criteria graphs.** Comput. Biol. Med. 2021; 132:104335Alves MA, Castro GZ, Oliveira BAS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812263>
5. **Atypical Presentations among Older Adults with COVID-19 Disease: A Need for Broadening the Differential Diagnosis.** Gerontol Geriatr Med 2021; 7:2333721421999313Ohuabunwa U, Turner J, Johnson T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786339>
6. **Infectious Diseases Seeker (IDS): An Innovative Tool for Prompt Identification of Infectious Diseases during Outbreaks.** Int J Environ Res Public Health 2021; 18Baldassi F, Carestia M, Moramarco S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804605>
7. **Extracting COVID-19 Diagnoses and Symptoms From Clinical Text: A New Annotated Corpus and Neural Event Extraction Framework.** J. Biomed. Inform. 2021:103761Lybarger K, Ostendorf M, Thompson M, Yetisgen M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781918>
8. **SARS-CoV-2 diagnostics: Towards a more comprehensive approach to routine patient testing.** J. Immunol. Methods 2021:113044Carter C, Hughes P, McHugh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785349>
9. **Low Sensitivity of Admission Lung US Compared to Chest CT for Diagnosis of Lung Involvement in a Cohort of 82 Patients with COVID-19 Pneumonia.** Medicina (Kaunas) 2021; 57Quarato CMI, Mirijello A, Lacedonia D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806432>
10. **Undiagnosed SARS-CoV-2 infection and outcome in patients with acute MI and no COVID-19 symptoms.** Open Heart 2021; 8Akhtar Z, Chowdhury F, Aleem MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811137>
11. **Not all anosmia and fever was COVID-19 infection: a case report.** Pan Afr. Med. J. 2020; 37:371Koffi NP, Abad CEA, Miloud G, Brahim EM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796184>
12. **Hyperparameter Optimization for COVID-19 Pneumonia Diagnosis Based on Chest CT.** Sensors (Basel) 2021; 21Lacerda P, Barros B, Albuquerque C, Conci A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804609>
13. **If Not COVID-19 What Is It? Analysis of COVID-19 versus Common Respiratory Viruses among Symptomatic Health Care Workers in a Tertiary Infectious Disease Referral Hospital in Manila, Philippines.** Trop Med Infect Dis 2021; 6Agrupis KA, Villanueva AMG, Sayo AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808524>

DM-MS-Obesity (17 articles)

1. **Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis.** Acta Diabetol 2021:1-10Kaminska H, Szarpak L, Kosior D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778910>
2. **No Negative Impact of a National State of Emergency by COVID-19 Outbreak on Hemoglobin A1c Levels in Patients with Type 2 Diabetes Living in Semi-Rural Japan.** Am. J. Med. Sci. 2021; Aso Y, Iijima T, Tomaru T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798459>
3. **Impact of the COVID-19 Epidemic on hospitalization for diabetic foot ulcers during lockdown: A French nationwide population-based study.** Diabet. Med. 2021:e14577Mariet AS, Benzenine E, Bouillet B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797791>
4. **ASSOCIATION OF HYPERGLYCAEMIA WITH HOSPITAL MORTALITY IN NONDIABETIC COVID-19 PATIENTS: A COHORT STUDY.** Diabetes Metab. 2021:101254Mamtani M, Athavale AM, Abraham M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781926>
5. **Diabetes-related acute metabolic emergencies in COVID-19 patients: a systematic review and meta-analysis.** Diabetol Int 2021:1-15Papadopoulos VP, Koutroulos MV, Zikoudi DG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777611>
6. **Diabetes, inflammation, and the adiponectin paradox: therapeutic targets in SARS-CoV-2.** Drug Discov Today 2021; Ho G, Ali A, Takamatsu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775925>
7. **Immunological Characteristics in Type 2 Diabetes Mellitus Among COVID-19 Patients.** Front. Endocrinol. (Lausanne) 2021; 12:596518Han M, Ma K, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776910>
8. **The Centrality of Obesity in the Course of Severe COVID-19.** Front. Endocrinol. (Lausanne) 2021; 12:620566Liu D, Zhang T, Wang Y, Xia L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776917>
9. **Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History.** Int J Mol Sci 2021; 22Kaneto H, Kimura T, Obata A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807522>
10. **What Every Diabetologist Should Know about SARS-CoV-2: State of Knowledge at the Beginning of 2021.** J Clin Med 2021; 10Abramczyk U, Kuzan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801468>
11. **Associations of Body Mass Index with Ventilation Management and Clinical Outcomes in Invasively Ventilated Patients with ARDS Related to COVID-19- Insights from the PROVENT-COVID Study.** J Clin Med 2021; 10Schavemaker R, Schultz MJ, Lagrand WK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799735>
12. **Predictive Biomarkers of COVID-19 Severity in SARS-CoV-2 Infected Patients with Obesity and Metabolic Syndrome.** J Pers Med 2021; 11Perpiñan C, Bertran L, Terra X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809913>
13. **Lifestyle Changes and Body Mass Index during COVID-19 Pandemic Lockdown: An Italian Online-Survey.** Nutrients 2021; 13Maffoni S, Brazzo S, De Giuseppe R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805291>

14. **Leading Factors for Weight Gain during COVID-19 Lockdown in a Spanish Population: A Cross-Sectional Study.** Nutrients 2021; 13Sánchez E, Lecube A, Bellido D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801989>
15. **COVID-19 and the Urgent Need for New Therapies for Obesity.** Popul Health Manag 2021; Greenway FL, Look M, Golden A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784481>
16. **Eating behaviors and weight outcomes in bariatric surgery patients amidst COVID-19.** Surg. Obes. Relat. Dis. 2021; Conceição E, de Lourdes M, Ramalho S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812789>
17. **Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role.** Trends Microbiol. 2021; Samuel SM, Varghese E, Büsselberg D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785249>

Education and training and science (68 articles)

1. **Thoughts on 2021-2022 visiting rotation recommendations from current and recent applicants in surgery.** Am. J. Surg. 2021; Singh NP, Fang HA, Lopez R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810835>
2. **Eating habits among primary and secondary school students in the Gaza Strip, Palestine: A cross-sectional study during the COVID-19 pandemic.** Appetite 2021;105222Radwan A, Radwan E, Radwan W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798621>
3. **Awareness and Behaviors Regarding COVID-19 among Albanian Undergraduates.** Behav Sci (Basel) 2021; 11Gallè F, Veshi A, Sabella EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807250>
4. **Preparing e-portfolio as an element of online training by clinical chemistry residents in the COVID-19 era.** Biochem Mol Biol Educ 2021; Das S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780126>
5. **Using the COVID-19 pandemic to reimagine global health teaching in high-income countries.** BMJ Glob Health 2021; 6Atkins S, Banerjee AT, Bachynski K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811100>
6. **Factors relating to working hours restriction that have impacted the professional identity of trainees in the last decade.** Br. J. Hosp. Med. (Lond.) 2021; 82:1-10Mukherjee S, Meacock J, Kissane E, Pal D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792379>
7. **Pitfalls when comparing COVID-19-related outcomes across studies-lessons learnt from the ERACODA collaboration.** Clin Kidney J 2021; 14:i14-i20Noordzij M, Vart P, Duivenvoorden R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796283>
8. **The utility of a local multidisciplinary working group to oversee the establishment of rapidly evolving standards of care and to support trial recruitment during the COVID-19 pandemic.** Clin Med (Lond) 2021; Satta G, Youngstein T, Lightstone L, Gilchrist M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782041>
9. **Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness.** Clin Microbiol Infect 2021; Martinuka O, von Cube M, Wolkewitz M.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813117>

10. **Perspectives on Virtual (Remote) Clinical Trials as the 'New Normal' to Accelerate Drug Development.** Clin Pharmacol Ther 2021; Alemayehu D, Hemmings R, Natarajan K, Roychoudhury S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792920>
11. **Privacy Concerns Over the Use of Webcams in Online Medical Education During the COVID-19 Pandemic.** Cureus 2021; 13:e13536Rajab MH, Soheib M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786243>
12. **The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond.** Curr. Hematol. Malig. Rep. 2021;1-8Banerjee R, Kelkar AH, Logan AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788125>
13. **Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge.** EBioMedicine 2021; 66:103291Winkler MS, Skirecki T, Brunkhorst FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813139>
14. **The Effects of Coronavirus Disease 2019 Outbreak on Medical Students.** Front Psychiatry 2021; 12:637946Bilgi K, Aytaş G, Karatoprak U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796035>
15. **Impact of Public Health Education Program on the Novel Coronavirus Outbreak in the United States.** Front Public Health 2021; 9:630974Iboi E, Richardson A, Ruffin R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791268>
16. **Transforming postgraduate medical education during the COVID-19 pandemic: creating a trainee-led virtual teaching platform.** Future Healthc J 2021; 8:e7-e10Collins E, Ahmad A, May H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791466>
17. **Chief registrars: Leading in a time of COVID-19.** Future Healthc J 2021; 8:e1-e4Colori A, Dilly M, Moriarty L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791464>
18. **Employment of medical and physician associate students in an NHS trust during the COVID-19 pandemic.** Future Healthc J 2021; 8:e146-e149Maas K, Wassef M, Kulkarni M, Bowker L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791495>
19. **What was the impact of COVID-19 on the foundation training programme in north Wales?** Future Healthc J 2021; 8:e5-e6Prince S, Adhiyaman V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791465>
20. **Experiences of a new training programme for final-year medical students during the COVID-19 pandemic.** Future Healthc J 2021; 8:e23-e26Simpson J, Gafson I, Mooncey M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791470>
21. **Rebooting medical education with virtual grand rounds during the COVID-19 pandemic.** Future Healthc J 2021; 8:e11-e14Sparkes D, Leong C, Sharrocks K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791467>
22. **Haematology morphology teaching during the COVID-19 pandemic: a UK teaching hospital experience.** Future Healthc J 2021; 8:e153-e155Westbury SK, Stewart A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791497>
23. **High-Fidelity Virtual Objective Structured Clinical Examinations with Standardized Patients in Nursing Students: An Innovative Proposal during the**

- COVID-19 Pandemic.** Healthcare (Basel) 2021; 9Arrogante O, López-Torre EM, Carrión-García L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804700>
24. **Analysis of Anxiety Levels of Nursing Students Because of e-Learning during the COVID-19 Pandemic.** Healthcare (Basel) 2021; 9García-González J, Ruqiong W, Alarcon-Rodriguez R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804344>
 25. **COVID-19 and the problem of clinical knowledge.** Hist Philos Life Sci 2021; 43:52Simon JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792789>
 26. **Available videoconferencing freeware and medical education.** Ind Psychiatry J 2020; 29:155-158Chail A, Chatterjee K, Chauhan VS, Prakash J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776289>
 27. **The Teaching Digital Competence of Health Sciences Teachers. A Study at Andalusian Universities (Spain).** Int J Environ Res Public Health 2021; 18Cabero-Almenara J, Barroso-Osuna J, Gutiérrez-Castillo JJ, Palacios-Rodríguez A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806483>
 28. **Facing the Coronavirus Pandemic: An Integrated Continuing Education Program in Taiwan.** Int J Environ Res Public Health 2021; 18Chiu TF, Chu D, Huang SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801232>
 29. **Who Got Infected with COVID-19? A Study of College Students in Wuhan (China).** Int J Environ Res Public Health 2021; 18Fan C, Li M, Li X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801267>
 30. **SARS-CoV-2 Infection, Risk Perception, Behaviour and Preventive Measures at Schools in Berlin, Germany, during the Early Post-Lockdown Phase: A Cross-Sectional Study.** Int J Environ Res Public Health 2021; 18Hommes F, van Loon W, Thielecke M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800392>
 31. **Remote Teaching Due to COVID-19: An Exploration of Its Effectiveness and Issues.** Int J Environ Res Public Health 2021; 18Kawasaki H, Yamasaki S, Masuoka Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800909>
 32. **COVID-19 Pandemic and Helsinki University Hospital Personnel Psychological Well-Being: Six-Month Follow-Up Results.** Int J Environ Res Public Health 2021; 18Laukkala T, Suvisaari J, Rosenström T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806283>
 33. **Evaluation of Service-Learning in Project WeCan under COVID-19 in a Chinese Context.** Int J Environ Res Public Health 2021; 18Leung H, Shek DTL, Dou D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808448>
 34. **Educational Disparities in COVID-19 Prevention in China: The Role of Contextual Danger, Perceived Risk, and Interventional Context.** Int J Environ Res Public Health 2021; 18Li M, Wang W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805222>
 35. **Health Literacy, Digital Health Literacy, and COVID-19 Pandemic Attitudes and Behaviors in U.S. College Students: Implications for Interventions.** Int J Environ Res Public Health 2021; 18Patil U, Kostareva U, Hadley M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806763>
 36. **French Public Familiarity and Attitudes toward Clinical Research during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Schultz É, Ward JK, Atlani-Duault L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807787>

37. **The Impact of COVID-19 on High School Student-Athlete Experiences with Physical Activity, Mental Health, and Social Connection.** Int J Environ Res Public Health 2021; 18Shepherd HA, Evans T, Gupta S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33805249>
38. **Class of 2020 in Poland: Students' Mental Health during the COVID-19 Outbreak in an Academic Setting.** Int J Environ Res Public Health 2021; 18Wieczorek T, Kołodziejczyk A, Ciulkowicz M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33799848>
39. **Expanding Our Understanding of COVID-19 from Biomedical Literature Using Word Embedding.** Int J Environ Res Public Health 2021; 18Yang H, Sohn E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804131>
40. **Experiences, emotional responses, and coping skills of nursing students as auxiliary health workers during the peak COVID-19 pandemic: A qualitative study.** Int. J. Ment. Health Nurs. 2021; Roca J, Canet-Vélez O, Cemeli T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33792160>
41. **COVID-19 Response Strategies at Large Institutes of Higher Education in the United States: A Landscape Analysis, Fall 2020.** J. Adolesc. Health 2021; 68:683-685Freeman S, Nguyen TV, Beliveau J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781472>
42. **Utilization of Instagram by Dermatology Residency Programs in the era of COVID-19.** J Am Acad Dermatol 2021; Schwartzman G, Qureshi A, Friedman AJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811936>
43. **The impact of COVID-19 on REI fellowship educational experience.** J. Assist. Reprod. Genet. 2021; Ghidei L, Gannon A, Schutt A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33797004>
44. **Creating and Implementing a COVID-19 Recruitment Data Mart.** J. Biomed. Inform. 2021:103765Helmer TT, Lewis AA, McEver M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798717>
45. **ELII: A Novel Inverted Index for Fast Temporal Query, with Application to a Large Covid-19 EHR Dataset.** J. Biomed. Inform. 2021:103744Huang Y, Li X, Zhang GQ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775815>
46. **Extracting COVID-19 Diagnoses and Symptoms From Clinical Text: A New Annotated Corpus and Neural Event Extraction Framework.** J. Biomed. Inform. 2021:103761Lybarger K, Ostendorf M, Thompson M, Yetisgen M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781918>
47. **COnVIDa: COVID-19 multidisciplinary data collection and dashboard.** J. Biomed. Inform. 2021:103760Martínez Beltrán ET, Pérez MQ, Pastor-Galindo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798715>
48. **A meta-research study revealed susceptibility of Covid-19 treatment research to white hat bias: First, do no harm.** J. Clin. Epidemiol. 2021; Bellos I.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775812>
49. **Stress of university students before and after campus closure in response to COVID-19.** J. Community Psychol. 2021; von Keyserlingk L, Yamaguchi-Pedroza K, Arum R, Eccles JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786864>
50. **Anesthesiology Training in the Time of COVID-19: Problems and Solutions.** J Educ Perioper Med 2021; 23:E659Streiff A, Ramachandran S, Choice C *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778104>

51. **6 feet apart but working together.** J Genet Couns 2021; Redlinger-Grosse K, Anderson K, Birkeland L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786902>
52. **COVID 19 and Dental Education: Transitioning from a Well-established Synchronous Format and Face to Face Teaching to an Asynchronous Format of Dental Clinical Teaching and Learning.** J Med Educ Curric Dev 2021; 8:2382120521999667Nasseripour M, Turner J, Rajadurai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796791>
53. **Interprofessional Education Competition During the COVID-19 Pandemic at King Saud University: Benefits and Challenges.** J Multidiscip Healthc 2021; 14:673-679Alrasheed A, Altulahi N, Tamsah MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776445>
54. **Predictors of Health Behaviors Among Undergraduate Students During the COVID-19 Pandemic: A Cross-Sectional Predictive Study.** J Multidiscip Healthc 2021; 14:727-734Suksatan W, Choompunuch B, Koontalay A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790571>
55. **Exploring Large Community- and Clinically-Generated Datasets to Understand Resilience Before and During the COVID-19 Pandemic.** J. Nurs. Scholarsh. 2021; Monsen KA, Austin RR, Goparaju B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811723>
56. **Urology Match Outcomes during the Coronavirus Pandemic.** J Urol 2021;101097ju0000000000001737Patel SR, Mayer WA, Taylor JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780285>
57. **How the COVID-19 Pandemic Impacted Medical Education during the Last Year of Medical School: A Class Survey.** Life (Basel) 2021; 11Franklin G, Martin C, Ruszaj M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808274>
58. **An Analysis of the Psychosocial Challenges Faced by the University Students During COVID-19 Pandemic, and the Students' Knowledge, Attitudes, and Practices Toward the Disease.** Noro Psikiyatr Ars 2021; 58:3-10Yorguner N, Bulut NS, Akvardar Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795945>
59. **Professional identity of Chinese nursing students during the COVID-19 pandemic outbreak: A nation-wide cross-sectional study.** Nurse Educ Pract 2021; 52:103040Zhang Z, Fu W, Tian C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813343>
60. **Virtual Education During COVID-19 and Beyond.** Pediatr. Neurol. 2021; 119:1-2Gelineau-Morel R, Dilts J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812265>
61. **Immediate consequences and solutions used to maintain medical education during the COVID-19 pandemic for residents and medical students: a restricted review.** Postgrad. Med. J. 2021; Chasset F, Barral M, Steichen O, Legrand A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795479>
62. **Medical education challenges and innovations during COVID-19 pandemic.** Postgrad. Med. J. 2021; Papapanou M, Routsis E, Tsamakis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782202>
63. **Optimizing e-learning in oncology during the COVID-19 pandemic and beyond.** Radiat Oncol J 2021; 39:1-7Malik M, Valiyaveetil D, Joseph D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794568>

64. **Topic evolution, disruption and resilience in early COVID-19 research.** Scientometrics 2021:1-29Zhang Y, Cai X, Fry CV *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776163>
65. **[Knowledge of thromboprophylaxis-COVID-19 in healthcare professionals in Spain].** Semergen 2021; García Vallejo O, Frías Vargas M, Gil Gil I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33810943>
66. **Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.** Trials 2021; 22:245Haran JP, Pinero JC, Zheng Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33810796>
67. **Effects of the COVID-19 Pandemic on Operative Volume and Residency Training at Two Academic Neurosurgery Centers in New Orleans.** World Neurosurg 2021; Kilgore MD, Scullen T, Mathkour M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812067>
68. **[Distance learning during the COVID-19-related school closings: the perspective of students from secondary schools].** Z Erziehungswiss 2021:1-24Züchner I, Jäkel HR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786014>

Elderly (28 articles)

1. **Aging and monocyte immunometabolism in COVID-19.** Aging (Albany NY) 2021; Pence BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795524>
2. **Why data on frailty and SARS-CoV-2 infection are basic to progress.** Aging Clin. Exp. Res. 2021; Zucchelli A, Bologna E, Marengoni A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33797742>
3. **Management of anaphylaxis due to COVID-19 vaccines in the elderly.** Allergy 2021; Bousquet J, Agache I, Blain H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811358>
4. **When Planning Meets Reality: COVID-19 Inter-pandemic Survey of Michigan Nursing Homes.** Am. J. Infect. Control 2021; Jones K, Mantey J, Washer L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33794312>
5. **The prognostic role of functional dependency in older inpatients with COVID-19.** BMC Geriatr. 2021; 21:219Plotnikov G, Waizman E, Tzur I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789578>
6. **Loneliness among older adults in the community during COVID-19: a cross-sectional survey in Canada.** BMJ Open 2021; 11:e044517Savage RD, Wu W, Li J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811054>
7. **Thymic Aging May Be Associated with COVID-19 Pathophysiology in the Elderly.** Cells 2021; 10Wang W, Thomas R, Oh J, Su DM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808998>
8. **COVID-19 Has Made the Elderly Lonelier.** Dement. Geriatr. Cogn. Dis. Extra 2021; 11:26-28Naeim M, Rezaeisharif A, Kamran A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790937>

9. **Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy.** Diagnostics (Basel) 2021; 11Polvere I, Parrella A, Casamassa G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803299>
10. **Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.** Eur. J. Cancer 2021; 148:359-370Ladoire S, Goussot V, Redersdorff E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780664>
11. **Virtual Group Exercises and Psychological Status among Community-Dwelling Older Adults during the COVID-19 Pandemic-A Feasibility Study.** Geriatrics (Basel) 2021; 6Ibrahim A, Chong MC, Khoo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810155>
12. **COVID-19 Infection among Older People Admitted to Hospital: A Cross-Sectional Analysis.** Geriatrics (Basel) 2021; 6Thiam CN, Hasmukharay K, Lim WC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800304>
13. **Rapid Support for Older Adults during the Initial Stages of the COVID-19 Pandemic: Results from a Geriatric Psychiatry Helpline.** Geriatrics (Basel) 2021; 6Wahl AS, Benson G, Hausner L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809840>
14. **Atypical Presentations among Older Adults with COVID-19 Disease: A Need for Broadening the Differential Diagnosis.** Gerontol Geriatr Med 2021; 7:2333721421999313Ohuabunwa U, Turner J, Johnson T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786339>
15. **Clinical Features of the 60 Years and Older Patients Infected with 2019 Novel Coronavirus: Can We Predict Mortality Earlier?** Gerontology 2021:1-8Genc Yavuz B, Colak S, Guven R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784699>
16. **Health, Psycho-Social Factors, and Ageism in Older Adults in Spain during the COVID-19 Pandemic.** Healthcare (Basel) 2021; 9Fernández-Ballesteros R, Sánchez-Izquierdo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804449>
17. **Hypothetical COVID-19 protection mechanism: hints from centenarians.** Immun. Ageing 2021; 18:15Guerini FR, Cesari M, Arosio B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785044>
18. **The Difficult Balance between Ensuring the Right of Nursing Home Residents to Communication and Their Safety.** Int J Environ Res Public Health 2021; 18Bolcato M, Trabucco Aurilio M, Di Mizio G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802378>
19. **Conversations in Times of Isolation: Exploring Rural-Dwelling Older Adults' Experiences of Isolation and Loneliness during the COVID-19 Pandemic in Manitoba, Canada.** Int J Environ Res Public Health 2021; 18Herron RV, Newall NEG, Lawrence BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804282>
20. **Older Users of a Befriending Service in Ireland and the Maintenance of Personal Autonomy during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Holton E, Fitzpatrick R, Maguire R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801822>
21. **Social Telepresence Robots: A Narrative Review of Experiments Involving Older Adults before and during the COVID-19 Pandemic.** Int J Environ Res

- Public Health 2021; 18Isabet B, Pino M, Lewis M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808457>
22. **Using Social Network Analysis to Identify Spatiotemporal Spread Patterns of COVID-19 around the World: Online Dashboard Development.** Int J Environ Res Public Health 2021; 18Yie KY, Chien TW, Yeh YT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802247>
 23. **Risk Perception, Preventive Behavior, and Medical Care Avoidance among American Older Adults During the COVID-19 Pandemic.** J. Aging Health 2021;8982643211002084Lu P, Kong D, Shelley M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779385>
 24. **Acceptance and Intake of COVID-19 Vaccines among Older Germans.** J Clin Med 2021; 10Malesza M, Wittmann E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808414>
 25. **Undetected Causes of Death in Hospitalized Elderly with COVID-19: Lessons from Autopsy.** J Clin Med 2021; 10Malézieux-Picard A, Ferrer Soler C, De Macedo Ferreira D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804890>
 26. **Prolonged viral clearance of severe acute respiratory syndrome coronavirus 2 in the older aged population.** J Infect Chemother 2021; Ueno A, Kawasuji H, Miyajima Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781692>
 27. **The Impact of Frailty on the Relationship between Life-Space Mobility and Quality of Life in Older Adults during the COVID-19 Pandemic.** J. Nutr. Health Aging 2021; 25:440-447Saraiva MD, Apolinario D, Avelino-Silva TJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786560>
 28. **More Active Participation in Voluntary Exercise of Older Users of Information and Communicative Technology even during the COVID-19 Pandemic, Independent of Frailty Status.** J. Nutr. Health Aging 2021; 25:516-519Satake S, Kinoshita K, Arai H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786570>

Epidemiology (130 articles)

1. **Theoretical and numerical analysis for transmission dynamics of COVID-19 mathematical model involving Caputo-Fabrizio derivative.** Adv Differ Equ 2021; 2021:184Thabet STM, Abdo MS, Shah K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777126>
2. **High-Resolution Agent-Based Modeling of COVID-19 Spreading in a Small Town.** Adv Theory Simul 2021; 4:2000277Truszkowska A, Behring B, Hasanyan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786413>
3. **Policy Interventions, Social Distancing, and SARS-CoV-2 Transmission in the United States: A Retrospective State-level Analysis.** Am. J. Med. Sci. 2021; Dreher N, Spiera Z, McAuley FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775425>
4. **The Australian Response to the COVID-19 Pandemic: A co-ordinated and effective strategy.** Anaesth Crit Care Pain Med 2021;100859Holley A, Coatsworth N, Lipman J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812079>
5. **COVID-19 pandemic: Data from New York.** Anesthesiologie Intensivmedizin Notfallmedizin Schmerztherapie 2021; 56:150-151Ventzke MM.

6. **Locking down the Impact of New Zealand's COVID-19 Alert Level Changes on Pets.** Animals (Basel) 2021; 11Esam F, Forrest R, Waran N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33801824>
7. **Insects and SARS-CoV-2: Analysis of the Potential Role of Vectors in European Countries.** Ann. Ig. 2021; Dutto M, Lauria G, Drago A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779675>
8. **Implications of a highly transmissible variant of SARS-CoV-2 for children.** Arch. Dis. Child. 2021; Ratmann O, Bhatt S, Flaxman S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785527>
9. **Effect of COVID-19 travel restrictions on Phoenix air quality after accounting for boundary layer variations.** Atmos Environ X 2021; 10:100105Miech JA, Herckes P, Fraser MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778482>
10. **Factors Affecting Voluntary Self-Isolation Behavior to Cope with a Pandemic: Empirical Evidence from Colombia vs. Spain in Times of COVID-19.** Behav Sci (Basel) 2021; 11Escandon-Barbosa D, Hurtado A, Gomez A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33803932>
11. **Effect of different resumption strategies to flatten the potential COVID-19 outbreaks amid society reopens: a modeling study in China.** BMC Public Health 2021; 21:604Ge Y, Zhang WB, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781224>
12. **Is Covid-19 community level testing effective in reaching at-risk populations? Evidence from spatial analysis of New Orleans patient data at walk-up sites.** BMC Public Health 2021; 21:632Hernandez JH, Karletsos D, Avegno J, Reed CH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789647>
13. **Epidemiological investigation and intergenerational clinical characteristics of 24 coronavirus disease patients associated with a supermarket cluster: a retrospective study.** BMC Public Health 2021; 21:647Tian S, Wu M, Chang Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33794836>
14. **Assessing critical gaps in COVID-19 testing capacity: the case of delayed results in Ecuador.** BMC Public Health 2021; 21:637Torres I, Sippy R, Sacoto F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33794837>
15. **Exploring the influence of human mobility factors and spread prediction on early COVID-19 in the USA.** BMC Public Health 2021; 21:615Zheng Z, Xie Z, Qin Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781260>
16. **Seroprevalence of anti-SARS-CoV-2 IgG among adolescents at military fitness-for-duty evaluation.** BMJ Mil Health 2021; Giuliano E, Gennaro V, Milani GP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811156>
17. **Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study.** BMJ Open 2021; 11:e048391Dennis A, Wamil M, Alberts J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785495>
18. **COVID-19 in Oromia Region of Ethiopia: a review of the first 6 months' surveillance data.** BMJ Open 2021; 11:e046764Gudina EK, Gobena D, Debela T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782023>
19. **Comparison of Cancer Patients to Non-Cancer Patients among COVID-19 Inpatients at a National Level.** Cancers (Basel) 2021; 13Bernard A, Cottenet J, Bonniaud P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801131>

20. **Socioeconomic Inequalities and Ethnicity Are Associated with a Positive COVID-19 Test among Cancer Patients in the UK Biobank Cohort.** Cancers (Basel) 2021; 13Lee SF, Nikšić M, Rachet B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806016>
21. **Sensitivity assessment and optimal economic evaluation of a new COVID-19 compartmental epidemic model with control interventions.** Chaos Solitons Fractals 2021;110885Asamoah JKK, Jin Z, Sun GQ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776250>
22. **A fractional-order model describing the dynamics of the novel coronavirus (COVID-19) with nonsingular kernel.** Chaos Solitons Fractals 2021;110859Boudaoui A, El Hadj Moussa Y, Hammouch Z, Ullah S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776249>
23. **Measuring the impact of mitigation measures on infection risk of covid-19 in Hong Kong since February 2020.** Cities 2021; 114:103192Shen J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776182>
24. **Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among Health Care Workers-Zambia, July 2020.** Clin Infect Dis 2021; Fwoloshi S, Hines JZ, Barradas DT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784382>
25. **Contact Tracing for COVID-19: The Use of Motivational Interviewing and the Role of Social Work.** Clin. Soc. Work J. 2021:1-10Hohman M, McMaster F, Woodruff SI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776159>
26. **Applying Laplace Adomian decomposition method (LADM) for solving a model of Covid-19.** Comput. Methods Biomech. Biomed. Engin. 2021:1-11Nave O, Shemesh U, HarTuv I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787397>
27. **Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy.** Diagnostics (Basel) 2021; 11Polvere I, Parrella A, Casamassa G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803299>
28. **Modeling COVID-19 Pandemic with Hierarchical Quarantine and Time Delay.** Dyn Games Appl 2021:1-23Yang W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777480>
29. **A privacy and security analysis of early-deployed COVID-19 contact tracing Android apps.** Empir Softw Eng 2021; 26:36Hatamian M, Wairimu S, Momen N, Fritsch L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776548>
30. **SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy.** Environ. Res. 2021:111097Vinceti M, Filippini T, Rothman KJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811866>
31. **Strategies for Ensuring Required Service Level for COVID-19 Herd Immunity in Indian Vaccine Supply Chain.** Eur J Oper Res 2021; Sinha P, Kumar S, Chandra C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776195>
32. **Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021.** Euro Surveill 2021; 26.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33797392>
33. **Practical recommendations for the prevention and management of COVID-19 in low-income and middle-income settings: adapting clinical experience from**

- the field.** *Fam Med Community Health* 2021; 9Fahme SA, Walsh KF, Rouzier V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811089>
34. **SARS-CoV-2 Testing of 11,884 Healthcare Workers at an Acute NHS Hospital Trust in England: A Retrospective Analysis.** *Front Med (Lausanne)* 2021; 8:636160Hanrath AT, Schim van der Loeff I, Lendrem DW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777979>
 35. **Epidemiology, Clinical Features and Prognostic Factors of Pediatric SARS-CoV-2 Infection: Results From an Italian Multicenter Study.** *Front Pediatr* 2021; 9:649358Garazzino S, Lo Vecchio A, Pierantoni L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796491>
 36. **Surveillance of Acute SARS-CoV-2 Infections in School Children and Point-Prevalence During a Time of High Community Transmission in Switzerland.** *Front Pediatr* 2021; 9:645577Kriemler S, Ulyte A, Ammann P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796490>
 37. **COVID-19 Mortality and Case-Fatality Rates in Sergipe State, Northeast Brazil, From April to June 2020.** *Front Public Health* 2021; 9:581618Martins-Filho PR, Araújo AAS, Góes MAO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791265>
 38. **The Traffic Light Approach: Indicators and Algorithms to Identify Covid-19 Epidemic Risk Across Italian Regions.** *Front Public Health* 2021; 9:650243Paroni L, D'Apice C, Ussai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796500>
 39. **The Quixotic Task of Forecasting Peaks of COVID-19: Rather Focus on Forward and Backward Projections.** *Front Public Health* 2021; 9:623521Reis RF, Oliveira RS, Quintela BM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796495>
 40. **Simulation of COVID-19 Propagation Scenarios in the Madrid Metropolitan Area.** *Front Public Health* 2021; 9:636023Singh DE, Marinescu MC, Guzmán-Merino M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796497>
 41. **A risk analysis of COVID-19 infections in Kolkata Metropolitan City: A GIS based study.** *Geohealth* 2021:e2020GH000368Nath B, Majumder S, Sen J, Rahman MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786406>
 42. **COVID-19 Infection among Older People Admitted to Hospital: A Cross-Sectional Analysis.** *Geriatrics (Basel)* 2021; 6Thiam CN, Hasmukharay K, Lim WC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800304>
 43. **Global Evidence of Temperature Acclimation of COVID-19 D614G Linage.** *Glob Chall* 2021:2000132Hao Z, Li R, Hao C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786200>
 44. **Racial Disparities in the Epidemiology of COVID-19 in Georgia: Trends Since State-Wide Reopening.** *Health Equity* 2021; 5:91-99Porter G, Desai K, George V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778312>
 45. **The association between socioeconomic status and mobility reductions in the early stage of England's COVID-19 epidemic.** *Health Place* 2021; 69:102563Lee WD, Qian M, Schwanen T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799134>
 46. **Impact of Central Quarantine Inside a Lockdown Hospital Due to COVID-19 Pandemic on Psychological Disorders among Health Care Staffs in Central Hospitals of Hanoi, Vietnam, 2020.** *Health Serv Insights* 2021;

- 14:1178632921999662Lan VTH, Dzung LT, Quyen BTT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33795936>
47. **Incidence and Death Rates from COVID-19 Are Not Always Coupled: An Analysis of Temporal Data on Local, Federal, and National Levels.** Healthcare (Basel) 2021; 9Borgmann S, Meintrup D, Reimer K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802866>
48. **Forecasting COVID-19 Confirmed Cases Using Empirical Data Analysis in Korea.** Healthcare (Basel) 2021; 9Lee DH, Kim YS, Koh YY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804380>
49. **Prevention and Control of COVID-19 Pandemic on International Cruise Ships: The Legal Controversies.** Healthcare (Basel) 2021; 9Zhang X, Wang C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806680>
50. **Potential Protective Effect from COVID-19 Conferred by Altitude: A Longitudinal Analysis in Peru During Full Lockdown.** High. Alt. Med. Biol. 2021; Thomson TM, Casas F, Guerrero HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780636>
51. **Findings from the first public COVID-19 temporary test centre in Hong Kong.** Hong Kong Med. J. 2021; Leung WLH, Yu ELM, Wong SC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33790053>
52. **Screening around a COVID-19 cluster: Exploring its impact on a local virus outbreak.** Infect Dis Now 2021; Gault G, Monpierre O, Carion G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781960>
53. **Molecular epidemiology analysis of early variants of SARS-CoV-2 reveals the potential impact of mutations P504L and Y541C (NSP13) in the clinical COVID-19 outcomes.** Infect Genet Evol 2021:104831Cao C, He L, Tian Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798758>
54. **Predictive analysis of COVID-19 eradication with vaccination in India, Brazil, and U.S.A.** Infect Genet Evol 2021:104834Chaturvedi D, Chakravarty U.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798755>
55. **Phylogenomic tracing of asymptomatic transmission in a COVID-19 outbreak.** Innovation (N Y) 2021:100099Zhang J, Ding N, Song Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778799>
56. **How fast should social restrictions be eased in England as COVID-19 vaccinations are rolled out?** Int J Clin Pract 2021:e14191Miles DK, Heald AH, Stedman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788370>
57. **Experience of the COVID-19 Pandemic in Rural Odisha, India: Knowledge, Preventative Actions, and Impacts on Daily Life.** Int J Environ Res Public Health 2021; 18Bauza V, Sclar GD, Bisoyi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799698>
58. **Altitude and SARS-CoV-2 Infection in the First Pandemic Wave in Spain.** Int J Environ Res Public Health 2021; 18Castilla J, Fresán U, Trobajo-Sanmartín C, Guevara M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806642>
59. **Adherence to COVID-19 Prevention Measures in the Democratic Republic of the Congo, Results of Two Consecutive Online Surveys.** Int J Environ Res Public Health 2021; 18Ditekemena JD, Mavoko HM, Obimpeh M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806286>

60. **Comparisons between the Neighboring States of Amazonas and Pará in Brazil in the Second Wave of COVID-19 Outbreak and a Possible Role of Early Ambulatory Treatment.** Int J Environ Res Public Health 2021; 18Emmerich FG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805135>
61. **Who Got Infected with COVID-19? A Study of College Students in Wuhan (China).** Int J Environ Res Public Health 2021; 18Fan C, Li M, Li X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801267>
62. **The Epidemiological Characteristics of the COVID-19 Pandemic in Europe: Focus on Italy.** Int J Environ Res Public Health 2021; 18Gabutti G, d'Anchera E, De Motoli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805624>
63. **The Geography of the Covid-19 Pandemic: A Data-Driven Approach to Exploring Geographical Driving Forces.** Int J Environ Res Public Health 2021; 18Hass FS, Jokar Arsanjani J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802001>
64. **Transmission Dynamics of SARS-CoV-2 during an Outbreak in a Roma Community in Thessaly, Greece-Control Measures and Lessons Learned.** Int J Environ Res Public Health 2021; 18Koureas M, Speletas M, Bogogiannidou Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799791>
65. **SEAHIR: A Specialized Compartmental Model for COVID-19.** Int J Environ Res Public Health 2021; 18Leontitsis A, Senok A, Alsheikh-Ali A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800896>
66. **Measuring Time-Varying Effective Reproduction Numbers for COVID-19 and Their Relationship with Movement Control Order in Malaysia.** Int J Environ Res Public Health 2021; 18Musa KI, Arifin WN, Mohd MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809958>
67. **Long Diagnostic Delay with Unknown Transmission Route Inversely Correlates with the Subsequent Doubling Time of Coronavirus Disease 2019 in Japan, February-March 2020.** Int J Environ Res Public Health 2021; 18Ogata T, Tanaka H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805162>
68. **The Neighborhood Contagion Focus as a Spatial Unit for Diagnosis and Epidemiological Action against COVID-19 Contagion in Urban Spaces: A Methodological Proposal for Its Detection and Delimitation.** Int J Environ Res Public Health 2021; 18Perles MJ, Sortino JF, Mérida MF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803729>
69. **A Two-Phase Stochastic Dynamic Model for COVID-19 Mid-Term Policy Recommendations in Greece: A Pathway towards Mass Vaccination.** Int J Environ Res Public Health 2021; 18Rachaniotis NP, Dasaklis TK, Fotopoulos F, Tinios P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802501>
70. **Effectiveness of Epidemic Preventive Policies and Hospital Strategies in Combating COVID-19 Outbreak in Taiwan.** Int J Environ Res Public Health 2021; 18Tan TW, Tan HL, Chang MN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810438>
71. **Pathways Improving Compliance with Preventive Behaviors during the Remission Period of the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Wang J, Rao N, Han B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800648>

72. **Racial and Ethnic Disparities in Years of Potential Life Lost Attributable to COVID-19 in the United States: An Analysis of 45 States and the District of Columbia.** Int J Environ Res Public Health 2021; 18Xu JJ, Chen JT, Belin TR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809240>
73. **Fine-Scale Space-Time Cluster Detection of COVID-19 in Mainland China Using Retrospective Analysis.** Int J Environ Res Public Health 2021; 18Xu M, Cao C, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808290>
74. **Using Social Network Analysis to Identify Spatiotemporal Spread Patterns of COVID-19 around the World: Online Dashboard Development.** Int J Environ Res Public Health 2021; 18Yie KY, Chien TW, Yeh YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802247>
75. **What Are the Reasons for the Different COVID-19 Situations in Different Cities of China? A Study from the Perspective of Population Migration.** Int J Environ Res Public Health 2021; 18Zheng Y, Huang J, Yin Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801124>
76. **A descriptive audit of healthcare workers exposed to COVID-19 at a tertiary care center in India.** Int J Gynaecol Obstet 2021; Mansoor S, Sharma KA, Ranjan P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792934>
77. **The impact of the non-essential business closure policy on Covid-19 infection rates.** Int J Health Econ Manag 2021;1-40Song H, McKenna R, Chen AT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792808>
78. **Emergence and outcome of the SARS-CoV-2 "Marseille-4" variant.** Int J Infect Dis 2021; Fournier PE, Colson P, Levasseur A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785459>
79. **COVID-19 and Syndemic challenges in 'Battling the Big Three': HIV, TB and malaria.** Int J Infect Dis 2021; Velavan TP, Meyer CG, Esen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781904>
80. **An investigation into the rates of transmission of SARS-CoV-2 during the first 6 weeks of the 2020-2021 academic year in primary and post-primary schools in Cork and Kerry, Ireland.** Ir. J. Med. Sci. 2021;1-6White P, O'Sullivan MB, Murphy N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792855>
81. **Is returning to school during the COVID-19 pandemic stressful? A study on immediate mental health status of Chinese college students.** J. Affect. Disord. 2021; 287:261-267Wang D, Chen H, Zhai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799046>
82. **Shifting US Patterns of COVID-19 Mortality by Race and Ethnicity From June - December 2020.** J. Am. Med. Dir. Assoc. 2021; Kumar A, Roy I, Karmarkar AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775597>
83. **Stability analysis of COVID-19 model with fractional-order derivative and a delay in implementing the quarantine strategy.** J Appl Math Comput 2021;1-27Hikal MM, Elsheikh MMA, Zahra WK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776609>
84. **Analysis of the Clinical and Epidemiological Meaning of Screening Test for SARS-CoV-2: Considerations in the Chronic Kidney Disease Patients during the COVID-19 Pandemic.** J Clin Med 2021; 10Martino F, Amici G, Grandesso S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803083>

85. **Assessing Interventions against Coronavirus Disease 2019 (COVID-19) in Osaka, Japan: A Modeling Study.** J Clin Med 2021; 10:Nakajo K, Nishiura H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803634>
86. **Complex network model for COVID-19: Human behavior, pseudo-periodic solutions and multiple epidemic waves.** J Math Anal Appl 2021:125171Silva CJ, Cantin G, Cruz C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776143>
87. **WHO guidance on ethics in outbreaks and the COVID-19 pandemic: a critical appraisal.** J. Med. Ethics 2021; Saxena A, Bouvier PA, Shamsi-Gooshki E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789948>
88. **COVID-19: Were Public Health Interventions and the Disclosure of Patients' Contact History Effective in Upholding Social Distancing? Evidence from South Korea.** J Multidiscip Healthc 2021; 14:705-712Im J, Kim J, Choeh JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790569>
89. **Exploring Large Community- and Clinically-Generated Datasets to Understand Resilience Before and During the COVID-19 Pandemic.** J. Nurs. Scholarsh. 2021; Monsen KA, Austin RR, Goparaju B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811723>
90. **The incubation period of coronavirus disease (COVID-19): A tremendous public health threat-Forecasting from publicly available case data in India.** J Public Aff 2021:e2619Dwivedi R, Athe R, Mahesh K, Modem PK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786017>
91. **Living with the virus: Infection and epidemiology of COVID-19 in hotspot area of India.** J Public Aff 2021:e2651Giri R, Kumar A, Saini M, Sharma RK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786027>
92. **COVID-19 pandemic and transmission factors: An empirical investigation of different countries.** J Public Aff 2021:e2648Singh PK, Kiran R, Bhatt RK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786025>
93. **Role of high-dose exposure in transmission hot zones as a driver of SARS-CoV-2 dynamics.** J R Soc Interface 2021; 18:20200916Wodarz D, Komarova NL, Schang LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784886>
94. **COVID-19 pandemic evolution in the Brazilian Indigenous population.** J Racial Ethn Health Disparities 2021:1-17Mendes MF, Pereira LR, Lima TM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782907>
95. **Limiting mobility during COVID-19, when and to what level? An international comparative study using change point analysis.** J Transp Health 2021; 20:101019Gargoum SA, Gargoum AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777694>
96. **CPMPARISON between COVID-19 and MERS demographic data in Saudi Arabia: a retrospective study.** Libyan J. Med. 2021; 16:1910195Mohamed R, Abdullah Thagfan F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797350>
97. **SARS-CoV-2 Molecular Transmission Clusters and Containment Measures in Ten European Regions during the First Pandemic Wave.** Life (Basel) 2021; 11Bousali M, Dimadi A, Kostaki EG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803490>
98. **Immunity credentials using self-sovereign identity for combating COVID-19 pandemic.** Mater Today Proc 2021; Shuaib M, Alam S, Shahnawaz Nasir M,

- Shabbir Alam M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777707>
99. **COVID-19 risk assessment at the opening ceremony of the Tokyo 2020 Olympic Games.** *Microb Risk Anal* 2021:100162Murakami M, Miura F, Kitajima M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778137>
 100. **Had COVID-19 spread in the community before the first confirmed case in Nagasaki, Japan?** *Microbes Infect* 2021:104812Kaku N, Ota K, Sasaki D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781868>
 101. **SARS-CoV-2 N501Y Introductions and Transmissions in Switzerland from Beginning of October 2020 to February 2021-Implementation of Swiss-Wide Diagnostic Screening and Whole Genome Sequencing.** *Microorganisms* 2021; 9Goncalves Cabecinhas AR, Roloff T, Stange M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806013>
 102. **Clinical and epidemiological characteristics of 646 hospitalised SARS-Cov-2 positive patients in Rivers State Nigeria: a prospective observational study.** *Pan Afr. Med. J.* 2021; 38:25Alasia D, Ow Honda G, Maduka O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777293>
 103. **[Epidemiological and clinical profile of children with Coronavirus disease (COVID-19) at the Center for the Treatment of Epidemics and Infection Prevention (CTEIP) of the University Hospital of Donka in Conakry].** *Pan Afr. Med. J.* 2020; 37:363Camara E, Barry IK, Diallo FB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796176>
 104. **COVID-19 control pitfalls and challenges and drivers of SARS-CoV-2 transmission in Zimbabwe.** *Pan Afr. Med. J.* 2021; 38:28Murewanhema G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777296>
 105. **Unexpected low burden of coronavirus disease 2019 (COVID-19) in sub-Saharan Africa region despite disastrous predictions: reasons and perspectives.** *Pan Afr. Med. J.* 2020; 37:352Tcheutchoua DN, Tankeu AT, Angong DLW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796166>
 106. **Molecular Analysis of SARS-CoV-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level.** *Pathogens* 2021; 10Sallam M, Mahafzah A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807556>
 107. **SEIR order parameters and eigenvectors of the three stages of completed COVID-19 epidemics: with an illustration for Thailand January to May 2020.** *Phys. Biol.* 2021; Frank T, Chiangga S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789256>
 108. **Epidemic models with discrete state structures.** *Physica D* 2021:132903Liu S, Li MY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782628>
 109. **Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers.** *Proc Natl Acad Sci U S A* 2021; 118Buckner JH, Chowell G, Springborn MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811185>
 110. **Forecasting Outbreak of COVID-19 in Turkey; Comparison of Box-Jenkins, Brown's Exponential Smoothing and Long Short-Term Memory Models.** *Process Saf Environ Prot* 2021; Guleryuz D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776248>

111. **Migration, ethnicity, racism and the COVID-19 pandemic: A conference marking the launch of a new Global Society.** Public Health Pract (Oxf) 2021; 2:100088Gruer L, Agyemang C, Bhopal R *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778793>
112. **COVID-19 Case Surveillance: Trends in Person-Level Case Data Completeness, United States, April 5-September 30, 2020.** Public Health Rep. 2021:333549211006973Gold JAW, DeCuir J, Coyle JP *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789540>
113. **Numerical analysis of COVID-19 model with constant fractional order and variable fractal dimension.** Results Phys 2021; 20:103673Alkahtani BST, Jain S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786293>
114. **A fractional order Sitr mathematical model for forecasting of transmission of COVID-19 of India with lockdown effect.** Results Phys 2021; 24:104067Askar SS, Ghosh D, Santra PK *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777667>
115. **Factor Analysis Approach to Classify COVID-19 Datasets in Several Regions.** Results Phys 2021:104071Reza Mahmoudi M, Baleanu D, Band SS, Mosavi A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777669>
116. **SARS-CoV-2 Spread Dynamics in Italy: The Calabria Experience.** Rev. Recent Clin. Trials 2021; Abenavoli L, Cinaglia P, Procopio AC *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33797377>
117. **Privacy versus Public Health? A Reassessment of Centralised and Decentralised Digital Contact Tracing.** Sci Eng Ethics 2021; 27:23White L, van Basshuysen P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779818>
118. **[Evaluation of social distancing measures on the transmissibility of COVID-19 in rural areas. Retrospective longitudinal study of posible cases].** Semergen 2021; Peña-Galo E, Turón-Alcaine JM, Gracia-Carrasco E, Alcedo-González J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812795>
119. **Applications of Big Data Analytics to Control COVID-19 Pandemic.** Sensors (Basel) 2021; 21Alsunaidi SJ, Almuhaideb AM, Ibrahim NM *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33805218>
120. **Count-Valued Time Series Models for COVID-19 Daily Death Dynamics.** Stat (Int Stat Inst) 2021:e369Palmer WR, Davis RA, Zheng T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786170>
121. **A hierarchical spatio-temporal model to analyze relative risk variations of COVID-19: a focus on Spain, Italy and Germany.** Stoch. Environ. Res. Risk Assess. 2021:1-16Jalilian A, Mateu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776559>
122. **Mobility and COVID-19 mortality across Scandinavia: A modeling study.** Travel Med Infect Dis 2021; 41:102039Sulyok M, Walker MD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785456>
123. **Multiple Early Introductions of SARS-CoV-2 to Cape Town, South Africa.** Viruses 2021; 13Engelbrecht S, Delaney K, Kleinhans B *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33810168>
124. **A Strong Seasonality Pattern for Covid-19 Incidence Rates Modulated by UV Radiation Levels.** Viruses 2021; 13Karapiperis C, Kouklis P, Papastratos S *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33805449>

125. **SARS-CoV-2 Infections in Animals: Reservoirs for Reverse Zoonosis and Models for Study.** Viruses 2021; 13Prince T, Smith SL, Radford AD *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802857>
126. **Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.** Viruses 2021; 13Singh J, Samal J, Kumar V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33803400>
127. **Spatiotemporal Analysis of COVID-19 Incidence Data.** Viruses 2021; 13Spassiani I, Sebastiani G, Palù G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799900>
128. **Variation in Non-external and External Causes of Death in Peru in Relation to the COVID-19 Lockdown.** Yale J. Biol. Med. 2021; 94:23-40Calderon-Anyosa RJC, Bilal U, Kaufman JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795980>
129. **The Impact of the Social Distancing Policy on COVID-19 Incidence Cases and Deaths in Iran from February 2020 to January 2021: Insights from an Interrupted Time Series Analysis.** Yale J. Biol. Med. 2021; 94:13-21Saki M, Ghanbari MK, Behzadifar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795979>
130. **COVID-19 pandemic: a health challenge for commoners during the first unlock phase in India.** Z Gesundh Wiss 2021; 1-7Halder B, Bandyopadhyay J, Banik P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777651>

Gastro-enterology (15 articles)

1. **Hepatic transplant during SARS-CoV-2 (COVID-19) pandemic. A literature review.** Cir. Cir. 2021; 89:269-274Pérez-González B, Thomas-Lora FC, Hoyo I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784290>
2. **Acute Recurrent Pancreatitis and COVID-19 Infection: A Case Report with Literature Review.** Cureus 2021; 13:e13490Sandhu H, Mallik D, Lokavarapu MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777577>
3. **A Pictorial Review of the Role of Imaging in the Detection, Management, Histopathological Correlations, and Complications of COVID-19 Pneumonia.** Diagnostics (Basel) 2021; 11Brogna B, Bignardi E, Brogna C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806423>
4. **Factors associated with risk of COVID-19 contagion for endoscopy healthcare workers: A survey from the Italian society of digestive endoscopy.** Dig. Liver Dis. 2021; Mariani A, Capurso G, Marasco G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785281>
5. **The Unique Impact of COVID-19 on Human Gut Microbiome Research.** Front Med (Lausanne) 2021; 8:652464Burchill E, Lymberopoulos E, Menozzi E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796545>
6. **Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.** Front Med (Lausanne) 2021; 8:626425Hegyi PJ, Váncsa S, Ocskay K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777974>
7. **COVID-19 in Children With Liver Disease.** Front Pediatr 2021; 9:616381Di Giorgio A, Hartleif S, Warner S, Kelly D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777974>

term=33777864

8. **Enhanced donor screening for faecal microbial transplantation during COVID-19.** Gut 2021; Parvathy SN, Lenehan JG, Fernandes R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789964>
9. **Alterations in the human oral and gut microbiomes and lipidomics in COVID-19.** Gut 2021; Ren Z, Wang H, Cui G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789966>
10. **Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment.** Gut Liver 2021; Song JE, Kang MK, Lee YR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782216>
11. **A case of neglected hepatorenal dysfunction during the COVID pandemic.** Indian J. Med. Microbiol. 2021; Chaudhry R, Batra P, Khullar S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781657>
12. **Cholestatic liver injury in COVID-19 is a rare and distinct entity and is associated with increased mortality.** J Intern Med 2021; Da BL, Suchman K, Roth N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786906>
13. **Skin and gastrointestinal symptoms in COVID-19.** Prz Gastroenterol 2020; 15:301-308 Ciechanowicz P, Lewandowski K, Szymańska E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777269>
14. **Approach to endoscopic procedures during COVID-19 pandemic - not as expected.** Prz Gastroenterol 2020; 15:275-278 Ratyński T, Bednarczuk A, Rydzewska G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777265>
15. **How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician.** World J. Gastroenterol. 2021; 27:1022-1042 Chebli JMF, Queiroz NSF, Damião A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776370>

Guidelines (12 articles)

1. **Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BeISACI).** Acta Clin. Belg. 2021;1-6 Tuyls S, Van Der Brempt X, Faber M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792500>
2. **Among equity and dignity: an argument-based review of European ethical guidelines under COVID-19.** BMC Med. Ethics 2021; 22:36 Perin M, De Panfilis L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789633>
3. **COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE).** Bull Cancer 2021; Rouger-Gaudichon J, Bertrand Y, Boissel N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781551>
4. **Corneal transplantation during the COVID-19 pandemic: An operational guide.** Eur. J. Ophthalmol. 2021;11206721211006565 Franch A, Fasolo A, Carraro P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775164>
5. **Developing a Thai national critical care allocation guideline during the COVID-19 pandemic: a rapid review and stakeholder consultation.** Health Res. Policy

- Syst. 2021; 19:47Marshall AI, Archer R, Witthayapipopsakul W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789671>
6. **The impact of coronavirus outbreak on breastfeeding guidelines among Brazilian hospitals and maternity services: a cross-sectional study.** Int Breastfeed J 2021; 16:30Gonçalves-Ferri WA, Pereira-Cellini FM, Coca K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789708>
 7. **Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19.** J Eur Acad Dermatol Venereol 2021; Arenbergerova M, Lallas A, Nagore E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33780557>
 8. **WHO guidance on ethics in outbreaks and the COVID-19 pandemic: a critical appraisal.** J. Med. Ethics 2021; Saxena A, Bouvier PA, Shamsi-Gooshki E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789948>
 9. **Measuring Awareness of Infection Control Guidelines for Patients with COVID-19 in Radiology Departments in Saudi Arabia.** Med Sci (Basel) 2021; 9Almatari M, Alghamdi A, Alamri S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809671>
 10. **People perceive themselves to adhere more strictly to COVID-19 guidelines than others.** Psychol Health Med 2021;1-8Mojzisch A, Elster C, Germar M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779442>
 11. **Editorial: The Need for Harmonised International Guidelines ahead of COVID-19 Human Infection Studies.** Public Health Rev. 2021; 42:1603962Kirchhelle C, Vanderslott S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796341>
 12. **Treatment Protocol for COVID-19 Based on T2R Phenotype.** Viruses 2021; 13Taha MA, Hall CA, Shortess CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803811>

Imaging (33 articles)

1. **Optical coherence tomography angiography features in post COVID-19 pneumonia patients: a pilot study.** Am. J. Ophthalmol. 2021; Cennamo G, Reibaldi M, Montorio D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781767>
2. **Federated learning for COVID-19 screening from Chest X-ray images.** Appl Soft Comput 2021; 106:107330Feki I, Ammar S, Kessentini Y, Muhammad K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776607>
3. **Retinal Microvascular Impairment in COVID-19 Bilateral Pneumonia Assessed by Optical Coherence Tomography Angiography.** Biomedicines 2021; 9González-Zamora J, Bilbao-Malavé V, Gándara E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33801324>
4. **SARS-CoV-2 reinfection: "New baseline" imaging concept in the era of COVID-19.** Clin Imaging 2021; 78:142-145Katal S, Myers L, Gholamrezanezhad A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813316>
5. **Pitfalls in chest CT findings of COVID-19 patients infected during hospitalisation.** Clin Imaging 2021; 78:146-153Shirota G, Sato Y, Itoh D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813317>

6. **Exploring the effect of image enhancement techniques on COVID-19 detection using chest X-ray images.** Comput. Biol. Med. 2021; 132:104319 Rahman T, Khandakar A, Qiblawey Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799220>
7. **Deep learning for diagnosis of COVID-19 using 3D CT scans.** Comput. Biol. Med. 2021; 132:104306 Serte S, Demirel H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780867>
8. **Vascular Abnormalities Detected with Chest CT in COVID-19: Spectrum, Association with Parenchymal Lesions, Cardiac Changes, and Correlation with Clinical Severity (COVID-CAVA Study).** Diagnostics (Basel) 2021; 11 Qanadli SD, Sauter AW, Alkadhi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805443>
9. **Artificial Intelligence Applied to Chest X-ray for Differential Diagnosis of COVID-19 Pneumonia.** Diagnostics (Basel) 2021; 11 Salvatore C, Interlenghi M, Monti CB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809625>
10. **Predicting the outcome in confirmed COVID-19 patients with coronary artery disease: a key role for the first chest computed tomography.** Egypt Heart J 2021; 73:35 Omid N, Lotfi-Tokaldany M, Shirani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788067>
11. **Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients.** Eur J Radiol 2021; 138:109676 Balbi M, Conti C, Imeri G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798931>
12. **Development and multicenter validation of a CT-based radiomics signature for predicting severe COVID-19 pneumonia.** Eur Radiol 2021:1-12 Li L, Wang L, Zeng F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786655>
13. **Echocardiographic Characteristics and Outcome in Patients With COVID-19 Infection and Underlying Cardiovascular Disease.** Front Cardiovasc Med 2021; 8:642973 Li Y, Fang L, Zhu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796573>
14. **Shedding Light on the Direct and Indirect Impact of the COVID-19 Pandemic on the Lebanese Radiographers or Radiologic Technologists: A Crisis within Crises.** Healthcare (Basel) 2021; 9 Itani R, Alnafeea M, Tannoury M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807020>
15. **Relationship between CT Severity Score and Capillary Blood Oxygen Saturation in Patients with COVID-19 Infection.** Indian J. Crit. Care Med. 2021; 25:279-283 Aalinezhad M, Alikhani F, Akbari P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790507>
16. **Early CT in COVID-19: Should I or Should I Not?** Indian J. Crit. Care Med. 2021; 25:251-252 Govil D, Kumar PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790500>
17. **Volume-of-Interest Aware Deep Neural Networks for Rapid Chest CT-Based COVID-19 Patient Risk Assessment.** Int J Environ Res Public Health 2021; 18 Chatzitofis A, Cancian P, Gkitsas V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799509>
18. **Role of Hybrid Deep Neural Networks (HDNNs), Computed Tomography, and Chest X-rays for the Detection of COVID-19.** Int J Environ Res Public Health

- 2021; 18Irfan M, Iftikhar MA, Yasin S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809665>
19. **Higher Accuracy of Lung Ultrasound over Chest X-ray for Early Diagnosis of COVID-19 Pneumonia.** Int J Environ Res Public Health 2021; 18Martínez Redondo J, Comas Rodríguez C, Pujol Salud J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801638>
 20. **Trends over Time of Lung Function and Radiological Abnormalities in COVID-19 Pneumonia: A Prospective, Observational, Cohort Study.** J Clin Med 2021; 10Santus P, Flor N, Saad M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801455>
 21. **Lung Ultrasound Patterns and Clinical-Laboratory Correlates during COVID-19 Pneumonia: A Retrospective Study from North East Italy.** J Clin Med 2021; 10Senter R, Capone F, Pasqualin S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804762>
 22. **Longitudinal Chest CT Features in Severe/Critical COVID-19 Cases and the Predictive Value of the Initial CT for Mortality.** J Inflamm Res 2021; 14:1111-1124Li H, Luo S, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790623>
 23. **A family case of COVID-19 pneumonia with different chest CT features and duration of SARS-CoV-2 shedding: a case report from Japan.** Jpn. J. Infect. Dis. 2021; Ochiai S, Kama Y, Hirai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790072>
 24. **A Cascade-SEME network for COVID-19 detection in chest c-ray images.** Med. Phys. 2021; Lv D, Wang Y, Wang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778966>
 25. **Low Sensitivity of Admission Lung US Compared to Chest CT for Diagnosis of Lung Involvement in a Cohort of 82 Patients with COVID-19 Pneumonia.** Medicina (Kaunas) 2021; 57Quarato CMI, Mirijello A, Lacedonia D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806432>
 26. **Recommendations for Performing Bronchoscopy in Times of the COVID-19 Pandemic - Update 12/2020.** Pneumologie 2021; 75:187-190Darwiche K, Ross B, Gesierich W *et al.*
 27. **Imaging Utilization and Outcomes in Vulnerable Populations during COVID-19 in New York City.** Radiol Cardiothorac Imaging 2020; 2:e200464Toy D, Mahmood SS, Rotman J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778647>
 28. **Clinical and radiological findings for the new multisystem inflammatory syndrome in children associated with COVID-19.** Radiologia (Roma) 2021; Sánchez-Oro R, Fatahi Bandpey ML, García Martínez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785227>
 29. **Hyperparameter Optimization for COVID-19 Pneumonia Diagnosis Based on Chest CT.** Sensors (Basel) 2021; 21Lacerda P, Barros B, Albuquerque C, Conci A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804609>
 30. **COVID-19 Recognition Using Ensemble-CNNs in Two New Chest X-ray Databases.** Sensors (Basel) 2021; 21Vantaggiato E, Paladini E, Bougourzi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802428>

31. **A Few-Shot U-Net Deep Learning Model for COVID-19 Infected Area Segmentation in CT Images.** Sensors (Basel) 2021; 21:Voulodimos A, Protopapadakis E, Katsamenis I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810066>
32. **COVID-19 Associated Pneumonia: A review of chest radiograph and computed tomography findings.** Sultan Qaboos Univ. Med. J. 2021; 21:e4-e11Al-Umairi RS, Al-Kalbani J, Al-Tai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777418>
33. **Ultrasound and Doppler findings in pregnant SARS-CoV-2 positive women.** Ultrasound Obstet Gynecol 2021; Soto-Torres E, Andrade EH, Huntley E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794060>

Immune response (30 articles)

1. **Detection of SARS-CoV-2 Specific Memory B cells to Delineate Long-Term COVID-19 Immunity.** Allergy 2021; Thieme CJ, Abou-El-Enein M, Fritsche E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33764510>
2. **SARS-CoV-2-specific serological and functional T-cell Immune responses during acute and early COVID-19 convalescence in Solid Organ Transplant patients.** Am J Transplant 2021; Favà A, Donadeu L, Sabé N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33756051>
3. **COVID-19-associated multisystem inflammatory syndrome in children presenting uniquely with sinus node dysfunction in the setting of shock.** Cardiol. Young 2021;1-3Tomlinson LG, Cohen MI, Levorson RE, Tzeng MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33745461>
4. **Bioinformatic analyses hinted at augmented T helper 17 cell differentiation and cytokine response as the central mechanism of COVID-19-associated Guillain-Barré syndrome.** Cell Prolif. 2021:e13024Li Z, Huang Z, Li X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33751722>
5. **Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands.** Clin Chem 2021; Tang MS, Farnsworth CW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33772260>
6. **Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand.** Clin Transl Immunology 2021; 10:e1261Whitcombe AL, McGregor R, Craigie A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33747511>
7. **Immunoglobulin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.** Eur. J. Cancer 2021; 148:328-339van Dam P, Huizing M, Roelant E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33773276>
8. **Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.** Eur. J. Immunol. 2021; Holenya P, Lange PJ, Reimer U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33772767>
9. **Enrichment of CCR6+CD8+ T cells and CCL20 in the lungs of mechanically ventilated patients with COVID-19.** Eur. J. Immunol. 2021; Saris A, Reijnders TDY, Reijm M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33768543>

10. **Perspective: Diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection.** Expert Rev. Clin. Immunol. 2021; Ameratunga R, Woon ST, Jordan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33745411>
11. **Physiological and Immunological Causes of the Susceptibility of Chronic Inflammatory Patients to COVID-19 Infection: Focus on Diabetes.** Front. Endocrinol. (Lausanne) 2021; 12:576412Rahmani-Kukia N, Abbasi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33746897>
12. **Editorial: Immune Responses to Persistent or Recurrent Antigens: Implications for Immunological Memory and Immunotherapy.** Front. Immunol. 2021; 12:643989Caserta S, Pera A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33767711>
13. **The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients.** Front. Immunol. 2021; 12:632814Luo H, Jia T, Chen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33763078>
14. **The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.** Front. Immunol. 2021; 12:637651Shah P, Canziani GA, Carter EP, Chaiken I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33767706>
15. **Endothelial dysfunction in COVID-19 calls for immediate attention: the emerging roles of the endothelium in inflammation caused by SARS-CoV-2.** Front Med 2021; Hang W, Chen C, Zhang XA, Wang DW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33748924>
16. **Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19.** Immunity 2021; Szabo PA, Dogra P, Gray JI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33765436>
17. **Prevalence of SARS-CoV-2 Specific Antibodies in Asymptomatic Hemodialysis Patients.** Immunol. Invest. 2021;1-12Etemadi J, Bordbar S, Soltani-Zangbar MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33752550>
18. **Severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibody: Seroprevalence among contacts of COVID-19 cases.** Indian J. Public Health 2021; 65:5-10Prakash O, Solanki B, Sheth JK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33753682>
19. **The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19.** Int Immunopharmacol 2021; 95:107586Delshad M, Tavakolinia N, Pourbagheri-Sigaroodi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33765611>
20. **Multisystem inflammatory syndrome in children (MIS-C) and retropharyngeal edema: A case series.** Int J Pediatr Otorhinolaryngol 2021; 144:110667Daube A, Rickert S, Madan RP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33752089>
21. **Neutrophil-to-Lymphocyte Ratio, derived Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio and Lymphocyte-to-Monocyte Ratio as risk factors in critically ill COVID-19 patients, a single centered study.** J. Ayub Med. Coll. Abbottabad 2020; 32(Suppl 1):S595-s601Noor A, Akhtar F, Tashfeen S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33754514>

22. **Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers in a non-epidemic region, Japan: A hospital-based study on May, 2020.** J Med Virol 2021; Nakamura A, Ando S, Endo H, Sato R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33760273>
23. **Broad phenotypic alterations and potential dysfunction of lymphocytes in individuals clinically recovered from COVID-19.** J. Mol. Cell. Biol. 2021; Yang J, Zhong M, Zhang E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33751111>
24. **Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure.** JCI Insight 2021; Demonbreun AR, McDade TW, Pesce LL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755598>
25. **Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection.** Kidney Int 2021; Clarke CL, Predecki M, Dhutia A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33774082>
26. **Point of care ultrasound (POCUS) in diagnosis of proximal deep vein thrombosis among COVID-19 hospitalized patients with a high rate of low molecular weight heparin prophylaxis.** Med Clin (Barc) 2021; García-Ceberino PM, Faro-Míguez N, Beltrán-Ávila FJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33773764>
27. **The real life performance of 7 automated anti-SARS-CoV-2 IgG and IgM/IgA immunoassays.** Pract Lab Med 2021; 25:e00212Swadźba J, Bednarczyk M, Anyszek T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33748381>
28. **The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.** Probiotics Antimicrob Proteins 2021:1-15Moradi-Kalbolandi S, Majidzadeh AK, Abdolvahab MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33770348>
29. **The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.** Virology 2021; 559:1-9Chen X, Rostad CA, Anderson LJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33774551>
30. **Immune dysregulation and system pathology in COVID-19.** Virulence 2021; 12:918-936Jamal M, Bangash HI, Habiba M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33757410>

Management miscellaneous diseases (111 articles)

1. **Decreased number of deaths related to severe traumatic brain injury in intensive care unit during the first lockdown in Normandy: at least one positive side effect of the COVID-19 pandemic.** Acta Neurochir. (Wien.) 2021; Rault F, Terrier L, Leclerc A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813617>
2. **Characterization of people living with HIV in a Montreal-based tertiary care center with COVID-19 during the first wave of the pandemic.** AIDS Care 2021:1-7Fehr D, Lebouché B, Ruppenthal L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779425>
3. **Effectively Confronting the COVID-19 Pandemic: Critical Lessons From HIV Prevention, Care, and Treatment and Innovative Strategies to Conduct**

Community-Based and Community-Engaged Research Safely. AIDS Educ. Prev. 2020; 32:455-471 Rhodes SD, Sy FS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779211>

4. **Hay fever, dust mites, insect venom: Allergen immunotherapy in spite of SARS CoV-2?** Allergologie 2020; 43:491-492 Pfaar O, Rhinologie S, Allergologie.
5. **Disentangling the root causes of COVID-19 related increases in alcohol consumption.** Am. J. Drug Alcohol Abuse 2021; 47:1-4 Molsberry R, Maskaly J, Reingle Gonzalez JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784218>
6. **The Impact of COVID-19 on Individuals Across the Spectrum of Visual Impairment.** Am. J. Ophthalmol. 2021; Shalaby WS, Odayappan A, Venkatesh R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781768>
7. **Colorectal surgery patient perspectives on healthcare during the CoVID-19 pandemic.** Am. J. Surg. 2021; Rivard SJ, Vitous CA, Cocroft S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812662>
8. **SARS-CoV-2 positive child—What to do if inhalation induction of anesthesia is unavoidable?** Anaesthesist 2021; Leister N, Yüce-tepe S, Ulrichs C *et al.*
9. **The situation at German hospitals from the perspective of anaesthesia and intensive medicine prior to the COVID-19 pandemic BDA survey on psychosocial support in acute medicine in the autumn of 2019.** Anesthesiologie und Intensivmedizin 2021; 62:92-100 Hinzmann D, Schiebl A, Kreitlow J *et al.*
10. **Otolaryngology Consult Protocols in the Setting of COVID-19: The University of Pittsburgh Approach.** Ann. Otol. Rhinol. Laryngol. 2021:34894211005937 Dharmarajan H, Belsky MA, Anderson JL, Sridharan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779296>
11. **Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital.** Antibiotics (Basel) 2021; 10 Di Gennaro F, Gualano G, Timelli L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800406>
12. **A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer.** Anticancer Res. 2021; 41:2193-2195 Hayashi K, Tamura M, Nagasaki E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813433>
13. **The Impact of the COVID-19 Pandemic on Breast Reconstruction Practices in the United States.** Anticancer Res. 2021; 41:1903-1908 Joseph WJ, Bustos SS, Losee JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813395>
14. **Symptom Burden in Patients Treated With Palliative Radiotherapy Before and During the COVID-19 Pandemic.** Anticancer Res. 2021; 41:1971-1974 Nieder C, Johnsen SK, Winther AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813403>
15. **DMARD Changes for Patients with Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A 3-Month Observational Study.** Arthritis Care Res. (Hoboken) 2021; Michaud K, Pedro S, Wipfler K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787086>
16. **Rapid SARS-CoV-2 antigen detection potentiates early diagnosis of COVID-19 disease.** Biosci Trends 2021; Lv Y, Ma Y, Si Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776018>

17. **The effect of COVID-19 on emergency medical service call volumes and patient acuity: a cross-sectional study in Niagara, Ontario.** BMC Emerg. Med. 2021; 21:39Ferron R, Agarwal G, Cooper R, Munkley D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781229>
18. **Effects of the COVID-19 pandemic on the sexual and mental health of adolescent and adult men who have sex with men and transgender women participating in two PrEP cohort studies in Brazil: COBra study protocol.** BMJ Open 2021; 11:e045258Ferraz D, Dourado I, Zucchi EM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33795308>
19. **Promoting exercise in patients with cancers of the head and neck during COVID-19 and beyond.** BMJ Open Sport Exerc Med 2021; 7:e001024Sindhu KK, Nehlsen AD, Bakst RL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791106>
20. **Safe elective surgery: addressing the need.** Bone Joint J 2021; 103-b:597-599Kader DF, Oussedik S, Kader N, Haddad FS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789476>
21. **Preprints in perioperative medicine: immediacy for the greater good.** Br J Anaesth 2021; Pearse RM, Ackland GL, Asai T, Hemmings HC, Jr.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33795134>
22. **Practical approach to prevent COVID-19 infection at breast cancer screening.** Breast Cancer 2021; Takada M, Tanaka G, Hashimoto H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811286>
23. **COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE).** Bull Cancer 2021; Rouger-Gaudichon J, Bertrand Y, Boissel N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781551>
24. **The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer.** Cancer Treat. Rev. 2021; 97:102188Surujballi J, Shah H, Hutton B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813329>
25. **Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era.** Cancers (Basel) 2021; 13Cherri S, Noventa S, Fanelli M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33801385>
26. **Liver Transplantation for T2 Hepatocellular Carcinoma during the COVID-19 Pandemic: A Novel Model Balancing Individual Benefit against Healthcare Resources.** Cancers (Basel) 2021; 13Cillo U, Vitale A, Volk ML *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808790>
27. **Continuity of Cancer Care: The Surgical Experience of Two Large Cancer Hubs in London and Milan.** Cancers (Basel) 2021; 13Monroy-Iglesias MJ, Tagliabue M, Dickinson H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808375>
28. **Surgical initial experience in patients with COVID-19.** Cir. Cir. 2021; 89:183-188Aguilar-Garduño CO, Aguilar-Garduño JC, Barreto-Rodríguez AK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784282>
29. **Hepatic transplant during SARS-CoV-2 (COVID-19) pandemic. A literature review.** Cir. Cir. 2021; 89:269-274Pérez-González B, Thomas-Lora FC, Hoyo I *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784290>

30. **Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center.** Clin. Med. Insights Circ. Respir. Pulm. Med. 2021; 15:11795484211001349 Spinella A, Magnani L, De Pinto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795941>
31. **Influence of COVID-19 pandemic on paediatric dental attendance.** Clin Oral Investig 2021;1-7 Üstün N, Akgöl BB, Bayram M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786650>
32. **The Poison Center as a pandemic response: establishment and characteristics of a COVID-19 hotline through the New Jersey Poison Center.** Clin. Toxicol. (Phila.) 2021;1-6 Meaden CW, Ramdin C, Ruck B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787430>
33. **COVID-19 and the Emergency Presentation of Colorectal Cancer.** Colorectal Dis 2021; Shinkwin M, Silva L, Vogel I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793063>
34. **Provision of medication abortion in Hawai'i during COVID-19: Practical experience with multiple care delivery models.** Contraception 2021; Kerestes C, Murayama S, Tyson J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789080>
35. **'Test Now, Stop HIV': COVID-19 and the idealisation of quarantine as the 'end of HIV'.** Cult Health Sex 2021;1-14 Ledin C, Weil B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792509>
36. **What Is New in Occupational Allergic Contact Dermatitis in the Year of the COVID Pandemic?** Curr. Allergy Asthma Rep. 2021; 21:26 Lee EB, Lobl M, Ford A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779825>
37. **Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel).** Curr. Oncol. 2021; 28:1249-1255 Franco F, Guirado M, Martínez-Banaclocha N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809772>
38. **Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.** Curr. Probl. Cancer 2021;100739 Fujii H, Tsuji T, Sugitani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810911>
39. **The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPA.** Ecancermedalscience 2021; 15:1187 Pritchard-Jones K, de CVAS, Esiashvili N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777180>
40. **The impact of national non-pharmaceutical interventions ('lockdowns') on the presentation of cancer patients.** Ecancermedalscience 2021; 15:1180 Purushotham A, Roberts G, Haire K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777173>
41. **Impact of the COVID-19 pandemic on the activity of the Radiological Emergency Department: the experience of the Maggiore della Carità Hospital in Novara.** Emerg Radiol 2021; Garlisi C, Licandro D, Siani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813649>

42. **Corneal transplantation during the COVID-19 pandemic: An operational guide.** Eur. J. Ophthalmol. 2021;11206721211006565Franch A, Fasolo A, Carraro P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775164>
43. **Early impact of school closure and social distancing for COVID-19 on the number of inpatients with childhood non-COVID-19 acute infections in Japan.** Eur. J. Pediatr. 2021;1-8Kishimoto K, Bun S, Shin JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791861>
44. **Increased 30-day mortality rate in patients admitted with hip fractures during the COVID-19 pandemic in the UK.** Eur. J. Trauma Emerg. Surg. 2021;1-8Barker T, Thompson J, Corbett J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783567>
45. **Change in mortality rates of respiratory disease during the COVID-19 pandemic.** Expert Rev. Respir. Med. 2021;1-6Huang C, Lu Y, Wang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787428>
46. **The UK foot and ankle COVID-19 national (FAICoN) audit - Regional variations in COVID-19 infection and national foot and ankle surgical activity.** Foot Ankle Surg. 2021; Mason LW, Malhotra K, Houchen-Wollof L, Mangwani J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785283>
47. **Pituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting.** Front. Endocrinol. (Lausanne) 2021; 12:656025Fleseriu M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776943>
48. **Effects of Lean Thinking and Emerging Technologies on Breast Cancer Patients' Therapeutic Process During COVID-19 Pandemic: A Case-Control Matched Study.** Front Surg 2021; 8:582980Pellini F, Di Filippo G, Mirandola S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791333>
49. **Are telephone consultations the future of the NHS? The outcomes and experiences of an NHS urological service in moving to telemedicine.** Future Healthc J 2021; 8:e15-e20Efthymiadis A, Hart EJ, Guy AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791468>
50. **Tracking cancer patients during COVID-19 using structured outcomes and keywords.** Future Healthc J 2021; 8:e32-e35Wathes R, van Ree K, Gwynn G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791472>
51. **Elective lung resection after treatment for COVID-19 pneumonia.** Gen. Thorac. Cardiovasc. Surg. 2021; Sakai T, Azuma Y, Aoki K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811611>
52. **Hip Fractures Before and During the COVID-19 Pandemic: Comparative Demographics and Outcomes.** Geriatr Orthop Surg Rehabil 2021; 12:21514593211003077Nazemi AK, Al-Humadi SM, Tantone R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796344>
53. **Immunotherapy and Radiotherapy for Older Cancer Patients during the COVID-19 Era: Proposed Paradigm by the International Geriatric Radiotherapy Group.** Gerontology 2021;1-7Nguyen NP, Baumert BG, Oboite E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784693>
54. **Dentists' Working Conditions during the First COVID-19 Pandemic Lockdown: An Online Survey.** Healthcare (Basel) 2021; 9Wiesmüller V, Bruckmoser E, Kapferer-Seebacher I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807082>

55. **Impact of the Lockdown due to COVID-19 Pandemic on the Spectrum and Outcome of Trauma in India.** Indian J. Crit. Care Med. 2021; 25:273-278 Hazra D, Jindal A, Fernandes JP, Abhilash KP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790506>
56. **Optimising Cancer Surgery During COVID-19: Experience of Tertiary Cancer Centre in Eastern India.** Indian J Gynecol Oncol 2021; 19:29 Das R, Nahak SR, Parija J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786366>
57. **Impact of COVID-19 on Orthopaedic Care and Practice: A Rapid Review.** Indian J. Orthop. 2021;1-14 Chatterji G, Patel Y, Jain V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776130>
58. **Spanish Dentists' Awareness, Knowledge, and Practice Regarding COVID-19: A Multiple Regression Analysis.** Int. Dent. J. 2021; Martínez-Beneyto Y, Ausina-Márquez V, Expósito-Delgado AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795144>
59. **The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.** Int Immunopharmacol 2021; 96:107602 Lin WT, Hung SH, Lai CC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812260>
60. **The effect of the first wave of COVID-19 pandemic on urology practice and anxiety scores of patients awaiting surgery.** Int J Clin Pract 2021:e14201 Micoogullari U, Kisa E, Yucel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794032>
61. **The effect of the first wave of COVID-19 pandemic on urology practice and anxiety scores of patients awaiting surgery.** Int J Clin Pract 2021:e14201 Micoogullari U, Kisa E, Yucel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794032>
62. **Oral health awareness, attitude towards dental treatment, fear of infection, and economic impact during COVID-19 pandemic in the Middle East.** Int. J. Dent. Hyg. 2021; Abdulkareem AA, Abdulbaqi HR, Alshami ML, Al-Rawi NH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797867>
63. **A Significant Decrease in the Incidence of Shigellosis in Israel during COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18 Bassal R, Keinan-Boker L, Cohen D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809746>
64. **Blood Donations and Transfusions during the COVID-19 Pandemic in Spain: Impact According to Autonomous Communities and Hospitals.** Int J Environ Res Public Health 2021; 18 García-Erce JA, Romón-Alonso Í, Jericó C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801650>
65. **General Practice in the Time of COVID-19: A Mixed-Methods Service Evaluation of a Primary Care COVID-19 Service.** Int J Environ Res Public Health 2021; 18 Hibberd J, Carter J, McCoy M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809000>
66. **COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis.** Int J Environ Res Public Health 2021; 18 Lee KW, Yap SF, Ngeow YF, Lye MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808066>
67. **The Impact of the First Wave of the COVID-19 Pandemic on Providing Special Care Dentistry: A Survey for Dentists.** Int J Environ Res Public Health 2021;

- 18Limeres Posse J, van Harten MT, Mac Giolla Phadraig C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33799369>
68. **The Impact of the COVID-19 Pandemic on the Spectrum of Performed Dental Procedures.** *Int J Environ Res Public Health* 2021; 18Nijakowski K, Cieřlik K, Łaganowski K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806148>
 69. **Dental Workload Reduction during First SARS-CoV-2/COVID-19 Lockdown in Germany: A Cross-Sectional Survey.** *Int J Environ Res Public Health* 2021; 18Wolf TG, Deschner J, Schrader H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808537>
 70. **The need for protecting and enhancing TB health policies and services for forcibly displaced and migrant populations during the ongoing COVID-19 pandemic.** *Int J Infect Dis* 2021; Knipper M, Sedas AC, Keshavjee S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775886>
 71. **Fecal Microbiota Transplantation during and Post-COVID-19 Pandemic.** *Int J Mol Sci* 2021; 22Kazemian N, Kao D, Pakpour S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809421>
 72. **Telegenetics for inherited retinal diseases in the COVID-19 environment.** *Int J Retina Vitreous* 2021; 7:25Al-Moujahed A, Kumar A, Chemudupati T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781332>
 73. **AFES A.S.-O.N.E.: ASEAN Survey Of Needs in Endocrinology in the Time of the COVID-19 Pandemic.** *J ASEAN Fed Endocr Soc* 2020; 35:5-13Jasul G, Jr., Paz-Pacheco E, Jimeno C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790494>
 74. **The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD.** *J Clin Med* 2021; 10Borrelli E, Battista M, Vella G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803808>
 75. **Impact of the COVID-19 Pandemic on the Loading and Quality of an Emergency Department in Taiwan: Enlightenment from a Low-Risk Country in a Public Health Crisis.** *J Clin Med* 2021; 10Chen JY, Chang FY, Lin CS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801792>
 76. **Biologics for Psoriasis during the COVID-19 Pandemic.** *J Clin Med* 2021; 10Kamiya K, Komine M, Ohtsuki M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808455>
 77. **Management Challenges in Chronic Obstructive Pulmonary Disease in the COVID-19 Pandemic: Telehealth and Virtual Reality.** *J Clin Med* 2021; 10Rutkowski S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803853>
 78. **Characteristics and Detection Rate of SARS-CoV-2 in Alternative Sites and Specimens Pertaining to Dental Practice: An Evidence Summary.** *J Clin Med* 2021; 10Shirazi S, Stanford CM, Cooper LF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802043>
 79. **Impact of the 1st and 2nd Wave of the COVID-19 Pandemic on Primary or Revision Total Hip and Knee Arthroplasty-A Cross-Sectional Single Center Study.** *J Clin Med* 2021; 10Simon S, Frank BJH, Aichmair A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803721>

80. **Operation theatre protocol for COVID-19 cases requiring orthopaedic surgery: A workflow without altering the existing infrastructure.** J Clin Orthop Trauma 2021; 17:163-168Bhat AK, Vijayan S, Acharya AM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776361>
81. **Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19.** J Eur Acad Dermatol Venereol 2021; Arenbergerova M, Lallas A, Nagore E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33780557>
82. **The impact of the COVID-19 coronavirus pandemic on the surgical management of gynecological cancers : Analysis of the multicenter database of the French SCGP and the FRANCOGYN group.** J Gynecol Obstet Hum Reprod 2021;102133Jouen T, Gauthier T, Azais H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789183>
83. **Turning threats into opportunities: how to implement and advance quality TB services for people with HIV during the COVID-19 pandemic and beyond.** J Int AIDS Soc 2021; 24:e25696Roberts T, Sahu S, Malar J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33787058>
84. **Assessing Barriers Faced by Surgeons While Providing Surgical Care During the COVID-19 Pandemic in Pakistan: An Online Cross-Sectional Study.** J Multidiscip Healthc 2021; 14:665-672Majeed A, Hussain I, Imran I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776444>
85. **Delayed hospital admission for traumatic hip fractures during the COVID-19 pandemic.** J. Orthop. Surg. Res. 2021; 16:237Jarvis S, Salottolo K, Madayag R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794939>
86. **Symptom and needs assessment screening in oncology patients: Alternate outreach methods during COVID-19.** J. Psychosoc. Oncol. 2021:1-8Davis K MMM, Wilbur K MSW, Metzger S BSN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792515>
87. **Shifting psychosocial oncology care to telepsychology during the COVID-19 pandemic.** J. Psychosoc. Oncol. 2021:1-9Myers Virtue S, Howrey HL, Duffy NM, Wallace M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792503>
88. **COVID-19 Pandemic and the Cholecystitis Experience at a Major Urban Safety-Net Hospital.** J. Surg. Res. 2021; 264:117-123Vallès KF, Neufeld MY, Caron E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812090>
89. **The impact of the COVID-19 pandemic on cancer diagnosis and service access in New Zealand-a country pursuing COVID-19 elimination.** Lancet Reg Health West Pac 2021; 10:100127Gurney JK, Millar E, Dunn A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778794>
90. **[Patient in the otolaryngology office in the time of the COVID-19 pandemic in the light of current recommendations, legal regulations and authors' own experience].** Med. Pr. 2021; Obrębski J, Skorek P, Tretiakow D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33783435>
91. **[Impact of the COVID-19 pandemic on appendicitis in COVID-19 negative children].** Monatsschr Kinderheilkd 2021:1-6Meyer T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782626>

92. **Impact of the COVID-19 pandemic on appendicitis in COVID-19 negative children.** Monatsschr. Kinderheilkd. 2021; Meyer T.
93. **COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update.** Mult Scler Relat Disord 2021; 51:102929 Jack D, Damian D, Nolting A, Galazka A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813097>
94. **Impact of the Novel Coronavirus 2019 (COVID-19) Pandemic on Head and Neck Cancer Care.** Otolaryngol Head Neck Surg 2021:1945998211004544 Thompson JA, Lubek JE, Amin N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784206>
95. **The impact of the COVID-19 pandemic on the continuity of transfusion care for thalassemic patients: a case report.** Pan Afr. Med. J. 2021; 38:33 Bouhou S, Benajiba M, Masrar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777301>
96. **Urological activity at the time of COVID-19 pandemic: is there any difference between public and private field?** Pan Afr. Med. J. 2020; 37:389 Zouari S, Saadi A, Chakroun M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796202>
97. **Saudi experts' recommendation for RSV prophylaxis in the era of COVID-19: Consensus from the Saudi Pediatric Pulmonology Association.** Saudi Med. J. 2021; 42:355-362 Alharbi AS, Alzahrani M, Alodayani AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795490>
98. **Trends in reasons for emergency calls during the COVID-19 crisis in the department of Gironde, France using artificial neural network for natural language classification.** Scand. J. Trauma Resusc. Emerg. Med. 2021; 29:55 Gil-Jardiné C, Chenais G, Pradeau C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789721>
99. **Positive and negative perceptions of the COVID-19 pandemic: Does personality play a role?** Soc. Sci. Med. 2021; 276:113859 Schmiedeberg C, Thönnissen C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799202>
100. **Addressing the social needs of individuals with food allergy and celiac disease during COVID-19: A new practice model for sustained social care.** Soc. Work Health Care 2021:1-10 Bilaver LA, Das R, Martinez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775233>
101. **The Early Impact of Social Distancing Measures on Drug Use.** Subst. Use Misuse 2021:1-8 Christie NC, Vojvodic V, Monterosso JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784957>
102. **Managing Vascular Surgery Emergencies and Referrals During the COVID-19 Pandemic at a Tertiary Centre in Oman.** Sultan Qaboos Univ. Med. J. 2021; 21:e116-e119 Stephen E, Al-Adawi SSH, Abdelhady I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777432>
103. **Visitation policies at NCI-designated comprehensive cancer centers during the COVID-19 pandemic.** Support. Care Cancer 2021; Yeh JC, Subbiah IM, Dhawan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796936>
104. **Development of a Low-Resource Operating Room and a Wide-Awake Orthopedic Surgery Program During the COVID-19 Pandemic.** Surg. Innov. 2021:15533506211003530 Turcotte JJ, Gelfand JM, Jones CM, Jackson RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780646>
105. **Lessons from lockdown: Virtual Clinics and service reorganisation in fracture management during COVID 19 experience of an Irish Regional Trauma Unit.**

- Surgeon 2021; Stanley C, Kelly M, Elzaki M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775562>
106. **Decrease in hospital admissions for respiratory diseases during the COVID-19 pandemic: a nationwide claims study.** Thorax 2021; Huh K, Kim YE, Ji W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782081>
 107. **Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation.** Transplant Cell Ther 2021; 27:270.e271-270.e276Worel N, Shaw BE, Aljurf M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781537>
 108. **Workforce Issues in Urology.** Urol. Clin. North Am. 2021; 48:161-171Dornbier R, Gonzalez CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795049>
 109. **Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19.** Viruses 2021; 13Qeadan F, Tingey B, Gu LY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807920>
 110. **Effects of the COVID-19 Pandemic on Operative Volume and Residency Training at Two Academic Neurosurgery Centers in New Orleans.** World Neurosurg 2021; Kilgore MD, Scullen T, Mathkour M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812067>
 111. **[Observation of therapeutic effect on coronavirus disease 2019 with insomnia in treatment with baduanjin and auricular point sticking therapy].** Zhongguo Zhen Jiu 2021; 41:243-246Yang C, Ma Y, Mei JH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798303>

Management (52 articles)

1. **Perspective: Nutritional Strategies Targeting the Gut Microbiome to Mitigate COVID-19 Outcomes.** Adv. Nutr. 2021; Daoust L, Pilon G, Marette A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33783468>
2. **Beneficial effect of Arbidol in the management of COVID-19 infection.** Aging (Albany NY) 2021; 13Jie X, Hongmei Y, Ping F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811756>
3. **Preparedness to Face the COVID-19 Pandemic in Hospice and Palliative Care Services in the Asia-Pacific Region: A Rapid Online Survey.** Am. J. Hosp. Palliat. Care 2021:10499091211002797Lin CP, Boufkhed S, Kizawa Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789503>
4. **Fever: Could A Cardinal Sign of COVID-19 Infection Reduce Mortality?** Am. J. Med. Sci. 2021; 361:420-426Cann SAH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781387>
5. **The interest of fluticasone nasal spray in COVID-19 related anosmia is still not demonstrated.** Am. J. Otolaryngol. 2021:103008Lechien JR, Hoch CC, Vaira LA, Saussez S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810883>
6. **Anticoagulation in COVID-19: not strong for too long?** Anaesth Crit Care Pain Med 2021:100857Tacquard C, Mansour A, Godon A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798761>
7. **Inter-hospital transport of critically ill patients to manage the intensive care unit surge during the COVID-19 pandemic in France.** Ann Intensive Care 2021;

11:54Painvin B, Messet H, Rodriguez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788010>

8. **The Primary Prevention of Venous Thromboembolism in Patients with COVID-19 in Japan: Current Status and Future Perspective.** Ann Vasc Dis 2021; 14:1-4 Yamashita Y, Yamada N, Mo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786092>
9. **Finding ways for children's doctors to care for big 'Kids' and save adults in a pandemic.** Arch. Dis. Child. 2021; Robison J, Remy KE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785528>
10. **Probiotics in Prevention and Treatment of COVID-19: Current Perspective and Future Prospects.** Arch Med Res 2021; Kurian SJ, Unnikrishnan MK, Miraj SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785208>
11. **Civil-military cooperation in the early response to the COVID-19 pandemic in six European countries.** BMJ Mil Health 2021; Gad M, Kazibwe J, Quirk E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785587>
12. **Which parameters support disposition decision in suspected COVID-19 cases in the emergency department (ED): a German clinical cohort study.** BMJ Open 2021; 11:e044853 Möckel M, Stegemann MS, Burst V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789854>
13. **Supplementary Therapeutic Possibilities to Alleviate Myocardial Damage Due to Microvascular Dysfunction in Coronavirus Disease 2019 (COVID-19).** Cardiol Ther 2021; Medvegy M, Simonyi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811310>
14. **The utility of a local multidisciplinary working group to oversee the establishment of rapidly evolving standards of care and to support trial recruitment during the COVID-19 pandemic.** Clin Med (Lond) 2021; Satta G, Youngstein T, Lightstone L, Gilchrist M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782041>
15. **Adaptations of an Integrated Behavioral Health Program During COVID-19.** Cogn. Behav. Pract. 2021; Bogucki OE, Mattson AB, Leasure WB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776398>
16. **COVID-19 and the Emergency Presentation of Colorectal Cancer.** Colorectal Dis 2021; Shinkwin M, Silva L, Vogel I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793063>
17. **Isolate and treat: Respiratory tract infections in times of corona.** Deutsche Apotheker Zeitung 2021; 161.
18. **Impact of COVID-19: urging a need for multi-domain assessment of COVID-19 inpatients.** Eur. Geriatr. Med. 2021;1-8 Heyns A, Dupont J, Gielen E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786747>
19. **Managing the risk of shortages and medication errors with curares during the COVID-19 pandemic: a hospital pharmacy experience.** Eur J Hosp Pharm 2021; Bohand X, Jordan D, Dubois F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789989>
20. **Practical recommendations for the prevention and management of COVID-19 in low-income and middle-income settings: adapting clinical experience from**

- the field.** Fam Med Community Health 2021; 9Fahme SA, Walsh KF, Rouzier V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811089>
21. **Corrigendum: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.** Front Med (Lausanne) 2020; 7:604640Chaudhary S, Natt B, Bime C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777966>
 22. **Optimizing Management to Reduce the Mortality of COVID-19: Experience From a Designated Hospital for Severely and Critically Ill Patients in China.** Front Med (Lausanne) 2021; 8:582764Zhu W, Zhang H, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777967>
 23. **SWOT Analysis and Preliminary Study on Prevention and Control Management of Temporary Integrated Isolation Ward During COVID-19 Outbreak.** Front Public Health 2021; 9:558565Zhou Y, Bai L, Guo H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791264>
 24. **Rapid transformation of the medical on-call rotas to deal with the COVID-19 pandemic: a case study.** Future Healthc J 2021; 8:e36-e41Aziz A, Patel N, Chakravorty T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791473>
 25. **The rapid development and deployment of a new multidisciplinary CPAP service outside of a critical care environment during the early stages of the COVID-19 pandemic.** Future Healthc J 2021; 8:e156-e159Robinson RE, Nightingale R, Frost F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791498>
 26. **Towards a standardised method of patient prioritisation that accounts for clinical harm.** Future Healthc J 2021; 8:e42-e46Wathes R, Malhotra K, Flott K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791474>
 27. **Primary Care Strategies and Cooperation During the First Phase of the COVID-19 Pandemic in Baden-Wuerttemberg, Germany.** Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)) 2021; Stengel S, Roth C, Breckner A *et al.*
 28. **Impact of COVID-19 Outbreak on Emergency Department Admissions in a Specialized Hospital.** Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)) 2021; Stöwhas M, Lippert H.
 29. **The Impact of COVID-19 on Essential Medicines and Personal Protective Equipment Availability and Prices in Saudi Arabia.** Healthcare (Basel) 2021; 9Aljadeed R, AlRuthia Y, Balkhi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800012>
 30. **High-Fidelity Virtual Objective Structured Clinical Examinations with Standardized Patients in Nursing Students: An Innovative Proposal during the COVID-19 Pandemic.** Healthcare (Basel) 2021; 9Arrogante O, López-Torre EM, Carrión-García L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804700>
 31. **Cognitive Diversity as the Quality of Leadership in Crisis: Team Performance in Health Service during the COVID-19 Pandemic.** Healthcare (Basel) 2021; 9Joniaková Z, Jankelová N, Blštáková J, Némethová I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799831>
 32. **[Novel Coronavirus: Applying Transformational Leadership to the Combat of COVID-19 in Nursing Practice].** Hu Li Za Zhi 2021; 68:92-98Liu TY, Sun JJ, Hsiao CT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792023>

33. **A Proposal for Dedicated "Prone Team" and "Prone Bundle of Care" in COVID-19 ICU.** Indian J. Crit. Care Med. 2021; 25:349-350 Anand RK, Baidya DK, Maitra S, Ray BR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790522>
34. **Prognostic Value of "Cycle Threshold" in Confirmed COVID-19 Patients.** Indian J. Crit. Care Med. 2021; 25:322-326 Rajyalakshmi B, Samavedam S, Reddy PR, Aluru N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790515>
35. **Changes in Mode of Oxygen Delivery and Physiological Parameters with Physiotherapy in COVID-19 Patients: A Retrospective Study.** Indian J. Crit. Care Med. 2021; 25:317-321 Verma CV, Arora RD, Mistry HM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790514>
36. **Development and validation of a predictive model to determine the level of care in patients confirmed with COVID-19.** Infect Dis (Lond) 2021;1-10 Diep AN, Gilbert A, Saegerman C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793352>
37. **How to Treat COVID-19 Patients at Home in the Italian Context: An Expert Opinion.** Infect Dis Rep 2021; 13:251-258 Donno DR, Grattagliano I, Rossi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804737>
38. **Approaches to Nutritional Screening in Patients with Coronavirus Disease 2019 (COVID-19).** Int J Environ Res Public Health 2021; 18:Ali AM, Kunugi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803339>
39. **Effects of a Comprehensive Pulmonary Rehabilitation in Severe Post-COVID-19 Patients.** Int J Environ Res Public Health 2021; 18:Spilmanns M, Pekacka-Egli AM, Schoendorf S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800094>
40. **The use of non-invasive ventilation in COVID-19: a systematic review.** Int J Infect Dis 2021; Wang Z, Wang Y, Yang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798720>
41. **Dietary and Protective Factors to Halt or Mitigate Progression of Autoimmunity, COVID-19 and Its Associated Metabolic Diseases.** Int J Mol Sci 2021; 22:Ricordi C, Pacifici F, Lanzoni G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808574>
42. **Effect Estimates of COVID-19 Non-Pharmaceutical Interventions are Non-Robust and Highly Model-Dependent.** J. Clin. Epidemiol. 2021; Chin V, Ioannidis JPA, Tanner MA, Cripps S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781862>
43. **Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns.** J Clin Med 2021; 10:Martínez-Botía P, Bernardo Á, Acebes-Huerta A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806709>
44. **Prone Position in Mechanically Ventilated COVID-19 Patients: A Multicenter Study.** J Clin Med 2021; 10:Vollenberg R, Matern P, Nowacki T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802479>
45. **The effects of combination of Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial.** J Complement Integr Med 2021; Mesri M, Esmaeili Saber SS, Godazi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787192>
46. **Licorice: A Potential Herb in Overcoming SARS-CoV-2 Infections.** J Evid Based Integr Med 2021; 26:2515690x21996662 Ng SL, Khaw KY, Ong YS *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33787349>

47. **Functional status of mechanically ventilated COVID-19 survivors at ICU and hospital discharge.** J Intensive Care 2021; 9:31Musheyev B, Borg L, Janowicz R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789772>
48. **Factors Affecting Nurses' Professional Commitment During the COVID-19 Pandemic: A Cross-Sectional Study.** J. Nurs. Manag. 2021; Duran S, Celik I, Ertugrul B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794061>
49. **Extracorporeal Membrane Oxygenation with Right Ventricular Assist Device for COVID-19 ARDS.** J. Surg. Res. 2021; 264:81-89Cain MT, Smith NJ, Barash M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789179>
50. **Case study of a critically ill person with COVID-19 on ECMO successfully treated with Ieronlimab.** J Transl Autoimmun 2021:100097Elneil S, Lalezari JP, Pourhassan NZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778462>
51. **Shared Decision Making during the COVID-19 Pandemic.** Med. Decis. Making 2021:272989x211004147Köther AK, Siebenhaar KU, Alpers GW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783266>
52. **Ketogenic Diet as a Preventive and Supportive Care for COVID-19 Patients.** Nutrients 2021; 13Gangitano E, Tozzi R, Gandini O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804603>
53. **Lifestyle Changes and Body Mass Index during COVID-19 Pandemic Lockdown: An Italian Online-Survey.** Nutrients 2021; 13Maffoni S, Brazzo S, De Giuseppe R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805291>
54. **The Role of Nutrition in the COVID-19 Pandemic.** Nutrients 2021; 13Mentella MC, Scadaferri F, Gasbarrini A, Miggiano GAD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801645>
55. **COVID-19: Role of Nutrition and Supplementation.** Nutrients 2021; 13Moscatelli F, Sessa F, Valenzano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803015>
56. **Missing the human connection: A rapid appraisal of healthcare workers' perceptions and experiences of providing palliative care during the COVID-19 pandemic.** Palliat. Med. 2021:2692163211004228Mitchinson L, Dowrick A, Buck C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775169>
57. **Anesthesia Machine Ventilators for Use in Critical Care During the COVID-19 Pandemic.** Respir. Care 2021; Austin PN, Branson RD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785549>
58. **[The advanced practice nurse in post-COVID-19 respiratory follow up].** Soins 2021; 66:32-34Blanchard PY, Ruppert AM, Faure M, Nion N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775300>
59. **Care of the critically ill patient.** Surgery (Oxf) 2021; 39:29-36Jackson M, Cairns T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776181>
60. **Spatial Accessibility Assessment of COVID-19 Patients to Healthcare Facilities: A Case Study of Florida.** Travel Behav Soc 2021; 24:95-101Ghorbanzadeh M, Kim K, Erman Ozguven E, Horner MW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777697>
61. **Effects of pomegranate juice (Punica Granatum) on inflammatory biomarkers and complete blood count in patients with COVID-19: a structured summary of a study protocol for a randomized clinical trial.** Trials 2021; 22:246Yousefi M,

Sadriirani M, PourMahmoudi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810808>

62. **The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score.** *Viruses* 2021; 13Ghidini M, Indini A, Rijavec E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808623>

Mental – public health (258 articles)

1. **Mental health impact of COVID-19 in frontline healthcare workers in a Belgian Tertiary care hospital: a prospective longitudinal study.** *Acta Clin. Belg.* 2021;1-8Van Steenkiste E, Schoofs J, Gilis S, Messiaen P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779529>
2. **Mental disorders, psychopharmacological treatments, and mortality in 2,150 COVID-19 Spanish inpatients.** *Acta Psychiatr. Scand.* 2021; Diez-Quevedo C, Iglesias-González M, Giralt-López M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792912>
3. **Emergency department utilization for mental health conditions before and after the COVID-19 outbreak.** *Am J Emerg Med* 2021; 47:164-168Stroeever S, Brett C, Michael K, Petrini J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813148>
4. **Perceived Beliefs, Uncertainty, and Behavioral Responses During the COVID-19 Outbreak in China: Findings From a Convenience Sample.** *Am. J. Health Promot.* 2021;8901171211004249Wu D, Rockett IRH, Yang T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787350>
5. **The Experiences of Family Members of Ventilated COVID-19 Patients in the Intensive Care Unit: A Qualitative Study.** *Am. J. Hosp. Palliat. Care* 2021;10499091211006914Chen C, Wittenberg E, Sullivan SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789492>
6. **Policy Interventions, Social Distancing, and SARS-CoV-2 Transmission in the United States: A Retrospective State-level Analysis.** *Am. J. Med. Sci.* 2021; Dreher N, Spiera Z, McAuley FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775425>
7. **The Australian Response to the COVID-19 Pandemic: A co-ordinated and effective strategy.** *Anaesth Crit Care Pain Med* 2021;100859Holley A, Coatsworth N, Lipman J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812079>
8. **Attachment to Pets Moderates Transitions in Latent Patterns of Mental Health Following the Onset of the COVID-19 Pandemic: Results of a Survey of U.S. Adults.** *Animals (Basel)* 2021; 11McDonald SE, O'Connor KE, Matijczak A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801041>
9. **Companion Animal Relationships and Adolescent Loneliness during COVID-19.** *Animals (Basel)* 2021; 11Mueller MK, Richer AM, Callina KS, Charmaraman L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808941>
10. **The impact of Covid-19 healthcare emergency on the psychological well-being of health professionals: a review of literature.** *Ann. Ig.* 2021; Della Monica A, Ferrara P, Dal Mas F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779676>
11. **Awareness and Behaviors Regarding COVID-19 among Albanian Undergraduates.** *Behav Sci (Basel)* 2021; 11Gallè F, Veshi A, Sabella EA *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807250>

12. **Breastfeeding during COVID-19: A Narrative Review of the Psychological Impact on Mothers.** Behav Sci (Basel) 2021; 11Pacheco F, Sobral M, Guiomar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799384>
13. **Burnout in nurses during the COVID-19 pandemic in China: New challenges for public health.** Biosci Trends 2021; Zhang L, Chai L, Zhao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776019>
14. **Experiences of frontline Pakistani emigrant physicians combating COVID-19 in the United Kingdom: a qualitative phenomenological analysis.** BMC Health Serv. Res. 2021; 21:291Saleem J, Ishaq M, Zakar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789650>
15. **Socioeconomic, demographic and healthcare determinants of the COVID-19 pandemic: an ecological study of Spain.** BMC Public Health 2021; 21:606García CN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781245>
16. **Psychosocial health of school-aged children during the initial COVID-19 safer-at-home school mandates in Florida: a cross-sectional study.** BMC Public Health 2021; 21:603McKune SL, Acosta D, Diaz N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781220>
17. **Effects of medical resource capacities and intensities of public mitigation measures on outcomes of COVID-19 outbreaks.** BMC Public Health 2021; 21:605Wang X, Li Q, Sun X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781225>
18. **Psychological and occupational impact of the COVID-19 pandemic on UK surgeons: a qualitative investigation.** BMJ Open 2021; 11:e045699Al-Ghunaim TA, Johnson J, Biyani CS, O'Connor D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795311>
19. **Effects of the COVID-19 pandemic on the sexual and mental health of adolescent and adult men who have sex with men and transgender women participating in two PrEP cohort studies in Brazil: COBra study protocol.** BMJ Open 2021; 11:e045258Ferraz D, Dourado I, Zucchi EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795308>
20. **A cross-sectional study of the association of age, gender, education and economic status with individual perceptions of governmental response to COVID-19.** BMJ Open 2021; 11:e047310Lazarus JV, Palayew A, Rabin K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789857>
21. **Loneliness among older adults in the community during COVID-19: a cross-sectional survey in Canada.** BMJ Open 2021; 11:e044517Savage RD, Wu W, Li J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811054>
22. **A mediating role for mental health in associations between COVID-19-related self-stigma, PTSD, quality of life, and insomnia among patients recovered from COVID-19.** Brain Behav 2021:e02138Mahmoudi H, Saffari M, Movahedi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811451>
23. **Differential Susceptibility to the Impact of the COVID-19 Pandemic on Working Memory, Empathy, and Perceived Stress: The Role of Cortisol and Resilience.** Brain Sci 2021; 11Baliyan S, Cimadevilla JM, de Vidania S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803413>

24. **Design of Fear and Anxiety of COVID-19 Assessment Tool in Spanish Adult Population.** Brain Sci. 2021; 11Gómez-Salgado J, Allande-Cussó R, Domínguez-Salas S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807643>
25. **Detect - assess - implement: How has the public health authorities responded to the COVID-19 pandemic?** Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2021; Bremer V, Schaade L.
26. **Air and maritime transport during the COVID-19 pandemic in Germany: challenges for the public health service.** Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2021; Kleine-Kampmann S, Schöll M, Ehlers L *et al.*
27. **Perceived Stress among Iranians during COVID-19 Pandemic; Stressors and Coping Mechanisms: A Mixed-methods Approach: Stress perçu chez les Iraniens durant la pandémie de la COVID-19; stressseurs et mécanismes d'adaptation: Une approche de méthodes mixtes.** Can. J. Psychiatry. 2021:7067437211004881Faghankhani M, Sodagari F, Shokrani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792374>
28. **Quality of Life in Brain Tumor Patients and Their Relatives Heavily Depends on Social Support Factors during the COVID-19 Pandemic.** Cancers (Basel) 2021; 13Troschel FM, Ahndorf F, Wille LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805663>
29. **Experiences With COVID-19 Stressors and Parents' Use of Neglectful, Harsh, and Positive Parenting Practices in the Northeastern United States.** Child Maltreat 2021:10775595211006465Connell CM, Strambler MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787377>
30. **A Longitudinal Study of Subjective Daytime Sleepiness Changes in Elementary School Children Following a Temporary School Closure Due to COVID-19.** Children (Basel) 2021; 8Komada Y, Ishibashi Y, Hagiwara S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804339>
31. **Insomnia during the COVID-19 pandemic: the role of depression and COVID-19-related risk factors.** Cogn. Behav. Ther. 2021:1-15Pizzonia KL, Koscinski B, Suhr JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787448>
32. **The relationship between burden caused by coronavirus (Covid-19), addictive social media use, sense of control and anxiety.** Comput. Human Behav. 2021; 119:106720Brailovskaia J, Margraf J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785982>
33. **"Staying Home - Feeling Positive": Effectiveness of an on-line positive psychology group intervention during the COVID-19 pandemic.** Curr. Psychol. 2021:1-13Brouzos A, Vassilopoulos SP, Baourda VC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776381>
34. **Individuals' conceptions of COVID-19 pandemic through metaphor analysis.** Curr. Psychol. 2021:1-10Gök A, Kara A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776382>
35. **The interplay between risk and protective factors during the initial height of the COVID-19 crisis in Italy: The role of risk aversion and intolerance of ambiguity on distress.** Curr. Psychol. 2021:1-12Petrocchi S, Iannello P, Ongaro G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776380>

36. **COVID-19 Has Made the Elderly Lonelier.** Dement. Geriatr. Cogn. Dis. Extra 2021; 11:26-28 Naeim M, Rezaeisharif A, Kamran A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790937>
37. **Association of job loss, income loss, and financial burden with adverse mental health outcomes during coronavirus disease 2019 pandemic in Thailand: A nationwide cross-sectional study.** Depress. Anxiety 2021; Ruengorn C, Awiphan R, Wongpakaran N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793028>
38. **Psychometric Analysis for fear of COVID-19 Scale (FCV-19S) and its association with depression in patients with diabetes: A cross sectional study from a Tertiary Care Centre in Karachi, Pakistan.** Diabetes Metab Syndr 2021; 15:733-737 Basit KA, Zafar AB, Fawwad A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813249>
39. **Analyzing Indian general public's perspective on anxiety, stress and trauma during Covid-19 - A machine learning study of 840,000 tweets.** Diabetes Metab Syndr 2021; 15:667-671 Praveen SV, Ittamalla R, Deepak G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813239>
40. **Clinical characterization of brief psychotic disorders triggered by the COVID-19 pandemic: a multicenter observational study.** Eur. Arch. Psychiatry Clin. Neurosci. 2021; Valdés-Flórido MJ, López-Díaz Á, Palermo-Zeballos FJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811552>
41. **Practical recommendations for the prevention and management of COVID-19 in low-income and middle-income settings: adapting clinical experience from the field.** Fam Med Community Health 2021; 9 Fahme SA, Walsh KF, Rouzier V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811089>
42. **A Community-Based Model to the COVID-19 Humanitarian Crisis.** Front Cell Infect Microbiol 2021; 11:639579 Nacoti M, Ciocca A, Brambillasca P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796484>
43. **Anxiety and Its Associated Factors During the Initial Phase of the COVID-19 Pandemic in Indonesia.** Front Psychiatry 2021; 12:634585 Anindyajati G, Wiguna T, Murtani BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790817>
44. **Impact of the Coronavirus Pandemic (COVID-19) Lockdown on Mental Health and Well-Being in the United Arab Emirates.** Front Psychiatry 2021; 12:633230 Cheikh Ismail L, Mohamad MN, Bataineh MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796033>
45. **Psychological Impact of the COVID-19 Pandemic on Adults and Their Children in Italy.** Front Psychiatry 2021; 12:572997 Davico C, Ghiggia A, Marcotulli D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776812>
46. **Coping Styles, Mental Health, and the COVID-19 Quarantine: A Nationwide Survey in Poland.** Front Psychiatry 2021; 12:625355 Kołodziejczyk A, Misiak B, Szcześniak D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776817>
47. **Responding to COVID-19: Emerging Practices in Addiction Medicine in 17 Countries.** Front Psychiatry 2021; 12:634309 Scheibin F, Stowe MJ, Arya S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796034>
48. **A Longitudinal Study on Generalized Anxiety Among University Students During the First Wave of the COVID-19 Pandemic in Switzerland.** Front. Psychol.

2021; 12:643171Amendola S, von Wyl A, Volken T *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776867>

49. **Mediating Effect of Personal Meaning in the Prediction of Life Satisfaction and Mental Health Problems Based on Coronavirus Suffering.** *Front. Psychol.* 2021; 12:638379Arslan G, Yildirim M, Leung MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796048>
50. **Psychosocial Framework of Resilience: Navigating Needs and Adversities During the Pandemic, A Qualitative Exploration in the Indian Frontline Physicians.** *Front. Psychol.* 2021; 12:622132Banerjee D, Sathyanarayana Rao TS, Kallivayalil RA, Javed A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796046>
51. **The Moderating Role of the Hostile-World Scenario in the Connections Between COVID-19 Worries, Loneliness, and Anxiety.** *Front. Psychol.* 2021; 12:645655Bergman YS, Shrira A, Palgi Y, Shmotkin D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796056>
52. **The Effect of Religion on Psychological Resilience in Healthcare Workers During the Coronavirus Disease 2019 Pandemic.** *Front. Psychol.* 2021; 12:628894Chang MC, Chen PF, Lee TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776851>
53. **Positive Environments and Precautionary Behaviors During the COVID-19 Outbreak.** *Front. Psychol.* 2021; 12:624155Corral-Verdugo V, Corral-Frías NS, Frías-Armenta M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790838>
54. **"What If We Get Sick?": Spanish Adaptation and Validation of the Fear of Illness and Virus Evaluation Scale in a Non-clinical Sample Exposed to the COVID-19 Pandemic.** *Front. Psychol.* 2021; 12:590283Cottin M, Hernández C, Núñez C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776833>
55. **Behavioral Changes After the COVID-19 Lockdown in Italy.** *Front. Psychol.* 2021; 12:617315Cucchiarini V, Caravona L, Macchi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776842>
56. **Assessing the Importance of Psychosocial Factors Associated With Sustainable Organizational Development During COVID-19.** *Front. Psychol.* 2021; 12:647435Dragan F, Luo C, Ivascu L, Ali M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776872>
57. **Perceived Impact of Quarantine on Loneliness, Death Obsession, and Preoccupation With God: Predictors of Increased Fear of COVID-19.** *Front. Psychol.* 2021; 12:643977Enea V, Eisenbeck N, Petrescu TC, Carreno DF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776871>
58. **Social Support and Hope Mediate the Relationship Between Gratitude and Depression Among Front-Line Medical Staff During the Pandemic of COVID-19.** *Front. Psychol.* 2021; 12:623873Feng L, Yin R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776846>
59. **A Study on Traditional Teaching Method Transferring to E-Learning Under the Covid-19 Pandemic: From Chinese Students' Perspectives.** *Front. Psychol.* 2021; 12:632787Jin YQ, Lin CL, Zhao Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776854>
60. **Relationships Between the Life Satisfaction, Meaning in Life, Hope and COVID-19 Fear for Turkish Adults During the COVID-19 Outbreak.** *Front.*

[Psychol.](#) 2021; 12:633384Karataş Z, Uzun K, Tagay Ö.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776856>

61. **The Public's Risk Information Seeking and Avoidance in China During Early Stages of the COVID-19 Outbreak.** [Front. Psychol.](#) 2021; 12:649180Liu M, Chen Y, Shi D, Yan T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776873>
62. **Albert Camus - A Psychobiographical Approach in Times of Covid-19.** [Front. Psychol.](#) 2021; 12:644579Mayer CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796053>
63. **Don't Think That Kids Aren't Noticing: Indirect Pathways to Children's Fear of COVID-19.** [Front. Psychol.](#) 2021; 12:635952Radanović A, Micić I, Pavlović S, Krstić K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776863>
64. **Psychological Impact of the Lockdown in Italy Due to the COVID-19 Outbreak: Are There Gender Differences?** [Front. Psychol.](#) 2021; 12:567470Rania N, Coppola I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796039>
65. **The Role of Musical Aesthetic Emotions in Social Adaptation to the Covid-19 Pandemic.** [Front. Psychol.](#) 2021; 12:611639Sarasso P, Ronga I, Neppi-Modona M, Sacco K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776839>
66. **Abilities, Motivations, and Opportunities of Furloughed Employees in the Context of Covid-19: Preliminary Evidence From the UK.** [Front. Psychol.](#) 2021; 12:635144Szulc JM, Smith R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776862>
67. **Individual, Sociodemographic, and Environmental Factors Related to Physical Activity During the Spring 2020 COVID-19 Lockdown.** [Front. Psychol.](#) 2021; 12:643109Teran-Escobar C, Forestier C, Ginoux C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796051>
68. **Compliance and Self-Reporting During the COVID-19 Pandemic: A Cross-Cultural Study of Trust and Self-Conscious Emotions in the United States, Italy, and South Korea.** [Front. Psychol.](#) 2021; 12:565845Travaglino GA, Moon C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796038>
69. **Finding Meaning Amidst COVID-19: An Existential Positive Psychology Model of Suffering.** [Front. Psychol.](#) 2021; 12:641747Van Tongeren DR, Showalter Van Tongeren SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776866>
70. **Longitudinal Trajectories of Study Characteristics and Mental Health Before and During the COVID-19 Lockdown.** [Front. Psychol.](#) 2021; 12:633533van Zyl LE, Rothmann S, Zondervan-Zwijnenburg MAJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776857>
71. **Physical Activity Protects Against the Negative Impact of Coronavirus Fear on Adolescent Mental Health and Well-Being During the COVID-19 Pandemic.** [Front. Psychol.](#) 2021; 12:580511Wright LJ, Williams SE, Veldhuijzen van Zanten J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776827>
72. **Noncompliance With Safety Guidelines as a Free-Riding Strategy: An Evolutionary Game-Theoretic Approach to Cooperation During the COVID-19 Pandemic.** [Front. Psychol.](#) 2021; 12:646892Yong JC, Choy BKC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796057>
73. **Economic Policy Uncertainty in China and Bitcoin Returns: Evidence From the COVID-19 Period.** [Front Public Health](#) 2021; 9:651051Chen T, Lau CKM, Cheema S, Koo CK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777889>

74. **Impact of Public Health Education Program on the Novel Coronavirus Outbreak in the United States.** Front Public Health 2021; 9:630974Iboi E, Richardson A, Ruffin R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791268>
75. **The Epidemiology of COVID 19 in the Amazon and the Guianas: Similarities, Differences, and International Comparisons.** Front Public Health 2021; 9:586299Nacher M, Rousseau C, Succo T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777876>
76. **Women Face to Fear and Safety Devices During the COVID-19 Pandemic in Italy: Impact of Physical Distancing on Individual Responsibility, Intimate, and Social Relationship.** Front Public Health 2021; 9:622155Parisi R, Lagomarsino F, Rania N, Coppola I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777882>
77. **The Traffic Light Approach: Indicators and Algorithms to Identify Covid-19 Epidemic Risk Across Italian Regions.** Front Public Health 2021; 9:650243Paroni L, D'Apice C, Ussai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796500>
78. **COVID-19 Is Not the Flu: Four Graphs From Four Countries.** Front Public Health 2021; 9:628479Stojanovic J, Boucher VG, Boyle J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777883>
79. **Pandemic Uncertainty and Socially Responsible Investments.** Front Public Health 2021; 9:661482Zhu W, Yang J, Lv H, Zhuang M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777890>
80. **The value of healthcare worker support strategies to enhance wellbeing and optimise patient care.** Future Healthc J 2021; 8:e60-e66Diver S, Buccheri N, Ohri C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791478>
81. **Love in the time of COVID-19: Social prescribing and the paradox of isolation.** Future Healthc J 2021; 8:53-56Dixon M, Ornish D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791461>
82. **The impact of and response to the COVID-19 pandemic on a hospital palliative care team.** Future Healthc J 2021; 8:62-64Edmonds PM, Sleeman KE, Lovell N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791463>
83. **COVID-19: The disease of loneliness and solitary demise.** Future Healthc J 2021; 8:e164-e165Trivedi H, Trivedi N, Trivedi V, Moorthy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791500>
84. **The impact of COVID-19 shielding on the wellbeing, mental health and treatment adherence of adults with cystic fibrosis.** Future Healthc J 2021; 8:e47-e49Westcott KA, Wilkins F, Chancellor A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791475>
85. **What do people hospitalised with COVID-19 think about their care? Results of a satisfaction survey during the first wave of COVID-19 in Liverpool.** Future Healthc J 2021; 8:e70-e75Wu MS, Watson R, Hayat F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791480>
86. **Virtual Group Exercises and Psychological Status among Community-Dwelling Older Adults during the COVID-19 Pandemic-A Feasibility Study.** Geriatrics (Basel) 2021; 6Ibrahim A, Chong MC, Khoo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810155>
87. **Rapid Support for Older Adults during the Initial Stages of the COVID-19 Pandemic: Results from a Geriatric Psychiatry Helpline.** Geriatrics (Basel) 2021;

6Wahl AS, Benson G, Hausner L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809840>

88. **Evaluation of Cancer Patients with Older Adult for Awareness and Hospital Arrival Process of COVID-19 Pandemic During: A Cross-Sectional Study.** Gerontol Geriatr Med 2021; 7:2333721421997666 Sipahi Karslı Z, Kurt B, Karadağ İ, Çakmak Öksüzoğlu B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796629>
89. **Relational solidarity and COVID-19: an ethical approach to disrupt the global health disparity pathway.** Glob Bioeth 2021; 32:34-50 Ho A, Dascalu I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795927>
90. **Mental burden and its risk and protective factors during the early phase of the SARS-CoV-2 pandemic: systematic review and meta-analyses.** Global Health 2021; 17:34 Kunzler AM, Röthke N, Günthner L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781283>
91. **Typhoon eye effect versus ripple effect: the role of family size on mental health during the COVID-19 pandemic in Pakistan.** Global Health 2021; 17:32 Lateef T, Chen J, Tahir M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781286>
92. **All Hands on Deck: Local Public Health Agencies Leveraging the Incident Command System During Crises.** Health Secur 2021; Baskin CR, Barry M, Cohen RE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794098>
93. **Impact of Central Quarantine Inside a Lockdown Hospital Due to COVID-19 Pandemic on Psychological Disorders among Health Care Staffs in Central Hospitals of Hanoi, Vietnam, 2020.** Health Serv Insights 2021; 14:1178632921999662 Lan VTH, Dzung LT, Quyen BTT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795936>
94. **Work Engagement in Nurses during the Covid-19 Pandemic: A Cross-Sectional Study.** Healthcare (Basel) 2021; 9 Allande-Cussó R, García-Iglesias JJ, Ruiz-Frutos C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804351>
95. **Predictors of Burnout in Healthcare Workers during the COVID-19 Pandemic.** Healthcare (Basel) 2021; 9 Cotel A, Golu F, Pantea Stoian A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803286>
96. **Health, Psycho-Social Factors, and Ageism in Older Adults in Spain during the COVID-19 Pandemic.** Healthcare (Basel) 2021; 9 Fernández-Ballesteros R, Sánchez-Izquierdo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804449>
97. **Analysis of Anxiety Levels of Nursing Students Because of e-Learning during the COVID-19 Pandemic.** Healthcare (Basel) 2021; 9 García-González J, Ruqiong W, Alarcon-Rodriguez R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804344>
98. **Measuring the Response Performance of U.S. States against COVID-19 Using an Integrated DEA, CART, and Logistic Regression Approach.** Healthcare (Basel) 2021; 9 Xu Y, Park YS, Park JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802276>
99. **Development of the Indian scale of the fear of COVID-19.** Ind Psychiatry J 2020; 29:47-50 Sayeed N, Patel S, Das S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776275>
100. **COVID-19 pandemic and its aftermath: Knowledge, attitude, behavior, and mental health-care needs of medical undergraduates.** Ind Psychiatry J 2020;

- 29:51-60 Shailaja B, Singh H, Chaudhury S, Thyloth M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776276>
101. **Twenty-one Days of Solitude.** *Indian J. Crit. Care Med.* 2021; 25:249-250 Prabhakar H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790499>
 102. **Effect of COVID-19-Related Home Confinement on Sleep Quality, Screen Time and Physical Activity in Tunisian Boys and Girls: A Survey.** *Int J Environ Res Public Health* 2021; 18 Abid R, Ammar A, Maaloul R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809697>
 103. **Health Risks, Preventive Behaviours and Respiratory Illnesses at the 2019 Arbaeen: Implications for COVID-19 and Other Pandemics.** *Int J Environ Res Public Health* 2021; 18 Al-Ansari F, Mirzaei M, Al-Ansari B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33810092>
 104. **Activities and Perceived Risk of Transmission and Spread of SARS-CoV-2 among Specialists and Residents in a Third Level University Hospital in Spain.** *Int J Environ Res Public Health* 2021; 18 Aranaz-Andrés JM, McGee-Laso A, Galán JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802207>
 105. **Time for 'Green' during COVID-19? Inequities in Green and Blue Space Access, Visitation and Felt Benefits.** *Int J Environ Res Public Health* 2021; 18 Astell-Burt T, Feng X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803166>
 106. **Trust and Compliance with COVID-19 Preventive Behaviors during the Pandemic.** *Int J Environ Res Public Health* 2021; 18 Ayalon L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807977>
 107. **Mental Health in the Era of the Second Wave of SARS-CoV-2: A Cross-Sectional Study Based on an Online Survey among Online Respondents in Poland.** *Int J Environ Res Public Health* 2021; 18 Babicki M, Szewczykowska I, Mastalerz-Migas A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806271>
 108. **Psychosocial Effects and Use of Communication Technologies during Home Confinement in the First Wave of the COVID-19 Pandemic in Italy and The Netherlands.** *Int J Environ Res Public Health* 2021; 18 Bastoni S, Wrede C, Ammar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807851>
 109. **Experience of the COVID-19 Pandemic in Rural Odisha, India: Knowledge, Preventative Actions, and Impacts on Daily Life.** *Int J Environ Res Public Health* 2021; 18 Bauza V, Sclar GD, Bisoyi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799698>
 110. **Loneliness among Homeless Individuals during the First Wave of the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2021; 18 Bertram F, Heinrich F, Fröb D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809484>
 111. **COVID-Well Study: Qualitative Evaluation of Supported Wellbeing Centres and Psychological First Aid for Healthcare Workers during the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2021; 18 Blake H, Gupta A, Javed M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807306>
 112. **The Difficult Balance between Ensuring the Right of Nursing Home Residents to Communication and Their Safety.** *Int J Environ Res Public Health* 2021; 18 Bolcato M, Trabucco Aurilio M, Di Mizio G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802378>

113. **Proposal for a Fitness Program in the School Setting during the COVID 19 Pandemic: Effects of an 8-Week CrossFit Program on Psychophysical Well-Being in Healthy Adolescents.** Int J Environ Res Public Health 2021; 18Cataldi S, Francavilla VC, Bonavolontà V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803694>
114. **The Psychological Responses of Nurses Caring for COVID-19 Patients: A Q Methodological Approach.** Int J Environ Res Public Health 2021; 18Cho KH, Kim B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807138>
115. **Mental Health during the Second Wave of the COVID-19 Pandemic-Polish Studies.** Int J Environ Res Public Health 2021; 18Chodkiewicz J, Miniszewska J, Krajewska E, Biliński P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806163>
116. **COVID-19 and Health-Related Quality of Life: A Community-Based Online Survey in Hong Kong.** Int J Environ Res Public Health 2021; 18Choi EPH, Hui BPH, Wan EYF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804725>
117. **The Determinants of Panic Buying during COVID-19.** Int J Environ Res Public Health 2021; 18Chua G, Yuen KF, Wang X, Wong YD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801077>
118. **Psychological Health Status of Psychiatric Patients Living in Treatment Communities before and during the COVID-19 Lockdown: A Brief Report.** Int J Environ Res Public Health 2021; 18Cordellieri P, Barchielli B, Masci V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808178>
119. **Fear of COVID-19 for Individuals and Family Members: Indications from the National Cross-Sectional Study of the EPICOV19 Web-Based Survey.** Int J Environ Res Public Health 2021; 18Cori L, Curzio O, Adorni F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801074>
120. **Portuguese Nurses' Stress, Anxiety, and Depression Reduction Strategies during the COVID-19 Outbreak.** Int J Environ Res Public Health 2021; 18de Pinho LG, Sampaio F, Sequeira C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801740>
121. **Mental Health among Adults during the COVID-19 Pandemic Lockdown: A Cross-Sectional Multi-Country Comparison.** Int J Environ Res Public Health 2021; 18Ding K, Yang J, Chin MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800008>
122. **Perception of Risk, Self-Efficacy and Social Trust during the Diffusion of Covid-19 in Italy.** Int J Environ Res Public Health 2021; 18Diotaiuti P, Valente G, Mancone S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806194>
123. **Adherence to COVID-19 Prevention Measures in the Democratic Republic of the Congo, Results of Two Consecutive Online Surveys.** Int J Environ Res Public Health 2021; 18Ditekemena JD, Mavoko HM, Obimpeh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806286>
124. **Comparisons between the Neighboring States of Amazonas and Pará in Brazil in the Second Wave of COVID-19 Outbreak and a Possible Role of Early Ambulatory Treatment.** Int J Environ Res Public Health 2021; 18Emmerich FG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805135>
125. **A Scoping Review of Psychosocial Risks to Health Workers during the Covid-19 Pandemic.** Int J Environ Res Public Health 2021; 18Franklin P, Gkiouleka A.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33801517>

126. **Impact of COVID-19 Pandemic on Behavioral and Emotional Aspects and Daily Routines of Arab Israeli Children.** Int J Environ Res Public Health 2021; 18Ghanamah R, Eghbaria-Ghanamah H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805644>
127. **Burnout Determinants among Nurses Working in Palliative Care during the Coronavirus Disease 2019 Pandemic.** Int J Environ Res Public Health 2021; 18Gonçalves JV, Castro L, Rêgo G, Nunes R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805141>
128. **Smokers Are More Likely to Smoke More after the COVID-19 California Lockdown Order.** Int J Environ Res Public Health 2021; 18Gonzalez M, Epperson AE, Halpern-Felsher B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807503>
129. **Assessing the Psychological Impacts of COVID-19 in Undergraduate Medical Students.** Int J Environ Res Public Health 2021; 18Guo AA, Crum MA, Fowler LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805787>
130. **Is It Possible to Be Happy during the COVID-19 Lockdown? A Longitudinal Study of the Role of Emotional Regulation Strategies and Pleasant Activities in Happiness.** Int J Environ Res Public Health 2021; 18Gutiérrez-Cobo MJ, Megías-Robles A, Gómez-Leal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808852>
131. **Investigating Racial Differences among Men in COVID-19 Diagnosis, and Related Psychosocial and Behavioral Factors: Data from the Michigan Men's Health Event.** Int J Environ Res Public Health 2021; 18Hawkins J, Gilcher K, Schwenzer C, Lutz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810055>
132. **Conversations in Times of Isolation: Exploring Rural-Dwelling Older Adults' Experiences of Isolation and Loneliness during the COVID-19 Pandemic in Manitoba, Canada.** Int J Environ Res Public Health 2021; 18Herron RV, Newall NEG, Lawrence BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804282>
133. **Older Users of a Befriending Service in Ireland and the Maintenance of Personal Autonomy during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Holton E, Fitzpatrick R, Maguire R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801822>
134. **The Progression of COVID-19 and the Government Response in China.** Int J Environ Res Public Health 2021; 18Hu X, Flahault A, Temerev A, Rozanova L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804022>
135. **Outdoor Activity Participation Improves Adolescents' Mental Health and Well-Being during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Jackson SB, Stevenson KT, Larson LR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802521>
136. **Impact of COVID-19 on Mental Health in Adolescents: A Systematic Review.** Int J Environ Res Public Health 2021; 18Jones EAK, Mitra AK, Bhuiyan AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802278>
137. **COVID-19 Pandemic and Helsinki University Hospital Personnel Psychological Well-Being: Six-Month Follow-Up Results.** Int J Environ Res Public Health 2021; 18Laukkala T, Suvisaari J, Rosenström T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806283>

138. **Psychological Impact of COVID-19 Pandemic and Related Variables: A Cross-Sectional Study in a Sample of Workers in a Spanish Tertiary Hospital.** Int J Environ Res Public Health 2021; 18Leira-Sanmartín M, Madoz-Gúrpide A, Ochoa-Mangado E, Ibáñez Á. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807155>
139. **Intolerance of COVID-19-Related Uncertainty and Negative Emotions among Chinese Adolescents: A Moderated Mediation Model of Risk Perception, Social Exclusion and Perceived Efficacy.** Int J Environ Res Public Health 2021; 18Li Q, Luo R, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799731>
140. **A Cross-Country Examination on the Fear of COVID-19 and the Sense of Loneliness during the First Wave of COVID-19 Outbreak.** Int J Environ Res Public Health 2021; 18Lo Coco G, Gentile A, Bosnar K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807549>
141. **Mental Health, Greenness, and Nature Related Behaviors in the Adult Population of Stockholm County during COVID-19-Related Restrictions.** Int J Environ Res Public Health 2021; 18Löhmus M, Stenfors CUD, Lind T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806787>
142. **Impact of COVID-19 on the Anxiety Perceived by Healthcare Professionals: Differences between Primary Care and Hospital Care.** Int J Environ Res Public Health 2021; 18Londoño-Ramírez AC, García-Pla S, Bernabeu-Juan P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810004>
143. **Time in Nature Associated with Decreased Fatigue in UK Truck Drivers.** Int J Environ Res Public Health 2021; 18Longman DP, Shaw CN, Varela-Mato V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803843>
144. **COVID-19 Confinement and Sexual Activity in Spain: A Cross-Sectional Study.** Int J Environ Res Public Health 2021; 18López-Bueno R, López-Sánchez GF, Gil-Salmerón A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806553>
145. **Trends in Healthcare Access in Japan during the First Wave of the COVID-19 Pandemic, up to June 2020.** Int J Environ Res Public Health 2021; 18Makiyama K, Kawashima T, Nomura S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809955>
146. **Investigating the Self-Reported Health Status of Domestic and Overseas Chinese Populations during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Mao Z, Chen B, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809532>
147. **The Impact of the COVID-19 Pandemic on Vulnerable People Suffering from Depression: Two Studies on Adults in France.** Int J Environ Res Public Health 2021; 18Martinelli N, Gil S, Chevalère J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801095>
148. **Mental Health of Children and Adolescents Amidst COVID-19 and Past Pandemics: A Rapid Systematic Review.** Int J Environ Res Public Health 2021; 18Meherali S, Punjani N, Louie-Poon S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810225>
149. **Keep Calm and Stay Safe: The Relationship between Anxiety and Other Psychological Factors, Media Exposure and Compliance with COVID-19 Regulations.** Int J Environ Res Public Health 2021; 18Mevorach T, Cohen J, Apter A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799609>

150. **Relation among Perceived Weight Change, Sedentary Activities and Sleep Quality during COVID-19 Lockdown: A Study in an Academic Community in Northern Italy.** Int J Environ Res Public Health 2021; 18Micheletti Cremasco M, Mulasso A, Moroni A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805640>
151. **A Model for the Implementation of Lean Improvements in Healthcare Environments as Applied in a Primary Care Center.** Int J Environ Res Public Health 2021; 18Morell-Santandreu O, Santandreu-Mascarell C, Garcia-Sabater JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799752>
152. **Social Isolation and Loneliness during COVID-19 Lockdown: Associations with Depressive Symptoms in the German Old-Age Population.** Int J Environ Res Public Health 2021; 18Müller F, Röhr S, Reininghaus U, Riedel-Heller SG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807232>
153. **Burnout of Healthcare Workers amid the COVID-19 Pandemic: A Japanese Cross-Sectional Survey.** Int J Environ Res Public Health 2021; 18Nishimura Y, Miyoshi T, Hagiya H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801349>
154. **'Should I Stay, or Should I Go?' Psychological Distress Predicts Career Change Ideation among Intensive Care Staff in Lithuania and the UK Amid COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Norkiene I, Jovarauskaite L, Kvedaraite M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800903>
155. **Access to Healthcare during COVID-19.** Int J Environ Res Public Health 2021; 18Núñez A, Sreeganga SD, Ramaprasad A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799417>
156. **The Loneliness-Life Satisfaction Relationship: The Parallel and Serial Mediating Role of Hopelessness, Depression and Ego-Resilience among Young Adults in South Africa during COVID-19.** Int J Environ Res Public Health 2021; 18Padmanabhanunni A, Pretorius T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807204>
157. **Sleep and Awakening Quality during COVID-19 Confinement: Complexity and Relevance for Health and Behavior.** Int J Environ Res Public Health 2021; 18Paiva T, Reis C, Feliciano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800607>
158. **From Recession to Depression? Prevalence and Correlates of Depression, Anxiety, Traumatic Stress and Burnout in Healthcare Workers during the COVID-19 Pandemic in Greece: A Multi-Center, Cross-Sectional Study.** Int J Environ Res Public Health 2021; 18Pappa S, Athanasiou N, Sakkas N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804505>
159. **Preventive Behavioral Insights for Emerging Adults: A Survey during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Park S, Kim B, Kim KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806586>
160. **Associations between Relationship Quality and Mental Health during COVID-19 in the United Kingdom.** Int J Environ Res Public Health 2021; 18Pieh C, Probst T, Budimir S, Humer E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799677>
161. **Eating Habits and Sleep Quality during the COVID-19 Pandemic in Adult Population of Ecuador.** Int J Environ Res Public Health 2021; 18Ramos-Padilla P,

Villavicencio-Barriga VD, Cárdenas-Quintana H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807140>

162. **Psychological Distress among Italian University Students Compared to General Workers during the COVID-19 Pandemic.** [Int J Environ Res Public Health](#) 2021; 18Romeo A, Benfante A, Castelli L, Di Tella M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802514>
163. **Depression and Anxiety in Patients with Rare Diseases during the COVID-19 Pandemic.** [Int J Environ Res Public Health](#) 2021; 18Sánchez-García JC, Cortés-Martín J, Rodríguez-Blanco R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800980>
164. **Flexibility and Bed Margins of the Community of Madrid's Hospitals during the First Wave of the SARS-CoV-2 Pandemic.** [Int J Environ Res Public Health](#) 2021; 18Sánchez-Úbeda EF, Sánchez-Martín P, Torrego-Ellacuría M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33800638>
165. **Nine Months into the COVID-19 Pandemic: A Longitudinal Study Showing Mental Health and Movement Behaviours Are Impaired in UK Students.** [Int J Environ Res Public Health](#) 2021; 18Savage MJ, Hennis PJ, Magistro D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809313>
166. **Sources of Health Anxiety for Hospital Staff Working during the Covid-19 Pandemic.** [Int J Environ Res Public Health](#) 2021; 18Shayganfar M, Mahdavi F, Haghighi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802863>
167. **Association between Viral Infections and Risk of Autistic Disorder: An Overview.** [Int J Environ Res Public Health](#) 2021; 18Shuid AN, Jayusman PA, Shuid N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802042>
168. **Coronavirus Trauma and African Americans' Mental Health: Seizing Opportunities for Transformational Change.** [Int J Environ Res Public Health](#) 2021; 18Snowden LR, Snowden JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808216>
169. **Effects of Lifestyle Changes on the Mental Health of Healthcare Workers with Different Sense of Coherence Levels in the Era of COVID-19 Pandemic.** [Int J Environ Res Public Health](#) 2021; 18Tanaka K, Tahara M, Mashizume Y, Takahashi K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801912>
170. **Sleep and Mental Health Disturbances Due to Social Isolation during the COVID-19 Pandemic in Mexico.** [Int J Environ Res Public Health](#) 2021; 18Terán-Pérez G, Portillo-Vásquez A, Arana-Lechuga Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33801928>
171. **Community Health Workers as a Strategy to Tackle Psychosocial Suffering Due to Physical Distancing: A Randomized Controlled Trial.** [Int J Environ Res Public Health](#) 2021; 18Vanden Bossche D, Lagaert S, Willems S, Decat P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802870>
172. **Pathways Improving Compliance with Preventive Behaviors during the Remission Period of the COVID-19 Pandemic.** [Int J Environ Res Public Health](#) 2021; 18Wang J, Rao N, Han B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800648>
173. **Class of 2020 in Poland: Students' Mental Health during the COVID-19 Outbreak in an Academic Setting.** [Int J Environ Res Public Health](#) 2021;

- 18Wieczorek T, Kołodziejczyk A, Ciułkowicz M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33799848>
174. **The Coronavirus Pandemic and the Occurrence of Psychosomatic Symptoms: Are They Related?** *Int J Environ Res Public Health* 2021; 18Zidkova R, Malinakova K, van Dijk JP, Tavel P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808214>
 175. **The Relationship between Cognitive Function, Lifestyle Behaviours and Perception of Stress during the COVID-19 Induced Confinement: Insights from Correlational and Mediation Analyses.** *Int J Environ Res Public Health* 2021; 18Znazen H, Slimani M, Bragazzi NL, Tod D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808777>
 176. **Characteristics and Behaviors Associated with Prevalent SARS-CoV-2 Infection.** *Int. J. Gen. Med.* 2021; 14:1063-1067Aung S, Vittinghoff E, Nah G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790635>
 177. **The impact of the non-essential business closure policy on Covid-19 infection rates.** *Int J Health Econ Manag* 2021:1-40Song H, McKenna R, Chen AT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792808>
 178. **The mental health status among nurses from low-risk areas under normalized COVID-19 pandemic prevention and control in China: A cross-sectional study.** *Int. J. Ment. Health Nurs.* 2021; Chen X, Arber A, Gao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811426>
 179. **Experiences, emotional responses, and coping skills of nursing students as auxiliary health workers during the peak COVID-19 pandemic: A qualitative study.** *Int. J. Ment. Health Nurs.* 2021; Roca J, Canet-Vélez O, Cemeli T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792160>
 180. **Psychological distress experienced by self-quarantined undergraduate university students in Lebanon during the COVID-19 outbreak.** *Int. J. Psychiatry Clin. Pract.* 2021:1-8Kassir G, El Hayek S, Zalzale H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775208>
 181. **Prevalence of anxiety, depression, and psychological distress among the general population during the COVID-19 pandemic: A systematic review and meta-analysis.** *Int J Soc Psychiatry* 2021:207640211003121Necho M, Tsehay M, Birkie M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794717>
 182. **The impact of reduced working on mental health in the early months of the COVID-19 pandemic: Results from the understanding society COVID-19 study.** *J. Affect. Disord.* 2021; 287:308-315Ferry F, Bunting B, Rosato M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812244>
 183. **Perceived family adaptability and cohesion and depressive symptoms: A comparison of adolescents and parents during COVID-19 pandemic.** *J. Affect. Disord.* 2021; 287:255-260Li M, Li L, Wu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799045>
 184. **Is returning to school during the COVID-19 pandemic stressful? A study on immediate mental health status of Chinese college students.** *J. Affect. Disord.* 2021; 287:261-267Wang D, Chen H, Zhai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799046>
 185. **The prevalence of psychiatric comorbidities during the SARS and COVID-19 epidemics: a systematic review and meta-analysis of observational studies.** *J.*

- Affect. Disord.* 2021; 287:145-157Zhao YJ, Jin Y, Rao WW *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33799032>
186. **Risk Perception, Preventive Behavior, and Medical Care Avoidance among American Older Adults During the COVID-19 Pandemic.** *J. Aging Health* 2021;8982643211002084Lu P, Kong D, Shelley M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779385>
 187. **The Association between ADHD and the Severity of COVID-19 Infection.** *J Atten Disord* 2021;10870547211003659Merzon E, Weiss MD, Cortese S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33797281>
 188. **Suicide among adolescents and youths during the COVID-19 pandemic lockdowns: A press media reports-based exploratory study.** *J. Child Adolesc. Psychiatr. Nurs.* 2021; Manzar MD, Albougami A, Usman N, Mamun MA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811706>
 189. **The effects of the COVID-19 pandemic on children's lifestyles and anxiety levels.** *J. Child Adolesc. Psychiatr. Nurs.* 2021; Zengin M, Yayan EH, Vicnelioğlu E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33793012>
 190. **Implementation of telehealth during COVID-19: Implications for providing behavioral health services to pediatric patients.** *J Child Health Care* 2021;13674935211007329Frye WS, Gardner L, Campbell JM, Katzenstein JM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779352>
 191. **Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak.** *J Clin Med* 2021; 10Carotenuto A, Scandurra C, Costabile T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809698>
 192. **The Outbreak of SARS-CoV-2 Pandemic and the Well-Being of Polish Students: The Risk Factors of the Emotional Distress during COVID-19 Lockdown.** *J Clin Med* 2021; 10Juchnowicz D, Baj J, Forma A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804368>
 193. **COVID-19 Pandemic Influence on Healthcare Professionals.** *J Clin Med* 2021; 10Klimkiewicz A, Schmalenberg A, Klimkiewicz J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808828>
 194. **The Psychological Impact of the COVID-19 Pandemic on Dentists in Germany.** *J Clin Med* 2021; 10Mekhemar M, Attia S, Dörfer C, Conrad J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33801333>
 195. **Assessing Interventions against Coronavirus Disease 2019 (COVID-19) in Osaka, Japan: A Modeling Study.** *J Clin Med* 2021; 10Nakajo K, Nishiura H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33803634>
 196. **The Impact of the COVID-19 Pandemic on Psychological Health and Insomnia among People with Chronic Diseases.** *J Clin Med* 2021; 10Wańkiewicz P, Szylińska A, Rotter I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799371>
 197. **The impact of lockdown on sleep patterns of children and adolescents with ADHD.** *J. Clin. Sleep Med.* 2021; Bruni O, Giallonardo M, Sacco R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33792536>
 198. **Barriers Related to Mask Wearing in African American Neighborhood Businesses.** *J. Community Health* 2021; Jones HJ, Hutchins R, Brown P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811572>

199. **COVID-19-related psychiatric impact on Italian adolescent population: A cross-sectional cohort study.** *J. Community Psychol.* 2021; Mensi MM, Capone L, Rogantini C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778970>
200. **Stress of university students before and after campus closure in response to COVID-19.** *J. Community Psychol.* 2021; von Keyserlingk L, Yamaguchi-Pedroza K, Arum R, Eccles JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786864>
201. **Post-traumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge.** *J Gen Intern Med* 2021;1-6Tarsitani L, Vassalini P, Koukopoulos A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782888>
202. **Meaning in Life among New Mothers before and during the COVID-19 Pandemic: The Role of Mothers' Marital Satisfaction and Perception of the Infant.** *J Happiness Stud* 2021:1-14Chasson M, Ben-Yaakov O, Taubman-Ben-Ari O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776553>
203. **COVID-19 and Mental Health: Should We Expect an Increase in Disability?** *J. Insur. Med.* 2021; 49:1-8Meagher T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784745>
204. **COVID-19: Were Public Health Interventions and the Disclosure of Patients' Contact History Effective in Upholding Social Distancing? Evidence from South Korea.** *J Multidiscip Healthc* 2021; 14:705-712Im J, Kim J, Choeh JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790569>
205. **Predictors of Health Behaviors Among Undergraduate Students During the COVID-19 Pandemic: A Cross-Sectional Predictive Study.** *J Multidiscip Healthc* 2021; 14:727-734Suksatan W, Choompunuch B, Koontalay A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790571>
206. **Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients.** *J Nucl Med* 2021; Blazhenets G, Schröter N, Bormann T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789937>
207. **Factors Affecting Nurses' Professional Commitment During the COVID-19 Pandemic: A Cross-Sectional Study.** *J. Nurs. Manag.* 2021; Duran S, Celik I, Ertugrul B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794061>
208. **How workplace violence correlates turnover intention among Chinese healthcare workers in COVID-19 context: The mediating role of perceived social support and mental health.** *J. Nurs. Manag.* 2021; Yang Y, Wang P, Kelifa MO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792990>
209. **Impact of COVID-19 pandemic on orthopaedic surgeons in terms of anxiety, sleep outcomes and change in management practices: A cross-sectional study from India.** *J. Orthop. Surg. (Hong Kong)* 2021; 29:23094990211001621Sharma V, Kumar N, Gupta B, Mahajan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779373>
210. **Development of a Remote Public Health Advanced Pharmacy Practice Experience in Response to COVID-19.** *J. Pharm. Pract.* 2021:8971900211004830Kiles TM, Hagemann T, Felts B, Crill C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789494>
211. **The COVID-19 Inventory: Measuring anxiety related to illness pandemic across college males and females.** *J Prev Interv Community* 2021:1-16Mohlman J,

- Watson LM, Basch CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797333>
212. **Bereavement via Zoom during COVID-19.** *J. Psychosoc. Oncol.* 2021:1-4Morris SE, Ryan AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775229>
 213. **Finding my way home: Ambiguous loss reconceptualized to bridge the conversion from in-person therapy to teletherapy during COVID-19.** *J. Psychosoc. Oncol.* 2021:1-3Suk L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775240>
 214. **Finding the power within and without: How can we strengthen resilience against symptoms of stress, anxiety, and depression in Australian parents during the COVID-19 pandemic?** *J. Psychosom. Res.* 2021:110433Mikocka-Walus A, Stokes M, Evans S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812660>
 215. **Covid-19 pandemic: Current scenario and public risk perception in Pakistan.** *J Public Aff* 2021:e2617Gul A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786016>
 216. **Coronavirus disease 2019 (COVID-19) and individuals with intellectual and developmental disabilities in Nigeria.** *J Public Aff* 2021:e2601Ijezie OA, Okagbue HI, Oloyede OA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786015>
 217. **Demand smoothing response by street-level bureaucrats (SLB) in delivering public services during COVID-19 scenario: A system dynamics modeling study.** *J Public Aff* 2021:e2633Prusty SK, Mahapatra D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786023>
 218. **COVID-19 pandemic and transmission factors: An empirical investigation of different countries.** *J Public Aff* 2021:e2648Singh PK, Kiran R, Bhatt RK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786025>
 219. **"We Need a Song of Hope": Responding to the COVID-19 Informational and Psychospiritual Needs of Residents of a Gated Community in the Philippines.** *J Relig Health* 2021:1-13Aja GN, Francisco J, Matunga M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782845>
 220. **Does Religion Influence the Motivations of Future Healthcare Professionals to Volunteer During the COVID-19 Pandemic in Poland? An Exploratory Study.** *J Relig Health* 2021; Domaradzki J, Walkowiak D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797729>
 221. **Digital Mental Health Challenges and the Horizon Ahead for Solutions.** *JMIR Ment Health* 2021; 8:e26811Balcombe L, De Leo D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779570>
 222. **Managing bereavement when a family member dies in an aged care home: the impact of COVID-19.** *Med. J. Aust.* 2021; O'Connor M, Wilson B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811340>
 223. **An Analysis of the Psychosocial Challenges Faced by the University Students During COVID-19 Pandemic, and the Students' Knowledge, Attitudes, and Practices Toward the Disease.** *Noro Psikiyatr Ars* 2021; 58:3-10Yorguner N, Bulut NS, Akvardar Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795945>
 224. **Professional identity of Chinese nursing students during the COVID-19 pandemic outbreak: A nation-wide cross-sectional study.** *Nurse Educ Pract* 2021; 52:103040Zhang Z, Fu W, Tian C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813343>

225. **COVID-19 Infection-Related Weight Loss Decreases Eating/Swallowing Function in Schizophrenic Patients.** Nutrients 2021; 13:Kikutani T, Ichikawa Y, Kitazume E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805263>
226. **COVID-19 Stress and Food Intake: Protective and Risk Factors for Stress-Related Palatable Food Intake in U.S. Adults.** Nutrients 2021; 13:Sadler JR, Thapaliya G, Jansen E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802066>
227. **A qualitative study of bereaved relatives' end of life experiences during the COVID-19 pandemic.** Palliat. Med. 2021:2692163211004210Hanna JR, Rapa E, Dalton LJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784908>
228. **Mental health in Japanese children during school closures due to the COVID-19.** Pediatr. Int. 2021; Saito M, Kikuchi Y, Lefor AK, Hoshina M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792099>
229. **The Lègami/Legàmi Service-An Experience of Psychological Intervention in Maternal and Child Care during COVID-19.** Pediatr. Rep. 2021; 13:142-161Perricone G, Rotolo I, Beninati V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810190>
230. **Fear of COVID-19, poor quality of sleep, irritability, and intention to quit school among nursing students: A cross-sectional study.** Perspect. Psychiatr. Care 2021; De Los Santos JAA, Labrague LJ, Falguera CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792054>
231. **A COVID-19-ready public health surveillance system: The FDA's Sentinel System.** Pharmacoepidemiol. Drug Saf. 2021; Cocoros NM, Fuller CC, Adimadhyam S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797815>
232. **Disruptive Resilience: Harnessing Leadership to Build a More Equitable Health Care System After COVID-19.** Popul Health Manag 2021; Mitton JA, Urquieta de Hernandez B, Pasupuleti N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784488>
233. **Doctors underestimate 2 m social distancing more than other health care workers.** Postgrad. Med. J. 2021; Lennie I, Muralidharan S, Rimbi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790032>
234. **Longitudinal evidence on mental health changes of college students with and without mental disorder background during the Argentina's lengthy mandatory quarantine.** Prog. Neuropsychopharmacol. Biol. Psychiatry 2021:110308Steinmetz LCL, Fong SB, Godoy JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775744>
235. **Post-traumatic Stress and Related Factors Among Hospital Nurses during the COVID-19 Outbreak in Korea.** Psychiatr. Q. 2021:1-11Moon DJ, Han MA, Park J, Ryu SY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788071>
236. **The Effects of the 1(st) National COVID 19 Lockdown on Emergency Psychiatric Visit Trends in a Tertiary General Hospital in Israel.** Psychiatry Res 2021; 300:113903Dvorak L, Sar-El R, Mordel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799196>
237. **COVID-19 and psychiatric admissions: An observational study of the first six months of lockdown in Melbourne.** Psychiatry Res 2021; 300:113902Jagadheesan K, Danivas V, Itrat Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799197>

238. **Five Months Later: The Psychodynamic Psychiatrist and Psychiatric Care in the Era of COVID-19.** Psychodyn Psychiatry 2020; 48:363-391 Best K, Ingram DH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779226>
239. **How does stress affect life satisfaction during the COVID-19 pandemic? Moderated mediation analysis of sense coherence and fear of coronavirus.** Psychol Health Med 2021;1-9 Dymecka J, Gerymski R, Machnik-Czerwik A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784897>
240. **Resilience, coping style, and COVID-19 stress: effects on the quality of life in frontline health care workers.** Psychol Health Med 2021;1-13 Li WQ, Yuan P, Sun J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779436>
241. **People perceive themselves to adhere more strictly to COVID-19 guidelines than others.** Psychol Health Med 2021;1-8 Mojzisch A, Elster C, Germar M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779442>
242. **Feelings of Culpability: Just Following Orders Versus Making the Decision Oneself.** Psychol. Sci. 2021;9567976211002821 Malter MS, Kim SS, Metcalfe J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798001>
243. **Public choice and public health.** Public Choice 2021;1-37 Leeson PT, Thompson HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776157>
244. **Public health information on COVID-19 for international travellers: lessons learned from a mixed-method evaluation.** Public Health 2021; 193:116-123 Zhang T, Robin C, Cai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780897>
245. **Exploring Barriers to Effective Implementation of Public Health Measures for Prevention and Control of COVID-19 Pandemic in Gamo Zone of Southern Ethiopia: Using a Modified Tanahashi Model.** Risk Manag. Healthc. Policy 2021; 14:1219-1232 Boti Sidamo N, Hussien S, Shibiru T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776499>
246. **Preparedness level and associated factors of health professionals regarding COVID-19.** SAGE Open Med 2021; 9:20503121211001151 Eshetie Adane D, Demilew BC, Ayenew NT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786185>
247. **Psychological impact of COVID-19 on health workers in Ghana: A multicentre, cross-sectional study.** SAGE Open Med 2021; 9:20503121211000919 Ofori AA, Osarfo J, Agbeno EK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786183>
248. **Sleep quality and insomnia during the COVID-19 lockdown among the Saudi public: A cross-sectional study.** Saudi Med. J. 2021; 42:384-390 Alharbi AS, Alshahrani SM, Alsaadi MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795493>
249. **[Evaluation of social distancing measures on the transmissibility of COVID-19 in rural areas. Retrospective longitudinal study of possible cases].** Semergen 2021; Peña-Galo E, Turón-Alcaine JM, Gracia-Carrasco E, Alcedo-González J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812795>
250. **The Association of the COVID-19 Pandemic on Male Sexual Function in the United States: A Survey Study of Male Cannabis Users.** Sex Med 2021; 9:100340 Chen T, Bhambhani HP, Kasman AM, Eisenberg ML.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789175>

251. **Sexual health (excluding reproductive health, intimate partner violence and gender-based violence) and COVID-19: a scoping review.** Sex. Transm. Infect. 2021; Kumar N, Janmohamed K, Nyhan K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782145>
252. **Breaking bad news to cancer patients in times of COVID-19.** Support. Care Cancer 2021;1-4Hauk H, Bernhard J, McConnell M, Wohlfarth B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782762>
253. **Psychological distress among cancer survivors during implementation of a nationwide Movement Control Order over the COVID-19 pandemic.** Support. Care Cancer 2021; Wong LP, Lai LL, See MH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796935>
254. **Mental Health and Physical Activity among Children and Adolescents during the COVID-19 Pandemic.** Tohoku J. Exp. Med. 2021; 253:203-215Okuyama J, Seto S, Fukuda Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775993>
255. **The interplay between anxiety, fear, protective behaviors, compassion, and resilience among older adults during a COVID-19 lockdown: a structural equation modeling study.** Transl. Behav. Med. 2021; Lim XY, Yap AC, Mahendran R, Yu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793946>
256. **Impact of COVID-19 lockdown on suicide attempts : A retrospective analysis of the springtime admissions to the trauma resuscitation room at the Medical University of Vienna from 2015-2020.** Wien. Klin. Wochenschr. 2021:1-8Carlin GL, Baumgartner JS, Moftakhar T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788013>
257. **The Impact of the Social Distancing Policy on COVID-19 Incidence Cases and Deaths in Iran from February 2020 to January 2021: Insights from an Interrupted Time Series Analysis.** Yale J. Biol. Med. 2021; 94:13-21Saki M, Ghanbari MK, Behzadifar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795979>
258. **Promoting social distancing and preventing panic buying during the epidemic of COVID-19: the contributions of people's psychological and behavioural factors.** Z Gesundh Wiss 2021:1-15Zhang Y, Zhou R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777652>

Meta-analyses - systematic reviews (16 articles)

1. **Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis.** Acta Diabetol 2021:1-10Kaminska H, Szarpak L, Kosior D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778910>
2. **Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.** BMC Neurol. 2021; 21:138Yassin A, Nawaiseh M, Shaban A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784985>
3. **The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysis.** Clin Epidemiol Glob Health

2021:100727Mahat RK, Panda S, Rathore V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778183>

4. **Diabetes-related acute metabolic emergencies in COVID-19 patients: a systematic review and meta-analysis.** Diabetol Int 2021;1-15Papadopoulos VP, Koutroulos MV, Zikoudi DG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777611>
5. **Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.** Front Med (Lausanne) 2021; 8:626425Hegyí PJ, Váncsa S, Ocskay K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777974>
6. **Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis.** Front. Pharmacol. 2021; 12:607408Abdelrahman Z, Liu Q, Jiang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790785>
7. **Mental burden and its risk and protective factors during the early phase of the SARS-CoV-2 pandemic: systematic review and meta-analyses.** Global Health 2021; 17:34Kunzler AM, Röthke N, Günthner L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781283>
8. **The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.** Int Immunopharmacol 2021; 96:107602Lin WT, Hung SH, Lai CC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812260>
9. **Cardiac abnormalities due to multisystem inflammatory syndrome temporally associated with Covid-19 among children: A systematic review and meta-analysis.** Int J Cardiol Heart Vasc 2021:100764Haghighi Aski B, Manafi Anari A, Abolhasan Choobdar F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778151>
10. **Smokers Are More Likely to Smoke More after the COVID-19 California Lockdown Order.** Int J Environ Res Public Health 2021; 18Gonzalez M, Epperson AE, Halpern-Felsher B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807503>
11. **COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis.** Int J Environ Res Public Health 2021; 18Lee KW, Yap SF, Ngeow YF, Lye MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808066>
12. **The prevalence of psychiatric comorbidities during the SARS and COVID-19 epidemics: a systematic review and meta-analysis of observational studies.** J. Affect. Disord. 2021; 287:145-157Zhao YJ, Jin Y, Rao WW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799032>
13. **A meta-research study revealed susceptibility of Covid-19 treatment research to white hat bias: First, do no harm.** J. Clin. Epidemiol. 2021; Bellos I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775812>
14. **Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies.** J. Steroid Biochem. Mol. Biol. 2021:105883Petrelli F, Luciani A, Perego G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775818>
15. **The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.** Pharmacol. Rep. 2021:1-7Kow CS, Merchant HA, Mustafa ZU, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779964>

16. **Cardiovascular complications of SARS-CoV-2 infection (COVID-19): a systematic review and meta-analysis.** Rev Cardiovasc Med 2021; 22:159-165 Zhao YH, Zhao L, Yang XC, Wang P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792257>

Mortality (30 articles)

1. **Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis.** Acta Diabetol 2021;1-10 Kaminska H, Szarpak L, Kosior D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778910>
2. **Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem.** Adv Ther 2021;1-8 Cugno M, Gualtierotti R, Casazza G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792889>
3. **Preparedness to Face the COVID-19 Pandemic in Hospice and Palliative Care Services in the Asia-Pacific Region: A Rapid Online Survey.** Am. J. Hosp. Palliat. Care 2021;10499091211002797 Lin CP, Boufkhed S, Kizawa Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789503>
4. **Peripheral Plasma Cells Associated with Mortality Benefit in Severe COVID-19: A Marker of Disease Resolution.** Am. J. Med. 2021; Boulanger M, Molina E, Wang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811876>
5. **Fever: Could A Cardinal Sign of COVID-19 Infection Reduce Mortality?** Am. J. Med. Sci. 2021; 361:420-426 Cann SAH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781387>
6. **Characteristics and Risk Factors Associated With Mortality in a Multicenter Spanish Cohort of Patients With COVID-19 Pneumonia.** Arch. Bronconeumol. 2021; Muñoz-Rodríguez JR, Gómez-Romero FJ, Pérez-Ortiz JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785236>
7. **Association between Postmortem Kidney Biopsy Findings and Acute Kidney Injury from Patients with SARS-CoV-2 (COVID-19).** Clin J Am Soc Nephrol 2021; Rivero J, Merino-López M, Olmedo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782033>
8. **A model to predict the risk of mortality in severely ill COVID-19 patients.** Comput Struct Biotechnol J 2021; Chen B, Gu H, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777331>
9. **A model to predict the risk of mortality in severely ill COVID-19 patients.** Comput Struct Biotechnol J 2021; 19:1694-1700 Chen B, Gu HQ, Liu 刘艺 Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777331>
10. **COVID-19: How did mortality change?** Deutsche Medizinische Wochenschrift 2021; 146:426 Kolks O.
11. **COVID-19: Mortality in Germany 2020 - Reply to the Letter.** Deutsche Medizinische Wochenschrift 2021; 146:427 Morfeld P, Timmermann B, Groß JV *et al.*
12. **Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage.** Elife 2021; 10 Deinhardt-Emmer S, Wittschieber D, Sanft J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781385>

13. **COVID-19 Mortality and Case-Fatality Rates in Sergipe State, Northeast Brazil, From April to June 2020.** Front Public Health 2021; 9:581618Martins-Filho PR, Araújo AAS, Góes MAO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791265>
14. **The impact of and response to the COVID-19 pandemic on a hospital palliative care team.** Future Healthc J 2021; 8:62-64Edmonds PM, Sleeman KE, Lovell N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791463>
15. **Incidence and Death Rates from COVID-19 Are Not Always Coupled: An Analysis of Temporal Data on Local, Federal, and National Levels.** Healthcare (Basel) 2021; 9Borgmann S, Meintrup D, Reimer K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802866>
16. **Impact of COVID-19 pandemic and infection on in hospital survival for patients presenting with acute coronary syndromes: A multicenter registry.** Int J Cardiol 2021; D'Ascenzo F, De Filippo O, Borin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794235>
17. **Exposure to Perfluoroalkyl Substances and Mortality for COVID-19: A Spatial Ecological Analysis in the Veneto Region (Italy).** Int J Environ Res Public Health 2021; 18Catelan D, Biggeri A, Russo F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800362>
18. **Survived COVID-19 patient presented with death on arrival: A case report.** Int. J. Surg. Case Rep. 2021; 81:105826Hama Amin AA, Awakhti AH, Hama Hussein LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777663>
19. **Shifting US Patterns of COVID-19 Mortality by Race and Ethnicity From June - December 2020.** J. Am. Med. Dir. Assoc. 2021; Kumar A, Roy I, Karmarkar AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775597>
20. **Impact of environmental factors on COVID-19 cases and mortalities in major cities of Pakistan.** J Biosaf Biosecur 2021; 3:10-16Basray R, Malik A, Waqar W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786420>
21. **Undetected Causes of Death in Hospitalized Elderly with COVID-19: Lessons from Autopsy.** J Clin Med 2021; 10Malézieux-Picard A, Ferrer Soler C, De Macedo Ferreira D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804890>
22. **Cholestatic liver injury in COVID-19 is a rare and distinct entity and is associated with increased mortality.** J Intern Med 2021; Da BL, Suchman K, Roth N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786906>
23. **Elevated Monocyte to Lymphocyte Ratio and Increased Mortality among Patients with Chronic Kidney Disease Hospitalized for COVID-19.** J Pers Med 2021; 11Dávila-Collado R, Jarquín-Durán O, Solís-Vallejo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809858>
24. **The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.** Pharmacol. Rep. 2021:1-7Kow CS, Merchant HA, Mustafa ZU, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779964>
25. **Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study.** Phytomedicine 2021; 85:153531Zhang L, Zheng X, Bai X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799224>
26. **Count-Valued Time Series Models for COVID-19 Daily Death Dynamics.** Stat (Int Stat Inst) 2021:e369Palmer WR, Davis RA, Zheng T.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786170>

27. **Mobility and COVID-19 mortality across Scandinavia: A modeling study.** Travel Med Infect Dis 2021; 41:102039 Sulyok M, Walker MD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785456>
28. **Scores based on neutrophil percentage and lactate dehydrogenase with or without oxygen saturation predict hospital mortality risk in severe COVID-19 patients.** Virology 2021; 18:67 Fan X, Zhu B, Nouri-Vaskeh M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789703>
29. **Variation in Non-external and External Causes of Death in Peru in Relation to the COVID-19 Lockdown.** Yale J. Biol. Med. 2021; 94:23-40 Calderon-Anyosa RJC, Bilal U, Kaufman JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795980>
30. **The Impact of the Social Distancing Policy on COVID-19 Incidence Cases and Deaths in Iran from February 2020 to January 2021: Insights from an Interrupted Time Series Analysis.** Yale J. Biol. Med. 2021; 94:13-21 Saki M, Ghanbari MK, Behzadifar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795979>

Online – IT – Apps (73 articles)

1. **Is COVID-19 Immune to Misinformation? A Brief Overview.** Asian Bioeth Rev 2021;1-23 Ali S, Khalid A, Zahid E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777228>
2. **Preparing e-portfolio as an element of online training by clinical chemistry residents in the COVID-19 era.** Biochem Mol Biol Educ 2021; Das S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33780126>
3. **The Relevance of Bioinformatics Applications in the Discovery of Vaccine Candidates and Potential Drugs for COVID-19 Treatment.** Bioinform. Biol. Insights 2021; 15:11779322211002168 Chukwudozie OS, Duru VC, Ndiribe CC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33795932>
4. **Continuity of Cancer Care: The Surgical Experience of Two Large Cancer Hubs in London and Milan.** Cancers (Basel) 2021; 13 Monroy-Iglesias MJ, Tagliabue M, Dickinson H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808375>
5. **As a patient, we should embrace digital health tools available since COVID.** Cardiovasc Digit Health J 2021; Rupp J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778800>
6. **Telemedicine in Pediatric Infectious Diseases.** Children (Basel) 2021; 8 Pappalardo M, Fanelli U, Chiné V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800549>
7. **Perspectives on Virtual (Remote) Clinical Trials as the 'New Normal' to Accelerate Drug Development.** Clin Pharmacol Ther 2021; Alemayehu D, Hemmings R, Natarajan K, Roychoudhury S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792920>
8. **The relationship between burden caused by coronavirus (Covid-19), addictive social media use, sense of control and anxiety.** Comput. Human Behav. 2021;

119:106720Brailovskaia J, Margraf J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785982>

9. **Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic.** Contraception 2021; Chong E, Shochet T, Raymond E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781762>
10. **The Focused Neurosurgical Examination During Telehealth Visits: Guidelines During the COVID-19 Pandemic and Beyond.** Cureus 2021; 13:e13503Basil G, Luther E, Burks JD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786212>
11. **Privacy Concerns Over the Use of Webcams in Online Medical Education During the COVID-19 Pandemic.** Cureus 2021; 13:e13536Rajab MH, Soheib M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786243>
12. **Artificial Intelligence Applied to Chest X-ray for Differential Diagnosis of COVID-19 Pneumonia.** Diagnostics (Basel) 2021; 11Salvatore C, Interlenghi M, Monti CB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809625>
13. **A privacy and security analysis of early-deployed COVID-19 contact tracing Android apps.** Empir Softw Eng 2021; 26:36Hatamian M, Wairimu S, Momen N, Fritsch L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776548>
14. **Internet and Pornography Use During the COVID-19 Pandemic: Presumed Impact and What Can Be Done.** Front Psychiatry 2021; 12:623508Awan HA, Aamir A, Diwan MN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796031>
15. **Editorial: Telemedicine During and Beyond COVID-19.** Front Public Health 2021; 9:662617Bhaskar S, Nurtazina A, Mittoo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796502>
16. **A Smart Tendon Hammer System for Remote Neurological Examination.** Front Robot AI 2021; 8:618656Meinhold W, Yamakawa Y, Honda H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796552>
17. **Transforming postgraduate medical education during the COVID-19 pandemic: creating a trainee-led virtual teaching platform.** Future Healthc J 2021; 8:e7-e10Collins E, Ahmad A, May H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791466>
18. **Are telephone consultations the future of the NHS? The outcomes and experiences of an NHS urological service in moving to telemedicine.** Future Healthc J 2021; 8:e15-e20Efthymiadis A, Hart EJ, Guy AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791468>
19. **Teleophthalmology and COVID-19: the patient perspective.** Future Healthc J 2021; 8:e54-e59Golash V, Athwal S, Khandwala M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791477>
20. **Analysis of Anxiety Levels of Nursing Students Because of e-Learning during the COVID-19 Pandemic.** Healthcare (Basel) 2021; 9García-González J, Ruqiong W, Alarcon-Rodriguez R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804344>
21. **The Digital Divide in the Era of COVID-19: An Investigation into an Important Obstacle to the Access to the mHealth by the Citizen.** Healthcare (Basel) 2021; 9Giansanti D, Veltro G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810572>
22. **Telehealth in Times of COVID-19: Spotlight on Austria.** Healthcare (Basel) 2021; 9Kletečka-Pulker M, Völkl-Kernstock S, Fassel A *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806673>

23. **How disinformation kills: philosophical challenges in the post-Covid society.** Hist Philos Life Sci 2021; 43:51 Palomo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783652>
24. **Available videoconferencing freeware and medical education.** Ind Psychiatry J 2020; 29:155-158 Chail A, Chatterjee K, Chauhan VS, Prakash J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776289>
25. **Combat COVID-19 infodemic using explainable natural language processing models.** Inf. Process. Manag. 2021; 58:102569 Ayoub J, Yang XJ, Zhou F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776192>
26. **Infectious Diseases Seeker (IDS): An Innovative Tool for Prompt Identification of Infectious Diseases during Outbreaks.** Int J Environ Res Public Health 2021; 18:18 Baldassi F, Carestia M, Moramarco S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804605>
27. **Psychosocial Effects and Use of Communication Technologies during Home Confinement in the First Wave of the COVID-19 Pandemic in Italy and The Netherlands.** Int J Environ Res Public Health 2021; 18:18 Bastoni S, Wrede C, Ammar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807851>
28. **The Teaching Digital Competence of Health Sciences Teachers. A Study at Andalusian Universities (Spain).** Int J Environ Res Public Health 2021; 18:18 Cabero-Almenara J, Barroso-Osuna J, Gutiérrez-Castillo JJ, Palacios-Rodríguez A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806483>
29. **Precise Transmission for COVID-19 Information: Based on China's Experience.** Int J Environ Res Public Health 2021; 18:18 Chen W, Zhang W, Li L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804120>
30. **Social Telepresence Robots: A Narrative Review of Experiments Involving Older Adults before and during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18:18 Isabet B, Pino M, Lewis M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808457>
31. **Remote Teaching Due to COVID-19: An Exploration of Its Effectiveness and Issues.** Int J Environ Res Public Health 2021; 18:18 Kawasaki H, Yamasaki S, Masuoka Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800909>
32. **Information and Communications Technology (ICT) Usage during COVID-19: Motivating Factors and Implications.** Int J Environ Res Public Health 2021; 18:18 Lee YC, Malcein LA, Kim SC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808218>
33. **Impact of COVID-19 Restrictions on Western Australian Children's Physical Activity and Screen Time.** Int J Environ Res Public Health 2021; 18:18 Nathan A, George P, Ng M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807520>
34. **Engagement of Government Social Media on Facebook during the COVID-19 Pandemic in Macao.** Int J Environ Res Public Health 2021; 18:18 Pang PC, Cai Q, Jiang W, Chan KS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800621>
35. **Telerehabilitation Intervention in Patients with COVID-19 after Hospital Discharge to Improve Functional Capacity and Quality of Life. Study Protocol for a Multicenter Randomized Clinical Trial.** Int J Environ Res Public Health 2021; 18:18 Pastora-Bernal JM, Estebanez-Pérez MJ, Molina-Torres G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809277>

36. **Health Literacy, Digital Health Literacy, and COVID-19 Pandemic Attitudes and Behaviors in U.S. College Students: Implications for Interventions.** Int J Environ Res Public Health 2021; 18Patil U, Kostareva U, Hadley M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806763>
37. **The Influence of Digital Tools and Social Networks on the Digital Competence of University Students during COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Rodríguez-Moreno J, Ortiz-Colón AM, Córdón-Pozo E, Agreda-Montoro M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802185>
38. **Using Social Network Analysis to Identify Spatiotemporal Spread Patterns of COVID-19 around the World: Online Dashboard Development.** Int J Environ Res Public Health 2021; 18Yie KY, Chien TW, Yeh YT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802247>
39. **Robotics cyber security: vulnerabilities, attacks, countermeasures, and recommendations.** Int J Inf Secur 2021;1-44Yaacoub JA, Noura HN, Salman O, Chehab A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776611>
40. **Telegenetics for inherited retinal diseases in the COVID-19 environment.** Int J Retina Vitreous 2021; 7:25Al-Moujahed A, Kumar A, Chemudupati T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781332>
41. **Utilization of Instagram by Dermatology Residency Programs in the era of COVID-19.** J Am Acad Dermatol 2021; Schwartzman G, Qureshi A, Friedman AJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811936>
42. **COVID-19 Insights Partnership: Leveraging Big Data from the Department of Veterans Affairs and Supercomputers at the Department of Energy under the Public Health Authority.** J Am Med Inform Assoc 2021; Ramoni R, Klote M, Muralidhar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779710>
43. **Extracting COVID-19 Diagnoses and Symptoms From Clinical Text: A New Annotated Corpus and Neural Event Extraction Framework.** J. Biomed. Inform. 2021;103761Lybarger K, Ostendorf M, Thompson M, Yetisgen M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781918>
44. **Implementation of telehealth during COVID-19: Implications for providing behavioral health services to pediatric patients.** J Child Health Care 2021;13674935211007329Frye WS, Gardner L, Campbell JM, Katzenstein JM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779352>
45. **Many Nationalisms, One Disaster: Categories, Attitudes and Evolution of Chinese Nationalism on Social Media during the COVID -19 Pandemic.** J Chin Polit Sci 2021;1-24Wang Z, Tao Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782630>
46. **6 feet apart but working together.** J Genet Couns 2021; Redlinger-Grosse K, Anderson K, Birkeland L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786902>
47. **COVID 19 and Dental Education: Transitioning from a Well-established Synchronous Format and Face to Face Teaching to an Asynchronous Format of Dental Clinical Teaching and Learning.** J Med Educ Curric Dev 2021; 8:2382120521999667Nasseripour M, Turner J, Rajadurai S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796791>
48. **Development of a Remote Public Health Advanced Pharmacy Practice Experience in Response to COVID-19.** J. Pharm. Pract.

- 2021:8971900211004830Kiles TM, Hagemann T, Felts B, Crill C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789494>
49. **Bereavement via Zoom during COVID-19.** J. Psychosoc. Oncol. 2021:1-4Morris SE, Ryan AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775229>
 50. **Finding my way home: Ambiguous loss reconceptualized to bridge the conversion from in-person therapy to teletherapy during COVID-19.** J. Psychosoc. Oncol. 2021:1-3Suk L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775240>
 51. **Digital Mental Health Challenges and the Horizon Ahead for Solutions.** JMIR Ment Health 2021; 8:e26811Balcombe L, De Leo D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779570>
 52. **Meditating in Virtual Reality 3: 360° Video of Perceptual Presence of Instructor.** Mindfulness (N Y) 2021:1-14Waller M, Mistry D, Jetly R, Frewen P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777253>
 53. **Tree parity machine guided patients' privileged based secure sharing of electronic medical record: cybersecurity for telehealth during COVID-19.** Multimed Tools Appl 2021:1-25Sarkar A, Sarkar M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776546>
 54. **Pea Protein Nanoemulsion Effectively Stabilizes Vitamin D in Food Products: A Potential Supplementation during the COVID-19 Pandemic.** Nanomaterials (Basel) 2021; 11Akkam Y, Rababah T, Costa R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807206>
 55. **Digital Is Political: Why We Need a Feminist Conceptual Lens on Determinants of Digital Health.** OMICS 2021; Özdemir V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794130>
 56. **Virtual Education During COVID-19 and Beyond.** Pediatr. Neurol. 2021; 119:1-2Gelineau-Morel R, Dilts J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812265>
 57. **Transitioning Competency-Based Communication Assessments to the Online Platform: Examples and Student Outcomes.** Pharmacy (Basel) 2021; 9Scouler S, Huntsberry A, Patel T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807737>
 58. **Medical education challenges and innovations during COVID-19 pandemic.** Postgrad. Med. J. 2021; Papapanou M, Routsis E, Tsamakidis K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782202>
 59. **Optimizing e-learning in oncology during the COVID-19 pandemic and beyond.** Radiat Oncol J 2021; 39:1-7Malik M, Valiyaveetil D, Joseph D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33794568>
 60. **Technological advancement in the era of COVID-19.** SAGE Open Med 2021; 9:20503121211000912Renu N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786181>
 61. **Evaluation of COVID-19 myths in Saudi Arabia.** Saudi Med. J. 2021; 42:377-383Alhousseini NK, Sajid MR, Alsheikh HA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33795492>
 62. **Trends in reasons for emergency calls during the COVID-19 crisis in the department of Gironde, France using artificial neural network for natural language classification.** Scand. J. Trauma Resusc. Emerg. Med. 2021; 29:55Gil-

Jardiné C, Chenais G, Pradeau C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789721>

63. **Privacy versus Public Health? A Reassessment of Centralised and Decentralised Digital Contact Tracing.** *Sci Eng Ethics* 2021; 27:23White L, van Basshuysen P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779818>
64. **[Telemedicine satisfaction of primary care patients during COVID-19 pandemics].** *Semergen* 2021; Gomes-de Almeida S, Marabujo T, do Carmo-Gonçalves M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781673>
65. **Repigmentation of White Forelock in a Familial Case of Piebaldism Reported via Teledermatology in the COVID-19 Era.** *Skin Appendage Disord* 2021; 7:120-122Gaudiello F, Ferrillo M, Vastarella M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791342>
66. **Telehealth in a Washington, DC African American Religious Community at the Onset of COVID-19: Showcasing a Virtual Health Ministry Project.** *Soc. Work Health Care* 2021:1-16Shelton RL, Hall M, Ford S, Cosby RL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779526>
67. **Media framing of fighting COVID-19 in China.** *Sociol. Health Illn.* 2021; Gui L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782963>
68. **A Review on the use of Telemedicine in Glaucoma and Possible Roles in COVID-19 Outbreak.** *Surv. Ophthalmol.* 2021; Lam PY, Chuen CS, Lai JSM, Choy BNK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811912>
69. **The impact of the pandemic declaration on public awareness and behavior: Focusing on COVID-19 google searches.** *Technol Forecast Soc Change* 2021; 166:120592Jun SP, Yoo HS, Lee JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776154>
70. **Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.** *Trials* 2021; 22:245Haran JP, Pinero JC, Zheng Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810796>
71. **Media usage predicts intention to be vaccinated against SARS-CoV-2 in the US and the UK.** *Vaccine* 2021; Allington D, McAndrew S, Moxham-Hall VL, Duffy B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810905>
72. **[Distance learning during the COVID-19-related school closings: the perspective of students from secondary schools].** *Z Erziehungswiss* 2021:1-24Züchner I, Jäkel HR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786014>
73. **Media consumption and mental health during COVID-19 lockdown: a UK cross-sectional study across England, Wales, Scotland and Northern Ireland.** *Z Gesundh Wiss* 2021:1-9Neill RD, Blair C, Best P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777650>

Other – Miscellaneous (108 articles)

1. **Within-city Variation in Reactive Oxygen Species from Fine Particle Air Pollution and COVID-19.** Am J Respir Crit Care Med 2021; Stieb DM, Evans GJ, To TM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798018>
2. **SARS-CoV-2 Seroprevalence in Household Domestic Ferrets (*Mustela putorius furo*).** Animals (Basel) 2021; 11Giner J, Villanueva-Saz S, Tobajas AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801548>
3. **Methods to Prevent Future Severe Animal Welfare Problems Caused by COVID-19 in the Pork Industry.** Animals (Basel) 2021; 11Grandin T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809412>
4. **Interacting Proteins, Polymorphisms and the Susceptibility of Animals to SARS-CoV-2.** Animals (Basel) 2021; 11Hancock JT, Rouse RC, Stone E, Greenhough A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809265>
5. **[Incidence and predictors of peri-traumatic reactions in an Algerian population faced with COVID-19].** Ann. Med. Psychol. (Paris) 2021; Djillali S, Ouandelous NN, Zouani N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776062>
6. **A fresh (air) look at ventilation for COVID-19: Estimating the global energy savings potential of coupling natural ventilation with novel radiant cooling strategies.** Appl Energy 2021; 292:116848Aviv D, Chen KW, Teitelbaum E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776191>
7. **Effect of COVID-19 travel restrictions on Phoenix air quality after accounting for boundary layer variations.** Atmos Environ X 2021; 10:100105Miech JA, Herckes P, Fraser MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778482>
8. **Journalistic Denial of Death during the Very First Traumatic Period of the Italian COVID-19 Pandemic.** Behav Sci (Basel) 2021; 11Solomon S, Rostellato D, Testoni I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806901>
9. **If fetuses are persons, abortion is a public health crisis.** Bioethics 2021; Blackshaw B, Rodger D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811355>
10. **The impact of COVID-19 on health behaviour, well-being, and long-term physical health.** Br. J. Health Psychol. 2021; McBride E, Arden MA, Chater A, Chilcot J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787000>
11. **Prevalence and risk factors for chalazion in an older veteran population.** Br J Ophthalmol 2021; Patel S, Tohme N, Gorrin E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789846>
12. **The possible effects of the COVID-19 pandemic on the contents and organization of autobiographical memory: A Transition-Theory perspective.** Cognition 2021; 212:104694Brown NR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798951>
13. **Protocols for Managing Food Allergies in Elementary and Secondary Schools.** Compr Child Adolesc Nurs 2021;1-13Heideman K, Poronsky CB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792445>
14. **Spektrum 1/2021 has been published: ADEXA members know more.** Deutsche Apotheker Zeitung 2021; 161.
15. **Home office: Also a topic for pharmacies? - Labor law pointers on the Corona Occupational Health and Safety Ordinance.** Deutsche Apotheker Zeitung 2021; 161Hansen RM.

16. **The effect of income support programs on job search, workplace mobility and COVID-19: International evidence.** Econ. Hum. Biol. 2021; 41:100997Asfaw AA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813156>
17. **High resolution mapping of nighttime light and air pollutants during the COVID-19 lockdown in Wuhan.** Environ. Chem. Lett. 2021:1-9Zheng S, Fu Y, Sun Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776610>
18. **How Covid-19 pandemic and partial lockdown decisions affect air quality of a city? The case of Istanbul, Turkey.** Environ Dev Sustain 2021:1-39Celik E, Gul M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776552>
19. **Modeling the relationship between carbon emissions and environmental sustainability during COVID-19: a new evidence from asymmetric ARDL cointegration approach.** Environ Dev Sustain 2021:1-19Sarfraz M, Mohsin M, Naseem S, Kumar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782633>
20. **Spatial analysis of COVID-19 and traffic-related air pollution in Los Angeles.** Environ Int 2021; 153:106531Lipsitt J, Chan-Golston AM, Liu J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812043>
21. **How far climatic parameters associated with air quality induced risk state (AQIRS) during COVID-19 persuaded lockdown in India.** Environ Pollut 2021; 280:116975Mahato S, Talukdar S, Pal S, Debanshi S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784565>
22. **Environmental survival of SARS-CoV-2 - A solid waste perspective.** Environ. Res. 2021; 197:111015Iyer M, Tiwari S, Renu K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775678>
23. **Environmental Survival of SARS-CoV-2 - A solid waste perspective.** Environ. Res. 2021:111015Iyer M, Tiwari S, Renu K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775678>
24. **Influence of air pollution and meteorological factors on the spread of COVID-19 in the Bangkok Metropolitan Region and Air Quality during the Outbreak.** Environ. Res. 2021:111104Sangkham S, Thongtip S, Vongruang P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798521>
25. **Assessment of CO(2) and aerosol (PM(2.5), PM(10), UFP) concentrations during the reopening of schools in the COVID-19 pandemic: the case of a metropolitan area in Central-Southern Spain.** Environ. Res. 2021:111092Villanueva F, Notario A, Cabañas B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785326>
26. **COVID-19 outbreak, lockdown, and air quality: fresh insights from New York City.** Environ. Sci. Pollut. Res. Int. 2021:1-13Shehzad K, Bilgili F, Koçak E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779900>
27. **Can COVID-19 and environmental research in developing countries support these countries to meet the environmental challenges induced by the pandemic?** Environ. Sci. Pollut. Res. Int. 2021:1-21Wang Q, Zhang C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782826>
28. **Moral Injury and the COVID-19 Pandemic: A Philosophical Viewpoint.** Ethics Med Public Health 2021:100661Akram F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778145>

29. **Factors determining household-level food insecurity during COVID-19 epidemic: a case of Wuhan, China.** Food Nutr. Res. 2021; 65Zhang Y, Yang K, Hou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776620>
30. **The Impact of COVID-19 Outbreak in Italy on the Sustainable Food Consumption Intention From a "One Health" Perspective.** Front Nutr 2021; 8:622122Castellini G, Savarese M, Graffigna G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791331>
31. **The Study of Factors on the Small and Medium Enterprises' Adoption of Mobile Payment: Implications for the COVID-19 Era.** Front Public Health 2021; 9:646592Cao T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796499>
32. **Pandemic Uncertainty and Socially Responsible Investments.** Front Public Health 2021; 9:661482Zhu W, Yang J, Lv H, Zhuang M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777890>
33. **Staying Connected and Prepared for Collegiate Athletic Competitions During the COVID-19 Pandemic.** Front Sports Act Living 2021; 3:663918Reynolds A, Hamidian Jahromi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778487>
34. **Assessing the COVID-19 Impact on Air Quality: A Machine Learning Approach.** Geophys. Res. Lett. 2021; 48:e2020GL091202Rybarczyk Y, Zalakeviciute R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785973>
35. **COVID-19 Crisis Reduces Free Tropospheric Ozone Across the Northern Hemisphere.** Geophys. Res. Lett. 2021; 48:e2020GL091987Steinbrecht W, Kubistin D, Plass-Dülmer C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785974>
36. **Global Significant Changes in Formaldehyde (HCHO) Columns Observed From Space at the Early Stage of the COVID-19 Pandemic.** Geophys. Res. Lett. 2021; 48:2e020GL091265Sun W, Zhu L, De Smedt I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785972>
37. **Global Evidence of Temperature Acclimation of COVID-19 D614G Linage.** Glob Chall 2021:2000132Hao Z, Li R, Hao C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786200>
38. **COVID-19 and the political geography of racialisation: Ethnographic cases in San Francisco, Los Angeles and Detroit.** Glob Public Health 2021:1-15Whitacre R, Oni-Orisan A, Gaber N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784231>
39. **COVID-19 and the political geography of racialisation: Ethnographic cases in San Francisco, Los Angeles and Detroit.** Glob Public Health 2021:1-15Whitacre R, Oni-Orisan A, Gaber N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784231>
40. **The rise and fall of global health issues: an arenas model applied to the COVID-19 pandemic shock.** Global Health 2021; 17:33Smith SL, Shiffman J, Shawar YR, Shroff ZC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781272>
41. **COVID-19 and Gaza: The Ideal Time to Establish a Medical Reserve Corps of Public Health Preventive Medicine Specialists.** Health Secur 2021; Mahayosnand PP, Sabra ZM, Sabra DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784477>
42. **Prevention and Control of COVID-19 Pandemic on International Cruise Ships: The Legal Controversies.** Healthcare (Basel) 2021; 9Zhang X, Wang C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806680>

43. **Sum of the parts: Ensuring a resilient global drug supply chain.** Infect Control Hosp Epidemiol 2021;1-6Suda KJ, Tadrus M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775273>
44. **Polycyclic Aromatic Hydrocarbons in Indoor Dust Collected during the COVID-19 Pandemic Lockdown in Saudi Arabia: Status, Sources and Human Health Risks.** Int J Environ Res Public Health 2021; 18Alamri SH, Ali N, Ali Albar HMS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800440>
45. **Altitude and SARS-CoV-2 Infection in the First Pandemic Wave in Spain.** Int J Environ Res Public Health 2021; 18Castilla J, Fresán U, Trobajo-Sanmartín C, Guevara M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806642>
46. **Old Tricks, New Opportunities: How Companies Violate the International Code of Marketing of Breast-Milk Substitutes and Undermine Maternal and Child Health during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Ching C, Zambrano P, Nguyen TT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804481>
47. **Casual Sex among Men Who Have Sex with Men (MSM) during the Period of Sheltering in Place to Prevent the Spread of COVID-19.** Int J Environ Res Public Health 2021; 18de Sousa AFL, de Oliveira LB, Queiroz A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809916>
48. **Occupational Exposure in the Lombardy Region (Italy) to SARS-CoV-2 Infection: Results from the MUSTANG-OCCUPATION-COVID-19 Study.** Int J Environ Res Public Health 2021; 18Della Valle P, Fabbri M, Madotto F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806578>
49. **The Effect of Lockdown Period during the COVID-19 Pandemic on Air Quality in Sydney Region, Australia.** Int J Environ Res Public Health 2021; 18Duc H, Salter D, Azzi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805343>
50. **Impact of Covid-19 Lockdown on Availability of Drinking Water in the Arsenic-Affected Ganges River Basin.** Int J Environ Res Public Health 2021; 18Duttagupta S, Bhanja SN, Dutta A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802172>
51. **Air Pollution Status in 10 Mega-Cities in China during the Initial Phase of the COVID-19 Outbreak.** Int J Environ Res Public Health 2021; 18Ethan CJ, Mokoena KK, Yu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808577>
52. **Lived Experience Related to the COVID-19 Pandemic among Arabic-, Russian- and Somali-Speaking Migrants in Finland.** Int J Environ Res Public Health 2021; 18Finell E, Tiilikainen M, Jasinskaja-Lahti I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807723>
53. **Physical Activity and Adherence to the Mediterranean Diet among Spanish Employees in a Health-Promotion Program before and during the COVID-19 Pandemic: The Sanitas-Healthy Cities Challenge.** Int J Environ Res Public Health 2021; 18Franco E, Urosa J, Barakat R, Refoyo I.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33800372>
54. **Possible Roles of Permafrost Melting, Atmospheric Transport, and Solar Irradiance in the Development of Major Coronavirus and Influenza Pandemics.** Int J Environ Res Public Health 2021; 18Hofmeister AM, Seckler JM, Criss GM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809626>

55. **Telecommuting, Off-Time Work, and Intrusive Leadership in Workers' Well-Being.** *Int J Environ Res Public Health* 2021; 18Magnavita N, Tripepi G, Chiorri C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804828>
56. **Effects of a 48-Day Home Quarantine during the Covid-19 Pandemic on the First Outdoor Running Session among Recreational Runners in Spain.** *Int J Environ Res Public Health* 2021; 18Mosqueira-Ourens M, Sánchez-Sáez JM, Pérez-Morcillo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800404>
57. **Eco-Environmental Aspects of COVID-19 Pandemic and Potential Control Strategies.** *Int J Environ Res Public Health* 2021; 18Nazir R, Ali J, Rasul I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801704>
58. **Variability in Forest Visit Numbers in Different Regions and Population Segments before and during the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2021; 18Pichlerová M, Önkál D, Bartlett A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810557>
59. **Effects of COVID-19 Lockdown on Adherence to Individual Home- or Gym-Based Exercise Training among Women with Postmenopausal Osteoporosis.** *Int J Environ Res Public Health* 2021; 18Pinelli E, Barone G, Marini S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801389>
60. **Evolving Disaster Response Practices during COVID-19 Pandemic.** *Int J Environ Res Public Health* 2021; 18Potutan G, Arakida M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803695>
61. **The Impact of the COVID-19 Pandemic on the Brazilian Immigrant Community in the U.S: Results from a Qualitative Study.** *Int J Environ Res Public Health* 2021; 18Priebe Rocha L, Rose R, Hoch A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805055>
62. **Concerns or Desires Post-Pandemic: An Extended MGB Model for Understanding South Korean Residents' Perceptions and Intentions to Travel to China.** *Int J Environ Res Public Health* 2021; 18Qiao G, Zhao XL, Xin L, Kim S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806384>
63. **Monitoring Sound and Its Perception during the Lockdown and De-Escalation of COVID-19 Pandemic: A Spanish Study.** *Int J Environ Res Public Health* 2021; 18Redel-Macías MD, Aparicio-Martinez P, Pinzi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805936>
64. **Reduction of Human Mobility Matters during Early COVID-19 Outbreaks: Evidence from India, Japan and China.** *Int J Environ Res Public Health* 2021; 18Ren Z, Li R, Zhang T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802103>
65. **COVID-19 Impact on SDGs and the Fiscal Measures: Case of Indonesia.** *Int J Environ Res Public Health* 2021; 18Safitri Y, Ningsih RD, Agustianingsih DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809128>
66. **COVID-19 and Heat Illness in Tokyo, Japan: Implications for the Summer Olympic and Paralympic Games in 2021.** *Int J Environ Res Public Health* 2021; 18Shimizu K, Gilmour S, Mase H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807268>
67. **Relationship of Decrease in Frequency of Socialization to Daily Life, Social Life, and Physical Function in Community-Dwelling Adults Aged 60 and Over after the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2021;

- 18Shimokihara S, Maruta M, Hidaka Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806599>
68. **Changes in Physical Activity among United Kingdom University Students Following the Implementation of Coronavirus Lockdown Measures.** Int J Environ Res Public Health 2021; 18Wickersham A, Carr E, Hunt R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801836>
 69. **The Changing Patterns of Consumers' Behavior in China: A Comparison during and after the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Yuan X, Li C, Zhao K, Xu X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801491>
 70. **Accentuating the Interrelation between Consumer Intention and Healthy Packaged Food Selection during COVID-19: A Case Study of Pakistan.** Int J Environ Res Public Health 2021; 18Zafar MZ, Maqbool A, Cioca LI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799559>
 71. **The Impact of the COVID-19 Pandemic on Ambient Air Quality in China: A Quasi-Difference-in-Difference Approach.** Int J Environ Res Public Health 2021; 18Zhang T, Tang M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806039>
 72. **Addressing Systemic Racism in Nursing Homes: A Time for Action.** J. Am. Med. Dir. Assoc. 2021; Sloane PD, Yearby R, Konetzka RT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775548>
 73. **Navigating a Pandemic: The Unique Role of the Medical Director.** J. Insur. Med. 2021; Meagher T, Guzman G, Heltemes B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784743>
 74. **Immigration Status as a Health Care Barrier in the USA during COVID-19.** J Migr Health 2021:100036Hill J, Rodriguez DX, McDaniel PN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778797>
 75. **Impact of COVID-19 on portfolio allocation decisions of individual investors.** J Public Aff 2021:e2649Himanshu, Ritika, Mushir N, Suryavanshi R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786026>
 76. **COVID-19 health safety practices: Influence on grocery shopping behavior.** J Public Aff 2021:e2624Shamim K, Ahmad S, Alam MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786020>
 77. **Stimulating economy via fiscal package: The only way out to save vulnerable Workers' lives and livelihood in Covid-19 pandemic.** J Public Aff 2021:e2632Thakur N, Kumar M, Vaishali. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786022>
 78. **Electoral concerns reduce restrictive measures during the COVID-19 pandemic.** J Public Econ 2021:104387Pulejo M, Querubín P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776156>
 79. **COVID-19 policy analysis: labour structure dictates lockdown mobility behaviour.** J R Soc Interface 2021; 18:20201035Heroy S, Loaiza I, Pentland A, O'Clery N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784887>
 80. **Physical activity and its relationship with COVID-19 cases and deaths: Analysis of U.S. counties.** J Sport Health Sci 2021; Cunningham GB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775882>

81. **Influence of COVID-19 on lifestyle behaviors in the Middle East and North Africa Region: a survey of 5896 individuals.** J Transl Med 2021; 19:129Abouzid M, El-Sherif DM, Elteuacy NK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785043>
82. **Methylene blue: Subduing the post COVID-19 blues!** Med. Hypotheses 2021; 150:110574Magoon R, Bansal N, Singh A, Kashav R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799158>
83. **Our Postpandemic World: What Will It Take to Build a Better Future for People and Planet?** Milbank Q. 2021; MC VANS, Maani N, Cohen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783865>
84. **Tax-free and contribution-exempt corona bonus for your employees.** MMW-Fortschritte der Medizin 2021; 163:38-39Walbert H.
85. **Eating Habits and Lifestyles during the Initial Stage of the COVID-19 Lockdown in China: A Cross-Sectional Study.** Nutrients 2021; 13Yang GY, Lin XL, Fang AP, Zhu HL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802743>
86. **COVID-19: are not all workers 'essential'?** Occup. Environ. Med. 2021; De Matteis S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811176>
87. **COVID-19 and Preparing Planetary Health for Future Ecological Crises: Hopes from Glycomics for Vaccine Innovation.** OMICS 2021; Wang X, Zhong Z, Wang W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794117>
88. **Zoonotic Risk: One More Good Reason Why Cats Should Be Kept Away from Bats.** Pathogens 2021; 10Salinas-Ramos VB, Mori E, Bosso L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807760>
89. **Travelling to High Altitude Destinations after Recovery from COVID-19-infection: New Aspects of Medical Advice in Altitude Medicine.** Pneumologie 2021; 75:214-220Grannemann JJ, Röper A.
90. **SNAP Participants and High Levels of Food Insecurity in the Early Stages of the COVID-19 Pandemic.** Public Health Rep. 2021:333549211007152Siddiqi SM, Cantor J, Dastidar MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789530>
91. **COVID-19: impact on quality of work life in real estate sector.** Qual Quant 2021:1-15Majumder S, Biswas D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776150>
92. **Road traffic and air pollution: Evidence from a nationwide traffic control during coronavirus disease 2019 outbreak.** Sci Total Environ 2021; 781:146618Jia C, Li W, Wu T, He M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780836>
93. **Body Temperature-Indoor Condition Monitor and Activity Recognition by MEMS Accelerometer Based on IoT-Alert System for People in Quarantine Due to COVID-19.** Sensors (Basel) 2021; 21Hoang ML, Carratù M, Paciello V, Pietrosanto A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810301>
94. **Covid-19: A critical time for cross-sector social work care management.** Soc. Work Health Care 2021:1-11Franceschini D, Grabowski J, Sefilyan E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775235>
95. **Impact of COVID-19 on an established physical activity and behaviour change support programme for cancer survivors: An exploratory survey of the Macmillan Move More service for Northern Ireland.** Support. Care Cancer 2021;

- Brown M, O'Connor D, Murphy C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811517>
96. **Global economic crisis, energy use, CO(2) emissions, and policy roadmap amid COVID-19.** Sustain Prod Consum 2021; 26:770-781 Aktar MA, Alam MM, Al-Amin AQ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786357>
 97. **Impact of COVID-19 lockdown on smoking consumption in a large representative sample of Italian adults.** Tob. Control 2021; Carreras G, Lugo A, Stival C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782199>
 98. **Vulnerability and Burden of All-Cause Mortality Associated with Particulate Air Pollution during COVID-19 Pandemic: A Nationwide Observed Study in Italy.** Toxics 2021; 9Ye T, Xu R, Yu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804264>
 99. **On the degree of synchronization between air transport connectivity and COVID-19 cases at worldwide level.** Transp Policy (Oxf) 2021; 105:115-123Sun X, Wandelt S, Zhang A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776252>
 100. **Recovery preparedness of global air transport influenced by COVID-19 pandemic: policy intervention analysis.** Transp Policy (Oxf) 2021; Zhu C, JianpingWu, Liu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785994>
 101. **Recovery preparedness of global air transport influenced by COVID-19 pandemic: Policy intervention analysis.** Transp Policy (Oxf) 2021; 106:54-63Zhu C, Wu J, Liu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785994>
 102. **Impact of Singapore's COVID-19 confinement on atmospheric CO(2) fluxes at neighborhood scale.** Urban Clim 2021; 37:100822Velasco E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777687>
 103. **Cumulative Effects of Particulate Matter Pollution and Meteorological Variables on the Risk of Influenza-Like Illness.** Viruses 2021; 13Toczyłowski K, Wietlicka-Piszc M, Grabowska M, Sulik A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810283>
 104. **Quantitative evaluation of infectious health care wastes from numbers of confirmed, suspected and out-patients during COVID-19 pandemic: A case study of Wuhan.** Waste Manag 2021; 126:323-330Wang J, Chen Z, Lang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794444>
 105. **Impact of COVID-19 pandemic on medical waste management in Lebanon.** Waste Manag. Res. 2021:734242x211003970Maalouf A, Maalouf H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794685>
 106. **Floods and the COVID-19 pandemic-A new double hazard problem.** WIREs Water 2021; 8:e1509Simonovic SP, Kundzewicz ZW, Wright N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786171>
 107. **The Low-Wage Essential Worker: Occupational Concerns and Needs in the COVID-19 Pandemic-A Round Table.** Workplace Health Saf. 2021:2165079920988682Gallagher S, Roy A, Domeracki SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787420>
 108. **Who is Biking for? Urban Bikeshare Networks' Responses to the COVID-19 Pandemic, Disparities in Bikeshare Access, and a Way Forward.** Yale J. Biol. Med. 2021; 94:159-164Nguemeni Tiako MJ, Stokes DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795993>

Pathology (6 articles)

1. **Association between Postmortem Kidney Biopsy Findings and Acute Kidney Injury from Patients with SARS-CoV-2 (COVID-19).** Clin J Am Soc Nephrol 2021; Rivero J, Merino-López M, Olmedo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782033>
2. **Safe Management Strategies in Clinical Forensic Autopsies of Confirmed COVID-19 Cases.** Diagnostics (Basel) 2021; 11 Pomara C, Salerno M, Sessa F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800905>
3. **Review and Prospects of Pathogen Detection Related to Autopsy of Coronavirus Infectious Diseases.** Fa Yi Xue Za Zhi 2021; 37:69-76 Wang YY, Zhou N, Yue JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780188>
4. **Renal Morphology in Coronavirus Disease: A Literature Review.** Medicina (Kaunas) 2021; 57 de Oliveira P, Cunha K, Neves P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799854>
5. **Autopsy Tool in Unknown Diseases: The Experience with Coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2).** Medicina (Kaunas) 2021; 57 Sessa F, Salerno M, Pomara C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806100>
6. **31st Brazilian Online Society for Virology (SBV) 2020 Annual Meeting.** Viruses 2021; 13 Arruda LB, Campos FS, Abrahão JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807596>

Protection (65 articles)

1. **Association Between Actual and Perceived U.S. COVID-19 Policies and Preventive Behavior.** Ann. Behav. Med. 2021; Li M, Colby H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787856>
2. **Comfort rules for face masks among healthcare workers during COVID-19 spread.** Ann. Ig. 2021; Maniaci A, Ferlito S, Bubbico L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797548>
3. **How do the general population behave with facemasks to prevent COVID-19 in the community? A multi-site observational study.** Antimicrob Resist Infect Control 2021; 10:61 Deschanvres C, Haudebourg T, Peiffer-Smadja N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781341>
4. **Consistency of global recommendations regarding open versus laparoscopic surgery during the COVID-19 pandemic: a systematic review.** ANZ J Surg 2021; Jacob S, Hameed A, Lam V, Pang TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792122>
5. **A Fresh (Air) Look at Ventilation for COVID-19: Estimating the global energy savings potential of coupling natural ventilation with novel radiant cooling strategies.** Appl Energy 2021; 116848 Aviv D, Wee Chen K, Teitelbaum E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776191>
6. **Acute Effects of Surgical and FFP2 Face Masks on Physiological Responses and Strength Performance in Persons with Sarcopenia.** Biology (Basel) 2021; 10 Ramos-Campo DJ, Pérez-Piñero S, Muñoz-Carrillo JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799555>

7. **Effects of combined oxygen and surgical masks on inspired fraction of oxygen: relevance to COVID-19-induced respiratory failure.** Br J Anaesth 2021; Hamada S, Tanabe N, Hirai T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775386>
8. **Practical approach to prevent COVID-19 infection at breast cancer screening.** Breast Cancer 2021; Takada M, Tanaka G, Hashimoto H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811286>
9. **SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region.** Cancers (Basel) 2021; 13Ciniselli CM, Micali A, De Cecco L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801186>
10. **"Endoshield": A Physical Protective Box for Pediatric Endoscopy during the COVID-19 Pandemic.** Clin Endosc 2021; Charoenwat B, Sirirattanakul S, Hangnak K, Muikham I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794561>
11. **How does working in pandemic units affect the risk of occupational hand eczema in healthcare workers during the coronavirus disease-2019 (COVID-19) pandemic: a comparative analysis with non-pandemic units.** Contact Dermatitis 2021; Erdem Y, Inal S, Sivaz O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797109>
12. **Changes in skin characteristics after using respiratory protective equipment (medical masks and respirators) in the COVID-19 pandemic among health care workers.** Contact Dermatitis 2021; Han HS, Shin SH, Park JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813749>
13. **Reusing N95 Respirators at Weekly Intervals During the COVID-19 Pandemic.** Cureus 2021; 13:e13542Nakamoto K, Saraya T, Sr., Kurai D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786247>
14. **Safe Management Strategies in Clinical Forensic Autopsies of Confirmed COVID-19 Cases.** Diagnostics (Basel) 2021; 11Pomara C, Salerno M, Sessa F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800905>
15. **Factors associated with risk of COVID-19 contagion for endoscopy healthcare workers: A survey from the Italian society of digestive endoscopy.** Dig. Liver Dis. 2021; Mariani A, Capurso G, Marasco G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785281>
16. **Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.** Eur. J. Cancer 2021; 148:359-370Ladoire S, Goussot V, Redersdorff E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780664>
17. **Bronchoscopy during the COVID-19 pandemic: effect on current practices and strategies to reduce procedure-associated transmission.** Expert Rev. Respir. Med. 2021; Sampsonas F, Kakoullis L, Karampitsakos T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798401>
18. **SARS-CoV-2 Testing of 11,884 Healthcare Workers at an Acute NHS Hospital Trust in England: A Retrospective Analysis.** Front Med (Lausanne) 2021; 8:636160Hanrath AT, Schim van der Loeff I, Lendrem DW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777979>
19. **SWOT Analysis and Preliminary Study on Prevention and Control Management of Temporary Integrated Isolation Ward During COVID-19**

- Outbreak.** Front Public Health 2021; 9:558565Zhou Y, Bai L, Guo H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33791264>
20. **The mixed reality medical ward round with the MS HoloLens 2: Innovation in reducing COVID-19 transmission and PPE usage.** Future Healthc J 2021; 8:e127-e130Levy JB, Kong E, Johnson N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33791491>
 21. **Partition walls as effective protection from bio-aerosols in classrooms - an experimental investigation.** GMS Hyg Infect Control 2021; 16:Doc09Epple P, Steppert M, Florschütz M, Dahlem P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796437>
 22. **The Impact of COVID-19 on Essential Medicines and Personal Protective Equipment Availability and Prices in Saudi Arabia.** Healthcare (Basel) 2021; 9Aljadeed R, AlRuthia Y, Balkhi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800012>
 23. **Dentists' Working Conditions during the First COVID-19 Pandemic Lockdown: An Online Survey.** Healthcare (Basel) 2021; 9Wiesmüller V, Bruckmoser E, Kapferer-Seebacher I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807082>
 24. **Prevention and Control of COVID-19 Pandemic on International Cruise Ships: The Legal Controversies.** Healthcare (Basel) 2021; 9Zhang X, Wang C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806680>
 25. **Intubation outcomes using the aerosol box during the COVID-19 pandemic: A prospective, observational study.** Indian J. Anaesth. 2021; 65:221-228Venketeswaran MV, Srinivasaraghavan N, Balakrishnan K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776113>
 26. **Video Laryngoscopy-guided Nasal Intubation: One More Bullet in Our Rifle.** Indian J. Crit. Care Med. 2021; 25:351Cittadini A, Marsigli F, Sica A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33790523>
 27. **A Survey of Personnel Protective equipment's (PPE) Use and Comfort Levels Among Surgeons During Routine Cancer Surgery in the COVID-19 Pandemic.** Indian J Surg Oncol 2021;1-9Thiagarajan S, Shetty P, Gulia A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785996>
 28. **Prevalence of COVID-19 in healthcare professionals working in hospital emergencies during first wave peak in 2020, Porto Alegre - Brazil.** Infect Control Hosp Epidemiol 2021;1-8Dubiel ALF, Dalla Lana DF, Aerts APK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775261>
 29. **Activities and Perceived Risk of Transmission and Spread of SARS-CoV-2 among Specialists and Residents in a Third Level University Hospital in Spain.** Int J Environ Res Public Health 2021; 18Aranaz-Andrés JM, McGee-Laso A, Galán JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802207>
 30. **Time for 'Green' during COVID-19? Inequities in Green and Blue Space Access, Visitation and Felt Benefits.** Int J Environ Res Public Health 2021; 18Astell-Burt T, Feng X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803166>
 31. **Effectiveness of SARS-CoV-2 Decontamination and Containment in a COVID-19 ICU.** Int J Environ Res Public Health 2021; 18Brune Z, Kuschner CE, Mootz J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802332>

32. **Community Use of Face Masks against the Spread of COVID-19.** Int J Environ Res Public Health 2021; 18Bubbico L, Mastrangelo G, Larese-Filon F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808861>
33. **Occupational Health and Safety Measures in German Outpatient Care Services during the COVID-19 Pandemic: A Qualitative Study.** Int J Environ Res Public Health 2021; 18Hetzmann MS, Mojtahedzadeh N, Nienhaus A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799465>
34. **SARS-CoV-2 Infection, Risk Perception, Behaviour and Preventive Measures at Schools in Berlin, Germany, during the Early Post-Lockdown Phase: A Cross-Sectional Study.** Int J Environ Res Public Health 2021; 18Hommes F, van Loon W, Thielecke M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800392>
35. **First Detection of Severe Acute Respiratory Syndrome Coronavirus 2 on the Surfaces of Tourist-Recreational Facilities in Italy.** Int J Environ Res Public Health 2021; 18Montagna MT, De Giglio O, Calia C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801099>
36. **An Overview of Thermal Infrared Imaging-Based Screenings during Pandemic Emergencies.** Int J Environ Res Public Health 2021; 18Perpetuini D, Filippini C, Cardone D, Merla A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810086>
37. **COVID-19 Preventive Behaviours in Cameroon: A Six-Month Online National Survey.** Int J Environ Res Public Health 2021; 18Siewe Fodjo JN, Ngarka L, Njamnshi WY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806495>
38. **Effectiveness of Epidemic Preventive Policies and Hospital Strategies in Combating COVID-19 Outbreak in Taiwan.** Int J Environ Res Public Health 2021; 18Tan TW, Tan HL, Chang MN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810438>
39. **A descriptive audit of healthcare workers exposed to COVID-19 at a tertiary care center in India.** Int J Gynaecol Obstet 2021; Mansoor S, Sharma KA, Ranjan P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792934>
40. **Mitigating the Transmission of COVID-19 with the Appropriate Usage of Personal Protective Protocols and Equipment in Breast Imaging and Intervention.** J Breast Imaging 2021; 3:215-220Moseley TW, Connors AL, He H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778489>
41. **Clear plastic bags effectively limit aerosolization and droplet spray during extubation in the era of COVID-19.** J. Clin. Anesth. 2021; 71:110253Ajimi J, Kosaka M, Takahashi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799092>
42. **Impact of Personal Protective Equipment on the First-Pass Success of Endotracheal Intubation in the ED: A Propensity-Score-Matching Analysis.** J Clin Med 2021; 10Choi J, Shin TG, Park JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806528>
43. **Operation theatre protocol for COVID-19 cases requiring orthopaedic surgery: A workflow without altering the existing infrastructure.** J Clin Orthop Trauma 2021; 17:163-168Bhat AK, Vijayan S, Acharya AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776361>
44. **Barriers Related to Mask Wearing in African American Neighborhood Businesses.** J. Community Health 2021; Jones HJ, Hutchins R, Brown P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811572>

45. **SARS-CoV-2 Positivity in Asymptomatic-Screened Dental Patients.** J Dent Res 2021;220345211004849Conway DI, Culshaw S, Edwards M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779355>
46. **Anesthesiology Training in the Time of COVID-19: Problems and Solutions.** J Educ Perioper Med 2021; 23:E659Streiff A, Ramachandran S, Choice C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778104>
47. **Impact of incentives for health-care workers wearing personal protective equipment while dealing with coronavirus disease in Japan.** J Occup Health 2021; 63:e12213Morishita K, Takase K, Ishikane M, Otomo Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33788328>
48. **Prevention of Covid-19 Infection and Related Complications by Ozonized Oils.** J Pers Med 2021; 11Izzotti A, Fracchia E, Au W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809879>
49. **Headache related to mask use of healthcare workers in COVID-19 pandemic.** Korean J. Pain 2021; 34:241-245Köseoğlu Toksoy C, Demirbaş H, Bozkurt E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785677>
50. **Measuring Awareness of Infection Control Guidelines for Patients with COVID-19 in Radiology Departments in Saudi Arabia.** Med Sci (Basel) 2021; 9Almatari M, Alghamdi A, Alamri S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809671>
51. **Nanofiber-Based Face Masks and Respirators as COVID-19 Protection: A Review.** Membranes (Basel) 2021; 11Essa WK, Yasin SA, Saeed IA, Ali GAM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808380>
52. **SiO(2)-Ag Composite as a Highly Virucidal Material: A Roadmap that Rapidly Eliminates SARS-CoV-2.** Nanomaterials (Basel) 2021; 11Assis M, Simoes LGP, Tremiliosi GC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806671>
53. **Inactivation of Human Coronavirus by FATHHOME's Dry Sanitizer Device: Rapid and Eco-Friendly Ozone-Based Disinfection of SARS-CoV-2.** Pathogens 2021; 10Uppal T, Khazaieli A, Snijders AM, Verma SC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33799334>
54. **Effectiveness of Preventive Measures in Keeping Low Prevalence of SARS-CoV-2 Infection in Health Care Workers in a Referral Children's Hospital in Southern Italy.** Pediatr. Rep. 2021; 13:118-124Caselli D, Loconsole D, Dario R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806472>
55. **Alcohol-Based Hand Sanitizers in COVID-19 Prevention: A Multidimensional Perspective.** Pharmacy (Basel) 2021; 9Abuga K, Nyamweya N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808754>
56. **EVALUATION OF THE EFFECT OF N95 FACE MASK USED BY HEALTHCARE PROFESSIONALS ON CHOROÏDAL THICKNESS.** Photodiagnosis Photodyn. Ther. 2021;102279Karatas Durusoy G, Gumus G, Demir G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813019>
57. **Doctors underestimate 2 m social distancing more than other health care workers.** Postgrad. Med. J. 2021; Lennie I, Muralidharan S, Rimbi M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33790032>
58. **Approach to endoscopic procedures during COVID-19 pandemic - not as expected.** Prz Gastroenterol 2020; 15:275-278Ratyński T, Bednarczuk A,

Rydzewska G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777265>

59. **Occupational Health Safety of Health Professionals and Associated Factors During COVID-19 Pandemics at North Showa Zone, Oromia Regional State, Ethiopia.** Risk Manag. Healthc. Policy 2021; 14:1299-1310 Hailu D, Benayew M, Liknaw T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790675>
60. **Potential Risk and Safety Measures in Laparoscopy in COVID-19 Positive Patients.** Surg. Innov. 2021:15533506211003527 Tummers FH, Draaisma WA, Demirkiran A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788655>
61. **Methods to disinfect and decontaminate SARS-CoV-2: a systematic review of in vitro studies.** Ther Adv Infect Dis 2021; 8:2049936121998548 Kwok CS, Dashti M, Tafuro J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796289>
62. **Autonomous delivery vehicles to fight the spread of Covid-19 - How do men and women differ in their acceptance?** Transp Res Part A Policy Pract 2021; Kapser S, Abdelrahman M, Bernecker T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776251>
63. **SARS-CoV-2 Survival on Surfaces and the Effect of UV-C Light.** Viruses 2021; 13:Gidari A, Sabbatini S, Bastianelli S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807521>
64. **Pulsed Broad-Spectrum UV Light Effectively Inactivates SARS-CoV-2 on Multiple Surfaces and N95 Material.** Viruses 2021; 13:Jureka AS, Williams CG, Basler CF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799842>
65. **How we prepared our operating theatre for patients with SARS-CoV-2 virus.** Wideochir Inne Tech Maloinwazyjne 2021; 16:117-122 Rymarowicz J, Pędziwiatr M, Major P, Nowakowski M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786124>

Pulmonary disease (23 articles)

1. **Evaluating the impact of COVID-19 on asthma morbidity: a comprehensive analysis of potential influencing factors.** Ann. Allergy. Asthma. Immunol. 2021; Guijon OL, Morphey T, Consulting M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775900>
2. **The aging lung: Physiology, disease, and immunity.** Cell 2021; Schneider JL, Rowe JH, Garcia-de-Alba C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811810>
3. **Impact of Chronic Obstructive Pulmonary Disease and Emphysema on Outcomes of Hospitalized Patients with COVID-19 Pneumonia.** Chronic Obstr Pulm Dis 2021; Marron RM, Zheng M, Fernandez Romero G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780602>
4. **Viral Respiratory Pathogens and Lung Injury.** Clin. Microbiol. Rev. 2021; 34:Clementi N, Ghosh S, De Santis M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789928>
5. **Isolate and treat: Respiratory tract infections in times of corona.** Deutsche Apotheker Zeitung 2021; 161.
6. **Corrigendum: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.** Front Med (Lausanne) 2020; 7:604640 Chaudhary S, Natt B, Bime C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777966>

7. **Effects of a Comprehensive Pulmonary Rehabilitation in Severe Post-COVID-19 Patients.** *Int J Environ Res Public Health* 2021; 18Spielmanns M, Pekacka-Egli AM, Schoendorf S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800094>
8. **Hospitalization of mild cases of community-acquired pneumonia decreased more than severe ones during the COVID-19 epidemic.** *Int J Infect Dis* 2021; Nagano H, Takada D, Shin JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794382>
9. **The History and Mystery of Alveolar Epithelial Type II Cells: Focus on Their Physiologic and Pathologic Role in Lung.** *Int J Mol Sci* 2021; 22Ruaro B, Salton F, Braga L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806395>
10. **Morphological and molecular changes in the lung of COVID-19 patients.** *Internist* 2020; 61:1304-1307Augustin M, Hallek M, Nitschmann S.
11. **2021 Acute Respiratory Distress Syndrome Update, With Coronavirus Disease 2019 Focus.** *J Cardiothorac Vasc Anesth* 2021; Welker C, Huang J, Gil IJN, Ramakrishna H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781671>
12. **Residual Lung Function Impairment Is Associated with Hyperventilation in Patients Recovered from Hospitalised COVID-19: A Cross-Sectional Study.** *J Clin Med* 2021; 10Crisafulli E, Gabbiani D, Magnani G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802359>
13. **Spontaneous Pneumomediastinum, Pneumothorax, Pneumopericardium and Subcutaneous Emphysema-Not So Uncommon Complications in Patients with COVID-19 Pulmonary Infection-A Series of Cases.** *J Clin Med* 2021; 10Cut TG, Tudoran C, Lazureanu VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805118>
14. **Management Challenges in Chronic Obstructive Pulmonary Disease in the COVID-19 Pandemic: Telehealth and Virtual Reality.** *J Clin Med* 2021; 10Rutkowski S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803853>
15. **Trends over Time of Lung Function and Radiological Abnormalities in COVID-19 Pneumonia: A Prospective, Observational, Cohort Study.** *J Clin Med* 2021; 10Santus P, Flor N, Saad M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801455>
16. **Post COVID-19 Organizing Pneumonia: The Right Time to Interfere.** *Medicina (Kaunas)* 2021; 57Bieksiene K, Zaveckiene J, Malakauskas K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803690>
17. **COVID-19 and Pneumocystis jirovecii Pulmonary Coinfection-The First Case Confirmed through Autopsy.** *Medicina (Kaunas)* 2021; 57Jeican, II, Inişca P, Gheban D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804963>
18. **Spontaneous pneumomediastinum and subcutaneous emphysema in a non-intubated COVID-19 patient: a case report.** *Pan Afr. Med. J.* 2021; 38:37Jatoi TA, Khan AA, Mohiuddin O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777305>
19. **Recommendations for Performing Bronchoscopy in Times of the COVID-19 Pandemic - Update 12/2020.** *Pneumologie* 2021; 75:187-190Darwiche K, Ross B, Gesierich W *et al.*
20. *Pneumologie* 2021; 75:163Grohe C.
21. **Pericardial and pleural effusion in an elderly woman with Covid-19 pneumonia: CT findings.** *Radiol Case Rep* 2021; Messina F, Turano L, Tebala C *et*

al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777279>

22. **Impact of COVID-19 lockdown on emergency asthma admissions and deaths: national interrupted time series analyses for Scotland and Wales.** *Thorax* 2021; Davies GA, Alsallakh MA, Sivakumaran S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782079>
23. **Impact of COVID-19 national lockdown on asthma exacerbations: interrupted time-series analysis of English primary care data.** *Thorax* 2021; Shah SA, Quint JK, Nwaru BI, Sheikh A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782080>

Renal disease (20 articles)

1. **The effectiveness of continuous renal replacement therapy in critical COVID-19 patients with cytokine release syndrome: a retrospective, multicenter, descriptive study from Wuhan, China.** *Aging (Albany NY)* 2021; 13Xiang H, Song B, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811755>
2. **Association between Postmortem Kidney Biopsy Findings and Acute Kidney Injury from Patients with SARS-CoV-2 (COVID-19).** *Clin J Am Soc Nephrol* 2021; Rivero J, Merino-López M, Olmedo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782033>
3. **COVID-19 pandemic era: is it time to promote home dialysis and peritoneal dialysis?** *Clin Kidney J* 2021; 14:i6-i13Cozzolino M, Conte F, Zappulo F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796282>
4. **Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: implications for management of the pandemic in outpatient hemodialysis settings.** *Clin Kidney J* 2021; 14:805-813Haarhaus M, Santos C, Haase M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777363>
5. **Pathology of COVID-19-associated acute kidney injury.** *Clin Kidney J* 2021; 14:i30-i39Sharma P, Ng JH, Bijol V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796284>
6. **Oral Symptoms Associated with COVID-19 and Their Pathogenic Mechanisms: A Literature Review.** *Dent J (Basel)* 2021; 9Tsuchiya H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799583>
7. **The Good Treatment, the Bad Virus, and the Ugly Inflammation: Pathophysiology of Kidney Involvement During COVID-19.** *Front. Physiol.* 2021; 12:613019Le Stang MB, Desenclos J, Flamant M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776785>
8. **A case of neglected hepatorenal dysfunction during the COVID pandemic.** *Indian J. Med. Microbiol.* 2021; Chaudhry R, Batra P, Khullar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781657>
9. **Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial.** *J Clin Med* 2021; 10Esposito P, Cipriani L, Verzola D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808205>
10. **Severe Acute Kidney Injury in Critically Ill Patients with COVID-19 Admitted to ICU: Incidence, Risk Factors, and Outcomes.** *J Clin Med* 2021; 10Ghosn M, Attallah N, Badr M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804100>

11. **Analysis of the Clinical and Epidemiological Meaning of Screening Test for SARS-CoV-2: Considerations in the Chronic Kidney Disease Patients during the COVID-19 Pandemic.** J Clin Med 2021; 10Martino F, Amici G, Grandesso S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803083>
12. **Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: a retrospective study.** J Med Virol 2021; Movahed SMM, Akhavizadegan H, Dolatkhani F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792956>
13. **Elevated Monocyte to Lymphocyte Ratio and Increased Mortality among Patients with Chronic Kidney Disease Hospitalized for COVID-19.** J Pers Med 2021; 11Dávila-Collado R, Jarquín-Durán O, Solís-Vallejo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809858>
14. **Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients.** Kidney Int 2021; Benotmane I, Gautier-Vargas G, Cognard N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775674>
15. **Renal Morphology in Coronavirus Disease: A Literature Review.** Medicina (Kaunas) 2021; 57de Oliveira P, Cunha K, Neves P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799854>
16. **COVID-19 infection in a pediatric kidney transplant population: A single-center experience.** Pediatr. Transplant. 2021:e14018Singer PS, Sethna C, Molmenti E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813782>
17. **Caring for patients with end-stage renal disease during COVID-19 lockdown: What (additional) challenges to family caregivers?** Scand. J. Caring Sci. 2021; Sousa H, Frontini R, Ribeiro O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778978>
18. **Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis.** Ther. Adv. Chronic Dis. 2021; 12:2040622321998860Lin YC, Lai TS, Lin SL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796245>
19. **Successful Management of T-Cell Mediated Rejection in a Recent Kidney Transplant Recipient with COVID-19 associated Severe Acute Respiratory Syndrome.** Transpl Infect Dis 2021:e13598Mohamed M, Smith J, Parajuli S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780103>
20. **IgA-Dominant Infection-Associated Glomerulonephritis Following SARS-CoV-2 Infection.** Viruses 2021; 13Pérez A, Torregrosa I, D'Marco L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807151>

Reviews (49 articles)

1. **The association of ABO blood type with the risk and severity of COVID-19 infection.** Am. J. Blood Res. 2021; 11:53-58Mullins J, Al-Tarbsheh AH, Chieng H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796389>
2. **Literature Review of COVID-19, Pulmonary and Extrapulmonary Disease.** Am. J. Med. Sci. 2021; Yazdanpanah F, Asmarz HY, Shadman S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785204>

3. **Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature.** Am. J. Otolaryngol. 2020; 42:102640 De Luca P, Scarpa A, De Bonis E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33780902>
4. **Clotting in COVID-19: Is It All in the Genes?** Am. J. Respir. Cell Mol. Biol. 2021; Hernandez Cordero AI, Sin DD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784208>
5. **COVID-19 and ethics: We learn as we go. But where are we going?** Anaesth Crit Care Pain Med 2021;100856 Le Dorze M, Kandelman S, Gateau V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785423>
6. **COVID 19 - Possible interrelations with respiratory comorbidities caused by occupational exposure to various hazardous bioaerosols. Part II. Clinical course, diagnostics, treatment and prevention.** Ann. Agric. Environ. Med. 2021; 28:27-43 Mackiewicz B, Lemieszek MK, Dutkiewicz J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775065>
7. **Consistency of global recommendations regarding open versus laparoscopic surgery during the COVID-19 pandemic: a systematic review.** ANZ J Surg 2021; Jacob S, Hameed A, Lam V, Pang TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792122>
8. **A systematic review of pregnant women with COVID-19 and their neonates.** Arch. Gynecol. Obstet. 2021; Mirbeyk M, Saghazadeh A, Rezaei N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33797605>
9. **Breastfeeding during COVID-19: A Narrative Review of the Psychological Impact on Mothers.** Behav Sci (Basel) 2021; 11 Pacheco F, Sobral M, Guiomar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799384>
10. **Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions.** Biomedicines 2021; 9 Matsuishi Y, Mathis BJ, Shimojo N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33801921>
11. **Treatment of COVID-19: a review of current and prospective pharmacotherapies.** Br. J. Hosp. Med. (Lond.) 2021; 82:1-9 Quek E, Tahir H, Kumar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792391>
12. **The Relationship between COVID-19 and Innate Immunity in Children: A Review.** Children (Basel) 2021; 8 Valentini P, Sodero G, Buonsenso D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808490>
13. **Hepatic transplant during SARS-CoV-2 (COVID-19) pandemic. A literature review.** Cir. Cir. 2021; 89:269-274 Pérez-González B, Thomas-Lora FC, Hoyo I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784290>
14. **Renin-angiotensin system blockade in the COVID-19 pandemic.** Clin Kidney J 2021; 14:i48-i59 Cohen JB, South AM, Shaltout HA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796285>
15. **COVID-19: The Ivermectin African Enigma.** Colomb Med (Cali) 2020; 51:e2014613 Guerrero R, Bravo LE, Muñoz E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33795896>
16. **Acute Recurrent Pancreatitis and COVID-19 Infection: A Case Report with Literature Review.** Cureus 2021; 13:e13490 Sandhu H, Mallik D, Lokavarapu MJ *et*

al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777577>

17. **Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review.** *Dermatol Ther (Heidelb)* 2021; Gisondi P, Di Leo S, Bellinato F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811315>
18. **A Pictorial Review of the Role of Imaging in the Detection, Management, Histopathological Correlations, and Complications of COVID-19 Pneumonia.** *Diagnostics (Basel)* 2021; 11 Brogna B, Bignardi E, Brogna C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806423>
19. **Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.** *Diagnostics (Basel)* 2021; 11 Doroftei B, Ciobica A, Ilie OD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804914>
20. **Diabetes, inflammation, and the adiponectin paradox: therapeutic targets in SARS-CoV-2.** *Drug Discov Today* 2021; Ho G, Ali A, Takamatsu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775925>
21. **The Double Edge Sword of Testosterone's Role in the COVID-19 Pandemic.** *Front. Endocrinol. (Lausanne)* 2021; 12:607179 Younis JS, Skorecki K, Abassi Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796068>
22. **Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.** *Front. Immunol.* 2021; 12:657711 Lombardi A, Bozzi G, Ungaro R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777055>
23. **Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.** *Front. Immunol.* 2021; 12:635371 Martinez MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777024>
24. **Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.** *Front. Immunol.* 2021; 12:645013 Tang KT, Hsu BC, Chen DY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777042>
25. **Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of renin-angiotensin-aldosterone system (RAAS) inhibitors: a systematic review.** *Futur J Pharm Sci* 2021; 7:73 Iheanacho CO, Odili VU, Eze UIH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778087>
26. **Developing a Thai national critical care allocation guideline during the COVID-19 pandemic: a rapid review and stakeholder consultation.** *Health Res. Policy Syst.* 2021; 19:47 Marshall AI, Archer R, Witthayapipopsakul W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789671>
27. **Splenic infarction as a complication of covid-19 in a patient without respiratory symptoms: A case report and literature review.** *IDCases* 2021:e01062 Castro GRA, Collaço IA, Dal Bosco CLB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777695>
28. **Impact of COVID-19 on Orthopaedic Care and Practice: A Rapid Review.** *Indian J. Orthop.* 2021; 1-14 Chatterji G, Patel Y, Jain V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776130>
29. **A review on antiviral and immunomodulatory polysaccharides from Indian medicinal plants, which may be beneficial to COVID-19 infected patients.** *Int. J. Biol. Macromol.* 2021; 181:462-470 Sen IK, Chakraborty I, Mandal AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794238>

30. **Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification.** Int J Environ Res Public Health 2021; 18Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807869>
31. **A Scoping Review of Psychosocial Risks to Health Workers during the Covid-19 Pandemic.** Int J Environ Res Public Health 2021; 18Franklin P, Gkiouleka A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801517>
32. **Impact of COVID-19 on Mental Health in Adolescents: A Systematic Review.** Int J Environ Res Public Health 2021; 18Jones EAK, Mitra AK, Bhuiyan AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802278>
33. **The use of non-invasive ventilation in COVID-19: a systematic review.** Int J Infect Dis 2021; Wang Z, Wang Y, Yang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798720>
34. **The Year in Coagulation: Selected Highlights from 2020.** J Cardiothorac Vasc Anesth 2021; Patel PA, Henderson RA, Jr., Bolliger D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781668>
35. **2021 Acute Respiratory Distress Syndrome Update, With Coronavirus Disease 2019 Focus.** J Cardiothorac Vasc Anesth 2021; Welker C, Huang J, Gil IJN, Ramakrishna H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781671>
36. **Disparities in H1N1 Vaccination Rates: a Systematic Review and Evidence Synthesis to Inform COVID-19 Vaccination Efforts.** J Gen Intern Med 2021;1-12Ayers CK, Kondo KK, Williams BE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791935>
37. **An overview of Covid-19 pandemic: immunology and pharmacology.** J. Immunoassay Immunochem. 2021;1-20Arif A, Ansari S, Ahsan H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788668>
38. **Long COVID - An Early Perspective.** J. Insur. Med. 2021; Meagher T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784738>
39. **Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials.** J Integr Med 2021; Zhao MZ, Zhao C, Tu SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789839>
40. **The potential of miRNA-based therapeutics in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: a review.** J Pharm Anal 2021; Rizkita LD, Astuti I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782640>
41. **Renal Morphology in Coronavirus Disease: A Literature Review.** Medicina (Kaunas) 2021; 57de Oliveira P, Cunha K, Neves P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799854>
42. **Corona Viruses: A Review on SARS, MERS and COVID-19.** Microbiol Insights 2021; 14:11786361211002481Chathappady House NN, Palissery S, Sebastian H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795938>
43. **Zoonotic and reverse zoonotic transmission of severe acute respiratory syndrome coronavirus 2: a review and implications for Africa.** Pan Afr. Med. J. 2021; 38:39Anjorin AA, Ashaka OS, Tijani SO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777307>

44. **A status report with critical analysis of research trends in exploring medicinal plants as antiviral: Let us dig into the history to predict the future.** Phytother. Res. 2021; Mukherjee S, Chouhan KBS, Tandey R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793009>
45. **Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis.** Ther. Adv. Chronic Dis. 2021; 12:2040622321998860 Lin YC, Lai TS, Lin SL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796245>
46. **The neurological symptoms of COVID-19: a systematic overview of systematic reviews, comparison with other neurological conditions and implications for healthcare services.** Ther. Adv. Chronic Dis. 2021; 12:2040622320976979 Wildwing T, Holt N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796241>
47. **Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages.** Ther Adv Drug Saf 2021; 12:2042098621998876 Mangoni AA, Erre GL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796258>
48. **Methods to disinfect and decontaminate SARS-CoV-2: a systematic review of in vitro studies.** Ther Adv Infect Dis 2021; 8:2049936121998548 Kwok CS, Dashti M, Tafuro J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796289>
49. **A Comparative Systematic Review of COVID-19 and Influenza.** Viruses 2021; 13 Osman M, Klopfenstein T, Belfeki N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802155>

Risk factors (73 articles)

1. **Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis.** Acta Diabetol 2021:1-10 Kaminska H, Szarpak L, Kosior D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778910>
2. **Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem.** Adv Ther 2021:1-8 Cugno M, Gualtierotti R, Casazza G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792889>
3. **Severe vitamin D deficiency is not related to SARS-CoV-2 infection but may increase mortality risk in hospitalized adults: a retrospective case-control study in an Arab Gulf country.** Aging Clin. Exp. Res. 2021:1-8 Alguwaihes AM, Sabico S, Hasanato R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788172>
4. **Peripheral Plasma Cells Associated with Mortality Benefit in Severe COVID-19: A Marker of Disease Resolution.** Am. J. Med. 2021; Boulanger M, Molina E, Wang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811876>
5. **Characteristics and Risk Factors Associated With Mortality in a Multicenter Spanish Cohort of Patients With COVID-19 Pneumonia.** Arch. Bronconeumol. 2021; Muñoz-Rodríguez JR, Gómez-Romero FJ, Pérez-Ortiz JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785236>
6. **Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome.** Biomedicines 2021; 9 Morales A, Rojo Rello S, Cristóbal H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810394>

7. **Blood Levels of Galectin-9, an Immuno-Regulating Molecule, Reflect the Severity for the Acute and Chronic Infectious Diseases.** Biomolecules 2021; 11Iwasaki-Hozumi H, Chagan-Yasutan H, Ashino Y, Hattori T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804076>
8. **Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak.** BMC Infect. Dis. 2021; 21:308Sabaka P, Koščálová A, Straka I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781216>
9. **Variables associated with COVID-19 severity: an observational study of non-paediatric confirmed cases from the general population of the Basque Country, Spain.** BMJ Open 2021; 11:e049066Vrotsou K, Rotaecche R, Mateo-Abad M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795313>
10. **Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study.** Cancers (Basel) 2021; 13Di Cosimo S, Tagliaferri B, Generali D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809465>
11. **Socioeconomic Inequalities and Ethnicity Are Associated with a Positive COVID-19 Test among Cancer Patients in the UK Biobank Cohort.** Cancers (Basel) 2021; 13Lee SF, Nikšić M, Rachet B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806016>
12. **Thymic Aging May Be Associated with COVID-19 Pathophysiology in the Elderly.** Cells 2021; 10Wang W, Thomas R, Oh J, Su DM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808998>
13. **Role of Non-Thyroidal Illness Syndrome in Predicting Adverse Outcomes in COVID-19 Patients Predominantly of Mild to Moderate Severity.** Clin. Endocrinol. (Oxf.) 2021; Lui DTW, Lee CH, Chow WS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33813743>
14. **Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: implications for management of the pandemic in outpatient hemodialysis settings.** Clin Kidney J 2021; 14:805-813Haarhaus M, Santos C, Haase M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777363>
15. **A model to predict the risk of mortality in severely ill COVID-19 patients.** Comput Struct Biotechnol J 2021; Chen B, Gu H, Liu Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777331>
16. **A model to predict the risk of mortality in severely ill COVID-19 patients.** Comput Struct Biotechnol J 2021; 19:1694-1700Chen B, Gu HQ, Liu 刘艺 Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777331>
17. **SARS-CoV-2 infection and smoking: What is the association? A brief review.** Comput Struct Biotechnol J 2021; 19:1654-1660Gupta I, Sohail MU, Elzawawi KE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777332>
18. **SARS-CoV-2 Infection and Smoking: What is the association? A brief review.** Comput Struct Biotechnol J 2021; 19:1654-1660Gupta I, Sohail MU, Elzawawi KE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777332>
19. **Serum IP-10 and IL-7 levels are associated with disease severity of coronavirus disease 2019.** Cytokine 2021; 155500Wang GL, Gao HX, Wang YL *et*

- al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810947>
20. **Detecting severe courses early: Urine test helps in prediction of severe COVID-19 diseases.** Deutsche Apotheker Zeitung 2021; 161 Daubitz T.
 21. **ASSOCIATION OF HYPERGLYCAEMIA WITH HOSPITAL MORTALITY IN NONDIABETIC COVID-19 PATIENTS: A COHORT STUDY.** Diabetes Metab. 2021;101254 Mamtani M, Athavale AM, Abraham M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781926>
 22. **Risk Score for Predicting In-Hospital Mortality in COVID-19 (RIM Score).** Diagnostics (Basel) 2021; 11 López-Escobar A, Madurga R, Castellano JM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33810534>
 23. **Modeling the Contribution of Male Testosterone Levels to the Duration of Positive COVID Testing among Hospitalized Male COVID-19 Patients.** Diagnostics (Basel) 2021; 11 Salciccia S, Eisenberg ML, Maggi M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804969>
 24. **Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020.** Euro Surveill 2021; 26 Sermet-Gaudelus I, Temmam S, Huon C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33797390>
 25. **The effects of some essential and toxic metals/metalloids in COVID-19: A review.** Food Chem. Toxicol. 2021; 152:112161 Domingo JL, Marquès M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33794307>
 26. **Dooming Phagocyte Responses: Inflammatory Effects of Endogenous Oxidized Phospholipids.** Front. Endocrinol. (Lausanne) 2021; 12:626842 Di Gioia M, Zandoni I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790857>
 27. **The Centrality of Obesity in the Course of Severe COVID-19.** Front. Endocrinol. (Lausanne) 2021; 12:620566 Liu D, Zhang T, Wang Y, Xia L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776917>
 28. **The Double Edge Sword of Testosterone's Role in the COVID-19 Pandemic.** Front. Endocrinol. (Lausanne) 2021; 12:607179 Younis JS, Skorecki K, Abassi Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796068>
 29. **Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.** Front Med (Lausanne) 2021; 8:626425 Hegyi PJ, Váncsa S, Ocskay K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777974>
 30. **Epidemiology, Clinical Features and Prognostic Factors of Pediatric SARS-CoV-2 Infection: Results From an Italian Multicenter Study.** Front Pediatr 2021; 9:649358 Garazzino S, Lo Vecchio A, Pierantoni L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796491>
 31. **Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of renin-angiotensin-aldosterone system (RAAS) inhibitors: a systematic review.** Futur J Pharm Sci 2021; 7:73 Iheanacho CO, Odili VU, Eze UIH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778087>
 32. **Clinical Features of the 60 Years and Older Patients Infected with 2019 Novel Coronavirus: Can We Predict Mortality Earlier?** Gerontology 2021;1-8 Genc Yavuz B, Colak S, Guven R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784699>

33. **Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment.** Gut Liver 2021; Song JE, Kang MK, Lee YR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782216>
34. **Atrial Fibrillation as a Predictor of Mortality in High Risk COVID-19 Patients: A Multicentre Study of 171 Patients.** Heart Lung Circ. 2021; Ip RJ, Ali A, Baloch ZQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781697>
35. **Hypothetical COVID-19 protection mechanism: hints from centenarians.** Immun. Ageing 2021; 18:15Guerini FR, Cesari M, Arosio B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785044>
36. **Haemophilus influenzae and SARS-CoV-2: Is there a role for investigation?** Indian J. Med. Microbiol. 2021; Borkakoty B, Bali NK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781659>
37. **Detectable respiratory SARS-CoV-2 RNA is associated with low vitamin D levels and high social deprivation.** Int J Clin Pract 2021:e14166Livingston M, Plant A, Dunmore S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797849>
38. **Exposure to Perfluoroalkyl Substances and Mortality for COVID-19: A Spatial Ecological Analysis in the Veneto Region (Italy).** Int J Environ Res Public Health 2021; 18Catelan D, Biggeri A, Russo F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800362>
39. **Vitamin D Levels Are Reduced at the Time of Hospital Admission in Sicilian SARS-CoV-2-Positive Patients.** Int J Environ Res Public Health 2021; 18Gaudio A, Murabito AR, Agodi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801759>
40. **Possible Roles of Permafrost Melting, Atmospheric Transport, and Solar Irradiance in the Development of Major Coronavirus and Influenza Pandemics.** Int J Environ Res Public Health 2021; 18Hofmeister AM, Seckler JM, Criss GM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809626>
41. **Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich.** Int J Environ Res Public Health 2021; 18Pritsch M, Radon K, Bakuli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808249>
42. **Racial and Ethnic Disparities in Years of Potential Life Lost Attributable to COVID-19 in the United States: An Analysis of 45 States and the District of Columbia.** Int J Environ Res Public Health 2021; 18Xu JJ, Chen JT, Belin TR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809240>
43. **Circulating activated neutrophils in COVID-19: an independent predictor for mechanical ventilation and death.** Int J Infect Dis 2021; Dennison D, Khabori MA, Mamari SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781906>
44. **The ROX index can be a useful tool for the triage evaluation of COVID-19 patients with dyspnoea.** J. Adv. Nurs. 2021; Zaboli A, Ausserhofer D, Pfeifer N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792953>
45. **Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark.** J Autoimmun 2021; 120:102632Kjeldsen J, Nielsen J, Ellingsen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812171>
46. **Impact of environmental factors on COVID-19 cases and mortalities in major cities of Pakistan.** J Biosaf Biosecur 2021; 3:10-16Basray R, Malik A, Waqar W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786420>

47. **Predictors of Worse Prognosis in Young and Middle-Aged Adults Hospitalized with COVID-19 Pneumonia: A Multi-Center Italian Study (COVID-UNDER50).** J Clin Med 2021; 10Bonifazi M, Mei F, Skrami E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804084>
48. **Arginase 1 (Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy.** J Clin Med 2021; 10Derakhshani A, Hemmat N, Asadzadeh Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806290>
49. **Hypertension and Related Comorbidities as Potential Risk Factors for COVID-19 Hospitalization and Severity: A Prospective Population-Based Cohort Study.** J Clin Med 2021; 10Fresán U, Guevara M, Trobajo-Sanmartín C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809217>
50. **Severe Acute Kidney Injury in Critically Ill Patients with COVID-19 Admitted to ICU: Incidence, Risk Factors, and Outcomes.** J Clin Med 2021; 10Ghosn M, Attallah N, Badr M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804100>
51. **Electronic Cigarette Aerosol Is Cytotoxic and Increases ACE2 Expression on Human Airway Epithelial Cells: Implications for SARS-CoV-2 (COVID-19).** J Clin Med 2021; 10McAlinden KD, Lu W, Ferdowsi PV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802256>
52. **Associations of Body Mass Index with Ventilation Management and Clinical Outcomes in Invasively Ventilated Patients with ARDS Related to COVID-19- Insights from the PROVENT-COVID Study.** J Clin Med 2021; 10Schavemaker R, Schultz MJ, Lagrand WK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799735>
53. **Cytokeratin 18 cell death assays as biomarkers for quantification of apoptosis and necrosis in COVID-19: a prospective, observational study.** J. Clin. Pathol. 2021; Henry BM, Cheruiyot I, Benoit SW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789919>
54. **Prognostic Implication of Baseline Sarcopenia for Length of Hospital Stay and Survival in Patients with Coronavirus Disease 2019.** J Gerontol A Biol Sci Med Sci 2021; Kim JW, Yoon JS, Kim EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780535>
55. **Cholestatic liver injury in COVID-19 is a rare and distinct entity and is associated with increased mortality.** J Intern Med 2021; Da BL, Suchman K, Roth N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786906>
56. **Elevated Monocyte to Lymphocyte Ratio and Increased Mortality among Patients with Chronic Kidney Disease Hospitalized for COVID-19.** J Pers Med 2021; 11Dávila-Collado R, Jarquín-Durán O, Solís-Vallejo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809858>
57. **Early Warning Scores in Patients with Suspected COVID-19 Infection in Emergency Departments.** J Pers Med 2021; 11Martín-Rodríguez F, Martín-Conty JL, Sanz-García A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801375>
58. **Predictive Biomarkers of COVID-19 Severity in SARS-CoV-2 Infected Patients with Obesity and Metabolic Syndrome.** J Pers Med 2021; 11Perpiñan C, Bertran L, Terra X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809913>

59. **Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies.** J. Steroid Biochem. Mol. Biol. 2021:105883 Petrelli F, Luciani A, Perego G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775818>
60. **Arterial hypertension—What was important in 2020?** Kardiologe 2021; 15:127-132 Mahfoud F, Böhm M, Dörr O *et al.*
61. **Frequency and predictive validity of olfactory and taste dysfunction in patients with SARS-CoV-2 infection.** Med Clin (Barc) 2021; Pérula de Torres L, González-Lama J, Jiménez García C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775400>
62. **An update: the emerging evidence of complement involvement in COVID-19.** Med. Microbiol. Immunol. 2021; Li Q, Chen Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811541>
63. **EFFECT OF RAMIPRIL ON KIDNEY, LUNG AND HEART ACE2 IN A DIABETIC MICE MODEL.** Mol. Cell. Endocrinol. 2021:111263 Vergara A, Jacobs-Cachá C, Molina-Van den Bosch M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811970>
64. **Folate Levels in Patients Hospitalized with Coronavirus Disease 2019.** Nutrients 2021; 13 Meisel E, Efros O, Bleier J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801194>
65. **Risk of COVID-19 in patients with cancer receiving immune checkpoint inhibitors.** Oncologist 2021; Klebanov N, Pahalyants V, Murphy WS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783099>
66. **Prolonged QT predicts prognosis in COVID-19.** Pacing Clin. Electrophysiol. 2021; Akhtar Z, Gallagher MM, Yap YG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792080>
67. **The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection.** Pathogens 2021; 10 Kaseb AO, Mohamed YI, Malek AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809851>
68. **Evaluation of "Caterina assay": An Alternative Tool to the Commercialized Kits Used for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Identification.** Pathogens 2021; 10 Orrù G, Scano A, Fais S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802049>
69. **Higher airborne pollen concentrations correlated with increased SARS-CoV-2 infection rates, as evidenced from 31 countries across the globe.** Proc Natl Acad Sci U S A 2021; 118 Damialis A, Gilles S, Sofiev M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798095>
70. **C1q Complement/Tumor Necrosis Factor-Associated Proteins in Cardiovascular Disease and COVID-19.** Proteomes 2021; 9 Xie Y, Meng Z, Gao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804408>
71. **Immunogenetic Predictors of Severe COVID-19.** Vaccines (Basel) 2021; 9 Malkova A, Kudlay D, Kudryavtsev I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802310>
72. **Scores based on neutrophil percentage and lactate dehydrogenase with or without oxygen saturation predict hospital mortality risk in severe COVID-19**

patients. *Virol J* 2021; 18:67Fan X, Zhu B, Nouri-Vaskeh M *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789703>

73. **Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19.** *Viruses* 2021; 13Qeadan F, Tingey B, Gu LY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807920>

Safety (32 articles)

1. **Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem.** *Adv Ther* 2021;1-8Cugno M, Gualtierotti R, Casazza G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792889>
2. **Management of anaphylaxis due to COVID-19 vaccines in the elderly.** *Allergy* 2021; Bousquet J, Agache I, Blain H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811358>
3. **Vaccines and Allergic reactions: the past, the current COVID-19 pandemic, and future perspectives.** *Allergy* 2021; Sampath V, Rabinowitz G, Shah M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811364>
4. **Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature.** *Am. J. Otolaryngol.* 2020; 42:102640De Luca P, Scarpa A, De Bonis E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33780902>
5. **Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.** *Ann. Agric. Environ. Med.* 2021; 28:122-126Majewski D, Majewska KA, Naskręcka M, Grygiel-Górniak B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775077>
6. **Polyethylene Glycol and Polysorbate Skin Testing in the Evaluation of COVID-19 Vaccine Reactions: Early Report.** *Ann. Allergy. Asthma. Immunol.* 2021; Pitlick MM, Sitek AN, Kinate SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775902>
7. **Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings.** *Biology (Basel)* 2021; 10Granata V, Fusco R, Setola SV *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33799618>
8. **Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19.** *Br J Cardiol* 2020; 27:109-111Esser N, Zraika S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795925>
9. **Renin-angiotensin system blockade in the COVID-19 pandemic.** *Clin Kidney J* 2021; 14:i48-i59Cohen JB, South AM, Shaltout HA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33796285>
10. **Adverse Drug Event Risk Assessment by the Virtual Addition of COVID-19 Repurposed Drugs to Medicare and Commercially Insured Patients' Drug Regimens: A Drug Safety Simulation Study.** *Clin Transl Sci* 2021; Smith MK, Bikmetov R, Al Rihani SB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786990>
11. **Lymphadenopathy Associated With the COVID-19 Vaccine.** *Cureus* 2021; 13:e13524Hiller N, Goldberg SN, Cohen-Cymberknoh M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786231>

12. **Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine.** Cureus 2021; 13:e14099Malayala SV, Mohan G, Vasireddy D, Atluri P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786251>
13. **Protein-ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.** Curr Med Chem 2021; de Azevedo Junior WF, Bitencourt-Ferreira G, Godoy JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781188>
14. **Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint.** Curr. Neuropharmacol. 2021; Alborghetti M, Bellucci G, Gentile A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784961>
15. **No new risk signal after COVID-19 vaccination: Initial reports of adverse reactions after vaccination with Comirnaty®.** Deutsche Apotheker Zeitung 2021; 161.
16. **Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.** Diagnostics (Basel) 2021; 11Doroftei B, Ciobica A, Ilie OD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804914>
17. **Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History.** Int J Mol Sci 2021; 22Kaneto H, Kimura T, Obata A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807522>
18. **Vigilance regarding immune thrombocytopenic purpura after COVID-19 vaccine.** Ir. J. Med. Sci. 2021;1-2Saudagar V, Patil S, Goh S, Pothiwala S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788135>
19. **Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine.** J Eur Acad Dermatol Venereol 2021; Ackerman M, Henry D, Finon A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783017>
20. **VACCINATION AGAINST SARS-COV-2 and PSORIASIS: the three things every dermatologist should know.** J Eur Acad Dermatol Venereol 2021; Diotallevi F, Campanati A, Radi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780556>
21. **Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: a retrospective study.** J Med Virol 2021; Movahed SMM, Akhavizadegan H, Dolatkhan F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792956>
22. **Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series.** Life (Basel) 2021; 11Małeck P, Faltin K, Mania A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802763>
23. **Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey.** Life (Basel) 2021; 11Mathioudakis AG, Ghrew M, Ustianowski A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803014>
24. **Strengthening CoViD-19 therapy via combinations of RAS modulators.** Med. Hypotheses 2021; 150:110571Uzunova VV, Todev A, Zarkos J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799164>
25. **SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention.** Microorganisms 2021; 9Inchingolo AD, Inchingolo AM, Bordea IR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806624>

26. **Effectiveness of Azithromycin as add-on Therapy in COVID-19 Management.** Mini Rev. Med. Chem. 2021; Wahab S, Ahmad MF, Hussain A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33797374>
27. **EFFECT OF RAMIPRIL ON KIDNEY, LUNG AND HEART ACE2 IN A DIABETIC MICE MODEL.** Mol. Cell. Endocrinol. 2021;111263Vergara A, Jacobs-Cachá C, Molina-Van den Bosch M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811970>
28. **An Integrative in Silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease.** Mol Inform 2021; Djokovic N, Ruzic D, Djikic T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787066>
29. **Case report of amiodarone-associated allergic pneumonitis amidst the COVID-19 pandemic.** Rev Cardiovasc Med 2021; 22:181-184Azraai M, McMahon M, Dick R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792260>
30. **Unfavorable hydroxychloroquine COVID-19 research associated with authors having a history of political party donations.** Rev Cardiovasc Med 2021; 22:191-198Berry AC, Gonnering RS, Rodriguez I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33792262>
31. **Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations.** Vaccines (Basel) 2021; 9Kounis NG, Koniari I, de Gregorio C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807579>
32. **Hydroxychloroquine-Induced cutaneous reaction in treatment of COVID-19.** Vis J Emerg Med 2021; 22:100979Papanagnou D, Capobianco S, Jean J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33786383>

Treatment options (112 articles)

1. **State-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2.** ACS Appl Mater Interfaces 2021; Derakhshan MA, Amani A, Faridi-Majidi R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33779135>
2. **The effectiveness of continuous renal replacement therapy in critical COVID-19 patients with cytokine release syndrome: a retrospective, multicenter, descriptive study from Wuhan, China.** Aging (Albany NY) 2021; 13Xiang H, Song B, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811755>
3. **Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment.** Am. J. Cancer Res. 2021; 11:827-836Chen Y, Huang WC, Yang CS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33791156>
4. **Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature.** Am. J. Otolaryngol. 2020; 42:102640De Luca P, Scarpa A, De Bonis E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33780902>
5. **A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples.** Am. J. Respir. Cell Mol. Biol. 2021; Madan T, Biswas B, Varghese PM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33784482>

6. **Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.** Ann. Agric. Environ. Med. 2021; 28:122-126Majewski D, Majewska KA, Naskręcka M, Grygiel-Górniak B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775077>
7. **Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia.** Antibiotics (Basel) 2021; 10Alghamdi S, Barakat B, Berrou I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807320>
8. **Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection.** Antiviral Res 2021:105064Ciccosanti F, Di Rienzo M, Romagnoli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781803>
9. **Perspectives on plant flavonoid quercetin-based drugs for novel SARS-CoV-2.** Beni Suef Univ J Basic Appl Sci 2021; 10:21Saakre M, Mathew D, Ravisankar V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33782651>
10. **Exaptation of Retroviral Syncytin for Development of Syncytialized Placenta, Its Limited Homology to the SARS-CoV-2 Spike Protein and Arguments against Disturbing Narrative in the Context of COVID-19 Vaccination.** Biology (Basel) 2021; 10Kloc M, Uosef A, Kubiak JZ, Ghobrial RM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808658>
11. **Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions.** Biomedicines 2021; 9Matsuishi Y, Mathis BJ, Shimojo N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33801921>
12. **Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19).** Biomolecules 2021; 11El-Demerdash A, Metwaly AM, Hassan A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33808721>
13. **Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis.** Biomolecules 2021; 11Hardy E, Fernandez-Patron C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800947>
14. **Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.** Blood Purif. 2021:1-14Sheervalilou R, Shirvaliloo M, Sargazi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789273>
15. **Impact of corticosteroids in hospitalised COVID-19 patients.** BMJ Open Respir Res 2021; 8Ho KS, Narasimhan B, Difabrizio L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811098>
16. **Treatment of COVID-19: a review of current and prospective pharmacotherapies.** Br. J. Hosp. Med. (Lond.) 2021; 82:1-9Quek E, Tahir H, Kumar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792391>
17. **BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.** Cell 2021; Mills RJ, Humphrey SJ, Fortuna PRJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811809>
18. **Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication.** Cell Rep. 2021:108940Garcia G, Jr., Sharma A, Ramaiah A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784499>

19. **Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class.** Cell Rep. 2021:108950 Rapp M, Guo Y, Reddem ER *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794145>
20. **Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients.** Cells 2021; 10 Raghav A, Khan ZA, Upadhayay VK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799966>
21. **Role of phytoconstituents in the management of COVID-19.** Chem. Biol. Interact. 2021:109449 Das A, Pandita D, Jain GK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798507>
22. **Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial.** Clin Microbiol Infect 2021; Dubée V, Roy PM, Vielle B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813110>
23. **Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness.** Clin Microbiol Infect 2021; Martinuka O, von Cube M, Wolkewitz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813117>
24. **Adverse Drug Event Risk Assessment by the Virtual Addition of COVID-19 Repurposed Drugs to Medicare and Commercially Insured Patients' Drug Regimens: A Drug Safety Simulation Study.** Clin Transl Sci 2021; Smith MK, Bikmetov R, Al Rihani SB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786990>
25. **COVID-19: The Ivermectin African Enigma.** Colomb Med (Cali) 2020; 51:e2014613 Guerrero R, Bravo LE, Muñoz E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795896>
26. **Posterior Reversible Encephalopathy Syndrome in a Patient With SARS-CoV-2 Infection Treated With Tocilizumab.** Cureus 2021; 13:e13475 Talluri K, Lall N, Moreno MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777563>
27. **Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson's Disease.** Curr Drug Deliv 2021; Islam N, Rahman S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797367>
28. **Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint.** Curr. Neuropharmacol. 2021; Alborghetti M, Bellucci G, Gentile A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784961>
29. **Taming of Covid-19: potential and emerging application of mesenchymal stem cells.** Cytotechnology 2021:1-46 Najafi-Ghalehlou N, Roudkenar MH, Langerodi HZ, Roushandeh AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776206>
30. **Clinical Predictors Of SARS-CoV-2 Neutralizing Antibody Titers In COVID-19 Convalescents: Implications For Convalescent Plasma Donor Recruitment.** Eur. J. Haematol. 2021; Focosi D, Franchini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780551>
31. **System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: Preliminary experience of a tertiary care institute in India.** Expert Rev. Anti Infect. Ther. 2021; Kumar MP, Mohindra R, Balla A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781166>
32. **Perspective: The nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection.**

- Expert Rev. Clin. Immunol. 2021; Ameratunga R, Woon ST, Steele R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33792473>
33. **Coronavirus-Induced Host Cubic Membranes and Lipid-Related Antiviral Therapies: A Focus on Bioactive Plasmalogens.** Front Cell Dev Biol 2021; 9:630242Deng Y, Angelova A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791293>
34. **Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.** Front. Immunol. 2021; 12:635371Martinez MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777024>
35. **Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.** Front. Immunol. 2021; 12:637982Srivastava V, Niu L, Phadke KS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33777030>
36. **COVID-19 Therapy: Could a Copper Derivative of Chlorophyll a Be Used to Treat Lymphopenia Associated With Severe Symptoms of SARS-CoV-2 Infection?** Front Med (Lausanne) 2021; 8:620175Clark NF, Taylor-Robinson AW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777973>
37. **Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis.** Front. Pharmacol. 2021; 12:607408Abdelrahman Z, Liu Q, Jiang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790785>
38. **Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing.** Front. Pharmacol. 2021; 12:625678Kern C, Schöning V, Chaccour C, Hammann F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776767>
39. **A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China.** Front. Pharmacol. 2020; 11:574562Zhang N, Shi N, Li S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776751>
40. **Plant in vitro Culture Technologies; A Promise Into Factories of Secondary Metabolites Against COVID-19.** Front Plant Sci 2021; 12:610194Khan T, Khan MA, Karam K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777062>
41. **Ethnomedicinal herbs in African traditional medicine with potential activity for the prevention, treatment, and management of coronavirus disease 2019.** Futur J Pharm Sci 2021; 7:72Adeleye OA, Femi-Oyewo MN, Bamiro OA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33778086>
42. **Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.** Indian J. Crit. Care Med. 2021; 25:260-266Bhandari S, Rankawat G, Singh A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790504>
43. **The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.** Int Immunopharmacol 2021; 96:107602Lin WT, Hung SH, Lai CC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812260>
44. **A review on antiviral and immunomodulatory polysaccharides from Indian medicinal plants, which may be beneficial to COVID-19 infected patients.** Int. J. Biol. Macromol. 2021; 181:462-470Sen IK, Chakraborty I, Mandal AK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33794238>
45. **Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study.** Int J Mol Sci 2021; 22Abdelaal

Ahmed Mahmoud MAA, Georgakis M, Montero Valenzuela LR *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33804129>

46. **A Novel Computational Approach for the Discovery of Drug Delivery System Candidates for COVID-19.** Int J Mol Sci 2021; 22Cho T, Han HS, Jeong J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802169>
47. **Potential Therapeutic Applications of Hydrogen in Chronic Inflammatory Diseases: Possible Inhibiting Role on Mitochondrial Stress.** Int J Mol Sci 2021; 22Hirano SI, Ichikawa Y, Sato B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806292>
48. **Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19.** Int. J. Quantum Chem. 2021:e26617Liu JB, Arockiaraj M, Arulperumjothi M, Prabhu S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33785968>
49. **Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2.** J Appl Phycol 2021:1-24Petit L, Vernès L, Cadoret JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776210>
50. **Polymer-based Nano-therapies to Combat COVID-19 related Respiratory Injury: Progress, Prospects, and Challenges.** J. Biomater. Sci. Polym. Ed. 2021:1-33Rana MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787467>
51. **Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors.** J Biomol Struct Dyn 2021:1-9Khorsandi Z, Afshinpour M, Molaei F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33784944>
52. **A meta-research study revealed susceptibility of Covid-19 treatment research to white hat bias: First, do no harm.** J. Clin. Epidemiol. 2021; Bellos I.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33775812>
53. **Angiotensin-(1-7)-A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic.** J Clin Med 2021; 10Heyman SN, Walther T, Abassi Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33805760>
54. **Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics.** J. Genet. Eng. Biotechnol. 2021; 19:52Hossain MU, Bhattacharjee A, Emon MTH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797663>
55. **An overview of Covid-19 pandemic: immunology and pharmacology.** J. Immunoassay Immunochem. 2021:1-20Arif A, Ansari S, Ahsan H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33788668>
56. **Evaluation of Adjunctive Photobiomodulation (PBMT) for COVID-19 Pneumonia via Clinical Status and Pulmonary Severity Indices in a Preliminary Trial.** J Inflamm Res 2021; 14:965-979Vetrici MA, Mokmeli S, Bohm AR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33776469>
57. **Remdesivir for the treatment of COVID-19 in pregnancy.** J Med Virol 2021; Lampejo DT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788273>
58. **Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: a retrospective study.** J Med Virol 2021; Movahed SMM, Akhavizadegan H, Dolatkhani F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33792956>

59. **Engineered ultra-high affinity synthetic antibodies for SARS-CoV-2 neutralization and detection.** J. Mol. Biol. 2021:166956Slezak T, Kossiakoff AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775667>
60. **Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.** J. Mol. Graph. Model. 2021; 105:107904Ibrahim MAA, Mohamed EAR, Abdelrahman AHM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798836>
61. **The potential of miRNA-based therapeutics in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: a review.** J Pharm Anal 2021; Rizkita LD, Astuti I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782640>
62. **Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies.** J. Steroid Biochem. Mol. Biol. 2021:105883Petrelli F, Luciani A, Perego G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775818>
63. **Proteinase K treatment in absence of RNA isolation classical procedures is a quick and cheaper alternative for SARS-CoV-2 molecular detection.** J. Virol. Methods 2021:114131Mallmann L, Hermann BS, Schallenberger K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798606>
64. **Regression of Coronary Aneurysms With Intravenous Immunoglobulins and Steroids for COVID-19 Adult Multisystem Inflammatory Syndrome.** JACC Case Rep 2021; Diakite S, Bousdira N, Tachon G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782672>
65. **In Vitro Evaluation of the Activity of Terpenes and Cannabidiol against Human Coronavirus E229.** Life (Basel) 2021; 11Chatow L, Nudel A, Nesher I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805385>
66. **Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series.** Life (Basel) 2021; 11Mąlecki P, Faltin K, Mania A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802763>
67. **Therapeutic Potential of EGCG, a Green Tea Polyphenol, for Treatment of Coronavirus Diseases.** Life (Basel) 2021; 11Park J, Park R, Jang M, Park YI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806274>
68. **Heparin prevents in vitro glycoalyx shedding induced by plasma from COVID-19 patients.** Life Sci 2021; 276:119376Potje SR, Costa TJ, Fraga-Silva TFC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781826>
69. **Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2.** Life Sci 2021:119437Tahmasebi S, Saeed BQ, Temirgalieva E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789145>
70. **Aminoglycosides and their potential as SARS-CoV-2 antivirals.** Med. Hypotheses 2021; 150:110559Cimolai N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780777>
71. **Strengthening CoViD-19 therapy via combinations of RAS modulators.** Med. Hypotheses 2021; 150:110571Uzunova VV, Todev A, Zarkos J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799164>
72. **The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.** Medicina (Kaunas) 2021; 57Tirnea L, Bratosin F, Vidican I *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33799535>

73. **Green micellar solvent-free HPLC and Spectrofluorimetric determination of Favipiravir as one of COVID-19 antiviral regimens.** Microchem. J. 2021;106:189Mikhail IE, Elmansi H, Belal F, Ehab Ibrahim A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776146>
74. **Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection.** Microorganisms 2021; 9Kostopoulos IV, Orologas-Stavrou N, Rousakis P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800807>
75. **Effectiveness of Azithromycin as add-on Therapy in COVID-19 Management.** Mini Rev. Med. Chem. 2021; Wahab S, Ahmad MF, Hussain A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797374>
76. **Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including SARS-CoV-2.** Molecules 2021; 26Anand AV, Balamuralikrishnan B, Kaviya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809963>
77. **Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform.** Molecules 2021; 26Chakravarty K, Antontsev VG, Khotimchenko M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805419>
78. **Natural Products from Medicinal Plants with Anti-Human Coronavirus Activities.** Molecules 2021; 26Hafez Ghoran S, El-Shazly M, Sekeroglu N, Kijjoa A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800977>
79. **Receptor-Based Pharmacophore Modeling in the Search for Natural Products for COVID-19 M(pro).** Molecules 2021; 26Saeed M, Saeed A, Alam MJ, Alreshidi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799871>
80. **Molecular Basis of the Therapeutical Potential of Clove (*Syzygium aromaticum* L.) and Clues to Its Anti-COVID-19 Utility.** Molecules 2021; 26Viciodini C, Roviello V, Roviello GN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810416>
81. **Alemtuzumab in Covid era.** Mult Scler Relat Disord 2021; 51:102908Iovino A, Olivieri N, Aruta F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33812222>
82. **In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.** Netw Model Anal Health Inform Bioinform 2021; 10:22Udofia IA, Gbayo KO, Oloba-Whenu OA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786291>
83. **Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study.** Pharmaceuticals (Basel) 2021; 14Darquennes G, Le Corre P, Le Moine O, Loas G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799977>
84. **Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids.** Pharmaceuticals (Basel) 2021; 14Diamond G, Molchanova N, Herlan C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807248>
85. **Rapamycin: Drug Repurposing in SARS-CoV-2 Infection.** Pharmaceuticals (Basel) 2021; 14Patocka J, Kuca K, Oleksak P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807743>

86. **Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection.** Pharmaceutics 2021; 13Castro-Balado A, Mondelo-García C, Barbosa-Pereira L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808025>
87. **The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.** Pharmacol. Rep. 2021;1-7Kow CS, Merchant HA, Mustafa ZU, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779964>
88. **Traditional Chinese Medicine (TCM) in the treatment of viral infections: Efficacies and mechanisms.** Pharmacol. Ther. 2021:107843Huang K, Zhang P, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811957>
89. **Photobiomodulation and antimicrobial photodynamic therapies for orofacial lesions in patients with COVID-19: a case series.** Photodiagnosis Photodyn. Ther. 2021:102281Teixeira IS, Leal FS, Tateno RY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813018>
90. **Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study.** Phytomedicine 2021; 85:153531Zhang L, Zheng X, Bai X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799224>
91. **In silico approach of secondary metabolites from Brazilian herbal medicines to search for potential drugs against SARS-CoV-2.** Phytother. Res. 2021; Amparo TR, Seibert JB, Almeida TC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33797123>
92. **Greater celandine (*Chelidonium majus* L.) for COVID-19: A twenty-case series.** Phytother. Res. 2021; Gardin NE, Braga AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778996>
93. **Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2.** Phytother. Res. 2021; Gour A, Manhas D, Bag S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786876>
94. **A status report with critical analysis of research trends in exploring medicinal plants as antiviral: Let us dig into the history to predict the future.** Phytother. Res. 2021; Mukherjee S, Chouhan KBS, Tandey R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33793009>
95. **Uncertain evidence base for tocilizumab in COVID-19 pneumonia.** Pneumologie 2021; 75Klein F.
96. **Treatment of COVID-19 patients with mild or moderate illness.** Pneumologie 2021; 75Lichert FF.
97. **Multiple Sites on SARS-CoV-2 Spike Protein are Susceptible to Proteolysis by Cathepsins B, K, L, S, and V.** Protein Sci. 2021; Bollavaram K, Leeman TH, Lee MW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786919>
98. **Unfavorable hydroxychloroquine COVID-19 research associated with authors having a history of political party donations.** Rev Cardiovasc Med 2021; 22:191-198Berry AC, Gonnering RS, Rodriguez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792262>
99. **Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia.** SAGE Open Med Case Rep 2021; 9:2050313x21991063Shinomiya S, Nakase K,

- Fujii A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796310>
100. **Ultraefficiently Calming Cytokine Storm Using Ti(3)C(2)T (x) MXene.** Small Methods 2021;2001108Wang T, Sun X, Guo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786372>
 101. **Compassionate Use of Rectal Ozone (O₃) in Severe COVID-19 Pneumonia: a Case-Control Study.** SN Compr Clin Med 2021;1-15Fernández-Cuadros ME, Albaladejo-Florín MJ, Álava-Rabasa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778374>
 102. **Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role.** Trends Microbiol. 2021; Samuel SM, Varghese E, Büsselberg D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785249>
 103. **The effect of the timing of dexamethasone administration in patients with COVID-19 pneumonia.** Tuberc Respir Dis (Seoul) 2021; Lee HW, Park J, Lee JK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779109>
 104. **Precision therapeutic targets for COVID-19.** Virology 2021; 18:66Krumm ZA, Lloyd GM, Francis CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781287>
 105. **Computationally approached inhibition potential of *Tinospora cordifolia* towards COVID-19 targets.** Virusdisease 2021;1-13Jena S, Munusami P, Mm B, Chanda K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778129>
 106. **Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19.** Viruses 2021; 13Biernat MM, Kolasińska A, Kwiatkowski J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800528>
 107. **Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions.** Viruses 2021; 13Brown AN, Strobel G, Hanrahan KC, Sears J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807769>
 108. **Amantadine Inhibits SARS-CoV-2 In Vitro.** Viruses 2021; 13Fink K, Nitsche A, Neumann M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804989>
 109. **Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.** Viruses 2021; 13Fricke-Galindo I, Falfán-Valencia R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807592>
 110. **In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2.** Viruses 2021; 13Kiani P, Scholey A, Dahl TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810356>
 111. **Treatment Protocol for COVID-19 Based on T2R Phenotype.** Viruses 2021; 13Taha MA, Hall CA, Shortess CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803811>
 112. **Hydroxychloroquine-Induced cutaneous reaction in treatment of COVID-19.** Vis J Emerg Med 2021; 22:100979Papanagnou D, Capobianco S, Jean J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=3378638>

Trials (15 articles)

1. **The effectiveness of continuous renal replacement therapy in critical COVID-19 patients with cytokine release syndrome: a retrospective, multicenter, descriptive study from Wuhan, China.** Aging (Albany NY) 2021; 13Xiang H, Song B, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811755>
2. **Pitfalls when comparing COVID-19-related outcomes across studies-lessons learnt from the ERACODA collaboration.** Clin Kidney J 2021; 14:i14-i20Noordzij M, Vart P, Duivenvoorden R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796283>
3. **Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial.** Clin Microbiol Infect 2021; Dubée V, Roy PM, Vielle B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813110>
4. **Perspectives on Virtual (Remote) Clinical Trials as the 'New Normal' to Accelerate Drug Development.** Clin Pharmacol Ther 2021; Alemayehu D, Hemmings R, Natarajan K, Roychoudhury S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792920>
5. **Identifying Clinical Phenotypes in Moderate to Severe Acute Respiratory Distress Syndrome Related to COVID-19: The COVADIS Study.** Front Med (Lausanne) 2021; 8:632933Lascarrou JB, Gaultier A, Soumagne T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777977>
6. **Creating and Implementing a COVID-19 Recruitment Data Mart.** J. Biomed. Inform. 2021:103765Helmer TT, Lewis AA, McEver M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798717>
7. **The effects of combination of Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial.** J Complement Integr Med 2021; Mesri M, Esmaeili Saber SS, Godazi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787192>
8. **Evaluation of Adjunctive Photobiomodulation (PBMT) for COVID-19 Pneumonia via Clinical Status and Pulmonary Severity Indices in a Preliminary Trial.** J Inflamm Res 2021; 14:965-979Vetrici MA, Mokmeli S, Bohm AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776469>
9. **Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials.** J Integr Med 2021; Zhao MZ, Zhao C, Tu SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789839>
10. **Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study.** Pharmaceuticals (Basel) 2021; 14Darquennes G, Le Corre P, Le Moine O, Loas G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799977>
11. **Alcohol-Based Hand Sanitizers in COVID-19 Prevention: A Multidimensional Perspective.** Pharmacy (Basel) 2021; 9Abuga K, Nyamweya N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808754>
12. **Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure**

- and function: a structured summary of a study protocol for a randomized controlled study.** Trials 2021; 22:245Haran JP, Pinero JC, Zheng Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810796>
13. **Effects of pomegranate juice (Punica Granatum) on inflammatory biomarkers and complete blood count in patients with COVID-19: a structured summary of a study protocol for a randomized clinical trial.** Trials 2021; 22:246Yousefi M, Sadriirani M, PourMahmoudi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810808>
 14. **Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.** Viruses 2021; 13Funk CD, Laferrière C, Ardakani A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807839>
 15. **The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Generation 2 questionnaire data capture May-July 2020.** Wellcome Open Res 2020; 5:278Smith D, Northstone K, Bowring C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791441>

Vaccines (100 articles)

1. **Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI).** Acta Clin. Belg. 2021;1-6Tuyls S, Van Der Brempt X, Faber M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33792500>
2. **Management of anaphylaxis due to COVID-19 vaccines in the elderly.** Allergy 2021; Bousquet J, Agache I, Blain H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811358>
3. **Vaccines and Allergic reactions: the past, the current COVID-19 pandemic, and future perspectives.** Allergy 2021; Sampath V, Rabinowitz G, Shah M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811364>
4. **COVID-19 screening, testing and vaccination: Perceptions from emergency medicine residents and medical students.** Am J Emerg Med 2021; Cronin AO, Coyne CJ, Castillo EM, Dameff C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810920>
5. **COVID-19 vaccine response in pregnant and lactating women: a cohort study.** Am J Obstet Gynecol 2021; Gray KJ, Bordt EA, Atyeo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775692>
6. **Anti-SARS-CoV-2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination: SARS-CoV-2 antibodies in breast milk after vaccination.** Am J Obstet Gynecol 2021; Kelly JC, Carter EB, Raghuraman N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798480>
7. **Polyethylene Glycol and Polysorbate Skin Testing in the Evaluation of COVID-19 Vaccine Reactions: Early Report.** Ann. Allergy. Asthma. Immunol. 2021; Pitlick MM, Sitek AN, Kinate SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775902>
8. **SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the**

- Australasian Medical Dermatology Group.** *Australas. J. Dermatol.* 2021; Wang C, Rademaker M, Tate B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786833>
9. **The Relevance of Bioinformatics Applications in the Discovery of Vaccine Candidates and Potential Drugs for COVID-19 Treatment.** *Bioinform. Biol. Insights* 2021; 15:11779322211002168Chukwudozie OS, Duru VC, Ndiribe CC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33795932>
 10. **Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings.** *Biology (Basel)* 2021; 10Granata V, Fusco R, Setola SV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799618>
 11. **Protective role of intravesical BCG in COVID-19 severity.** *BMC Urol.* 2021; 21:50Gallegos H, Rojas PA, Sepúlveda F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785004>
 12. **Acceptance of Covid-19 vaccine among healthcare personnel in India: A cross-sectional survey during the initial phase of vaccination.** *Clin Microbiol Infect* 2021; Singhania N, Kathiravan S, Pannu AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798698>
 13. **Lymphadenopathy Associated With the COVID-19 Vaccine.** *Cureus* 2021; 13:e13524Hiller N, Goldberg SN, Cohen-Cymerknoh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786231>
 14. **Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine.** *Cureus* 2021; 13:e14099Malayala SV, Mohan G, Vasireddy D, Atluri P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786251>
 15. **Waiting for the vaccines: Supply strategy of the EU under criticism.** *Deutsche Apotheker Zeitung* 2021; 161.
 16. **Vaccine probably also detect mutations: Concern about Comirnaty® vaccination against SARS-CoV-2 variants provisionally invalidated.** *Deutsche Apotheker Zeitung* 2021; 161.
 17. **No new risk signal after COVID-19 vaccination: Initial reports of adverse reactions after vaccination with Comirnaty®.** *Deutsche Apotheker Zeitung* 2021; 161.
 18. **First do not vaccinate: After SARS-CoV-2 infection.** *Deutsche Apotheker Zeitung* 2021; 161.
 19. **Vaccine number four: EU Commission approves COVID-19 vector vaccine of Johnson & Johnson.** *Deutsche Apotheker Zeitung* 2021; 161.
 20. **What way is the right one? - Struggling for the best corona vaccination strategy.** *Deutsche Apotheker Zeitung* 2021; 161Feldmeier H.
 21. **Better than its reputation: The first vector-based vaccine of AstraZeneca prevents severe courses of COVID-19.** *Deutsche Apotheker Zeitung* 2021; 161Winckler T.
 22. **What Indians Think of the COVID-19 vaccine: A qualitative study comprising focus group discussions and thematic analysis.** *Diabetes Metab Syndr* 2021; 15:679-682Kumari A, Ranjan P, Chopra S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813241>
 23. **Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.** *Diagnostics (Basel)* 2021; 11Doroftei B, Ciobica A, Ilie OD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804914>

24. **When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine.** Eur J Intern Med 2021; Dal-Ré R, Banzi R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810939>
25. **The power of choice: Experimental evidence that freedom to choose a vaccine against COVID-19 improves willingness to be vaccinated.** Eur J Intern Med 2021; Sprengholz P, Eitze S, Korn L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810941>
26. **Strategies for Ensuring Required Service Level for COVID-19 Herd Immunity in Indian Vaccine Supply Chain.** Eur J Oper Res 2021; Sinha P, Kumar S, Chandra C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33776195>
27. **Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?** Expert Rev Vaccines 2021; Shi Y, Guo M, Yang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33787439>
28. **Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar.** Healthcare (Basel) 2021; 9Kelkar AH, Blake JA, Cherabuddi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808758>
29. **BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?** Infect Drug Resist 2021; 14:1169-1184Koneru G, Batiha GE, Algammal AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33790587>
30. **Predictive analysis of COVID-19 eradication with vaccination in India, Brazil, and U.S.A.** Infect Genet Evol 2021;104834Chaturvedi D, Chakravarty U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798755>
31. **How fast should social restrictions be eased in England as COVID-19 vaccinations are rolled out?** Int J Clin Pract 2021:e14191Miles DK, Heald AH, Stedman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788370>
32. **Vaccine Willingness and Impact of the COVID-19 Pandemic on Women's Perinatal Experiences and Practices-A Multinational, Cross-Sectional Study Covering the First Wave of the Pandemic.** Int J Environ Res Public Health 2021; 18Ceulemans M, Foulon V, Panchaud A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33805097>
33. **Attitudes of Healthcare Personnel towards Vaccinations before and during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Ledda C, Costantino C, Cuccia M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33800187>
34. **Intention to Take COVID-19 Vaccine as a Precondition for International Travel: Application of Extended Norm-Activation Model.** Int J Environ Res Public Health 2021; 18Radic A, Koo B, Gil-Cordero E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803023>
35. **An Asia-Pacific study on healthcare worker's perception and willingness to receive COVID-19 vaccination.** Int J Infect Dis 2021; Chew NWS, Cheong C, Kong G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781902>
36. **Emergence and outcome of the SARS-CoV-2 "Marseille-4" variant.** Int J Infect Dis 2021; Fournier PE, Colson P, Levasseur A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785459>
37. **Bacille Calmette-Guérin (BCG) Vaccine and Potential Cross-Protection against SARS-CoV-2 Infection - Assumptions, Knowns, Unknowns and Need for Developing an Accurate Scientific Evidence Base.** Int J Infect Dis 2021; Nachega

- JB, Maeurer M, Sam-Agudu NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794380>
38. **Vigilance regarding immune thrombocytopenic purpura after COVID-19 vaccine.** *Ir. J. Med. Sci.* 2021;1-2Saudagar V, Patil S, Goh S, Pothiwala S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788135>
 39. **Acceptance and Intake of COVID-19 Vaccines among Older Germans.** *J Clin Med* 2021; 10Malesza M, Wittmann E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808414>
 40. **Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine.** *J Eur Acad Dermatol Venereol* 2021; Ackerman M, Henry D, Finon A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783017>
 41. **VACCINATION AGAINST SARS-COV-2 and PSORIASIS: the three things every dermatologist should know.** *J Eur Acad Dermatol Venereol* 2021; Diotallevi F, Campanati A, Radi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780556>
 42. **Disparities in H1N1 Vaccination Rates: a Systematic Review and Evidence Synthesis to Inform COVID-19 Vaccination Efforts.** *J Gen Intern Med* 2021;1-12Ayers CK, Kondo KK, Williams BE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33791935>
 43. **Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers.** *J Infect* 2021; Tré-Hardy M, Cupaiolo R, Papeux E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811939>
 44. **Beliefs regarding COVID-19 vaccines among Canadian workers in the intellectual disability sector prior to vaccine implementation.** *J. Intellect. Disabil. Res.* 2021; Lunskey Y, Kithulegoda N, Thai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788310>
 45. **COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.** *J Korean Med Sci* 2021; 36:e95Park JK, Lee EB, Shin K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783147>
 46. **What money can't buy: an argument against paying people to get vaccinated.** *J. Med. Ethics* 2021; Jecker NS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811111>
 47. **Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.** *J Med Virol* 2021; Callegaro A, Borleri D, Farina C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788281>
 48. **Transparency of the national government as key in promoting the rollout of COVID-19 vaccines.** *J Public Health (Oxf)* 2021; Dela Cruz MDM, Mendoza AJM, Gueco GEA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783541>
 49. **Shaping public opinion through the lens of agenda setting in rolling out COVID-19 vaccination program.** *J Public Health (Oxf)* 2021; Medina LM, Rodriguez JR, Sarmiento PJD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783540>
 50. **Addressing Justified Vaccine Hesitancy in the Black Community.** *J Racial Ethn Health Disparities* 2021;1-4Laurencin CT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33783755>

51. **Joint impacts of media, vaccination and treatment on an epidemic Filippov model with application to COVID-19.** J. Theor. Biol. 2021:110698Deng J, Tang S, Shu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794286>
52. **Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients.** Kidney Int 2021; Benotmane I, Gautier-Vargas G, Cognard N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775674>
53. **Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey.** Life (Basel) 2021; 11Mathioudakis AG, Ghrew M, Ustianowski A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803014>
54. **Does COVID-19 Vaccination Warrant the Classical Principle "ofelein i mi vlaplin"?** Medicina (Kaunas) 2021; 57Doulberis M, Papaefthymiou A, Kotronis G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803295>
55. **COVID-19: Insights into Potential Vaccines.** Microorganisms 2021; 9Loo KY, Letchumanan V, Ser HL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804162>
56. **Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines.** Microorganisms 2021; 9Villena J, Li C, Vizoso-Pinto MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810287>
57. **Pricing the COVID-19 Vaccine: A Mathematical Approach.** Omega 2021:102451Martonosi SE, Behzad B, Cummings K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785979>
58. **[Effect of COVID-19 on routine immunization schedule in Senegalese hospitals].** Pan Afr. Med. J. 2020; 37:364Sow A, Gueye M, Boiro D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33796177>
59. **BAME community hesitancy in the UK for COVID-19 vaccine: suggested solutions.** Postgrad. Med. J. 2021; 1yengar KP, Vaishya R, Jain VK, Ish P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33782200>
60. **Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers.** Proc Natl Acad Sci U S A 2021; 118Buckner JH, Chowell G, Springborn MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33811185>
61. **Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey.** Rheumatol. Int. 2021:1-10Yurttas B, Poyraz BC, Sut N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33779780>
62. **COVID-19 vaccination campaign in Nepal, emerging UK variant and futuristic vaccination strategies to combat the ongoing pandemic.** Travel Med Infect Dis 2021; 41:102037Sah R, Khatiwada AP, Shrestha S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781945>
63. **The COVID-19 vaccination campaign in Nepal, emerging UK variant and futuristic vaccination strategies to combat the ongoing pandemic.** Travel Med Infect Dis 2021:102037Sah R, Khatiwada AP, Shrestha S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781945>
64. **Media usage predicts intention to be vaccinated against SARS-CoV-2 in the US and the UK.** Vaccine 2021; Allington D, McAndrew S, Moxham-Hall VL, Duffy B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810905>

65. **Are vaccines against COVID-19 tailored to the most vulnerable people?** Vaccine 2021; Antonelli Incalzi R, Trevisan C, Del Signore S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33810907>
66. **Joining the herd? U.S. public opinion and vaccination requirements across educational settings during the COVID-19 pandemic.** Vaccine 2021; Haeder SF.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33810906>
67. **NIH funding for vaccine readiness before the COVID-19 pandemic.** Vaccine 2021; Kiszewski AE, Cleary EG, Jackson MJ, Ledley FD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33781600>
68. **COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization.** Vaccine 2021; Salmon DA, Dudley MZ, Brewer J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781601>
69. **Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada.** Vaccine 2021; Vilches TN, Zhang K, Van Exan R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33812742>
70. **Demographic, psychological, and experiential correlates of SARS-CoV-2 vaccination intentions in a sample of Canadian families.** Vaccine X 2021:100091 Lackner CL, Wang CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33778480>
71. **A Commentary on Realities of Developing COVID-19 Vaccines Discussed through the Global Health Safety Perspective.** Vaccines (Basel) 2021; 9Al-Qahtani WS, Alsafhi FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803704>
72. **Acceptability of a COVID-19 Vaccine among the Saudi Population.** Vaccines (Basel) 2021; 9Alfageeh EI, Alshareef N, Angawi K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33807732>
73. **Perception of COVID-19 Vaccination Amongst Physicians in Colombia.** Vaccines (Basel) 2021; 9Alvarado-Socarras JL, Vesga-Varela AL, Quintero-Lesmes DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808918>
74. **Italian Adults' Likelihood of Getting COVID-19 Vaccine: A Second Online Survey.** Vaccines (Basel) 2021; 9Biasio LR, Bonaccorsi G, Lorini C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33802873>
75. **COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab.** Vaccines (Basel) 2021; 9Chilimuri S, Mantri N, Gongati S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33806646>
76. **Exploring the Willingness to Accept SARS-CoV-2 Vaccine in a University Population in Southern Italy, September to November 2020.** Vaccines (Basel) 2021; 9Di Giuseppe G, Pelullo CP, Della Polla G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33803730>
77. **Is COVID-19 a Real Incentive for Flu Vaccination? Let the Numbers Speak for Themselves.** Vaccines (Basel) 2021; 9Di Pumpo M, Vetrugno G, Pascucci D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33803755>
78. **COVID-19 Vaccine Roll-Out in South Africa and Zimbabwe: Urgent Need to Address Community Preparedness, Fears and Hesitancy.** Vaccines (Basel) 2021; 9Dzinamarira T, Nachipo B, Phiri B, Musuka G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33809002>

79. **Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.** Vaccines (Basel)_2021; 9Gómez CE, Perdiguero B, Esteban M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799505>
80. **A Descriptive-Multivariate Analysis of Community Knowledge, Confidence, and Trust in COVID-19 Clinical Trials among Healthcare Workers in Uganda.** Vaccines (Basel)_2021; 9Kasozi KI, Laudisoit A, Osuwat LO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33809269>
81. **Correlates of Vaccine-Induced Protection against SARS-CoV-2.** Vaccines (Basel)_2021; 9Koch T, Mellinghoff SC, Shamsrizi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801831>
82. **Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations.** Vaccines (Basel)_2021; 9Kounis NG, Koniari I, de Gregorio C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807579>
83. **Willingness of Taiwan's Healthcare Workers and Outpatients to Vaccinate against COVID-19 during a Period without Community Outbreaks.** Vaccines (Basel)_2021; 9Kukreti S, Lu MY, Lin YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808950>
84. **COVID-19 Vaccination Willingness among Chinese Adults under the Free Vaccination Policy.** Vaccines (Basel)_2021; 9Liu R, Zhang Y, Nicholas S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801136>
85. **Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic.** Vaccines (Basel)_2021; 9Machida M, Nakamura I, Kojima T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802285>
86. **Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China.** Vaccines (Basel)_2021; 9Makhoul M, Chemaitelly H, Ayoub HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807647>
87. **Immunogenetic Predictors of Severe COVID-19.** Vaccines (Basel)_2021; 9Malkova A, Kudlay D, Kudryavtsev I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802310>
88. **How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists.** Vaccines (Basel)_2021; 9Papa A, Scaldaferri F, Vetrone LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808983>
89. **Factors Affecting Attitudes towards COVID-19 Vaccination: An Online Survey in Slovenia.** Vaccines (Basel)_2021; 9Petravić L, Arh R, Gabrovec T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808958>
90. **Opportunities for Refinement of Non-Human Primate Vaccine Studies.** Vaccines (Basel)_2021; 9Prescott MJ, Clark C, Dowling WE, Shurtleff AC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33808708>
91. **SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.** Vaccines (Basel)_2021; 9Rogliani P, Chetta A, Cazzola M, Calzetta L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807818>
92. **Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates.** Vaccines (Basel)_2021; 9Seo YB, Suh YS, Ryu JI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804981>

93. **Factors Associated with COVID-19 Vaccine Hesitancy.** *Vaccines (Basel)* 2021; 9Soares P, Rocha JV, Moniz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810131>
94. **Attitude and Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study from Poland.** *Vaccines (Basel)* 2021; 9Szmyd B, Karuga FF, Bartoszek A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33806641>
95. **COVID-19 Vaccine Acceptance among an Online Sample of Sexual and Gender Minority Men and Transgender Women.** *Vaccines (Basel)* 2021; 9Teixeira da Silva D, Biello K, Lin WY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804530>
96. **Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19.** *Vaccines (Basel)* 2021; 9Tong J, Zhu C, Lai H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810026>
97. **COVID-19 Vaccine Hesitancy among French People Living with HIV.** *Vaccines (Basel)* 2021; 9Vallée A, Fourn E, Majerholm C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33804808>
98. **Measurement Invariance of the Drivers of COVID-19 Vaccination Acceptance Scale: Comparison between Taiwanese and Mainland Chinese-Speaking Populations.** *Vaccines (Basel)* 2021; 9Yeh YC, Chen IH, Ahorsu DK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810036>
99. **Heightened Willingness toward Pneumococcal Vaccination in the Elderly Population in Shenzhen, China: A Cross-Sectional Study during the COVID-19 Pandemic.** *Vaccines (Basel)* 2021; 9Zhang M, Chen H, Wu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802327>
100. **Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.** *Viruses* 2021; 13Gobbi F, Buonfrate D, Moro L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807957>

Women – pregnancy (33 articles)

1. **COVID-19 vaccine response in pregnant and lactating women: a cohort study.** *Am J Obstet Gynecol* 2021; Gray KJ, Bordt EA, Atyeo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33775692>
2. **Anti-SARS-CoV-2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination: SARS-CoV-2 antibodies in breast milk after vaccination.** *Am J Obstet Gynecol* 2021; Kelly JC, Carter EB, Raghuraman N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798480>
3. **Pregnancy alters IL-1 β expression and anti-viral antibody responses during SARS-CoV-2 infection.** *Am J Obstet Gynecol* 2021; Sherer ML, Lei J, Creisher P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798476>
4. **How have women health care adjusted their approach to work-life balance as the world adapts to the "new normal" ?** *Am. J. Surg.* 2021; Ghasemi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785205>
5. **A systematic review of pregnant women with COVID-19 and their neonates.** *Arch. Gynecol. Obstet.* 2021; Mirbeyk M, Saghazadeh A, Rezaei N.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33797605>

6. **A survey of postpartum depression and health care needs among Chinese postpartum women during the pandemic of COVID-19.** Arch. Psychiatr. Nurs. 2021; 35:172-177An R, Chen X, Wu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781396>
7. **Breastfeeding during COVID-19: A Narrative Review of the Psychological Impact on Mothers.** Behav Sci (Basel) 2021; 11Pacheco F, Sobral M, Guiomar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33799384>
8. **Management of Comprehensive Care of multiple-birth infants from fetal to infancy period: challenges, training, strategies.** BMC Pediatr. 2021; 21:150Changiz T, Namnabati M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781214>
9. **The association between SARS-CoV-2 infection and preterm delivery: a prospective study with a multivariable analysis.** BMC Pregnancy Childbirth 2021; 21:273Martinez-Perez O, Prats Rodriguez P, Muner Hernandez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33794829>
10. **High Levels of Interferon-Alpha Expressing Macrophages in Human Breast Milk During SARS-CoV-2 Infection: A Case Report.** Breastfeed. Med. 2021; Yu JC, Khodadadi H, Salles É L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781080>
11. **Critical respiratory failure in pregnancy complicated with COVID-19: A case report.** Case Rep Womens Health 2021:e00309Chinen Y, Kinjo Y, Mekaru K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33777708>
12. **Addressing contraceptive needs exacerbated by COVID-19: A call for increasing choice and access to self-managed methods.** Contraception 2021; Haddad LB, RamaRao S, Hazra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781763>
13. **Clinical characteristics of COVID-19 in neonates and young infants.** Eur. J. Pediatr. 2021:1-5Spoulou V, Noni M, Koukou D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786658>
14. **The impact of coronavirus outbreak on breastfeeding guidelines among Brazilian hospitals and maternity services: a cross-sectional study.** Int Breastfeed J 2021; 16:30Gonçalves-Ferri WA, Pereira-Cellini FM, Coca K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33789708>
15. **Human milk banks in the response to COVID-19: a statement of the regional human milk bank network for Southeast Asia and beyond.** Int Breastfeed J 2021; 16:29Olonan-Jusi E, Zambrano PG, Duong VH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33781285>
16. **SARS-CoV-2 Infection and Inflammatory Response in a Twin Pregnancy.** Int J Environ Res Public Health 2021; 18Trombetta A, Comar M, Tommasini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33802696>
17. **Female Pelvic Floor Dysfunction Continues to Negatively Impact Quality-of-Life during the COVID-19 Lockdown.** J Clin Med 2021; 10Carlin GL, Kimberger O, Morgenbesser R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33807502>
18. **The impact of the COVID-19 coronavirus pandemic on the surgical management of gynecological cancers : Analysis of the multicenter database**

- of the French SCGP and the FRANCOGYN group.** J Gynecol Obstet Hum Reprod 2021;102:133Jouen T, Gauthier T, Azais H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33789183>
19. **Maternal and perinatal outcomes in pregnant women with confirmed severe and mild COVID-19 at one large maternity hospital in Chile.** J Matern Fetal Neonatal Med 2021;1-6Haye MT, Cartes G, Gutiérrez J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33792466>
 20. **Remdesivir for the treatment of COVID-19 in pregnancy.** J Med Virol 2021; Lampejo DT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33788273>
 21. **Obstetrical and Newborn Outcomes among Patients with SARS-CoV-2 during Pregnancy.** J. Obstet. Gynaecol. Can. 2021; Trahan MJ, Malhamé I, O'Farrell P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33785466>
 22. **Congenital and Intrapartum SARS-CoV-2 Infection in Neonates: Hypotheses, Evidence and Perspectives.** MEDICC Rev. 2021; 23:72-83Robaina-Castellanos GR, Riesgo-Rodríguez SC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33780426>
 23. **Becoming a mother in the 'new' social world in Australia during the first wave of the COVID-19 pandemic.** Midwifery 2021; 98:102996Sweet L, Bradfield Z, Vasilevski V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813305>
 24. **Maintaining Maternal-Newborn Safety During the COVID-19 Pandemic.** Nurs. Womens Health 2021; Patrick NA, Johnson TS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33811824>
 25. **New Methodologies for Conducting Maternal, Infant, and Child Nutrition Research in the Era of COVID-19.** Nutrients 2021; 13Gould JF, Best K, Netting MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33803970>
 26. **Trends and Dynamics in the First Four Years of Operation of the First Human Milk Bank in Vietnam.** Nutrients 2021; 13Tran HT, Nguyen TT, Barnett D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33800596>
 27. **Gynaecological surgeries in the era of COVID-19 pandemic: a prospective study.** Obstet Gynecol Sci 2021; Saha S, Roy KK, Zangmo R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33794565>
 28. **The Lègami/Legàmi Service-An Experience of Psychological Intervention in Maternal and Child Care during COVID-19.** Pediatr. Rep. 2021; 13:142-161Perricone G, Rotolo I, Beninati V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33810190>
 29. **A multicountry perspective on gender differences in time use during COVID-19.** Proc Natl Acad Sci U S A 2021; 118Giurge LM, Whillans AV, Yemiscigil A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33798094>
 30. **Relationship between viral load, infection-to-delivery interval and mother-to-child transfer of anti-SARS-CoV-2 antibodies.** Ultrasound Obstet Gynecol 2021; Poon LC, Leung BW, Ma T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33798280>
 31. **Ultrasound and Doppler findings in pregnant SARS-CoV-2 positive women.** Ultrasound Obstet Gynecol 2021; Soto-Torres E, Andrade EH, Huntley E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33794060>
 32. **Vertical Transmission of SARS-CoV-2 in Second Trimester Associated with Severe Neonatal Pathology.** Viruses 2021; 13Sukhikh G, Petrova U, Prikhodko A

et al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33801923>

33. **The Impact of the COVID-19 Pandemic on Pregnancy Planning Behaviors.**

Womens Health Rep (New Rochelle) 2021; 2:71-77 Flynn AC, Kavanagh K, Smith

AD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33786533>

to subscribe click [here](#)

mailing address is:
lansberg@gmail.com

© P.J. Lansberg